2020-12-20 12:03:28 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/phrase_4_tag_EMEA/', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../../../new_ver_nmt/checkpoints/EMEA_p_3/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2020-12-20 12:03:29 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2020-12-20 12:03:29 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2020-12-20 12:03:29 | INFO | fairseq.data.data_utils | loaded 2001 examples from: ../../../data-bin/phrase_4_tag_EMEA/test.de-en.de
2020-12-20 12:03:29 | INFO | fairseq.data.data_utils | loaded 2001 examples from: ../../../data-bin/phrase_4_tag_EMEA/test.de-en.en
2020-12-20 12:03:29 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase_4_tag_EMEA/ test de-en 2001 examples
2020-12-20 12:03:29 | INFO | fairseq_cli.generate | loading model(s) from ../../../new_ver_nmt/checkpoints/EMEA_p_3/checkpoint_best.pt
S-533	Welchen Nutzen hat Advate in diesen Studien gezeigt ?
T-533	What benefit has Advate shown during the studies ?
H-533	-0.4898853600025177	<unk> What benefit has Advate shown in these studies ? <unk>
D-533	-0.4898853600025177	<unk> What benefit has Advate shown in these studies ? <unk>
P-533	-1.2975 -0.1302 -0.0786 -0.5996 -0.8754 -0.1101 -0.0221 -0.2504 -0.1270 -1.1224 -0.7301 -0.8370 -0.1881
S-1044	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1044	- Use within three hours after reconstitution .
H-1044	-0.4263160824775696	<unk> Within three hours of reconstitution .
D-1044	-0.4263160824775696	<unk> Within three hours of reconstitution .
P-1044	-1.6569 -0.2756 -0.1562 -0.0796 -0.5994 -0.2046 -0.0722 -0.1830 -0.6092
S-263	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-263	The relevance to humans is unknown .
H-263	-0.6915563941001892	<unk> The significance of this observation for humans is not known .
D-263	-0.6915563941001892	<unk> The significance of this observation for humans is not known .
P-263	-2.4476 -0.3562 -2.3512 -0.2159 -0.1903 -1.4508 -0.0698 -0.1754 -1.0058 -0.1066 -0.8592 -0.1153 -0.1548 -0.1829
S-459	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-459	The relevance to humans is unknown .
H-459	-0.6915563941001892	<unk> The significance of this observation for humans is not known .
D-459	-0.6915563941001892	<unk> The significance of this observation for humans is not known .
P-459	-2.4476 -0.3562 -2.3512 -0.2159 -0.1903 -1.4508 -0.0698 -0.1754 -1.0058 -0.1066 -0.8592 -0.1153 -0.1548 -0.1829
S-868	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-868	- Use within three hours after reconstitution .
H-868	-0.4263160824775696	<unk> Within three hours of reconstitution .
D-868	-0.4263160824775696	<unk> Within three hours of reconstitution .
P-868	-1.6569 -0.2756 -0.1562 -0.0796 -0.5994 -0.2046 -0.0722 -0.1830 -0.6092
S-692	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-692	- Use within three hours after reconstitution .
H-692	-0.4263160824775696	<unk> Within three hours of reconstitution .
D-692	-0.4263160824775696	<unk> Within three hours of reconstitution .
P-692	-1.6569 -0.2756 -0.1562 -0.0796 -0.5994 -0.2046 -0.0722 -0.1830 -0.6092
S-1220	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1220	- Use within three hours after reconstitution .
H-1220	-0.4263160824775696	<unk> Within three hours of reconstitution .
D-1220	-0.4263160824775696	<unk> Within three hours of reconstitution .
P-1220	-1.6569 -0.2756 -0.1562 -0.0796 -0.5994 -0.2046 -0.0722 -0.1830 -0.6092
S-1396	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1396	- Use within three hours after reconstitution .
H-1396	-0.4263160824775696	<unk> Within three hours of reconstitution .
D-1396	-0.4263160824775696	<unk> Within three hours of reconstitution .
P-1396	-1.6569 -0.2756 -0.1562 -0.0796 -0.5994 -0.2046 -0.0722 -0.1830 -0.6092
S-1573	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1573	- Use within three hours after reconstitution .
H-1573	-0.4263160824775696	<unk> Within three hours of reconstitution .
D-1573	-0.4263160824775696	<unk> Within three hours of reconstitution .
P-1573	-1.6569 -0.2756 -0.1562 -0.0796 -0.5994 -0.2046 -0.0722 -0.1830 -0.6092
S-1883	Wie lautete die Empfehlung des CHMP zu diesem Zeitpunkt ?
T-1883	What was the recommendation of the CHMP at that time ?
H-1883	-0.5630071759223938	<unk> What was the CHMP recommendation at that time ?
D-1883	-0.5630071759223938	<unk> What was the CHMP recommendation at that time ?
P-1883	-1.2947 -0.1455 -0.1749 -0.1476 -0.1215 -0.0445 -2.8720 -0.1414 -0.1541 -0.5628 -0.5683 -0.7462 -0.3454
S-700	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-700	Place the vials on a flat clean surface .
H-700	-0.723984956741333	<unk> Put the vials on a level surface .
D-700	-0.723984956741333	<unk> Put the vials on a level surface .
P-700	-3.2901 -1.5879 -1.3726 -0.1523 -0.0596 -0.1189 -0.3081 -0.8320 -0.6035 -0.0495 -0.1447 -0.1686
S-1052	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1052	Place the vials on a flat clean surface .
H-1052	-0.723984956741333	<unk> Put the vials on a level surface .
D-1052	-0.723984956741333	<unk> Put the vials on a level surface .
P-1052	-3.2901 -1.5879 -1.3726 -0.1523 -0.0596 -0.1189 -0.3081 -0.8320 -0.6035 -0.0495 -0.1447 -0.1686
S-22	Reproduction is authorised provided the source is acknowledged .
T-22	Reproduction is authorised provided the source is acknowledged .
H-22	-0.4285638630390167	<unk> <unk> Reproduction is authorised provided the source is acknowledged .
D-22	-0.4285638630390167	<unk> <unk> Reproduction is authorised provided the source is acknowledged .
P-22	-0.3926 -0.9791 -0.5584 -0.4661 -0.1488 -0.3342 -0.2796 -0.7359 -0.1501 -0.0594 -0.1259 -1.3696 -0.1996 -0.2006
S-1228	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1228	Place the vials on a flat clean surface .
H-1228	-0.723984956741333	<unk> Put the vials on a level surface .
D-1228	-0.723984956741333	<unk> Put the vials on a level surface .
P-1228	-3.2901 -1.5879 -1.3726 -0.1523 -0.0596 -0.1189 -0.3081 -0.8320 -0.6035 -0.0495 -0.1447 -0.1686
S-1404	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1404	Place the vials on a flat clean surface .
H-1404	-0.723984956741333	<unk> Put the vials on a level surface .
D-1404	-0.723984956741333	<unk> Put the vials on a level surface .
P-1404	-3.2901 -1.5879 -1.3726 -0.1523 -0.0596 -0.1189 -0.3081 -0.8320 -0.6035 -0.0495 -0.1447 -0.1686
S-1581	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1581	Place the vials on a flat clean surface .
H-1581	-0.723984956741333	<unk> Put the vials on a level surface .
D-1581	-0.723984956741333	<unk> Put the vials on a level surface .
P-1581	-3.2901 -1.5879 -1.3726 -0.1523 -0.0596 -0.1189 -0.3081 -0.8320 -0.6035 -0.0495 -0.1447 -0.1686
S-876	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-876	Place the vials on a flat clean surface .
H-876	-0.723984956741333	<unk> Put the vials on a level surface .
D-876	-0.723984956741333	<unk> Put the vials on a level surface .
P-876	-3.2901 -1.5879 -1.3726 -0.1523 -0.0596 -0.1189 -0.3081 -0.8320 -0.6035 -0.0495 -0.1447 -0.1686
S-1875	Reproduction is authorised provided the source is acknowledged .
T-1875	Reproduction is authorised provided the source is acknowledged .
H-1875	-0.4285638630390167	<unk> <unk> Reproduction is authorised provided the source is acknowledged .
D-1875	-0.4285638630390167	<unk> <unk> Reproduction is authorised provided the source is acknowledged .
P-1875	-0.3926 -0.9791 -0.5584 -0.4661 -0.1488 -0.3342 -0.2796 -0.7359 -0.1501 -0.0594 -0.1259 -1.3696 -0.1996 -0.2006
S-35	Die zweite Studie erbrachte ähnliche Ergebnisse nach einem Jahr .
T-35	Similar results were seen in the second study after a year .
H-35	-0.7080991864204407	<unk> The second trial yielded similar results after one year .
D-35	-0.7080991864204407	<unk> The second trial yielded similar results after one year .
P-35	-3.0626 -0.2229 -0.0712 -1.1950 -2.0219 -0.0879 -0.1276 -0.1280 -0.1698 -1.9924 -0.3238 -0.1428 -0.1652 -0.2023
S-693	- Nach Rekonstitution nicht mehr kühlen .
T-693	- Do not refrigerate the preparation after reconstitution .
H-693	-0.798963189125061	- Do not store after reconstitution .
D-693	-0.798963189125061	- Do not store after reconstitution .
P-693	-2.6164 -1.5273 -0.0975 -1.1916 -0.9435 -0.4745 -0.0472 -0.1452 -0.1474
S-1045	- Nach Rekonstitution nicht mehr kühlen .
T-1045	- Do not refrigerate the preparation after reconstitution .
H-1045	-0.798963189125061	- Do not store after reconstitution .
D-1045	-0.798963189125061	- Do not store after reconstitution .
P-1045	-2.6164 -1.5273 -0.0975 -1.1916 -0.9435 -0.4745 -0.0472 -0.1452 -0.1474
S-1739	Im Zweifelsfall fragen Sie Ihren Arzt .
T-1739	If you are unsure about this , ask your doctor .
H-1739	-0.574600338935852	<unk> If in doubt , ask your doctor .
D-1739	-0.574600338935852	<unk> If in doubt , ask your doctor .
P-1739	-2.0736 -0.4146 -0.1054 -0.9853 -1.4363 -0.1511 -0.1267 -0.1303 -0.1581 -0.1647
S-869	- Nach Rekonstitution nicht mehr kühlen .
T-869	- Do not refrigerate the preparation after reconstitution .
H-869	-0.798963189125061	- Do not store after reconstitution .
D-869	-0.798963189125061	- Do not store after reconstitution .
P-869	-2.6164 -1.5273 -0.0975 -1.1916 -0.9435 -0.4745 -0.0472 -0.1452 -0.1474
S-288	Vitamin D einmal pro Tag wurde nicht untersucht .
T-288	The equivalence of intake of 5600 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 800 IU has not been studied .
H-288	-0.5412622690200806	<unk> vitamin D supplementation once a day was not investigated .
D-288	-0.5412622690200806	<unk> vitamin D supplementation once a day was not investigated .
P-288	-1.1355 -1.6954 -0.0682 -0.1573 -2.5216 -0.0281 -0.1196 -0.1384 -0.3632 -0.0941 -0.2632 -0.3036 -0.8889 -0.1622 -0.1796
S-1855	Wofür sollte Advexin angewendet werden ?
T-1855	What was Advexin expected to be used for ?
H-1855	-0.6074894070625305	<unk> What should Advexin be used for ?
D-1855	-0.6074894070625305	<unk> What should Advexin be used for ?
P-1855	-2.2900 -0.1509 -0.5252 -1.7716 -0.2317 -0.1388 -0.1358 -0.1050 -0.1151 -1.0151 -0.2033
S-1397	- Nach Rekonstitution nicht mehr kühlen .
T-1397	- Do not refrigerate the preparation after reconstitution .
H-1397	-0.798963189125061	- Do not store after reconstitution .
D-1397	-0.798963189125061	- Do not store after reconstitution .
P-1397	-2.6164 -1.5273 -0.0975 -1.1916 -0.9435 -0.4745 -0.0472 -0.1452 -0.1474
S-1221	- Nach Rekonstitution nicht mehr kühlen .
T-1221	- Do not refrigerate the preparation after reconstitution .
H-1221	-0.798963189125061	- Do not store after reconstitution .
D-1221	-0.798963189125061	- Do not store after reconstitution .
P-1221	-2.6164 -1.5273 -0.0975 -1.1916 -0.9435 -0.4745 -0.0472 -0.1452 -0.1474
S-1574	- Nach Rekonstitution nicht mehr kühlen .
T-1574	- Do not refrigerate the preparation after reconstitution .
H-1574	-0.798963189125061	- Do not store after reconstitution .
D-1574	-0.798963189125061	- Do not store after reconstitution .
P-1574	-2.6164 -1.5273 -0.0975 -1.1916 -0.9435 -0.4745 -0.0472 -0.1452 -0.1474
S-635	Verletzung , Vergiftung und durch Eingriffe
T-635	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-635	-1.3191579580307007	<unk> <unk> Injury , intoxication and <unk> <unk>
D-635	-1.3191579580307007	<unk> <unk> Injury , intoxication and <unk> <unk>
P-635	-0.6204 -2.9711 -0.7201 -3.0550 -0.1787 -3.4295 -0.0503 -0.4578 -0.1304 -0.1836 -3.6394 -1.1968 -0.5160
S-715	Nur klare , farblose Lösungen verwenden .
T-715	Only a clear and colourless solution should be used .
H-715	-0.3087058663368225	<unk> Use only clear , colourless solutions .
D-715	-0.3087058663368225	<unk> Use only clear , colourless solutions .
P-715	-1.3966 -0.5904 -0.2026 -0.0506 -0.2095 -0.0337 -0.0721 -0.0896 -0.2816 -0.1568 -0.3122
S-546	Die Genehmigung wurde am 2. März 2009 verlängert .
T-546	The marketing authorisation was renewed on 2 March 2009.
H-546	-0.7038608193397522	<unk> <unk> The marketing authorisation was renewed on 2 March 2009 .
D-546	-0.7038608193397522	<unk> <unk> The marketing authorisation was renewed on 2 March 2009 .
P-546	-2.3250 -1.2921 -0.2750 -1.5688 -0.0101 -0.0611 -0.1094 -1.7435 -0.1064 -0.1246 -1.2894 -0.5580 -0.2169 -0.1738
S-1067	Nur klare , farblose Lösungen verwenden .
T-1067	Only a clear and colourless solution should be used .
H-1067	-0.3087058663368225	<unk> Use only clear , colourless solutions .
D-1067	-0.3087058663368225	<unk> Use only clear , colourless solutions .
P-1067	-1.3966 -0.5904 -0.2026 -0.0506 -0.2095 -0.0337 -0.0721 -0.0896 -0.2816 -0.1568 -0.3122
S-1921	In der zweiten Studie wurden ähnliche Ergebnisse beobachtet .
T-1921	Similar results were seen in the second study .
H-1921	-0.6680570840835571	<unk> In the second study , similar results were observed .
D-1921	-0.6680570840835571	<unk> In the second study , similar results were observed .
P-1921	-3.1841 -1.2160 -0.1784 -0.0881 -1.0253 -1.1369 -0.1275 -0.2522 -0.1261 -0.3416 -0.1561 -0.1843
S-1885	Was waren die wesentlichen Bedenken des CHMP ?
T-1885	What were the main concerns of the CHMP ?
H-1885	-0.4598529636859894	<unk> What were the main concerns of the CHMP ?
D-1885	-0.4598529636859894	<unk> What were the main concerns of the CHMP ?
P-1885	-1.2559 -0.1446 -0.2184 -0.1714 -1.6762 -0.2510 -0.2478 -0.1975 -0.1963 -0.0558 -0.9233 -0.1801
S-891	Nur klare , farblose Lösungen verwenden .
T-891	Only a clear and colourless solution should be used .
H-891	-0.3087058663368225	<unk> Use only clear , colourless solutions .
D-891	-0.3087058663368225	<unk> Use only clear , colourless solutions .
P-891	-1.3966 -0.5904 -0.2026 -0.0506 -0.2095 -0.0337 -0.0721 -0.0896 -0.2816 -0.1568 -0.3122
S-1723	- Dieses Arzneimittel wurde Ihnen verschrieben .
T-1723	- This medicine has been prescribed for you .
H-1723	-0.48737832903862	<unk> This medicine has been prescribed for you .
D-1723	-0.48737832903862	<unk> This medicine has been prescribed for you .
P-1723	-1.1738 -0.2666 -1.5949 -0.6201 -0.0990 -0.0422 -0.0651 -0.6629 -0.1706 -0.1644 -0.5017
S-1243	Nur klare , farblose Lösungen verwenden .
T-1243	Only a clear and colourless solution should be used .
H-1243	-0.3087058663368225	<unk> Use only clear , colourless solutions .
D-1243	-0.3087058663368225	<unk> Use only clear , colourless solutions .
P-1243	-1.3966 -0.5904 -0.2026 -0.0506 -0.2095 -0.0337 -0.0721 -0.0896 -0.2816 -0.1568 -0.3122
S-1419	Nur klare , farblose Lösungen verwenden .
T-1419	Only a clear and colourless solution should be used .
H-1419	-0.3087058663368225	<unk> Use only clear , colourless solutions .
D-1419	-0.3087058663368225	<unk> Use only clear , colourless solutions .
P-1419	-1.3966 -0.5904 -0.2026 -0.0506 -0.2095 -0.0337 -0.0721 -0.0896 -0.2816 -0.1568 -0.3122
S-1596	Nur klare , farblose Lösungen verwenden .
T-1596	Only a clear and colourless solution should be used .
H-1596	-0.3087058663368225	<unk> Use only clear , colourless solutions .
D-1596	-0.3087058663368225	<unk> Use only clear , colourless solutions .
P-1596	-1.3966 -0.5904 -0.2026 -0.0506 -0.2095 -0.0337 -0.0721 -0.0896 -0.2816 -0.1568 -0.3122
S-1724	Es darf nicht an Dritte weitergegeben werden .
T-1724	Es darf nicht an Dritte weitergegeben werden . It may harm them , even
H-1724	-0.8283668160438538	<unk> <unk> Do not transfer it to third parties .
D-1724	-0.8283668160438538	<unk> <unk> Do not transfer it to third parties .
P-1724	-1.0845 -1.2112 -1.5798 -0.1367 -1.6659 -1.5057 -0.2561 -0.2472 -0.9739 -0.1526 -0.2985
S-633	Gelegentlich Gelegentlich Gelegentlich
T-633	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-633	-0.20283840596675873	<unk> Uncommon Uncommon Uncommon
D-633	-0.20283840596675873	<unk> Uncommon Uncommon Uncommon
P-633	-0.9566 -0.1792 -0.0607 -0.0766 -0.0617 -0.0685 -0.0610 -0.1584
S-629	Erkrankungen des Gastrointestinaltrakts
T-629	5 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-629	-0.13866403698921204	<unk> Gastrointestinal disorders
D-629	-0.13866403698921204	<unk> Gastrointestinal disorders
P-629	-0.4314 -0.1094 -0.0995 -0.0561 -0.0567 -0.0615 -0.0407 -0.0996 -0.2930
S-1793	Arzneimittel für Kinder unzugänglich aufbewahren .
T-1793	Keep out of the reach and sight of children .
H-1793	-0.6456748247146606	<unk> Keep the product out of the reach of children .
D-1793	-0.6456748247146606	<unk> Keep the product out of the reach of children .
P-1793	-1.8710 -0.4916 -1.9040 -1.1190 -0.6395 -0.1383 -0.9680 -0.0527 -0.1371 -0.0810 -0.1550 -0.1908
S-1406	Das Transfersystem nicht aus der Verpackung
T-1406	Do not remove the device from the package .
H-1406	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
D-1406	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
P-1406	-1.1888 -0.7847 -0.0579 -0.2296 -1.5090 -0.1483 -2.0977 -0.4941 -0.1517 -0.3127 -2.1016 -0.0832 -0.4437
S-1583	Das Transfersystem nicht aus der Verpackung
T-1583	Do not remove the device from the package .
H-1583	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
D-1583	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
P-1583	-1.1888 -0.7847 -0.0579 -0.2296 -1.5090 -0.1483 -2.0977 -0.4941 -0.1517 -0.3127 -2.1016 -0.0832 -0.4437
S-1666	Vor der Anwendung Gebrauchsinformation lesen .
T-1666	Vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-1666	-0.5720934867858887	<unk> Read leaflet before use .
D-1666	-0.5720934867858887	<unk> Read leaflet before use .
P-1666	-1.0848 -1.1376 -1.2989 -0.0530 -0.1378 -0.9170 -0.2051 -0.1499 -0.1647
S-1230	Das Transfersystem nicht aus der Verpackung
T-1230	Do not remove the device from the package .
H-1230	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
D-1230	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
P-1230	-1.1888 -0.7847 -0.0579 -0.2296 -1.5090 -0.1483 -2.0977 -0.4941 -0.1517 -0.3127 -2.1016 -0.0832 -0.4437
S-1054	Das Transfersystem nicht aus der Verpackung
T-1054	Do not remove the device from the package .
H-1054	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
D-1054	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
P-1054	-1.1888 -0.7847 -0.0579 -0.2296 -1.5090 -0.1483 -2.0977 -0.4941 -0.1517 -0.3127 -2.1016 -0.0832 -0.4437
S-878	Das Transfersystem nicht aus der Verpackung
T-878	Do not remove the device from the package .
H-878	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
D-878	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
P-878	-1.1888 -0.7847 -0.0579 -0.2296 -1.5090 -0.1483 -2.0977 -0.4941 -0.1517 -0.3127 -2.1016 -0.0832 -0.4437
S-1804	Diese Maßnahme hilft die Umwelt zu schützen .
T-1804	These measures will help to protect the environment .
H-1804	-0.41005679965019226	<unk> These measures will help to protect the environment .
D-1804	-0.41005679965019226	<unk> These measures will help to protect the environment .
P-1804	-2.0531 -0.6216 -0.0677 -0.2976 -0.1601 -0.6057 -0.0597 -0.1369 -0.1479 -0.1437 -0.2167
S-702	Das Transfersystem nicht aus der Verpackung
T-702	Do not remove the device from the package .
H-702	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
D-702	-0.7386841177940369	<unk> The transfer system does not come out of the packaging
P-702	-1.1888 -0.7847 -0.0579 -0.2296 -1.5090 -0.1483 -2.0977 -0.4941 -0.1517 -0.3127 -2.1016 -0.0832 -0.4437
S-1715	vor der Anwendung Gebrauchsinformation lesen .
T-1715	vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-1715	-0.4952884912490845	<unk> read leaflet before use .
D-1715	-0.4952884912490845	<unk> read leaflet before use .
P-1715	-1.2000 -0.2813 -1.5150 -0.0412 -0.1291 -0.8162 -0.1516 -0.1567 -0.1667
S-1745	Sie sollten über frühe Anzeichen einer solchen
T-1745	Sie sollten über frühe Anzeichen einer solchen These symptoms can constitute an early
H-1745	-0.7311037182807922	<unk> You should be aware of early signs of such
D-1745	-0.7311037182807922	<unk> You should be aware of early signs of such
P-1745	-0.4417 -1.9953 -0.1130 -2.0967 -1.9903 -0.1685 -0.2779 -0.0892 -0.2171 -0.4890 -0.1635
S-806	0,85 0,43 0,43 0,43
T-806	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-806	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
D-806	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
P-806	-0.6723 -1.4055 -0.2432 -1.1844 -0.1198 -0.5606 -0.0790 -1.5286 -0.1346 -0.1561
S-982	0,85 0,43 0,43 0,43
T-982	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-982	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
D-982	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
P-982	-0.6723 -1.4055 -0.2432 -1.1844 -0.1198 -0.5606 -0.0790 -1.5286 -0.1346 -0.1561
S-1158	0,85 0,43 0,43 0,43
T-1158	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1158	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
D-1158	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
P-1158	-0.6723 -1.4055 -0.2432 -1.1844 -0.1198 -0.5606 -0.0790 -1.5286 -0.1346 -0.1561
S-1334	0,85 0,43 0,43 0,43
T-1334	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1334	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
D-1334	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
P-1334	-0.6723 -1.4055 -0.2432 -1.1844 -0.1198 -0.5606 -0.0790 -1.5286 -0.1346 -0.1561
S-1511	0,85 0,43 0,43 0,43
T-1511	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1511	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
D-1511	-0.6084164381027222	<unk> 0.85 0.43 0.43 0.43
P-1511	-0.6723 -1.4055 -0.2432 -1.1844 -0.1198 -0.5606 -0.0790 -1.5286 -0.1346 -0.1561
S-1506	Infektionen und parasitäre Erkrankungen
T-1506	( % patients<<unk>> a Infections and infestations Blood and lymphatic system disorders
H-1506	-0.42665237188339233	<unk> infections and parasitic disorders
D-1506	-0.42665237188339233	<unk> infections and parasitic disorders
P-1506	-0.5460 -1.4157 -0.0598 -0.1520 -0.1574 -0.4029 -0.1773 -0.9373 -0.1085 -0.3095
S-1708	Für Kinder unzugänglich aufbewahren .
T-1708	Keep out of the reach and sight of children .
H-1708	-0.8224332332611084	<unk> and sight of children .
D-1708	-0.8224332332611084	<unk> and sight of children .
P-1708	-2.6475 -2.2996 -0.1126 -0.1308 -0.1440 -0.1613 -0.2611
S-1676	Für Kinder unzugänglich aufbewahren .
T-1676	Keep out of the reach and sight of children .
H-1676	-0.8224332332611084	<unk> and sight of children .
D-1676	-0.8224332332611084	<unk> and sight of children .
P-1676	-2.6475 -2.2996 -0.1126 -0.1308 -0.1440 -0.1613 -0.2611
S-1941	Erwachsene und Jugendliche ab 12 Jahren :
T-1941	Adults and adolescents 12 years of age and over :
H-1941	-0.2929060161113739	<unk> Adult and adolescents aged 12 years and over :
D-1941	-0.2929060161113739	<unk> Adult and adolescents aged 12 years and over :
P-1941	-1.0752 -0.2744 -0.2207 -0.1363 -0.0792 -0.0402 -0.0557 -0.8497 -0.1494 -0.3473 -0.1830 -0.3776 -0.1499 -0.1622
S-1692	Für Kinder unzugänglich aufbewahren .
T-1692	Keep out of the reach and sight of children .
H-1692	-0.8224332332611084	<unk> and sight of children .
D-1692	-0.8224332332611084	<unk> and sight of children .
P-1692	-2.6475 -2.2996 -0.1126 -0.1308 -0.1440 -0.1613 -0.2611
S-1642	Für Kinder unzugänglich aufbewahren .
T-1642	Keep out of the reach and sight of children .
H-1642	-0.8224332332611084	<unk> and sight of children .
D-1642	-0.8224332332611084	<unk> and sight of children .
P-1642	-2.6475 -2.2996 -0.1126 -0.1308 -0.1440 -0.1613 -0.2611
S-1659	Für Kinder unzugänglich aufbewahren .
T-1659	Keep out of the reach and sight of children .
H-1659	-0.8224332332611084	<unk> and sight of children .
D-1659	-0.8224332332611084	<unk> and sight of children .
P-1659	-2.6475 -2.2996 -0.1126 -0.1308 -0.1440 -0.1613 -0.2611
S-1626	Für Kinder unzugänglich aufbewahren .
T-1626	Keep out of the reach and sight of children .
H-1626	-0.8224332332611084	<unk> and sight of children .
D-1626	-0.8224332332611084	<unk> and sight of children .
P-1626	-2.6475 -2.2996 -0.1126 -0.1308 -0.1440 -0.1613 -0.2611
S-654	Pharmakotherapeutische Gruppe :
T-654	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-654	-0.20532086491584778	<unk> Pharmacotherapeutic group :
D-654	-0.20532086491584778	<unk> Pharmacotherapeutic group :
P-654	-0.7526 -0.2527 -0.1229 -0.0855 -0.0654 -0.1021 -0.1008 -0.2711 -0.1434 -0.1566
S-1533	Pharmakotherapeutische Gruppe :
T-1533	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1533	-0.20532086491584778	<unk> Pharmacotherapeutic group :
D-1533	-0.20532086491584778	<unk> Pharmacotherapeutic group :
P-1533	-0.7526 -0.2527 -0.1229 -0.0855 -0.0654 -0.1021 -0.1008 -0.2711 -0.1434 -0.1566
S-1356	Pharmakotherapeutische Gruppe :
T-1356	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1356	-0.20532086491584778	<unk> Pharmacotherapeutic group :
D-1356	-0.20532086491584778	<unk> Pharmacotherapeutic group :
P-1356	-0.7526 -0.2527 -0.1229 -0.0855 -0.0654 -0.1021 -0.1008 -0.2711 -0.1434 -0.1566
S-1180	Pharmakotherapeutische Gruppe :
T-1180	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1180	-0.20532086491584778	<unk> Pharmacotherapeutic group :
D-1180	-0.20532086491584778	<unk> Pharmacotherapeutic group :
P-1180	-0.7526 -0.2527 -0.1229 -0.0855 -0.0654 -0.1021 -0.1008 -0.2711 -0.1434 -0.1566
S-1004	Pharmakotherapeutische Gruppe :
T-1004	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1004	-0.20532086491584778	<unk> Pharmacotherapeutic group :
D-1004	-0.20532086491584778	<unk> Pharmacotherapeutic group :
P-1004	-0.7526 -0.2527 -0.1229 -0.0855 -0.0654 -0.1021 -0.1008 -0.2711 -0.1434 -0.1566
S-828	Pharmakotherapeutische Gruppe :
T-828	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-828	-0.20532086491584778	<unk> Pharmacotherapeutic group :
D-828	-0.20532086491584778	<unk> Pharmacotherapeutic group :
P-828	-0.7526 -0.2527 -0.1229 -0.0855 -0.0654 -0.1021 -0.1008 -0.2711 -0.1434 -0.1566
S-632	0,43 0,43 0,43
T-632	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-632	-0.48644551634788513	<unk> 0.43 0.43 0.43
D-632	-0.48644551634788513	<unk> 0.43 0.43 0.43
P-632	-0.6571 -1.1578 -0.1675 -0.8819 -0.1123 -0.6231 -0.1337 -0.1582
S-495	ADROVANCE
T-495	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-495	-0.4956244230270386	<unk> <unk> ADROVANCE
D-495	-0.4956244230270386	<unk> <unk> ADROVANCE
P-495	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-494	Alendronat
T-494	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-494	-0.6870766282081604	<unk> alendronate
D-494	-0.6870766282081604	<unk> alendronate
P-494	-1.8988 -1.7789 -0.1099 -0.0845 -0.0130 -0.2374
S-1023	PK-Parameter
T-1023	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1023	-0.3097260296344757	<unk> PK parameters
D-1023	-0.3097260296344757	<unk> PK parameters
P-1023	-0.5996 -0.5107 -0.1880 -0.2817 -0.3212 -0.1059 -0.1610
S-476	ADROVANCE
T-476	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-476	-0.4956244230270386	<unk> <unk> ADROVANCE
D-476	-0.4956244230270386	<unk> <unk> ADROVANCE
P-476	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-493	ADROVANCE
T-493	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-493	-0.4956244230270386	<unk> <unk> ADROVANCE
D-493	-0.4956244230270386	<unk> <unk> ADROVANCE
P-493	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-474	Alendronat
T-474	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-474	-0.6870766282081604	<unk> alendronate
D-474	-0.6870766282081604	<unk> alendronate
P-474	-1.8988 -1.7789 -0.1099 -0.0845 -0.0130 -0.2374
S-671	PK-Parameter
T-671	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-671	-0.3097260296344757	<unk> PK parameters
D-671	-0.3097260296344757	<unk> PK parameters
P-671	-0.5996 -0.5107 -0.1880 -0.2817 -0.3212 -0.1059 -0.1610
S-473	ADROVANCE
T-473	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-473	-0.4956244230270386	<unk> <unk> ADROVANCE
D-473	-0.4956244230270386	<unk> <unk> ADROVANCE
P-473	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-1199	PK-Parameter
T-1199	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1199	-0.3097260296344757	<unk> PK parameters
D-1199	-0.3097260296344757	<unk> PK parameters
P-1199	-0.5996 -0.5107 -0.1880 -0.2817 -0.3212 -0.1059 -0.1610
S-1375	PK-Parameter
T-1375	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1375	-0.3097260296344757	<unk> PK parameters
D-1375	-0.3097260296344757	<unk> PK parameters
P-1375	-0.5996 -0.5107 -0.1880 -0.2817 -0.3212 -0.1059 -0.1610
S-847	PK-Parameter
T-847	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-847	-0.3097260296344757	<unk> PK parameters
D-847	-0.3097260296344757	<unk> PK parameters
P-847	-0.5996 -0.5107 -0.1880 -0.2817 -0.3212 -0.1059 -0.1610
S-475	ADROVANCE
T-475	Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency .
H-475	-0.4956244230270386	<unk> <unk> ADROVANCE
D-475	-0.4956244230270386	<unk> <unk> ADROVANCE
P-475	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-1552	PK-Parameter
T-1552	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1552	-0.3097260296344757	<unk> PK parameters
D-1552	-0.3097260296344757	<unk> PK parameters
P-1552	-0.5996 -0.5107 -0.1880 -0.2817 -0.3212 -0.1059 -0.1610
S-1931	2,5 mg / 120 mg
T-1931	2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg
H-1931	-0.16511769592761993	<unk> 2.5 mg / 120 mg
D-1931	-0.16511769592761993	<unk> 2.5 mg / 120 mg
P-1931	-0.3905 -0.1499 -0.0654 -0.1608 -0.1454 -0.0859 -0.1580
S-497	ADROVANCE
T-497	47 5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-497	-0.4956244230270386	<unk> <unk> ADROVANCE
D-497	-0.4956244230270386	<unk> <unk> ADROVANCE
P-497	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-481	ADROVANCE
T-481	5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-481	-0.4956244230270386	<unk> <unk> ADROVANCE
D-481	-0.4956244230270386	<unk> <unk> ADROVANCE
P-481	-0.8379 -0.5568 -0.6629 -0.1385 -0.1680 -0.1253 -1.1122 -0.3635
S-1510	2 1 1 1
T-1510	2 1 1 1 2 2 1 1 3 1
H-1510	-0.38361379504203796	2 1 1 1
D-1510	-0.38361379504203796	2 1 1 1
P-1510	-1.0352 -0.1416 -0.1198 -0.1389 -0.4825
S-981	2 1 1 1
T-981	2 1 1 1 2 2 1 1 3 1
H-981	-0.38361379504203796	2 1 1 1
D-981	-0.38361379504203796	2 1 1 1
P-981	-1.0352 -0.1416 -0.1198 -0.1389 -0.4825
S-805	2 1 1 1
T-805	2 1 1 1 2 2 1 1 3 1
H-805	-0.38361379504203796	2 1 1 1
D-805	-0.38361379504203796	2 1 1 1
P-805	-1.0352 -0.1416 -0.1198 -0.1389 -0.4825
S-1333	2 1 1 1
T-1333	2 1 1 1 2 2 1 1 3 1
H-1333	-0.38361379504203796	2 1 1 1
D-1333	-0.38361379504203796	2 1 1 1
P-1333	-1.0352 -0.1416 -0.1198 -0.1389 -0.4825
S-204	32 % ) .
T-204	32 % , respectively ) , through week 15.
H-204	-0.5741020441055298	32 % ) .
D-204	-0.5741020441055298	32 % ) .
P-204	-2.2890 -0.1317 -0.1494 -0.1501 -0.1504
S-484	Informieren Sie
T-484	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-484	-1.5736294984817505	<unk> <unk> Tell <unk>
D-484	-1.5736294984817505	<unk> <unk> Tell <unk>
P-484	-2.5280 -0.9813 -3.9743 -0.0354 -1.6418 -0.2810
S-1157	2 1 1 1
T-1157	2 1 1 1 2 2 1 1 3 1
H-1157	-0.38361379504203796	2 1 1 1
D-1157	-0.38361379504203796	2 1 1 1
P-1157	-1.0352 -0.1416 -0.1198 -0.1389 -0.4825
S-1935	14 Tabletten
T-1935	2 tablets 4 tablets 7 tablets 10 tablets 14 tablets 20 tablets
H-1935	-0.20061226189136505	14 tablets
D-1935	-0.20061226189136505	14 tablets
P-1935	-0.4202 -0.1067 -0.1144 -0.1611
S-500	Informieren Sie
T-500	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-500	-1.5736294984817505	<unk> <unk> Tell <unk>
D-500	-1.5736294984817505	<unk> <unk> Tell <unk>
P-500	-2.5280 -0.9813 -3.9743 -0.0354 -1.6418 -0.2810
S-630	Verabreichungsort
T-630	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-630	-1.9912569522857666	<unk> Venue <unk>
D-630	-1.9912569522857666	<unk> Venue <unk>
P-630	-1.9970 -5.4728 -0.0729 -2.2798 -0.1338
S-392	32 % ) .
T-392	32 % , respectively ) , through week 15.
H-392	-0.5741020441055298	32 % ) .
D-392	-0.5741020441055298	32 % ) .
P-392	-2.2890 -0.1317 -0.1494 -0.1501 -0.1504
S-499	Gelegentlich
T-499	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-499	-0.3803846836090088	<unk> Uncommon
D-499	-0.3803846836090088	<unk> Uncommon
P-499	-1.0444 -0.2245 -0.0518 -0.2008
S-498	Häufig :
T-498	The following terms are used to describe how often side effects have been reported :
H-498	-1.3151212930679321	<unk> Common :
D-498	-1.3151212930679321	<unk> Common :
P-498	-3.9683 -2.1794 -0.1293 -0.1408 -0.1578
S-483	Gelegentlich
T-483	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-483	-0.3803846836090088	<unk> Uncommon
D-483	-0.3803846836090088	<unk> Uncommon
P-483	-1.0444 -0.2245 -0.0518 -0.2008
S-631	1 1 1
T-631	2 1 1 1 2 2 1 1 3 1
H-631	-0.7749808430671692	<unk> 1 1 1
D-631	-0.7749808430671692	<unk> 1 1 1
P-631	-1.6352 -1.4023 -0.1552 -0.3660 -0.3162
S-488	Tel . :
T-488	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-488	-0.5916513800621033	<unk> Tel . :
D-488	-0.5916513800621033	<unk> Tel . :
P-488	-1.9604 -0.4723 -0.2103 -0.1548 -0.1603
S-504	Tel . :
T-504	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-504	-0.5916513800621033	<unk> Tel . :
D-504	-0.5916513800621033	<unk> Tel . :
P-504	-1.9604 -0.4723 -0.2103 -0.1548 -0.1603
S-492	Tel : +
T-492	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-492	-0.662559449672699	<unk> Tel : +
D-492	-0.662559449672699	<unk> Tel : +
P-492	-1.9789 -0.8761 -0.1366 -0.1659 -0.1554
S-508	Tel : +
T-508	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-508	-0.662559449672699	<unk> Tel : +
D-508	-0.662559449672699	<unk> Tel : +
P-508	-1.9789 -0.8761 -0.1366 -0.1659 -0.1554
S-482	Häufig :
T-482	The following terms are used to describe how often side effects have been reported :
H-482	-1.3151212930679321	<unk> Common :
D-482	-1.3151212930679321	<unk> Common :
P-482	-3.9683 -2.1794 -0.1293 -0.1408 -0.1578
S-506	Tel :
T-506	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-506	-0.774690568447113	Tel :
D-506	-0.774690568447113	Tel :
P-506	-2.0305 -0.1378 -0.1558
S-507	Tel :
T-507	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-507	-0.774690568447113	Tel :
D-507	-0.774690568447113	Tel :
P-507	-2.0305 -0.1378 -0.1558
S-490	Tel :
T-490	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-490	-0.774690568447113	Tel :
D-490	-0.774690568447113	Tel :
P-490	-2.0305 -0.1378 -0.1558
S-491	Tel :
T-491	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-491	-0.774690568447113	Tel :
D-491	-0.774690568447113	Tel :
P-491	-2.0305 -0.1378 -0.1558
S-489	Tel :
T-489	Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-489	-0.774690568447113	Tel :
D-489	-0.774690568447113	Tel :
P-489	-2.0305 -0.1378 -0.1558
S-505	Tel :
T-505	50 Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-505	-0.774690568447113	Tel :
D-505	-0.774690568447113	Tel :
P-505	-2.0305 -0.1378 -0.1558
S-628	0,43
T-628	Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-628	-0.6358353495597839	<unk> 0.43
D-628	-0.6358353495597839	<unk> 0.43
P-628	-1.8171 -0.4489 -0.1154 -0.1619
S-486	Die
T-486	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-486	-1.4511396884918213	<unk> <unk>
D-486	-1.4511396884918213	<unk> <unk>
P-486	-3.1749 -0.7352 -0.4433
S-479	(
T-479	40 3 ) Do not lie down stay fully upright ( sitting , standing or walking ) for at least 30 minutes after swallowing the tablet .
H-479	-0.5737650990486145	(
D-479	-0.5737650990486145	(
P-479	-0.4273 -0.7202
S-1952	2
T-1952	2 a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke .
H-1952	-1.8365074396133423	<unk> <unk>
D-1952	-1.8365074396133423	<unk> <unk>
P-1952	-4.4022 -0.8758 -0.2316
S-480	(
T-480	4 ) Do not take ADROVANCE at bedtime or before getting up for the day .
H-480	-0.5737650990486145	(
D-480	-0.5737650990486145	(
P-480	-0.4273 -0.7202
S-502	Die
T-502	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-502	-1.4511396884918213	<unk> <unk>
D-502	-1.4511396884918213	<unk> <unk>
P-502	-3.1749 -0.7352 -0.4433
S-501	Das
T-501	The expiry date refers to the last day of that month .
H-501	-1.236171007156372	<unk> <unk>
D-501	-1.236171007156372	<unk> <unk>
P-501	-2.5925 -0.5152 -0.6008
S-471	2.
T-471	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-471	-1.7842007875442505	<unk> <unk>
D-471	-1.7842007875442505	<unk> <unk>
P-471	-4.0818 -1.0593 -0.2115
S-472	2.
T-472	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-472	-1.7842007875442505	<unk> <unk>
D-472	-1.7842007875442505	<unk> <unk>
P-472	-4.0818 -1.0593 -0.2115
S-477	Sie
T-477	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-477	-0.7251375913619995	<unk> <unk>
D-477	-0.7251375913619995	<unk> <unk>
P-477	-0.5772 -0.7412 -0.8570
S-496	Sie
T-496	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-496	-0.7251375913619995	<unk> <unk>
D-496	-0.7251375913619995	<unk> <unk>
P-496	-0.5772 -0.7412 -0.8570
S-478	(
T-478	2 ) After getting up for the day and before taking any food , drink , or other medicine , swallow your ADROVANCE tablet with a full glass of water only ( not mineral water ) ( not less than 200 ml or 7 fl . oz . ) . Do not take with mineral water ( still or sparkling ) . Do not take with coffee or tea . Do not take with juice or milk .
H-478	-0.5737650990486145	(
D-478	-0.5737650990486145	(
P-478	-0.4273 -0.7202
S-485	Das
T-485	The expiry date refers to the last day of that month .
H-485	-1.236171007156372	<unk> <unk>
D-485	-1.236171007156372	<unk> <unk>
P-485	-2.5925 -0.5152 -0.6008
S-698	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-698	Wash your hands thoroughly using soap and warm water .
H-698	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
D-698	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
P-698	-1.3634 -0.5702 -0.3972 -0.1792 -0.3920 -0.1550 -1.1888 -0.1234 -0.9527 -0.1109 -0.1297 -0.8432 -0.1694
S-874	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-874	Wash your hands thoroughly using soap and warm water .
H-874	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
D-874	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
P-874	-1.3634 -0.5702 -0.3972 -0.1792 -0.3920 -0.1550 -1.1888 -0.1234 -0.9527 -0.1109 -0.1297 -0.8432 -0.1694
S-268	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-268	Not all pack sizes may be marketed .
H-268	-0.47012776136398315	<unk> Not all sizes may be marketed .
D-268	-0.47012776136398315	<unk> Not all sizes may be marketed .
P-268	-0.9108 -0.7705 -0.1697 -0.5166 -0.1343 -0.5976 -0.6672 -0.6552 -0.0600 -0.1390 -0.5506
S-314	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-314	Most patients had relief of symptoms after stopping treatment .
H-314	-0.4194452166557312	<unk> In most patients the symptoms decreased after discontinuation of therapy .
D-314	-0.4194452166557312	<unk> In most patients the symptoms decreased after discontinuation of therapy .
P-314	-0.8944 -0.4858 -0.1216 -0.2069 -1.7209 -1.9055 -0.1302 -0.1003 -0.2872 -0.0323 -0.0250 -0.1263 -0.1529 -0.1708 -0.1574 -0.1937
S-57	Die empfohlene Dosis beträgt eine Tablette einmal wöchentlich .
T-57	The recommended dose is one tablet once a week .
H-57	-0.39682337641716003	<unk> The recommended dose is one tablet weekly .
D-57	-0.39682337641716003	<unk> The recommended dose is one tablet weekly .
P-57	-1.7596 -0.1810 -0.0621 -0.1349 -0.1334 -0.1674 -0.1600 -0.1035 -1.3155 -0.1432 -0.2045
S-547	Den vollständigen Wortlaut des EPAR für Advate finden Sie hier .
T-547	The full EPAR for Advate is available here .
H-547	-0.5561770796775818	<unk> The full EPAR for Advate is available here .
D-547	-0.5561770796775818	<unk> The full EPAR for Advate is available here .
P-547	-2.8866 -0.4605 -0.1897 -0.5135 -0.0387 -0.2043 -1.1872 -0.6892 -0.1562 -0.4409 -0.0964 -0.1605 -0.2066
S-250	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-250	Further hydroxylation occurs prior to elimination .
H-250	-0.4763331711292267	<unk> Before excretion , further hydroxylation occurs .
D-250	-0.4763331711292267	<unk> Before excretion , further hydroxylation occurs .
P-250	-1.3596 -2.7284 -0.5078 -0.0324 -0.1257 -0.8303 -0.2141 -0.0443 -0.1030 -0.1393 -0.1045 -0.5841 -0.0425 -0.1548 -0.1743
S-446	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-446	Further hydroxylation occurs prior to elimination .
H-446	-0.4763331711292267	<unk> Before excretion , further hydroxylation occurs .
D-446	-0.4763331711292267	<unk> Before excretion , further hydroxylation occurs .
P-446	-1.3596 -2.7284 -0.5078 -0.0324 -0.1257 -0.8303 -0.2141 -0.0443 -0.1030 -0.1393 -0.1045 -0.5841 -0.0425 -0.1548 -0.1743
S-464	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-464	Not all pack sizes may be marketed .
H-464	-0.47012776136398315	<unk> Not all sizes may be marketed .
D-464	-0.47012776136398315	<unk> Not all sizes may be marketed .
P-464	-0.9108 -0.7705 -0.1697 -0.5166 -0.1343 -0.5976 -0.6672 -0.6552 -0.0600 -0.1390 -0.5506
S-596	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-596	For instructions for reconstitution prior to administration , see section 6.6 .
H-596	-0.46603521704673767	<unk> Reconstitution information prior to administration see section 6.6 .
D-596	-0.46603521704673767	<unk> Reconstitution information prior to administration see section 6.6 .
P-596	-0.6396 -2.0053 -0.0324 -1.1773 -0.4645 -0.1226 -0.1106 -0.5885 -0.2301 -0.1685 -0.1840 -0.1780 -0.1571
S-525	Advate wird angewendet , um den fehlenden Faktor VIII zu ersetzen .
T-525	Advate is used to replace the missing factor VIII .
H-525	-0.7457455992698669	<unk> Advate is used to fill in the missing factor VIII .
D-525	-0.7457455992698669	<unk> Advate is used to fill in the missing factor VIII .
P-525	-0.9909 -3.6816 -0.1277 -0.1822 -0.0986 -0.1165 -2.2415 -1.4465 -0.2485 -0.6706 -0.1453 -0.7921 -0.0963 -0.1808 -0.1672
S-1050	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1050	Wash your hands thoroughly using soap and warm water .
H-1050	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
D-1050	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
P-1050	-1.3634 -0.5702 -0.3972 -0.1792 -0.3920 -0.1550 -1.1888 -0.1234 -0.9527 -0.1109 -0.1297 -0.8432 -0.1694
S-1226	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1226	Wash your hands thoroughly using soap and warm water .
H-1226	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
D-1226	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
P-1226	-1.3634 -0.5702 -0.3972 -0.1792 -0.3920 -0.1550 -1.1888 -0.1234 -0.9527 -0.1109 -0.1297 -0.8432 -0.1694
S-1402	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1402	Wash your hands thoroughly using soap and warm water .
H-1402	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
D-1402	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
P-1402	-1.3634 -0.5702 -0.3972 -0.1792 -0.3920 -0.1550 -1.1888 -0.1234 -0.9527 -0.1109 -0.1297 -0.8432 -0.1694
S-1579	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1579	Wash your hands thoroughly using soap and warm water .
H-1579	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
D-1579	-0.5057713389396667	<unk> Wash hands carefully with soap and warm water . .
P-1579	-1.3634 -0.5702 -0.3972 -0.1792 -0.3920 -0.1550 -1.1888 -0.1234 -0.9527 -0.1109 -0.1297 -0.8432 -0.1694
S-198	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-198	Supplemental vitamin D reduces these risks and their consequences .
H-198	-0.6444321274757385	<unk> A supplementation with vitamin D lowers these risks and their consequences .
D-198	-0.6444321274757385	<unk> A supplementation with vitamin D lowers these risks and their consequences .
P-198	-1.4389 -2.3699 -1.5983 -0.7911 -0.1406 -0.1660 -0.0717 -0.0882 -0.1287 -0.9856 -0.7705 -0.1613 -0.1995 -0.1465 -0.4832 -1.7139 -0.1564 -0.1894
S-211	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-211	5.0 , 5.8 % ) in the 10 mg daily group .
H-211	-0.28372931480407715	<unk> 5.0 , 5.8 % ) in the 10 mg daily group .
D-211	-0.28372931480407715	<unk> 5.0 , 5.8 % ) in the 10 mg daily group .
P-211	-1.3575 -0.1507 -0.1161 -0.1943 -0.1300 -0.1162 -0.1374 -0.1575 -0.1663 -0.1537 -0.6748 -0.0439 -0.5779 -0.2444 -0.1455 -0.1734
S-386	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-386	Supplemental vitamin D reduces these risks and their consequences .
H-386	-0.6444321274757385	<unk> A supplementation with vitamin D lowers these risks and their consequences .
D-386	-0.6444321274757385	<unk> A supplementation with vitamin D lowers these risks and their consequences .
P-386	-1.4389 -2.3699 -1.5983 -0.7911 -0.1406 -0.1660 -0.0717 -0.0882 -0.1287 -0.9856 -0.7705 -0.1613 -0.1995 -0.1465 -0.4832 -1.7139 -0.1564 -0.1894
S-407	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-407	5.0 , 5.8 % ) in the 10 mg daily group .
H-407	-0.28372931480407715	<unk> 5.0 , 5.8 % ) in the 10 mg daily group .
D-407	-0.28372931480407715	<unk> 5.0 , 5.8 % ) in the 10 mg daily group .
P-407	-1.3575 -0.1507 -0.1161 -0.1943 -0.1300 -0.1162 -0.1374 -0.1575 -0.1663 -0.1537 -0.6748 -0.0439 -0.5779 -0.2444 -0.1455 -0.1734
S-126	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-126	Most patients had relief of symptoms after stopping treatment .
H-126	-0.4194452166557312	<unk> In most patients the symptoms decreased after discontinuation of therapy .
D-126	-0.4194452166557312	<unk> In most patients the symptoms decreased after discontinuation of therapy .
P-126	-0.8944 -0.4858 -0.1216 -0.2069 -1.7209 -1.9055 -0.1302 -0.1003 -0.2872 -0.0323 -0.0250 -0.1263 -0.1529 -0.1708 -0.1574 -0.1937
S-1125	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1125	The product contains traces of mouse and hamster proteins .
H-1125	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
D-1125	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
P-1125	-0.7139 -1.0280 -0.1935 -0.0769 -0.4505 -0.1200 -0.1379 -0.2151 -0.0878 -0.1470 -0.9050 -0.0808 -0.1521 -0.0422 -0.1424 -0.1909
S-773	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-773	The product contains traces of mouse and hamster proteins .
H-773	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
D-773	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
P-773	-0.7139 -1.0280 -0.1935 -0.0769 -0.4505 -0.1200 -0.1379 -0.2151 -0.0878 -0.1470 -0.9050 -0.0808 -0.1521 -0.0422 -0.1424 -0.1909
S-1301	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1301	The product contains traces of mouse and hamster proteins .
H-1301	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
D-1301	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
P-1301	-0.7139 -1.0280 -0.1935 -0.0769 -0.4505 -0.1200 -0.1379 -0.2151 -0.0878 -0.1470 -0.9050 -0.0808 -0.1521 -0.0422 -0.1424 -0.1909
S-1477	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1477	The product contains traces of mouse and hamster proteins .
H-1477	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
D-1477	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
P-1477	-0.7139 -1.0280 -0.1935 -0.0769 -0.4505 -0.1200 -0.1379 -0.2151 -0.0878 -0.1470 -0.9050 -0.0808 -0.1521 -0.0422 -0.1424 -0.1909
S-1614	Zusammenfassung der Merkmale des Arzneimittels , Abschnitt 4.2 ) .
T-1614	Summary of Product Characteristics , section 4.2 )
H-1614	-0.17931514978408813	<unk> Summary of Product Characteristics , Section 4.2 ) .
D-1614	-0.17931514978408813	<unk> Summary of Product Characteristics , Section 4.2 ) .
P-1614	-0.9140 -0.1057 -0.0546 -0.1492 -0.0697 -0.0175 -0.0471 -0.0241 -0.2126 -0.1016 -0.1719 -0.5121 -0.0514 -0.1470 -0.1412 -0.1423 -0.2069 -0.1589
S-949	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-949	The product contains traces of mouse and hamster proteins .
H-949	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
D-949	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
P-949	-0.7139 -1.0280 -0.1935 -0.0769 -0.4505 -0.1200 -0.1379 -0.2151 -0.0878 -0.1470 -0.9050 -0.0808 -0.1521 -0.0422 -0.1424 -0.1909
S-102	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-102	Therefore no dosage adjustment is necessary for the elderly .
H-102	-0.42135611176490784	<unk> Therefore , in elderly patients dose adjustment is not necessary .
D-102	-0.42135611176490784	<unk> Therefore , in elderly patients dose adjustment is not necessary .
P-102	-1.4923 -0.3850 -0.0564 -0.3211 -1.5669 -0.2425 -0.2197 -0.9624 -0.0673 -0.0768 -0.1179 -0.1338 -0.6344 -0.1241 -0.1771 -0.1639
S-599	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-599	The product contains traces of mouse and hamster proteins .
H-599	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
D-599	-0.2927590012550354	<unk> This product contains traces of mouse and hamster proteins .
P-599	-0.7139 -1.0280 -0.1935 -0.0769 -0.4505 -0.1200 -0.1379 -0.2151 -0.0878 -0.1470 -0.9050 -0.0808 -0.1521 -0.0422 -0.1424 -0.1909
S-431	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-431	Protein binding in human plasma is approximately 78 % .
H-431	-0.22224414348602295	<unk> protein binding in human plasma is approximately 78 <unk>
D-431	-0.22224414348602295	<unk> protein binding in human plasma is approximately 78 <unk>
P-431	-0.6560 -0.0984 -0.0226 -0.0941 -0.2513 -0.5310 -0.1858 -0.0601 -0.0805 -0.1574 -0.0516 -0.1002 -0.1485 -0.6738
S-235	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-235	Protein binding in human plasma is approximately 78 % .
H-235	-0.22224414348602295	<unk> protein binding in human plasma is approximately 78 <unk>
D-235	-0.22224414348602295	<unk> protein binding in human plasma is approximately 78 <unk>
P-235	-0.6560 -0.0984 -0.0226 -0.0941 -0.2513 -0.5310 -0.1858 -0.0601 -0.0805 -0.1574 -0.0516 -0.1002 -0.1485 -0.6738
S-1917	Welchen Nutzen hat Aerinaze in diesen Studien gezeigt ?
T-1917	What benefit has Aerinaze shown during the studies ?
H-1917	-0.4392006993293762	<unk> What benefit has Aerinaze shown in these trials ?
D-1917	-0.4392006993293762	<unk> What benefit has Aerinaze shown in these trials ?
P-1917	-1.5743 -0.1490 -0.1004 -0.6504 -0.1350 -0.1172 -0.1287 -0.1327 -0.1523 -0.0250 -0.4114 -0.1626 -1.1595 -0.6986 -0.9908
S-74	Welchen Nutzen hat ADROVANCE in diesen Studien gezeigt ?
T-74	What benefit has ADROVANCE shown during the studies ?
H-74	-0.4813084006309509	<unk> What benefit has ADROVANCE shown in these studies ? <unk>
D-74	-0.4813084006309509	<unk> What benefit has ADROVANCE shown in these studies ? <unk>
P-74	-1.5153 -0.1373 -0.1262 -0.6933 -0.0351 -0.1102 -0.1504 -0.1069 -0.8693 -0.0438 -0.4378 -0.1344 -1.2011 -0.7397 -1.1996 -0.2006
S-1722	- Wenn Sie weitere Fragen haben , wenden Sie sich an Ihren Arzt .
T-1722	- If you have any further questions , ask your doctor .
H-1722	-0.7218853235244751	<unk> If you have any further questions , contact your doctor .
D-1722	-0.7218853235244751	<unk> If you have any further questions , contact your doctor .
P-1722	-1.3959 -0.2582 -0.1629 -0.2616 -0.1269 -0.3764 -4.1437 -0.5668 -1.0321 -0.1427 -0.1445 -0.1868 -0.5860
S-30	Der Harnsäurespiegel im Blut wurde jeden Monat bestimmt .
T-30	Blood uric acid levels were measured every month .
H-30	-0.6327257752418518	<unk> uric acid levels in the blood were determined each month .
D-30	-0.6327257752418518	<unk> uric acid levels in the blood were determined each month .
P-30	-0.8836 -2.5776 -0.0776 -0.1405 -0.6483 -0.6614 -0.9361 -0.0914 -0.1796 -0.9378 -1.2381 -0.1381 -0.1572 -0.1909
S-1315	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1315	4.5 Interaction with other medicinal products and other forms of interaction
H-1315	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
D-1315	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
P-1315	-1.2911 -0.1363 -0.8924 -0.4014 -0.2686 -0.3293 -0.1738 -0.2780 -0.0352 -0.1359 -1.2072 -0.1203 -0.1014 -0.1501
S-1828	Polska Baxter Poland Sp. z o.o. ul .
T-1828	Polska Baxter Poland Sp . z o. o. ul .
H-1828	-0.6495059132575989	<unk> Polska Baxter Poland Sp. z o.o. ul .
D-1828	-0.6495059132575989	<unk> Polska Baxter Poland Sp. z o.o. ul .
P-1828	-1.0839 -0.5893 -0.1006 -1.0589 -0.1412 -0.2182 -1.7757 -0.1231 -0.1318 -0.8881 -0.1550 -0.3748 -0.0552 -3.4024 -0.1405 -0.1535
S-11	Sie kann mit oder unabhängig von den Mahlzeiten eingenommen werden .
T-11	It can be taken with or without food .
H-11	-0.5413764715194702	<unk> It can be taken with or without meals .
D-11	-0.5413764715194702	<unk> It can be taken with or without meals .
P-11	-0.8817 -1.6692 -0.3683 -0.1682 -0.2341 -0.2193 -0.1042 -1.1550 -0.7969 -0.1414 -0.2170
S-1259	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1259	For a full list of excipients , see section 6.1 .
H-1259	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
D-1259	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
P-1259	-1.7657 -0.1408 -0.1342 -0.1535 -0.0779 -0.1414 -0.5862 -0.0162 -0.1233 -0.0746 -1.0384 -0.1049 -0.2784 -0.1639 -0.1440 -0.1788 -0.1614
S-1139	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1139	4.5 Interaction with other medicinal products and other forms of interaction
H-1139	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
D-1139	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
P-1139	-1.2911 -0.1363 -0.8924 -0.4014 -0.2686 -0.3293 -0.1738 -0.2780 -0.0352 -0.1359 -1.2072 -0.1203 -0.1014 -0.1501
S-1726	- Wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder Sie
T-1726	- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
H-1726	-0.49860045313835144	<unk> If any of the listed side effects significantly affects you or you
D-1726	-0.49860045313835144	<unk> If any of the listed side effects significantly affects you or you
P-1726	-1.8746 -0.1933 -0.3061 -0.1370 -0.1596 -0.3586 -1.1349 -0.0639 -0.4225 -1.1069 -0.1407 -0.3883 -0.5006 -0.1935
S-286	Die Äquivalenz der Einnahme von 5.600 I.E.
T-286	ADROVANCE should not be taken at bedtime or before arising for the day .
H-286	-0.518241822719574	<unk> The equivalent of taking 5.600 IU
D-286	-0.518241822719574	<unk> The equivalent of taking 5.600 IU
P-286	-1.0794 -0.3943 -0.5126 -0.1715 -0.5687 -1.9346 -0.1109 -0.1208 -0.0785 -0.2110
S-1796	Im Kühlschrank lagern ( 2<unk> C-8<unk> C ) .
T-1796	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1796	-0.5780608654022217	<unk> Refrigerate ( 2<unk> C-8<unk> C ) .
D-1796	-0.5780608654022217	<unk> Refrigerate ( 2<unk> C-8<unk> C ) .
P-1796	-2.1394 -5.3302 -0.0921 -0.0586 -0.0871 -0.1038 -0.2105 -0.1226 -0.1715 -0.1341 -0.1107 -0.1198 -0.1113 -0.1528 -0.1493 -0.1553
S-1491	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1491	4.5 Interaction with other medicinal products and other forms of interaction
H-1491	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
D-1491	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
P-1491	-1.2911 -0.1363 -0.8924 -0.4014 -0.2686 -0.3293 -0.1738 -0.2780 -0.0352 -0.1359 -1.2072 -0.1203 -0.1014 -0.1501
S-1435	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1435	For a full list of excipients , see section 6.1 .
H-1435	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
D-1435	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
P-1435	-1.7657 -0.1408 -0.1342 -0.1535 -0.0779 -0.1414 -0.5862 -0.0162 -0.1233 -0.0746 -1.0384 -0.1049 -0.2784 -0.1639 -0.1440 -0.1788 -0.1614
S-290	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-290	Therefore no dosage adjustment is necessary for the elderly .
H-290	-0.42135611176490784	<unk> Therefore , in elderly patients dose adjustment is not necessary .
D-290	-0.42135611176490784	<unk> Therefore , in elderly patients dose adjustment is not necessary .
P-290	-1.4923 -0.3850 -0.0564 -0.3211 -1.5669 -0.2425 -0.2197 -0.9624 -0.0673 -0.0768 -0.1179 -0.1338 -0.6344 -0.1241 -0.1771 -0.1639
S-907	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-907	For a full list of excipients , see section 6.1 .
H-907	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
D-907	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
P-907	-1.7657 -0.1408 -0.1342 -0.1535 -0.0779 -0.1414 -0.5862 -0.0162 -0.1233 -0.0746 -1.0384 -0.1049 -0.2784 -0.1639 -0.1440 -0.1788 -0.1614
S-556	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-556	For a full list of excipients , see section 6.1 .
H-556	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
D-556	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
P-556	-1.7657 -0.1408 -0.1342 -0.1535 -0.0779 -0.1414 -0.5862 -0.0162 -0.1233 -0.0746 -1.0384 -0.1049 -0.2784 -0.1639 -0.1440 -0.1788 -0.1614
S-1083	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1083	For a full list of excipients , see section 6.1 .
H-1083	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
D-1083	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
P-1083	-1.7657 -0.1408 -0.1342 -0.1535 -0.0779 -0.1414 -0.5862 -0.0162 -0.1233 -0.0746 -1.0384 -0.1049 -0.2784 -0.1639 -0.1440 -0.1788 -0.1614
S-963	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-963	4.5 Interaction with other medicinal products and other forms of interaction
H-963	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
D-963	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
P-963	-1.2911 -0.1363 -0.8924 -0.4014 -0.2686 -0.3293 -0.1738 -0.2780 -0.0352 -0.1359 -1.2072 -0.1203 -0.1014 -0.1501
S-787	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-787	4.5 Interaction with other medicinal products and other forms of interaction
H-787	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
D-787	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
P-787	-1.2911 -0.1363 -0.8924 -0.4014 -0.2686 -0.3293 -0.1738 -0.2780 -0.0352 -0.1359 -1.2072 -0.1203 -0.1014 -0.1501
S-731	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-731	For a full list of excipients , see section 6.1 .
H-731	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
D-731	-0.31079214811325073	<unk> For a full list of excipients , see section 6.1 .
P-731	-1.7657 -0.1408 -0.1342 -0.1535 -0.0779 -0.1414 -0.5862 -0.0162 -0.1233 -0.0746 -1.0384 -0.1049 -0.2784 -0.1639 -0.1440 -0.1788 -0.1614
S-613	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-613	4.5 Interaction with other medicinal products and other forms of interaction
H-613	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
D-613	-0.39436835050582886	4.5 Interactions with other medicinal products and other interactions
P-613	-1.2911 -0.1363 -0.8924 -0.4014 -0.2686 -0.3293 -0.1738 -0.2780 -0.0352 -0.1359 -1.2072 -0.1203 -0.1014 -0.1501
S-352	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-352	No additional adverse reactions have been identified for ADROVANCE .
H-352	-0.5389800667762756	<unk> No further adverse reactions were detected for ADROVANCE .
D-352	-0.5389800667762756	<unk> No further adverse reactions were detected for ADROVANCE .
P-352	-0.7998 -1.5150 -1.3083 -1.3109 -0.0560 -0.2698 -0.1129 -0.1149 -2.1682 -0.0659 -0.1784 -0.3239 -0.1205 -0.1658 -0.1024 -0.7460 -0.1813 -0.1615
S-856	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-856	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-856	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
D-856	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
P-856	-2.0906 -0.0712 -0.2844 -0.2568 -0.1080 -0.5524 -0.2024 -0.1861 -0.1369 -0.0246 -0.0669 -0.1241 -0.2266 -0.1540
S-164	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-164	No additional adverse reactions have been identified for ADROVANCE .
H-164	-0.5389800667762756	<unk> No further adverse reactions were detected for ADROVANCE .
D-164	-0.5389800667762756	<unk> No further adverse reactions were detected for ADROVANCE .
P-164	-0.7998 -1.5150 -1.3083 -1.3109 -0.0560 -0.2698 -0.1129 -0.1149 -2.1682 -0.0659 -0.1784 -0.3239 -0.1205 -0.1658 -0.1024 -0.7460 -0.1813 -0.1615
S-680	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-680	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-680	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
D-680	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
P-680	-2.0906 -0.0712 -0.2844 -0.2568 -0.1080 -0.5524 -0.2024 -0.1861 -0.1369 -0.0246 -0.0669 -0.1241 -0.2266 -0.1540
S-1806	Jede Pulver-Durchstechflasche enthält 250 I.E.
T-1806	Each powder vial contains 250 IU octocog alfa .
H-1806	-0.3945850431919098	<unk> Each vial contains 250 IU .
D-1806	-0.3945850431919098	<unk> Each vial contains 250 IU .
P-1806	-1.4901 -0.2006 -0.9229 -0.0538 -0.1203 -0.1225 -0.1055 -0.0845 -0.6674 -0.1783
S-1032	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1032	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1032	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
D-1032	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
P-1032	-2.0906 -0.0712 -0.2844 -0.2568 -0.1080 -0.5524 -0.2024 -0.1861 -0.1369 -0.0246 -0.0669 -0.1241 -0.2266 -0.1540
S-1208	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1208	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1208	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
D-1208	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
P-1208	-2.0906 -0.0712 -0.2844 -0.2568 -0.1080 -0.5524 -0.2024 -0.1861 -0.1369 -0.0246 -0.0669 -0.1241 -0.2266 -0.1540
S-1384	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1384	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1384	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
D-1384	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
P-1384	-2.0906 -0.0712 -0.2844 -0.2568 -0.1080 -0.5524 -0.2024 -0.1861 -0.1369 -0.0246 -0.0669 -0.1241 -0.2266 -0.1540
S-1561	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1561	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1561	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
D-1561	-0.32034748792648315	<unk> C 8 <unk> C ) in a refrigerator .
P-1561	-2.0906 -0.0712 -0.2844 -0.2568 -0.1080 -0.5524 -0.2024 -0.1861 -0.1369 -0.0246 -0.0669 -0.1241 -0.2266 -0.1540
S-1657	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen .
T-1657	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen . Read the package leaflet before use .
H-1657	-0.7358999252319336	<unk> Only for single-use Read leaflet before use .
D-1657	-0.7358999252319336	<unk> Only for single-use Read leaflet before use .
P-1657	-0.5117 -1.6241 -0.5693 -2.7973 -0.2250 -0.1039 -0.1685 -0.7766 -1.8298 -0.0291 -0.1409 -1.6620 -0.2483 -0.1900 -0.1619
S-1974	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1974	4.5 Interaction with other medicinal products and other forms of interaction
H-1974	-0.33462467789649963	4.5 Interactions with other medicinal products and other interactions
D-1974	-0.33462467789649963	4.5 Interactions with other medicinal products and other interactions
P-1974	-1.1168 -0.1521 -0.0513 -0.3841 -0.2182 -0.3654 -0.1861 -0.4260 -0.0358 -0.1343 -1.2396 -0.1244 -0.0990 -0.1515
S-331	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-331	4.5 Interaction with other medicinal products and other forms of interaction
H-331	-0.33462467789649963	4.5 Interactions with other medicinal products and other interactions
D-331	-0.33462467789649963	4.5 Interactions with other medicinal products and other interactions
P-331	-1.1168 -0.1521 -0.0513 -0.3841 -0.2182 -0.3654 -0.1861 -0.4260 -0.0358 -0.1343 -1.2396 -0.1244 -0.0990 -0.1515
S-1787	Häufige Nebenwirkungen Schwindel , Kopfschmerzen und Fieber
T-1787	Common side effects dizziness , headache and fever .
H-1787	-0.2577032744884491	<unk> Common side effects dizziness , headache and fever
D-1787	-0.2577032744884491	<unk> Common side effects dizziness , headache and fever
P-1787	-1.8012 -0.2288 -0.1398 -0.3995 -0.0763 -0.5606 -0.0249 -0.0637 -0.1648 -0.1137 -0.0418 -0.0746 -0.1444 -0.0614 -0.0599 -0.1680
S-1577	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1577	shows any sign of deterioration .
H-1577	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
D-1577	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
P-1577	-1.8100 -1.1751 -0.0993 -0.2446 -1.7000 -0.1673 -1.0408 -0.1707 -0.1438 -1.2152 -0.0619 -0.1670 -0.1508
S-1224	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1224	shows any sign of deterioration .
H-1224	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
D-1224	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
P-1224	-1.8100 -1.1751 -0.0993 -0.2446 -1.7000 -0.1673 -1.0408 -0.1707 -0.1438 -1.2152 -0.0619 -0.1670 -0.1508
S-1093	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1093	The dose is determined using the following formula :
H-1093	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
D-1093	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
P-1093	-2.6416 -0.2391 -1.6115 -0.0591 -0.2222 -1.9382 -0.1174 -1.1869 -0.1566 -0.2735 -0.3500 -0.2225 -0.1700
S-917	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-917	The dose is determined using the following formula :
H-917	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
D-917	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
P-917	-2.6416 -0.2391 -1.6115 -0.0591 -0.2222 -1.9382 -0.1174 -1.1869 -0.1566 -0.2735 -0.3500 -0.2225 -0.1700
S-741	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-741	The dose is determined using the following formula :
H-741	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
D-741	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
P-741	-2.6416 -0.2391 -1.6115 -0.0591 -0.2222 -1.9382 -0.1174 -1.1869 -0.1566 -0.2735 -0.3500 -0.2225 -0.1700
S-1445	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1445	The dose is determined using the following formula :
H-1445	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
D-1445	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
P-1445	-2.6416 -0.2391 -1.6115 -0.0591 -0.2222 -1.9382 -0.1174 -1.1869 -0.1566 -0.2735 -0.3500 -0.2225 -0.1700
S-1400	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1400	shows any sign of deterioration .
H-1400	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
D-1400	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
P-1400	-1.8100 -1.1751 -0.0993 -0.2446 -1.7000 -0.1673 -1.0408 -0.1707 -0.1438 -1.2152 -0.0619 -0.1670 -0.1508
S-1269	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1269	The dose is determined using the following formula :
H-1269	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
D-1269	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
P-1269	-2.6416 -0.2391 -1.6115 -0.0591 -0.2222 -1.9382 -0.1174 -1.1869 -0.1566 -0.2735 -0.3500 -0.2225 -0.1700
S-1048	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1048	shows any sign of deterioration .
H-1048	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
D-1048	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
P-1048	-1.8100 -1.1751 -0.0993 -0.2446 -1.7000 -0.1673 -1.0408 -0.1707 -0.1438 -1.2152 -0.0619 -0.1670 -0.1508
S-872	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-872	shows any sign of deterioration .
H-872	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
D-872	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
P-872	-1.8100 -1.1751 -0.0993 -0.2446 -1.7000 -0.1673 -1.0408 -0.1707 -0.1438 -1.2152 -0.0619 -0.1670 -0.1508
S-696	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-696	shows any sign of deterioration .
H-696	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
D-696	-0.6266438364982605	its packaging is damaged or shows signs of manipulation .
P-696	-1.8100 -1.1751 -0.0993 -0.2446 -1.7000 -0.1673 -1.0408 -0.1707 -0.1438 -1.2152 -0.0619 -0.1670 -0.1508
S-567	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-567	The dose is determined using the following formula :
H-567	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
D-567	-0.7068134546279907	<unk> The required dose is calculated using the following formula :
P-567	-2.6416 -0.2391 -1.6115 -0.0591 -0.2222 -1.9382 -0.1174 -1.1869 -0.1566 -0.2735 -0.3500 -0.2225 -0.1700
S-143	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-143	4.5 Interaction with other medicinal products and other forms of interaction
H-143	-0.33462467789649963	4.5 Interactions with other medicinal products and other interactions
D-143	-0.33462467789649963	4.5 Interactions with other medicinal products and other interactions
P-143	-1.1168 -0.1521 -0.0513 -0.3841 -0.2182 -0.3654 -0.1861 -0.4260 -0.0358 -0.1343 -1.2396 -0.1244 -0.0990 -0.1515
S-723	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-723	02 March 2004 Date of last renewal :
H-723	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
D-723	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
P-723	-1.5118 -0.3825 -2.0428 -1.5366 -0.1543 -0.1043 -0.1282 -0.0998 -1.5030 -0.1495 -0.4045 -0.1606
S-382	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-382	Vitamin D3 is required for normal bone formation .
H-382	-0.39757078886032104	<unk> Vitamin D3 is necessary for normal bone formation .
D-382	-0.39757078886032104	<unk> Vitamin D3 is necessary for normal bone formation .
P-382	-1.1299 -2.2282 -0.0838 -0.1999 -0.1316 -0.1158 -0.5122 -0.1515 -0.0672 -0.1200 -0.0711 -0.1461 -0.2112
S-1766	Dies ist besonders bei größeren , chirurgischen Eingriffen wichtig .
T-1766	This is particularly important if you are having major surgery .
H-1766	-0.5499989986419678	<unk> This is especially important for major surgery .
D-1766	-0.5499989986419678	<unk> This is especially important for major surgery .
P-1766	-1.6765 -0.4604 -0.1365 -0.1335 -0.0968 -0.4326 -1.3068 -0.3806 -0.5591 -0.3172
S-1795	Das Verfalldatum bezieht sich auf den letzten Tag des Monats .
T-1795	The expiry date refers to the last day of that month .
H-1795	-0.2873684763908386	<unk> The expiry date refers to the last day of the month .
D-1795	-0.2873684763908386	<unk> The expiry date refers to the last day of the month .
P-1795	-1.5774 -0.3267 -0.0292 -0.0431 -0.2406 -0.0794 -0.0876 -0.1152 -0.1399 -0.0865 -0.1186 -0.1460 -1.0584 -0.2174 -0.1541 -0.1778
S-1728	Was ist ADVATE und wofür wird es angewendet ?
T-1728	What ADVATE is and what it is used for 2.
H-1728	-0.37665292620658875	<unk> What ADVATE is and what it is used for ?
D-1728	-0.37665292620658875	<unk> What ADVATE is and what it is used for ?
P-1728	-1.4412 -0.1932 -0.6587 -0.2016 -0.0899 -0.1058 -0.1079 -0.1436 -0.1254 -0.1529 -0.1161 -0.1089 -0.3726 -1.5461 -0.2859
S-31	Welchen Nutzen hat Adenuric in diesen Studien gezeigt ?
T-31	What benefit has Adenuric shown during the studies ?
H-31	-0.47605210542678833	<unk> What benefit has Adenuric shown in these trials ?
D-31	-0.47605210542678833	<unk> What benefit has Adenuric shown in these trials ?
P-31	-1.6364 -0.1156 -0.0779 -0.9911 -0.1081 -0.1946 -0.1053 -0.1101 -0.0239 -0.3777 -0.1308 -1.1167 -0.7073 -0.9693
S-1075	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1075	02 March 2004 Date of last renewal :
H-1075	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
D-1075	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
P-1075	-1.5118 -0.3825 -2.0428 -1.5366 -0.1543 -0.1043 -0.1282 -0.0998 -1.5030 -0.1495 -0.4045 -0.1606
S-899	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-899	02 March 2004 Date of last renewal :
H-899	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
D-899	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
P-899	-1.5118 -0.3825 -2.0428 -1.5366 -0.1543 -0.1043 -0.1282 -0.0998 -1.5030 -0.1495 -0.4045 -0.1606
S-194	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-194	Vitamin D3 is required for normal bone formation .
H-194	-0.39757078886032104	<unk> Vitamin D3 is necessary for normal bone formation .
D-194	-0.39757078886032104	<unk> Vitamin D3 is necessary for normal bone formation .
P-194	-1.1299 -2.2282 -0.0838 -0.1999 -0.1316 -0.1158 -0.5122 -0.1515 -0.0672 -0.1200 -0.0711 -0.1461 -0.2112
S-1604	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1604	02 March 2004 Date of last renewal :
H-1604	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
D-1604	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
P-1604	-1.5118 -0.3825 -2.0428 -1.5366 -0.1543 -0.1043 -0.1282 -0.0998 -1.5030 -0.1495 -0.4045 -0.1606
S-1427	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1427	02 March 2004 Date of last renewal :
H-1427	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
D-1427	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
P-1427	-1.5118 -0.3825 -2.0428 -1.5366 -0.1543 -0.1043 -0.1282 -0.0998 -1.5030 -0.1495 -0.4045 -0.1606
S-1251	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1251	02 March 2004 Date of last renewal :
H-1251	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
D-1251	-0.6814984679222107	<unk> 02 March 2004 Date of last renewal :
P-1251	-1.5118 -0.3825 -2.0428 -1.5366 -0.1543 -0.1043 -0.1282 -0.0998 -1.5030 -0.1495 -0.4045 -0.1606
S-1564	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1564	The product may not be returned to refrigerated storage again .
H-1564	-0.6286421418190002	<unk> The product should not be stored refrigerated .
D-1564	-0.6286421418190002	<unk> The product should not be stored refrigerated .
P-1564	-2.4645 -0.7302 -0.1525 -1.0567 -0.1137 -0.1599 -0.5736 -0.1307 -2.6914 -0.1926 -0.0763 -0.1491 -0.1400 -0.1698
S-1387	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1387	The product may not be returned to refrigerated storage again .
H-1387	-0.6286421418190002	<unk> The product should not be stored refrigerated .
D-1387	-0.6286421418190002	<unk> The product should not be stored refrigerated .
P-1387	-2.4645 -0.7302 -0.1525 -1.0567 -0.1137 -0.1599 -0.5736 -0.1307 -2.6914 -0.1926 -0.0763 -0.1491 -0.1400 -0.1698
S-1211	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1211	The product may not be returned to refrigerated storage again .
H-1211	-0.6286421418190002	<unk> The product should not be stored refrigerated .
D-1211	-0.6286421418190002	<unk> The product should not be stored refrigerated .
P-1211	-2.4645 -0.7302 -0.1525 -1.0567 -0.1137 -0.1599 -0.5736 -0.1307 -2.6914 -0.1926 -0.0763 -0.1491 -0.1400 -0.1698
S-1035	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1035	The product may not be returned to refrigerated storage again .
H-1035	-0.6286421418190002	<unk> The product should not be stored refrigerated .
D-1035	-0.6286421418190002	<unk> The product should not be stored refrigerated .
P-1035	-2.4645 -0.7302 -0.1525 -1.0567 -0.1137 -0.1599 -0.5736 -0.1307 -2.6914 -0.1926 -0.0763 -0.1491 -0.1400 -0.1698
S-859	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-859	The product may not be returned to refrigerated storage again .
H-859	-0.6286421418190002	<unk> The product should not be stored refrigerated .
D-859	-0.6286421418190002	<unk> The product should not be stored refrigerated .
P-859	-2.4645 -0.7302 -0.1525 -1.0567 -0.1137 -0.1599 -0.5736 -0.1307 -2.6914 -0.1926 -0.0763 -0.1491 -0.1400 -0.1698
S-683	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-683	The product may not be returned to refrigerated storage again .
H-683	-0.6286421418190002	<unk> The product should not be stored refrigerated .
D-683	-0.6286421418190002	<unk> The product should not be stored refrigerated .
P-683	-2.4645 -0.7302 -0.1525 -1.0567 -0.1137 -0.1599 -0.5736 -0.1307 -2.6914 -0.1926 -0.0763 -0.1491 -0.1400 -0.1698
S-808	Erkrankungen der Haut und des Unterhautzellgewebes
T-808	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-808	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
D-808	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
P-808	-0.4007 -3.7406 -0.2822 -0.2450 -0.1803 -0.1655 -0.0973 -0.1323 -0.9802 -0.0265 -0.0889 -0.0876 -0.1194 -0.3763 -0.4143
S-1775	Fragen Sie Ihren Arzt , wenn Sie nicht ganz sicher sind .
T-1775	You should check with your doctor if you are not sure .
H-1775	-0.3840293288230896	<unk> Ask your doctor if you are not sure .
D-1775	-0.3840293288230896	<unk> Ask your doctor if you are not sure .
P-1775	-1.6034 -0.1033 -0.0966 -0.1233 -0.1345 -0.1251 -0.1178 -0.3158 -0.8244 -0.8312 -0.1486 -0.1844
S-62	Weitere Informationen sind der Packungsbeilage zu entnehmen .
T-62	For more information , see the Package Leaflet .
H-62	-0.5410325527191162	<unk> For more information see the Package Leaflet .
D-62	-0.5410325527191162	<unk> For more information see the Package Leaflet .
P-62	-2.3058 -1.5059 -1.4880 -0.0914 -0.5801 -0.1959 -0.1377 -0.1177 -0.1460 -0.0313 -0.0728 -0.1862 -0.1746
S-1944	Die Einnahme kann unabhängig von den Mahlzeiten erfolgen .
T-1944	The tablet may be taken with or without food .
H-1944	-0.7870093584060669	<unk> You can take it independent of meals .
D-1944	-0.7870093584060669	<unk> You can take it independent of meals .
P-1944	-0.6217 -3.7224 -0.4434 -0.1163 -0.3011 -1.3126 -0.9323 -0.0771 -0.1333 -0.2100
S-1899	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-1899	The medicine can only be obtained with a prescription .
H-1899	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
D-1899	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
P-1899	-1.1845 -1.7535 -0.6652 -0.0949 -0.0476 -1.5435 -0.0307 -0.1179 -0.0090 -0.1759 -0.1999 -0.0263 -0.1560 -0.2065
S-516	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-516	The medicine can only be obtained with a prescription .
H-516	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
D-516	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
P-516	-1.1845 -1.7535 -0.6652 -0.0949 -0.0476 -1.5435 -0.0307 -0.1179 -0.0090 -0.1759 -0.1999 -0.0263 -0.1560 -0.2065
S-1514	Hämatokritabfall Auffällige Laborwerte
T-1514	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1514	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
D-1514	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
P-1514	-0.3310 -2.1788 -0.0634 -0.0765 -0.1251 -0.7860 -0.8148 -1.1619 -1.0455 -0.4037 -0.0533 -0.6512 -0.1653
S-634	Positiver Test auf Antikörper gegen Faktor VIII
T-634	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-634	-0.441080242395401	<unk> Positive test for antibodies to factor VIII
D-634	-0.441080242395401	<unk> Positive test for antibodies to factor VIII
P-634	-0.2680 -2.4292 -0.1186 -0.4568 -1.1832 -0.0363 -0.0421 -0.2322 -0.1154 -0.1513 -0.0975 -0.1624
S-9	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-9	The medicine can only be obtained with a prescription .
H-9	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
D-9	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
P-9	-1.1845 -1.7535 -0.6652 -0.0949 -0.0476 -1.5435 -0.0307 -0.1179 -0.0090 -0.1759 -0.1999 -0.0263 -0.1560 -0.2065
S-809	Hämatokritabfall Auffällige Laborwerte
T-809	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-809	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
D-809	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
P-809	-0.3310 -2.1788 -0.0634 -0.0765 -0.1251 -0.7860 -0.8148 -1.1619 -1.0455 -0.4037 -0.0533 -0.6512 -0.1653
S-1159	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1159	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1159	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
D-1159	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
P-1159	-1.0096 -0.1881 -0.0602 -0.0824 -0.0642 -0.0694 -0.0675 -0.0953 -0.0650 -0.1548
S-1161	Hämatokritabfall Auffällige Laborwerte
T-1161	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1161	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
D-1161	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
P-1161	-0.3310 -2.1788 -0.0634 -0.0765 -0.1251 -0.7860 -0.8148 -1.1619 -1.0455 -0.4037 -0.0533 -0.6512 -0.1653
S-1337	Hämatokritabfall Auffällige Laborwerte
T-1337	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1337	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
D-1337	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
P-1337	-0.3310 -2.1788 -0.0634 -0.0765 -0.1251 -0.7860 -0.8148 -1.1619 -1.0455 -0.4037 -0.0533 -0.6512 -0.1653
S-1512	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1512	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1512	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
D-1512	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
P-1512	-1.0096 -0.1881 -0.0602 -0.0824 -0.0642 -0.0694 -0.0675 -0.0953 -0.0650 -0.1548
S-985	Hämatokritabfall Auffällige Laborwerte
T-985	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-985	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
D-985	-0.6043402552604675	<unk> Haematocrit Abnormal laboratory values
P-985	-0.3310 -2.1788 -0.0634 -0.0765 -0.1251 -0.7860 -0.8148 -1.1619 -1.0455 -0.4037 -0.0533 -0.6512 -0.1653
S-984	Erkrankungen der Haut und des Unterhautzellgewebes
T-984	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-984	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
D-984	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
P-984	-0.4007 -3.7406 -0.2822 -0.2450 -0.1803 -0.1655 -0.0973 -0.1323 -0.9802 -0.0265 -0.0889 -0.0876 -0.1194 -0.3763 -0.4143
S-1335	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1335	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1335	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
D-1335	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
P-1335	-1.0096 -0.1881 -0.0602 -0.0824 -0.0642 -0.0694 -0.0675 -0.0953 -0.0650 -0.1548
S-1160	Erkrankungen der Haut und des Unterhautzellgewebes
T-1160	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1160	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
D-1160	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
P-1160	-0.4007 -3.7406 -0.2822 -0.2450 -0.1803 -0.1655 -0.0973 -0.1323 -0.9802 -0.0265 -0.0889 -0.0876 -0.1194 -0.3763 -0.4143
S-983	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-983	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-983	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
D-983	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
P-983	-1.0096 -0.1881 -0.0602 -0.0824 -0.0642 -0.0694 -0.0675 -0.0953 -0.0650 -0.1548
S-807	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-807	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-807	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
D-807	-0.185646191239357	<unk> Uncommon Uncommon Uncommon Uncommon
P-807	-1.0096 -0.1881 -0.0602 -0.0824 -0.0642 -0.0694 -0.0675 -0.0953 -0.0650 -0.1548
S-1513	Erkrankungen der Haut und des Unterhautzellgewebes
T-1513	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1513	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
D-1513	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
P-1513	-0.4007 -3.7406 -0.2822 -0.2450 -0.1803 -0.1655 -0.0973 -0.1323 -0.9802 -0.0265 -0.0889 -0.0876 -0.1194 -0.3763 -0.4143
S-1336	Erkrankungen der Haut und des Unterhautzellgewebes
T-1336	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1336	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
D-1336	-0.4891434609889984	<unk> Diseases of the skin and subcutaneous tissue
P-1336	-0.4007 -3.7406 -0.2822 -0.2450 -0.1803 -0.1655 -0.0973 -0.1323 -0.9802 -0.0265 -0.0889 -0.0876 -0.1194 -0.3763 -0.4143
S-56	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-56	The medicine can only be obtained with a prescription .
H-56	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
D-56	-0.4436725080013275	<unk> This medicinal product can only be obtained with a prescription .
P-56	-1.1845 -1.7535 -0.6652 -0.0949 -0.0476 -1.5435 -0.0307 -0.1179 -0.0090 -0.1759 -0.1999 -0.0263 -0.1560 -0.2065
S-980	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-980	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-980	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
D-980	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
P-980	-0.7897 -0.3396 -1.7426 -0.0901 -0.0774 -0.0131 -1.7253 -0.0105 -0.0564 -0.0606 -1.0995 -0.0448 -0.0995 -0.0417 -0.0930 -0.1616
S-1932	Tablette mit veränderter Wirkstofffreisetzung
T-1932	Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet
H-1932	-0.7696465253829956	<unk> altered drug release tablet <unk>
D-1932	-0.7696465253829956	<unk> altered drug release tablet <unk>
P-1932	-0.3897 -1.9420 -0.1514 -1.7688 -0.7577 -0.1719 -0.0802 -1.0838 -0.5813
S-804	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-804	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-804	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
D-804	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
P-804	-0.7897 -0.3396 -1.7426 -0.0901 -0.0774 -0.0131 -1.7253 -0.0105 -0.0564 -0.0606 -1.0995 -0.0448 -0.0995 -0.0417 -0.0930 -0.1616
S-1933	Tablette mit veränderter Wirkstofffreisetzung
T-1933	Oral use Oral use Oral use Oral use Oral use Oral use
H-1933	-0.7696465253829956	<unk> altered drug release tablet <unk>
D-1933	-0.7696465253829956	<unk> altered drug release tablet <unk>
P-1933	-0.3897 -1.9420 -0.1514 -1.7688 -0.7577 -0.1719 -0.0802 -1.0838 -0.5813
S-1156	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1156	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1156	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
D-1156	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
P-1156	-0.7897 -0.3396 -1.7426 -0.0901 -0.0774 -0.0131 -1.7253 -0.0105 -0.0564 -0.0606 -1.0995 -0.0448 -0.0995 -0.0417 -0.0930 -0.1616
S-1332	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1332	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1332	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
D-1332	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
P-1332	-0.7897 -0.3396 -1.7426 -0.0901 -0.0774 -0.0131 -1.7253 -0.0105 -0.0564 -0.0606 -1.0995 -0.0448 -0.0995 -0.0417 -0.0930 -0.1616
S-1509	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1509	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1509	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
D-1509	-0.40283942222595215	<unk> <unk> Diarrhoea Abdominal pain nausea vomiting
P-1509	-0.7897 -0.3396 -1.7426 -0.0901 -0.0774 -0.0131 -1.7253 -0.0105 -0.0564 -0.0606 -1.0995 -0.0448 -0.0995 -0.0417 -0.0930 -0.1616
S-1930	Tablette mit veränderter Wirkstofffreisetzung
T-1930	EU/ 1/ 07/ 399/ 001 EU/ 1/ 07/ 399/ 002 EU/ 1/ 07/ 399/ 003 EU/ 1/ 07/ 399/ 004 EU/ 1/ 07/ 399/ 005 EU/ 1/ 07/ 399/ 006
H-1930	-0.7696465253829956	<unk> altered drug release tablet <unk>
D-1930	-0.7696465253829956	<unk> altered drug release tablet <unk>
P-1930	-0.3897 -1.9420 -0.1514 -1.7688 -0.7577 -0.1719 -0.0802 -1.0838 -0.5813
S-1889	Aus welchen Gründen hat das Unternehmen den Antrag zurückgenommen ?
T-1889	What were the reasons given by the company to withdraw the application ?
H-1889	-0.601884126663208	<unk> On what grounds has the company withdrawn the application ?
D-1889	-0.601884126663208	<unk> On what grounds has the company withdrawn the application ?
P-1889	-1.5864 -2.0649 -0.3394 -0.5663 -0.2921 -0.1542 -0.1954 -0.6832 -0.1730 -0.4931 -0.0221 -0.7837 -0.4708
S-615	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-615	Animal reproduction studies have not been conducted with factor VIII .
H-615	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
D-615	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
P-615	-0.6199 -0.4203 -0.0413 -0.2235 -0.1162 -0.0389 -0.6346 -0.8456 -0.1511 -0.0850 -0.6941 -0.1235 -0.4715 -0.3977 -0.5475
S-44	Den vollständigen Wortlaut des EPAR für Adenuric finden Sie hier .
T-44	The full EPAR for Adenuric can be found here .
H-44	-0.37785330414772034	<unk> The full EPAR for Adenuric is available here .
D-44	-0.37785330414772034	<unk> The full EPAR for Adenuric is available here .
P-44	-2.9330 -0.3758 -0.2034 -0.2400 -0.0411 -0.1580 -0.2166 -0.1638 -0.1352 -0.1152 -0.1790 -0.4710 -0.0905 -0.1590 -0.1862
S-748	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-748	Early haemarthrosis , muscle bleeding or oral bleeding .
H-748	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
D-748	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
P-748	-0.4069 -1.3381 -1.8533 -0.0412 -1.0900 -0.6834 -2.9061 -0.3724 -0.1539 -0.7685 -1.1055 -0.1506 -0.1527 -0.1672
S-789	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-789	Animal reproduction studies have not been conducted with factor VIII .
H-789	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
D-789	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
P-789	-0.6199 -0.4203 -0.0413 -0.2235 -0.1162 -0.0389 -0.6346 -0.8456 -0.1511 -0.0850 -0.6941 -0.1235 -0.4715 -0.3977 -0.5475
S-10	Die empfohlene Dosis von Adenuric beträgt 80 mg einmal täglich .
T-10	The recommended dose of Adenuric is 80 mg once a day .
H-10	-0.28274351358413696	<unk> The recommended dose of Adenuric is 80 mg once a day .
D-10	-0.28274351358413696	<unk> The recommended dose of Adenuric is 80 mg once a day .
P-10	-1.8646 -0.2436 -0.0540 -0.0781 -0.1337 -0.1751 -0.1823 -0.0986 -0.1254 -0.1148 -0.1416 -0.0451 -0.1503 -0.9779 -0.0920 -0.1505 -0.1791
S-1493	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1493	Animal reproduction studies have not been conducted with factor VIII .
H-1493	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
D-1493	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
P-1493	-0.6199 -0.4203 -0.0413 -0.2235 -0.1162 -0.0389 -0.6346 -0.8456 -0.1511 -0.0850 -0.6941 -0.1235 -0.4715 -0.3977 -0.5475
S-1317	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1317	Animal reproduction studies have not been conducted with factor VIII .
H-1317	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
D-1317	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
P-1317	-0.6199 -0.4203 -0.0413 -0.2235 -0.1162 -0.0389 -0.6346 -0.8456 -0.1511 -0.0850 -0.6941 -0.1235 -0.4715 -0.3977 -0.5475
S-1141	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1141	Animal reproduction studies have not been conducted with factor VIII .
H-1141	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
D-1141	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
P-1141	-0.6199 -0.4203 -0.0413 -0.2235 -0.1162 -0.0389 -0.6346 -0.8456 -0.1511 -0.0850 -0.6941 -0.1235 -0.4715 -0.3977 -0.5475
S-965	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-965	Animal reproduction studies have not been conducted with factor VIII .
H-965	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
D-965	-0.3607112169265747	<unk> Animal reproduction studies , factor VIII did not <unk> <unk>
P-965	-0.6199 -0.4203 -0.0413 -0.2235 -0.1162 -0.0389 -0.6346 -0.8456 -0.1511 -0.0850 -0.6941 -0.1235 -0.4715 -0.3977 -0.5475
S-801	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-801	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-801	-0.3283291757106781	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-801	-0.3283291757106781	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-801	-3.1926 -0.1776 -0.1867 -0.0617 -0.1325 -0.5561 -0.0343 -0.3927 -0.1006 -0.1484 -0.0885 -0.0869 -0.1399 -0.1532 -0.1150 -0.0961 -0.0944 -0.1526
S-574	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-574	Early haemarthrosis , muscle bleeding or oral bleeding .
H-574	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
D-574	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
P-574	-0.4069 -1.3381 -1.8533 -0.0412 -1.0900 -0.6834 -2.9061 -0.3724 -0.1539 -0.7685 -1.1055 -0.1506 -0.1527 -0.1672
S-1276	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1276	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1276	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
D-1276	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
P-1276	-0.4069 -1.3381 -1.8533 -0.0412 -1.0900 -0.6834 -2.9061 -0.3724 -0.1539 -0.7685 -1.1055 -0.1506 -0.1527 -0.1672
S-1994	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1994	4.7 Effects on ability to drive and use machines
H-1994	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-1994	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-1994	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-1610	Name und Anschrift des Herstellers , der für die Chargenfreigabe verantwortlich ist
T-1610	Name and address of the manufacturer responsible for batch release
H-1610	-0.3591861426830292	<unk> Name and address of the manufacturer responsible for batch release
D-1610	-0.3591861426830292	<unk> Name and address of the manufacturer responsible for batch release
P-1610	-1.1225 -0.1058 -0.1432 -0.0982 -0.1508 -0.1453 -0.7067 -0.1111 -0.1299 -0.1774 -0.0624 -1.0033 -0.7129
S-1496	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1496	4.7 Effects on ability to drive and use machines
H-1496	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-1496	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-1496	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-1320	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1320	4.7 Effects on ability to drive and use machines
H-1320	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-1320	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-1320	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-1144	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1144	4.7 Effects on ability to drive and use machines
H-1144	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-1144	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-1144	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-968	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-968	4.7 Effects on ability to drive and use machines
H-968	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-968	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-968	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-792	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-792	4.7 Effects on ability to drive and use machines
H-792	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-792	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-792	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-618	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-618	4.7 Effects on ability to drive and use machines
H-618	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-618	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-618	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-924	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-924	Early haemarthrosis , muscle bleeding or oral bleeding .
H-924	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
D-924	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
P-924	-0.4069 -1.3381 -1.8533 -0.0412 -1.0900 -0.6834 -2.9061 -0.3724 -0.1539 -0.7685 -1.1055 -0.1506 -0.1527 -0.1672
S-160	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-160	4.7 Effects on ability to drive and use machines
H-160	-0.29673394560813904	4.7 Effects on ability to drive and use machines
D-160	-0.29673394560813904	4.7 Effects on ability to drive and use machines
P-160	-0.8842 -0.1601 -0.0521 -0.0681 -0.1223 -0.0931 -0.1282 -1.3618 -0.1408 -0.1849 -0.2068 -0.1585
S-116	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-116	Many of these patients were also receiving chemotherapy and corticosteroids .
H-116	-0.2858276665210724	Many of these patients also received chemotherapy and corticosteroids .
D-116	-0.2858276665210724	Many of these patients also received chemotherapy and corticosteroids .
P-116	-2.6580 -0.2008 -0.1830 -0.0826 -0.3591 -0.2303 -0.1583 -0.0615 -0.0774 -0.1242 -0.2651 -0.0764 -0.0927 -0.0883 -0.1436 -0.0425 -0.1517 -0.1495
S-1454	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1454	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1454	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
D-1454	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
P-1454	-0.4842 -1.5698 -4.6360 -0.0747 -0.0546 -1.0220 -0.8415 -2.0409 -0.3379 -0.1795 -0.1689 -0.9177 -1.2802 -0.4988 -0.7291 -0.0564 -0.0642 -0.3325 -0.2061 -0.2534
S-780	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-780	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-780	-0.5327709913253784	<unk> In such cases it is recommended to contact a haemophile centre .
D-780	-0.5327709913253784	<unk> In such cases it is recommended to contact a haemophile centre .
P-780	-1.5555 -0.2499 -0.3075 -0.1270 -1.3619 -0.1508 -0.0678 -0.2805 -0.4992 -0.1451 -0.1397 -0.1534 -2.0486 -1.1046 -0.5469 -0.1477 -0.1711
S-627	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-627	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-627	-0.3283291757106781	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-627	-0.3283291757106781	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-627	-3.1926 -0.1776 -0.1867 -0.0617 -0.1325 -0.5561 -0.0343 -0.3927 -0.1006 -0.1484 -0.0885 -0.0869 -0.1399 -0.1532 -0.1150 -0.0961 -0.0944 -0.1526
S-606	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-606	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-606	-0.5327709913253784	<unk> In such cases it is recommended to contact a haemophile centre .
D-606	-0.5327709913253784	<unk> In such cases it is recommended to contact a haemophile centre .
P-606	-1.5555 -0.2499 -0.3075 -0.1270 -1.3619 -0.1508 -0.0678 -0.2805 -0.4992 -0.1451 -0.1397 -0.1534 -2.0486 -1.1046 -0.5469 -0.1477 -0.1711
S-447	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-447	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-447	-0.41493019461631775	<unk> A small fraction of vitamin D3 is glucuronised before excretion .
D-447	-0.41493019461631775	<unk> A small fraction of vitamin D3 is glucuronised before excretion .
P-447	-1.6737 -0.3414 -0.0505 -1.2626 -0.0903 -0.3154 -0.0796 -0.0712 -0.1756 -0.1319 -0.1616 -0.4222 -1.1677 -0.1541 -1.0878 -0.4399 -0.6072 -0.0273 -0.1341 -0.1525 -0.1669
S-272	Jede Tablette enthält 63 mg Lactose und 16 mg Sucrose .
T-272	Each tablet contains 63 mg lactose anhydrous and 16 mg sucrose .
H-272	-0.21502386033535004	<unk> Each tablet contains 63 mg lactose and 16 mg sucrose .
D-272	-0.21502386033535004	<unk> Each tablet contains 63 mg lactose and 16 mg sucrose .
P-272	-1.8665 -0.1565 -0.0855 -0.0835 -0.0726 -0.1059 -0.0580 -0.2637 -0.0825 -0.1267 -0.1247 -0.1392 -0.1682 -0.0771 -0.0434 -0.0845 -0.1552 -0.1767
S-251	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-251	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-251	-0.41493019461631775	<unk> A small fraction of vitamin D3 is glucuronised before excretion .
D-251	-0.41493019461631775	<unk> A small fraction of vitamin D3 is glucuronised before excretion .
P-251	-1.6737 -0.3414 -0.0505 -1.2626 -0.0903 -0.3154 -0.0796 -0.0712 -0.1756 -0.1319 -0.1616 -0.4222 -1.1677 -0.1541 -1.0878 -0.4399 -0.6072 -0.0273 -0.1341 -0.1525 -0.1669
S-85	Jede Tablette enthält 62 mg Lactose und 8 mg Sucrose .
T-85	Each tablet contains 62 mg lactose anhydrous and 8 mg sucrose .
H-85	-0.2167789191007614	<unk> Each tablet contains 62 mg lactose and 8 mg sucrose .
D-85	-0.2167789191007614	<unk> Each tablet contains 62 mg lactose and 8 mg sucrose .
P-85	-1.9031 -0.1564 -0.0909 -0.0829 -0.0791 -0.1138 -0.0541 -0.2626 -0.0850 -0.1267 -0.1220 -0.1259 -0.1572 -0.0788 -0.0438 -0.0852 -0.1575 -0.1769
S-304	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-304	Many of these patients were also receiving chemotherapy and corticosteroids .
H-304	-0.2858276665210724	Many of these patients also received chemotherapy and corticosteroids .
D-304	-0.2858276665210724	Many of these patients also received chemotherapy and corticosteroids .
P-304	-2.6580 -0.2008 -0.1830 -0.0826 -0.3591 -0.2303 -0.1583 -0.0615 -0.0774 -0.1242 -0.2651 -0.0764 -0.0927 -0.0883 -0.1436 -0.0425 -0.1517 -0.1495
S-1100	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1100	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1100	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
D-1100	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
P-1100	-0.4069 -1.3381 -1.8533 -0.0412 -1.0900 -0.6834 -2.9061 -0.3724 -0.1539 -0.7685 -1.1055 -0.1506 -0.1527 -0.1672
S-1452	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1452	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1452	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
D-1452	-0.7992790341377258	<unk> Early joints , muscle bleeding or mouth bleeding .
P-1452	-0.4069 -1.3381 -1.8533 -0.0412 -1.0900 -0.6834 -2.9061 -0.3724 -0.1539 -0.7685 -1.1055 -0.1506 -0.1527 -0.1672
S-1278	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1278	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1278	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
D-1278	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
P-1278	-0.4842 -1.5698 -4.6360 -0.0747 -0.0546 -1.0220 -0.8415 -2.0409 -0.3379 -0.1795 -0.1689 -0.9177 -1.2802 -0.4988 -0.7291 -0.0564 -0.0642 -0.3325 -0.2061 -0.2534
S-1102	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1102	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1102	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
D-1102	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
P-1102	-0.4842 -1.5698 -4.6360 -0.0747 -0.0546 -1.0220 -0.8415 -2.0409 -0.3379 -0.1795 -0.1689 -0.9177 -1.2802 -0.4988 -0.7291 -0.0564 -0.0642 -0.3325 -0.2061 -0.2534
S-926	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-926	More extensive haemarthrosis , muscle bleeding or haematoma .
H-926	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
D-926	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
P-926	-0.4842 -1.5698 -4.6360 -0.0747 -0.0546 -1.0220 -0.8415 -2.0409 -0.3379 -0.1795 -0.1689 -0.9177 -1.2802 -0.4988 -0.7291 -0.0564 -0.0642 -0.3325 -0.2061 -0.2534
S-750	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-750	More extensive haemarthrosis , muscle bleeding or haematoma .
H-750	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
D-750	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
P-750	-0.4842 -1.5698 -4.6360 -0.0747 -0.0546 -1.0220 -0.8415 -2.0409 -0.3379 -0.1795 -0.1689 -0.9177 -1.2802 -0.4988 -0.7291 -0.0564 -0.0642 -0.3325 -0.2061 -0.2534
S-576	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-576	More extensive haemarthrosis , muscle bleeding or haematoma .
H-576	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
D-576	-0.787421464920044	<unk> <unk> Increased joint haemoglobin , or <unk> <unk> haematoma .
P-576	-0.4842 -1.5698 -4.6360 -0.0747 -0.0546 -1.0220 -0.8415 -2.0409 -0.3379 -0.1795 -0.1689 -0.9177 -1.2802 -0.4988 -0.7291 -0.0564 -0.0642 -0.3325 -0.2061 -0.2534
S-327	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-327	Urine and serum calcium should be monitored in these patients .
H-327	-0.2738765776157379	<unk> In these patients urine and serum calcium should be monitored .
D-327	-0.2738765776157379	<unk> In these patients urine and serum calcium should be monitored .
P-327	-1.1580 -1.3490 -0.1937 -0.0865 -0.0323 -0.0875 -0.1313 -0.2001 -0.1038 -0.1025 -0.0549 -0.0945 -0.4060 -0.1906 -0.2516 -0.0732 -0.1603 -0.2539
S-139	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-139	Urine and serum calcium should be monitored in these patients .
H-139	-0.2738765776157379	<unk> In these patients urine and serum calcium should be monitored .
D-139	-0.2738765776157379	<unk> In these patients urine and serum calcium should be monitored .
P-139	-1.1580 -1.3490 -0.1937 -0.0865 -0.0323 -0.0875 -0.1313 -0.2001 -0.1038 -0.1025 -0.0549 -0.0945 -0.4060 -0.1906 -0.2516 -0.0732 -0.1603 -0.2539
S-1818	eská republika Baxter Czech spol.s.r.o .
T-1818	eská republika Baxter Czech spol . s. r. o.
H-1818	-0.28990963101387024	eská republika Baxter Czech spol.s.r.o .
D-1818	-0.28990963101387024	eská republika Baxter Czech spol.s.r.o .
P-1818	-0.8861 -0.1358 -0.0990 -0.0618 -0.0746 -0.8700 -0.1186 -0.2034 -0.5367 -0.0999 -0.0734 -0.3756 -0.8303 -0.0624 -0.3187 -0.1626 -0.1607 -0.1486
S-549	1 Durchstechflasche + 1 Durchstechflasche + Gerät zur Rekonstitution
T-549	1 vial + 1 vial + reconstitution device
H-549	-0.43399009108543396	1 vial + 1 vial + reconstitution unit
D-549	-0.43399009108543396	1 vial + 1 vial + reconstitution unit
P-549	-1.6512 -0.0719 -0.0856 -0.1342 -0.1128 -0.0400 -0.1002 -0.1087 -0.7493 -0.0965 -1.9015 -0.1559
S-1566	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1566	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1566	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
D-1566	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
P-1566	-0.8094 -1.4947 -0.3703 -0.1821 -0.1652 -0.2280 -0.0070 -0.0832 -0.1885 -0.4017 -0.2558 -0.1689 -0.1244 -0.1725 -0.1592
S-329	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-329	14 Excipients This medicinal product contains lactose and sucrose .
H-329	-0.13521739840507507	<unk> Excipients This medicinal product contains lactose and sucrose .
D-329	-0.13521739840507507	<unk> Excipients This medicinal product contains lactose and sucrose .
P-329	-0.6606 -0.3676 -0.0289 -0.0814 -0.0879 -0.1410 -0.0300 -0.1163 -0.0899 -0.0386 -0.0852 -0.0587 -0.1180 -0.1262 -0.0917 -0.0400 -0.0847 -0.1583 -0.1640
S-141	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-141	4 Excipients This medicinal product contains lactose and sucrose .
H-141	-0.13521739840507507	<unk> Excipients This medicinal product contains lactose and sucrose .
D-141	-0.13521739840507507	<unk> Excipients This medicinal product contains lactose and sucrose .
P-141	-0.6606 -0.3676 -0.0289 -0.0814 -0.0879 -0.1410 -0.0300 -0.1163 -0.0899 -0.0386 -0.0852 -0.0587 -0.1180 -0.1262 -0.0917 -0.0400 -0.0847 -0.1583 -0.1640
S-1993	Deshalb sollte Aerinaze in der Stillzeit nicht angewendet werden .
T-1993	Therefore Aerinaze should not be used in breast-feeding women .
H-1993	-0.3300561010837555	<unk> Therefore , Aerinaze should not be used while breast-feeding .
D-1993	-0.3300561010837555	<unk> Therefore , Aerinaze should not be used while breast-feeding .
P-1993	-1.5568 -0.5309 -0.0651 -0.6903 -0.6997 -0.1316 -0.1318 -0.1264 -0.1571 -0.1516 -0.0986 -0.1400 -0.1254 -1.3413 -0.1205 -0.0629 -0.1114 -0.0357 -0.1607 -0.1635
S-1389	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1389	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1389	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
D-1389	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
P-1389	-0.8094 -1.4947 -0.3703 -0.1821 -0.1652 -0.2280 -0.0070 -0.0832 -0.1885 -0.4017 -0.2558 -0.1689 -0.1244 -0.1725 -0.1592
S-1213	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1213	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1213	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
D-1213	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
P-1213	-0.8094 -1.4947 -0.3703 -0.1821 -0.1652 -0.2280 -0.0070 -0.0832 -0.1885 -0.4017 -0.2558 -0.1689 -0.1244 -0.1725 -0.1592
S-1037	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1037	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1037	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
D-1037	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
P-1037	-0.8094 -1.4947 -0.3703 -0.1821 -0.1652 -0.2280 -0.0070 -0.0832 -0.1885 -0.4017 -0.2558 -0.1689 -0.1244 -0.1725 -0.1592
S-861	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-861	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-861	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
D-861	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
P-861	-0.8094 -1.4947 -0.3703 -0.1821 -0.1652 -0.2280 -0.0070 -0.0832 -0.1885 -0.4017 -0.2558 -0.1689 -0.1244 -0.1725 -0.1592
S-1848	ADVATE darf nicht mit anderen Arzneimitteln oder Lösungen gemischt werden .
T-1848	ADVATE must not be mixed with other medicinal products or solvents .
H-1848	-0.2789466083049774	<unk> ADVATE should not be mixed with other medicinal products or solutions .
D-1848	-0.2789466083049774	<unk> ADVATE should not be mixed with other medicinal products or solutions .
P-1848	-0.7436 -0.2600 -0.2155 -0.1060 -0.1063 -0.8160 -0.1101 -0.1394 -0.3386 -0.1427 -0.2129 -0.4101 -0.5622 -0.0364 -0.1680 -0.3346 -0.1575 -0.1611
S-328	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-328	Patients with malabsorption may not adequately absorb vitamin D3 .
H-328	-0.31437692046165466	<unk> Patients with malabsorption may not take adequate vitamin D3 .
D-328	-0.31437692046165466	<unk> Patients with malabsorption may not take adequate vitamin D3 .
P-328	-0.4682 -0.2570 -0.0882 -0.2681 -0.0290 -0.0661 -0.0628 -0.3992 -0.0974 -1.1159 -1.2781 -0.1261 -0.0657 -0.2013 -0.1267 -0.5097 -0.1849
S-172	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-172	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-172	-0.40175092220306396	<unk> The following reactions were reported ( frequency unknown ) :
D-172	-0.40175092220306396	<unk> The following reactions were reported ( frequency unknown ) :
P-172	-1.1986 -1.0560 -0.1295 -0.0650 -0.0802 -1.1924 -0.1009 -0.2368 -0.2878 -0.0619 -0.7376 -0.1596 -0.1640 -0.1541
S-360	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-360	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-360	-0.40175092220306396	<unk> The following reactions were reported ( frequency unknown ) :
D-360	-0.40175092220306396	<unk> The following reactions were reported ( frequency unknown ) :
P-360	-1.1986 -1.0560 -0.1295 -0.0650 -0.0802 -1.1924 -0.1009 -0.2368 -0.2878 -0.0619 -0.7376 -0.1596 -0.1640 -0.1541
S-592	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-592	Method of administration ADVATE should be administered via the intravenous route .
H-592	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
D-592	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
P-592	-2.0622 -0.1391 -0.2560 -0.1326 -0.1931 -0.0778 -0.0781 -0.3807 -0.1204 -0.1772 -0.0967 -0.1705 -0.1105 -0.1136 -0.0998 -0.1520 -0.1477
S-766	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-766	Method of administration ADVATE should be administered via the intravenous route .
H-766	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
D-766	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
P-766	-2.0622 -0.1391 -0.2560 -0.1326 -0.1931 -0.0778 -0.0781 -0.3807 -0.1204 -0.1772 -0.0967 -0.1705 -0.1105 -0.1136 -0.0998 -0.1520 -0.1477
S-942	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-942	Method of administration ADVATE should be administered via the intravenous route .
H-942	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
D-942	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
P-942	-2.0622 -0.1391 -0.2560 -0.1326 -0.1931 -0.0778 -0.0781 -0.3807 -0.1204 -0.1772 -0.0967 -0.1705 -0.1105 -0.1136 -0.0998 -0.1520 -0.1477
S-1118	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1118	Method of administration ADVATE should be administered via the intravenous route .
H-1118	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
D-1118	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
P-1118	-2.0622 -0.1391 -0.2560 -0.1326 -0.1931 -0.0778 -0.0781 -0.3807 -0.1204 -0.1772 -0.0967 -0.1705 -0.1105 -0.1136 -0.0998 -0.1520 -0.1477
S-1294	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1294	Method of administration ADVATE should be administered via the intravenous route .
H-1294	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
D-1294	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
P-1294	-2.0622 -0.1391 -0.2560 -0.1326 -0.1931 -0.0778 -0.0781 -0.3807 -0.1204 -0.1772 -0.0967 -0.1705 -0.1105 -0.1136 -0.0998 -0.1520 -0.1477
S-1470	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1470	Method of administration ADVATE should be administered via the intravenous route .
H-1470	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
D-1470	-0.2651757299900055	method of administration ADVATE should be administered intravenously .
P-1470	-2.0622 -0.1391 -0.2560 -0.1326 -0.1931 -0.0778 -0.0781 -0.3807 -0.1204 -0.1772 -0.0967 -0.1705 -0.1105 -0.1136 -0.0998 -0.1520 -0.1477
S-45	Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-45	EU/ 1/ 08/ 447/ 001 EU/ 1/ 08/ 447/ 002 EU/ 1/ 08/ 447/ 003 EU/ 1/ 08/ 447/ 004
H-45	-0.2944105565547943	<unk> Blister ( Aclar/ PVC/ aluminium )
D-45	-0.2944105565547943	<unk> Blister ( Aclar/ PVC/ aluminium )
P-45	-1.7773 -0.7668 -0.0875 -0.2048 -0.1325 -0.2504 -0.1433 -0.1640 -0.1262 -0.1554 -0.1688 -0.1286 -0.2084 -0.0888 -0.1482 -0.1596
S-685	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-685	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-685	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
D-685	-0.3207220435142517	<unk> storage conditions of the reconstituted product see section 6.3 .
P-685	-0.8094 -1.4947 -0.3703 -0.1821 -0.1652 -0.2280 -0.0070 -0.0832 -0.1885 -0.4017 -0.2558 -0.1689 -0.1244 -0.1725 -0.1592
S-60	Die Tablette darf nicht gekaut werden und nicht im Mund zergehen .
T-60	The tablet should not be chewed or allowed to dissolve in the mouth .
H-60	-0.4464711546897888	<unk> The tablet should not be chewed or dissolved in the mouth .
D-60	-0.4464711546897888	<unk> The tablet should not be chewed or dissolved in the mouth .
P-60	-1.7384 -0.9018 -0.0536 -0.0752 -0.7314 -0.1308 -0.2071 -0.2191 -0.0947 -1.5229 -0.3448 -0.3380 -0.0833 -0.7629 -0.2926 -0.1943 -0.1498 -0.1956
S-140	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-140	Patients with malabsorption may not adequately absorb vitamin D3 .
H-140	-0.31437692046165466	<unk> Patients with malabsorption may not take adequate vitamin D3 .
D-140	-0.31437692046165466	<unk> Patients with malabsorption may not take adequate vitamin D3 .
P-140	-0.4682 -0.2570 -0.0882 -0.2681 -0.0290 -0.0661 -0.0628 -0.3992 -0.0974 -1.1159 -1.2781 -0.1261 -0.0657 -0.2013 -0.1267 -0.5097 -0.1849
S-1801	Das Arzneimittel unmittelbar nach dem vollständigen Lösen des Pulvers verbrauchen .
T-1801	Use the product immediately once the powder is completely dissolved .
H-1801	-0.4412635862827301	<unk> Use the product immediately after dissolving the powder .
D-1801	-0.4412635862827301	<unk> Use the product immediately after dissolving the powder .
P-1801	-0.6787 -0.4308 -0.6926 -0.5114 -0.0376 -0.3450 -1.5619 -0.5482 -0.1712 -0.3092 -0.1025 -0.1706 -0.1766
S-1608	Name und Anschrift des Herstellers des Wirkstoffs biologischen Ursprungs
T-1608	Name and address of the manufacturer of the biological active substance
H-1608	-0.4245356321334839	<unk> Name and address of the manufacturer of the active substance biological origin
D-1608	-0.4245356321334839	<unk> Name and address of the manufacturer of the active substance biological origin
P-1608	-1.0692 -0.0744 -0.1366 -0.1161 -0.1491 -0.1496 -1.3187 -0.1421 -0.1495 -1.4649 -0.0434 -1.1487 -0.1303 -0.4132 -0.1145 -0.1723
S-152	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-152	Additional vitamin D supplements may be considered on an individual basis .
H-152	-0.2714245617389679	<unk> Additional vitamin D supplementation should be considered on an individual basis .
D-152	-0.2714245617389679	<unk> Additional vitamin D supplementation should be considered on an individual basis .
P-152	-1.1028 -0.1432 -0.2752 -0.0701 -0.1395 -0.0564 -0.0331 -0.1230 -0.1056 -0.1332 -0.0621 -0.9125 -0.6791 -0.0856 -0.3508 -0.1708 -0.1712
S-1768	99 Inhibitoren liegen . Dies wird von Ihrem Arzt abgeklärt werden .
T-1768	This will be checked by your doctor .
H-1768	-0.43224528431892395	<unk> 99 inhibitors and this will be determined by your doctor .
D-1768	-0.43224528431892395	<unk> 99 inhibitors and this will be determined by your doctor .
P-1768	-2.3998 -0.2735 -0.1226 -0.0544 -0.0923 -0.1253 -1.2025 -0.2719 -0.2770 -0.1458 -1.2005 -0.1457 -0.1167 -0.1423 -0.1790 -0.1666
S-1858	Li-Fraumeni-Krebs kann in vielen Teilen des Körpers auftreten .
T-1858	People who have this mutation are more likely to develop cancer .
H-1858	-0.5411911010742188	<unk> Li-Fraumeni cancer can occur in many parts of the body .
D-1858	-0.5411911010742188	<unk> Li-Fraumeni cancer can occur in many parts of the body .
P-1858	-1.1505 -1.7843 -0.1526 -1.6546 -0.0402 -1.6243 -0.5624 -0.1518 -0.2938 -0.1228 -0.3935 -0.4414 -0.1351 -0.3078 -0.0624 -0.1570 -0.1656
S-340	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-340	Additional vitamin D supplements may be considered on an individual basis .
H-340	-0.2714245617389679	<unk> Additional vitamin D supplementation should be considered on an individual basis .
D-340	-0.2714245617389679	<unk> Additional vitamin D supplementation should be considered on an individual basis .
P-340	-1.1028 -0.1432 -0.2752 -0.0701 -0.1395 -0.0564 -0.0331 -0.1230 -0.1056 -0.1332 -0.0621 -0.9125 -0.6791 -0.0856 -0.3508 -0.1708 -0.1712
S-146	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-146	No other clinically significant interactions with medicinal products are anticipated .
H-146	-0.363037645816803	<unk> Other clinically important interactions with medicines are not to be expected .
D-146	-0.363037645816803	<unk> Other clinically important interactions with medicines are not to be expected .
P-146	-0.9682 -0.6156 -0.0095 -0.1232 -1.1710 -0.0902 -0.0589 -0.1135 -0.3484 -0.9550 -0.2251 -0.2795 -0.6119 -0.1730 -0.1013 -0.1585 -0.1690
S-1725	Es kann anderen Menschen schaden , auch wenn diese die gleichen Beschwerden haben wie Sie .
T-1725	if their symptoms are the same as yours .
H-1725	-0.6901874542236328	<unk> It can harm other people , even if they have the same symptoms as you .
D-1725	-0.6901874542236328	<unk> It can harm other people , even if they have the same symptoms as you .
P-1725	-1.7313 -0.5713 -0.6547 -1.3931 -0.1471 -1.1233 -0.2927 -0.4015 -0.2693 -0.1677 -0.4541 -0.1920 -0.3146 -3.8116 -0.2482 -0.0965 -0.1920 -0.3622
S-412	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-412	Total body BMD also increased significantly .
H-412	-0.35646629333496094	<unk> BMD of the total skeleton also increased significantly .
D-412	-0.35646629333496094	<unk> BMD of the total skeleton also increased significantly .
P-412	-0.8381 -0.1488 -0.1259 -0.2581 -0.1577 -0.6823 -0.8361 -0.5340 -0.0822 -0.3610 -0.5242 -0.1290 -0.1525 -0.1608
S-216	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-216	Total body BMD also increased significantly .
H-216	-0.35646629333496094	<unk> BMD of the total skeleton also increased significantly .
D-216	-0.35646629333496094	<unk> BMD of the total skeleton also increased significantly .
P-216	-0.8381 -0.1488 -0.1259 -0.2581 -0.1577 -0.6823 -0.8361 -0.5340 -0.0822 -0.3610 -0.5242 -0.1290 -0.1525 -0.1608
S-334	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-334	No other clinically significant interactions with medicinal products are anticipated .
H-334	-0.363037645816803	<unk> Other clinically important interactions with medicines are not to be expected .
D-334	-0.363037645816803	<unk> Other clinically important interactions with medicines are not to be expected .
P-334	-0.9682 -0.6156 -0.0095 -0.1232 -1.1710 -0.0902 -0.0589 -0.1135 -0.3484 -0.9550 -0.2251 -0.2795 -0.6119 -0.1730 -0.1013 -0.1585 -0.1690
S-1869	Welche Unterlagen hat das Unternehmen dem CHMP zur Stützung seines Antrags vorgelegt ?
T-1869	What documentation did the company present to support its application to the CHMP ?
H-1869	-0.5391944050788879	<unk> What documents has the company presented to the CHMP in support of its application ?
D-1869	-0.5391944050788879	<unk> What documents has the company presented to the CHMP in support of its application ?
P-1869	-1.0526 -0.2063 -2.9352 -1.4347 -0.1559 -0.1702 -0.3107 -0.2782 -0.4320 -0.1442 -0.0373 -0.2334 -0.1726 -0.1514 -0.1194 -0.0980 -0.8602 -0.9133
S-1043	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1043	For administration the use of a luer-lock syringe is required .
H-1043	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
D-1043	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
P-1043	-1.2877 -2.6946 -0.3602 -0.3180 -0.4081 -0.1499 -0.3498 -1.2441 -1.4342 -0.0949 -0.0298 -0.0313 -0.1119 -0.4687 -0.1541 -0.1779
S-1395	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1395	For administration the use of a luer-lock syringe is required .
H-1395	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
D-1395	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
P-1395	-1.2877 -2.6946 -0.3602 -0.3180 -0.4081 -0.1499 -0.3498 -1.2441 -1.4342 -0.0949 -0.0298 -0.0313 -0.1119 -0.4687 -0.1541 -0.1779
S-1572	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1572	For administration the use of a luer-lock syringe is required .
H-1572	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
D-1572	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
P-1572	-1.2877 -2.6946 -0.3602 -0.3180 -0.4081 -0.1499 -0.3498 -1.2441 -1.4342 -0.0949 -0.0298 -0.0313 -0.1119 -0.4687 -0.1541 -0.1779
S-86	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-86	For a full list of excipients , see section 6.1 .
H-86	-0.3430411219596863	<unk> For a full list of excipients , see section 6.1 .
D-86	-0.3430411219596863	<unk> For a full list of excipients , see section 6.1 .
P-86	-1.7308 -0.1222 -0.1326 -0.1178 -0.1127 -0.1611 -1.0159 -0.0131 -0.1188 -0.0735 -1.1690 -0.1031 -0.2958 -0.1760 -0.1472 -0.1778 -0.1643
S-1219	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1219	For administration the use of a luer-lock syringe is required .
H-1219	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
D-1219	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
P-1219	-1.2877 -2.6946 -0.3602 -0.3180 -0.4081 -0.1499 -0.3498 -1.2441 -1.4342 -0.0949 -0.0298 -0.0313 -0.1119 -0.4687 -0.1541 -0.1779
S-1738	- wenn Sie allergisch gegen Maus- oder Hamsterprotein sind .
T-1738	- if you are allergic to mouse or hamster proteins
H-1738	-0.31002363562583923	<unk> if you are allergic to mouse or hamster protein .
D-1738	-0.31002363562583923	<unk> if you are allergic to mouse or hamster protein .
P-1738	-1.0552 -1.0617 -0.1071 -0.2070 -0.1163 -0.0393 -0.1216 -0.0983 -0.0871 -0.1296 -1.0830 -0.0773 -0.1232 -0.1410 -0.2028
S-867	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-867	For administration the use of a luer-lock syringe is required .
H-867	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
D-867	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
P-867	-1.2877 -2.6946 -0.3602 -0.3180 -0.4081 -0.1499 -0.3498 -1.2441 -1.4342 -0.0949 -0.0298 -0.0313 -0.1119 -0.4687 -0.1541 -0.1779
S-1938	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1938	For a full list of excipients , see section 6.1 .
H-1938	-0.3430411219596863	<unk> For a full list of excipients , see section 6.1 .
D-1938	-0.3430411219596863	<unk> For a full list of excipients , see section 6.1 .
P-1938	-1.7308 -0.1222 -0.1326 -0.1178 -0.1127 -0.1611 -1.0159 -0.0131 -0.1188 -0.0735 -1.1690 -0.1031 -0.2958 -0.1760 -0.1472 -0.1778 -0.1643
S-273	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-273	For a full list of excipients , see section 6.1 .
H-273	-0.3430411219596863	<unk> For a full list of excipients , see section 6.1 .
D-273	-0.3430411219596863	<unk> For a full list of excipients , see section 6.1 .
P-273	-1.7308 -0.1222 -0.1326 -0.1178 -0.1127 -0.1611 -1.0159 -0.0131 -0.1188 -0.0735 -1.1690 -0.1031 -0.2958 -0.1760 -0.1472 -0.1778 -0.1643
S-691	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-691	For administration the use of a luer-lock syringe is required .
H-691	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
D-691	-0.5821985602378845	<unk> For administration a Luer-Lock syringe is necessary .
P-691	-1.2877 -2.6946 -0.3602 -0.3180 -0.4081 -0.1499 -0.3498 -1.2441 -1.4342 -0.0949 -0.0298 -0.0313 -0.1119 -0.4687 -0.1541 -0.1779
S-1802	Arzneimittel dürfen nicht im Abwasser oder Haushaltsabfall entsorgt werden .
T-1802	Medicines should not be disposed of via waste water or household waste .
H-1802	-0.3355002999305725	<unk> Medicines should not be disposed of via wastewater or household waste .
D-1802	-0.3355002999305725	<unk> Medicines should not be disposed of via wastewater or household waste .
P-1802	-0.6872 -0.8237 -0.0397 -0.2400 -0.1066 -0.1615 -0.0224 -0.0556 -0.2069 -0.5357 -2.3055 -0.0456 -0.0533 -0.1438 -0.0782 -0.1790 -0.1878 -0.1663
S-1416	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1416	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1416	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
D-1416	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
P-1416	-2.1838 -0.5393 -0.1727 -0.3346 -0.1069 -0.1113 -0.8469 -0.1529 -0.0647 -0.6721 -0.1204 -0.1256 -0.1239 -0.1914 -0.1576 -0.1713 -0.1652
S-1593	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1593	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1593	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
D-1593	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
P-1593	-2.1838 -0.5393 -0.1727 -0.3346 -0.1069 -0.1113 -0.8469 -0.1529 -0.0647 -0.6721 -0.1204 -0.1256 -0.1239 -0.1914 -0.1576 -0.1713 -0.1652
S-706	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-706	Do not remove the blue cap from the BAXJECT II device .
H-706	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
D-706	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
P-706	-1.1124 -0.7865 -0.1090 -1.4985 -0.1502 -0.1720 -0.3638 -0.1206 -0.2876 -0.9557 -0.2821 -1.0073 -0.1167 -0.1590 -0.1032 -0.1589 -0.1604
S-1817	H-1123 Budapest Tel . : <unk> 361 202 19 80
T-1817	H-1123 Budapest Tel . : <<unk>> 361 202 19 80
H-1817	-0.2988002598285675	H-1123 Budapest Tel . : <unk> 361 202 19 80
D-1817	-0.2988002598285675	H-1123 Budapest Tel . : <unk> 361 202 19 80
P-1817	-1.5276 -0.1557 -0.1574 -0.1982 -1.0210 -0.0486 -0.1462 -0.1335 -0.1131 -0.1477 -0.0558 -0.5036 -0.1189 -0.1576 -0.1494 -0.1466
S-1846	Beim Auflösen und bei der Anwendung sind aseptische Techniken erforderlich .
T-1846	Aseptic technique is required during preparation of the solution and administration .
H-1846	-0.5025945901870728	<unk> Aseptic techniques are necessary when dissolving and administration .
D-1846	-0.5025945901870728	<unk> Aseptic techniques are necessary when dissolving and administration .
P-1846	-1.0273 -1.0300 -0.7331 -0.6236 -0.0671 -0.0869 -0.3358 -0.5214 -0.7761 -0.0752 -0.1510 -0.1607 -0.1282 -1.9818 -0.1730 -0.1703
S-882	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-882	Do not remove the blue cap from the BAXJECT II device .
H-882	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
D-882	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
P-882	-1.1124 -0.7865 -0.1090 -1.4985 -0.1502 -0.1720 -0.3638 -0.1206 -0.2876 -0.9557 -0.2821 -1.0073 -0.1167 -0.1590 -0.1032 -0.1589 -0.1604
S-1058	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1058	Do not remove the blue cap from the BAXJECT II device .
H-1058	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
D-1058	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
P-1058	-1.1124 -0.7865 -0.1090 -1.4985 -0.1502 -0.1720 -0.3638 -0.1206 -0.2876 -0.9557 -0.2821 -1.0073 -0.1167 -0.1590 -0.1032 -0.1589 -0.1604
S-1240	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1240	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1240	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
D-1240	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
P-1240	-2.1838 -0.5393 -0.1727 -0.3346 -0.1069 -0.1113 -0.8469 -0.1529 -0.0647 -0.6721 -0.1204 -0.1256 -0.1239 -0.1914 -0.1576 -0.1713 -0.1652
S-1410	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1410	Do not remove the blue cap from the BAXJECT II device .
H-1410	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
D-1410	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
P-1410	-1.1124 -0.7865 -0.1090 -1.4985 -0.1502 -0.1720 -0.3638 -0.1206 -0.2876 -0.9557 -0.2821 -1.0073 -0.1167 -0.1590 -0.1032 -0.1589 -0.1604
S-1064	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1064	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1064	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
D-1064	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
P-1064	-2.1838 -0.5393 -0.1727 -0.3346 -0.1069 -0.1113 -0.8469 -0.1529 -0.0647 -0.6721 -0.1204 -0.1256 -0.1239 -0.1914 -0.1576 -0.1713 -0.1652
S-888	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-888	The product dissolves rapidly ( usually in less than 1 minute ) .
H-888	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
D-888	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
P-888	-2.1838 -0.5393 -0.1727 -0.3346 -0.1069 -0.1113 -0.8469 -0.1529 -0.0647 -0.6721 -0.1204 -0.1256 -0.1239 -0.1914 -0.1576 -0.1713 -0.1652
S-712	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-712	The product dissolves rapidly ( usually in less than 1 minute ) .
H-712	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
D-712	-0.36708736419677734	<unk> The product dissolves rapidly ( usually in less than 1 minute ) .
P-712	-2.1838 -0.5393 -0.1727 -0.3346 -0.1069 -0.1113 -0.8469 -0.1529 -0.0647 -0.6721 -0.1204 -0.1256 -0.1239 -0.1914 -0.1576 -0.1713 -0.1652
S-515	Advate ist sowohl zur kurz- als auch zur langfristigen Anwendung angezeigt .
T-515	Advate is intended for either short-term or long-term use .
H-515	-0.5574893355369568	<unk> Advate is indicated for both short- and long-term use .
D-515	-0.5574893355369568	<unk> Advate is indicated for both short- and long-term use .
P-515	-0.8836 -3.2176 -0.1246 -0.2289 -0.0978 -0.2974 -1.0419 -0.0425 -0.2016 -0.1395 -1.8232 -0.2951 -0.0803 -0.1303 -0.1455 -0.1700
S-1613	Arzneimittel auf eingeschränkte ärztliche Verschreibung ( siehe Anhang I :
T-1613	Medicinal product subject to restricted medical prescription ( See Annex I :
H-1613	-0.39900949597358704	<unk> Limited prescription medicinal products ( see Annex I :
D-1613	-0.39900949597358704	<unk> Limited prescription medicinal products ( see Annex I :
P-1613	-0.4799 -0.7804 -0.9111 -0.3274 -1.2075 -0.0712 -0.1463 -0.2852 -0.1324 -0.1178 -0.3682 -0.2028 -0.1570
S-1474	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1474	For instructions for reconstitution prior to administration , see section 6.6 .
H-1474	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
D-1474	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
P-1474	-0.6443 -2.0083 -0.0321 -1.1771 -0.4612 -0.1227 -0.1114 -0.5886 -0.2301 -0.1696 -0.1827 -0.1780 -0.1572
S-1298	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1298	For instructions for reconstitution prior to administration , see section 6.6 .
H-1298	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
D-1298	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
P-1298	-0.6443 -2.0083 -0.0321 -1.1771 -0.4612 -0.1227 -0.1114 -0.5886 -0.2301 -0.1696 -0.1827 -0.1780 -0.1572
S-1122	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1122	For instructions for reconstitution prior to administration , see section 6.6 .
H-1122	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
D-1122	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
P-1122	-0.6443 -2.0083 -0.0321 -1.1771 -0.4612 -0.1227 -0.1114 -0.5886 -0.2301 -0.1696 -0.1827 -0.1780 -0.1572
S-923	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-923	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-923	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
D-923	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
P-923	-0.8135 -1.6110 -0.0822 -0.4788 -0.0819 -0.0677 -0.0989 -0.1538 -0.1261 -0.1468 -0.1203 -1.2057 -0.1069 -0.2014 -0.2585 -0.1474 -0.1317 -0.1490 -0.1572
S-1234	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1234	Do not remove the blue cap from the BAXJECT II device .
H-1234	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
D-1234	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
P-1234	-1.1124 -0.7865 -0.1090 -1.4985 -0.1502 -0.1720 -0.3638 -0.1206 -0.2876 -0.9557 -0.2821 -1.0073 -0.1167 -0.1590 -0.1032 -0.1589 -0.1604
S-946	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-946	For instructions for reconstitution prior to administration , see section 6.6 .
H-946	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
D-946	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
P-946	-0.6443 -2.0083 -0.0321 -1.1771 -0.4612 -0.1227 -0.1114 -0.5886 -0.2301 -0.1696 -0.1827 -0.1780 -0.1572
S-1099	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1099	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1099	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
D-1099	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
P-1099	-0.8135 -1.6110 -0.0822 -0.4788 -0.0819 -0.0677 -0.0989 -0.1538 -0.1261 -0.1468 -0.1203 -1.2057 -0.1069 -0.2014 -0.2585 -0.1474 -0.1317 -0.1490 -0.1572
S-573	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-573	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-573	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
D-573	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
P-573	-0.8135 -1.6110 -0.0822 -0.4788 -0.0819 -0.0677 -0.0989 -0.1538 -0.1261 -0.1468 -0.1203 -1.2057 -0.1069 -0.2014 -0.2585 -0.1474 -0.1317 -0.1490 -0.1572
S-1934	Blister ( PCTFE<unk> PVC<unk> Alu )
T-1934	Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu )
H-1934	-0.520818293094635	<unk> Blister ( PCTFE<unk> PVC/ aluminium )
D-1934	-0.520818293094635	<unk> Blister ( PCTFE<unk> PVC/ aluminium )
P-1934	-1.9114 -1.2496 -0.0747 -0.1685 -2.1922 -0.1406 -0.1556 -0.1576 -0.2190 -0.1352 -0.1645 -0.1808 -0.1389 -0.2510 -1.4089 -0.1506 -0.1547
S-1951	Aerinaze ist ebenfalls kontraindiziert bei Patienten mit :
T-1951	Aerinaze is also contraindicated in patients with : narrow-angle glaucoma , urinary retention , cardiovascular diseases such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism ,
H-1951	-0.3212668001651764	<unk> Aerinaze is also contraindicated for patients with :
D-1951	-0.3212668001651764	<unk> Aerinaze is also contraindicated for patients with :
P-1951	-1.8493 -0.7364 -0.1580 -0.1625 -0.1493 -0.1860 -0.1175 -0.0846 -0.0865 -0.0434 -0.2180 -0.1368 -0.5851 -0.1509 -0.1548
S-1904	Aerinaze enthält zwei arzneilich wirksame Bestandteile :
T-1904	Aerinaze contains two active substances : desloratadine , an antihistamine , and pseudoephedrine , which is a nasal decongestant .
H-1904	-0.3761497139930725	<unk> Aerinaze contains two active ingredients :
D-1904	-0.3761497139930725	<unk> Aerinaze contains two active ingredients :
P-1904	-2.2200 -0.6031 -0.1856 -0.1601 -0.1484 -0.1830 -0.1223 -0.1228 -0.1393 -0.3101 -0.1646 -0.1546
S-1773	Am Ende der Packungsbeilage finden Sie genaue Informationen zur Selbstbehandlung .
T-1773	Detailed instructions for self-administration are given at the end of this package leaflet .
H-1773	-0.6217191219329834	<unk> At the end of the package leaflet you will find detailed information on self treatment .
D-1773	-0.6217191219329834	<unk> At the end of the package leaflet you will find detailed information on self treatment .
P-1773	-1.9108 -1.8240 -0.1371 -0.4062 -0.1609 -0.2535 -1.3880 -0.0737 -0.0202 -0.0681 -0.2969 -0.3549 -1.3235 -1.7064 -0.2030 -0.4222 -0.5112 -1.0500 -0.1557 -0.1679
S-1758	Normalerweise wird die Ersatztherapie mit ADVATE lebenslang durchgeführt .
T-1758	Usually , the replacement therapy with ADVATE is a life-long treatment .
H-1758	-0.5780985355377197	<unk> Replacement therapy with ADVATE is usually lifelong .
D-1758	-0.5780985355377197	<unk> Replacement therapy with ADVATE is usually lifelong .
P-1758	-1.0246 -2.8529 -0.1506 -0.4968 -0.0786 -0.1557 -0.1738 -0.1764 -0.0868 -0.0910 -0.2062 -0.1042 -3.0930 -0.2382 -0.1423 -0.1784
S-1451	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1451	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1451	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
D-1451	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
P-1451	-0.8135 -1.6110 -0.0822 -0.4788 -0.0819 -0.0677 -0.0989 -0.1538 -0.1261 -0.1468 -0.1203 -1.2057 -0.1069 -0.2014 -0.2585 -0.1474 -0.1317 -0.1490 -0.1572
S-1275	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1275	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1275	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
D-1275	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
P-1275	-0.8135 -1.6110 -0.0822 -0.4788 -0.0819 -0.0677 -0.0989 -0.1538 -0.1261 -0.1468 -0.1203 -1.2057 -0.1069 -0.2014 -0.2585 -0.1474 -0.1317 -0.1490 -0.1572
S-1587	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1587	Do not remove the blue cap from the BAXJECT II device .
H-1587	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
D-1587	-0.4437685012817383	<unk> Do not remove the blue cap from the BAXJECT II .
P-1587	-1.1124 -0.7865 -0.1090 -1.4985 -0.1502 -0.1720 -0.3638 -0.1206 -0.2876 -0.9557 -0.2821 -1.0073 -0.1167 -0.1590 -0.1032 -0.1589 -0.1604
S-747	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-747	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-747	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
D-747	-0.32309502363204956	<unk> frequency of dosage ( hours ) / duration of treatment ( days )
P-747	-0.8135 -1.6110 -0.0822 -0.4788 -0.0819 -0.0677 -0.0989 -0.1538 -0.1261 -0.1468 -0.1203 -1.2057 -0.1069 -0.2014 -0.2585 -0.1474 -0.1317 -0.1490 -0.1572
S-1983	Die Wechselwirkung zwischen Aerinaze und Alkohol wurde nicht untersucht .
T-1983	The interaction with Aerinaze and alcohol has not been studied .
H-1983	-0.3799154460430145	<unk> The interaction between Aerinaze and alcohol was not investigated .
D-1983	-0.3799154460430145	<unk> The interaction between Aerinaze and alcohol was not investigated .
P-1983	-2.4897 -0.8472 -0.3287 -0.0593 -0.2836 -0.3367 -0.1085 -0.1285 -0.1175 -0.1438 -0.1280 -0.0896 -0.1664 -0.1688 -0.7294 -0.1599 -0.1730
S-1800	Im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1800	Keep the vial in the outer carton in order to protect from light .
H-1800	-0.38505804538726807	<unk> Store in a carton to protect from light .
D-1800	-0.38505804538726807	<unk> Store in a carton to protect from light .
P-1800	-2.3140 -0.2251 -0.6449 -0.1870 -0.2188 -0.0388 -0.2530 -0.0821 -0.1604 -0.1535 -0.1641 -0.1790
S-1575	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1575	- Dispose any unused product or waste material in accordance with local requirements .
H-1575	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
D-1575	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
P-1575	-2.5290 -0.0519 -0.0721 -0.0967 -0.2020 -0.1413 -0.1938 -0.1036 -0.0693 -0.1530 -1.2314 -0.0346 -3.6559 -0.1136 -0.8820 -0.1560
S-1398	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1398	- Dispose any unused product or waste material in accordance with local requirements .
H-1398	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
D-1398	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
P-1398	-2.5290 -0.0519 -0.0721 -0.0967 -0.2020 -0.1413 -0.1938 -0.1036 -0.0693 -0.1530 -1.2314 -0.0346 -3.6559 -0.1136 -0.8820 -0.1560
S-1222	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1222	- Dispose any unused product or waste material in accordance with local requirements .
H-1222	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
D-1222	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
P-1222	-2.5290 -0.0519 -0.0721 -0.0967 -0.2020 -0.1413 -0.1938 -0.1036 -0.0693 -0.1530 -1.2314 -0.0346 -3.6559 -0.1136 -0.8820 -0.1560
S-1046	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1046	- Dispose any unused product or waste material in accordance with local requirements .
H-1046	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
D-1046	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
P-1046	-2.5290 -0.0519 -0.0721 -0.0967 -0.2020 -0.1413 -0.1938 -0.1036 -0.0693 -0.1530 -1.2314 -0.0346 -3.6559 -0.1136 -0.8820 -0.1560
S-870	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-870	- Dispose any unused product or waste material in accordance with local requirements .
H-870	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
D-870	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
P-870	-2.5290 -0.0519 -0.0721 -0.0967 -0.2020 -0.1413 -0.1938 -0.1036 -0.0693 -0.1530 -1.2314 -0.0346 -3.6559 -0.1136 -0.8820 -0.1560
S-694	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-694	- Dispose any unused product or waste material in accordance with local requirements .
H-694	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
D-694	-0.6053758859634399	- Any unused product or waste material should be disposed according to national
P-694	-2.5290 -0.0519 -0.0721 -0.0967 -0.2020 -0.1413 -0.1938 -0.1036 -0.0693 -0.1530 -1.2314 -0.0346 -3.6559 -0.1136 -0.8820 -0.1560
S-770	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-770	For instructions for reconstitution prior to administration , see section 6.6 .
H-770	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
D-770	-0.46639665961265564	<unk> Reconstitution information prior to administration see section 6.6 .
P-770	-0.6443 -2.0083 -0.0321 -1.1771 -0.4612 -0.1227 -0.1114 -0.5886 -0.2301 -0.1696 -0.1827 -0.1780 -0.1572
S-1138	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1138	To be taken into consideration by patients on a controlled sodium diet .
H-1138	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
D-1138	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
P-1138	-1.1289 -0.3647 -0.9708 -0.1711 -0.9042 -1.7804 -0.6945 -0.2326 -0.0413 -0.7106 -0.3031 -0.0660 -0.1748 -0.1999
S-786	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-786	To be taken into consideration by patients on a controlled sodium diet .
H-786	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
D-786	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
P-786	-1.1289 -0.3647 -0.9708 -0.1711 -0.9042 -1.7804 -0.6945 -0.2326 -0.0413 -0.7106 -0.3031 -0.0660 -0.1748 -0.1999
S-179	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-179	No specific information is available on the treatment of overdose with alendronate .
H-179	-0.491680383682251	<unk> Specific experience in the treatment of overdose with alendronate is not available .
D-179	-0.491680383682251	<unk> Specific experience in the treatment of overdose with alendronate is not available .
P-179	-1.4599 -0.9089 -0.0726 -0.1457 -0.1938 -0.8990 -0.1533 -0.1366 -0.6729 -0.2723 -0.1401 -0.0810 -0.1087 -0.0754 -0.0162 -1.5212 -1.5560 -1.0953 -0.1561 -0.1684
S-90	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-90	The recommended dosage is one ADROVANCE tablet once weekly .
H-90	-0.3733346164226532	<unk> The recommended dose is one ADROVANCE tablet weekly .
D-90	-0.3733346164226532	<unk> The recommended dose is one ADROVANCE tablet weekly .
P-90	-1.6223 -0.2042 -0.0492 -0.4178 -0.1303 -0.1532 -0.1660 -0.1022 -0.1583 -0.1005 -0.8060 -0.1473 -0.1101 -1.4677 -0.1450 -0.1931
S-1850	Fragen und Antworten zur Rücknahme des Antrags auf Genehmigung für das Inverkehrbringen von Advexin
T-1850	Questions and answers on the withdrawal of the marketing application for Advexin
H-1850	-0.6277233362197876	<unk> Questions and Answers on the withdrawal of the marketing authorisation application for Advexin
D-1850	-0.6277233362197876	<unk> Questions and Answers on the withdrawal of the marketing authorisation application for Advexin
P-1850	-0.6331 -3.1059 -0.2543 -0.1889 -1.1740 -0.5040 -1.9193 -0.4062 -0.6215 -0.1395 -0.3977 -0.6077 -0.0489 -0.0546 -0.3122 -0.2285 -1.4609 -0.2024 -0.1360 -0.1587
S-863	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-863	19 6.6 Special precautions for disposal and other handling
H-863	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
D-863	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
P-863	-1.2805 -0.1556 -0.0957 -0.3883 -0.0484 -0.0911 -0.1356 -0.2846 -0.1414 -0.1318 -0.1990 -0.1251 -0.8466 -0.1614
S-1314	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1314	To be taken into consideration by patients on a controlled sodium diet .
H-1314	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
D-1314	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
P-1314	-1.1289 -0.3647 -0.9708 -0.1711 -0.9042 -1.7804 -0.6945 -0.2326 -0.0413 -0.7106 -0.3031 -0.0660 -0.1748 -0.1999
S-367	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-367	No specific information is available on the treatment of overdose with alendronate .
H-367	-0.491680383682251	<unk> Specific experience in the treatment of overdose with alendronate is not available .
D-367	-0.491680383682251	<unk> Specific experience in the treatment of overdose with alendronate is not available .
P-367	-1.4599 -0.9089 -0.0726 -0.1457 -0.1938 -0.8990 -0.1533 -0.1366 -0.6729 -0.2723 -0.1401 -0.0810 -0.1087 -0.0754 -0.0162 -1.5212 -1.5560 -1.0953 -0.1561 -0.1684
S-962	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-962	To be taken into consideration by patients on a controlled sodium diet .
H-962	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
D-962	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
P-962	-1.1289 -0.3647 -0.9708 -0.1711 -0.9042 -1.7804 -0.6945 -0.2326 -0.0413 -0.7106 -0.3031 -0.0660 -0.1748 -0.1999
S-684	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-684	Keep the vial in the outer carton in order to protect from light .
H-684	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
D-684	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
P-684	-3.4421 -0.9831 -0.1538 -0.0927 -0.1198 -0.1464 -0.1598 -0.7657 -0.0375 -0.3154 -0.0887 -0.2152 -0.1420 -0.1721 -0.1814
S-612	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-612	To be taken into consideration by patients on a controlled sodium diet .
H-612	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
D-612	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
P-612	-1.1289 -0.3647 -0.9708 -0.1711 -0.9042 -1.7804 -0.6945 -0.2326 -0.0413 -0.7106 -0.3031 -0.0660 -0.1748 -0.1999
S-1215	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1215	39 6.6 Special precautions for disposal and other handling
H-1215	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
D-1215	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
P-1215	-1.2805 -0.1556 -0.0957 -0.3883 -0.0484 -0.0911 -0.1356 -0.2846 -0.1414 -0.1318 -0.1990 -0.1251 -0.8466 -0.1614
S-1039	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1039	29 6.6 Special precautions for disposal and other handling
H-1039	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
D-1039	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
P-1039	-1.2805 -0.1556 -0.0957 -0.3883 -0.0484 -0.0911 -0.1356 -0.2846 -0.1414 -0.1318 -0.1990 -0.1251 -0.8466 -0.1614
S-158	5 Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-158	It is not known whether alendronate is excreted into human breast milk .
H-158	-0.4857214689254761	5 It is not known whether alendronate contributes to breast milk .
D-158	-0.4857214689254761	5 It is not known whether alendronate contributes to breast milk .
P-158	-0.6762 -0.4727 -0.1047 -0.2562 -0.0862 -0.2523 -0.0562 -0.0983 -0.0579 -0.0069 -5.2475 -0.0403 -0.1748 -0.3237 -0.1012 -0.1547 -0.1475
S-1568	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1568	6.6 Special precautions for disposal and other handling
H-1568	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
D-1568	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
P-1568	-1.2805 -0.1556 -0.0957 -0.3883 -0.0484 -0.0911 -0.1356 -0.2846 -0.1414 -0.1318 -0.1990 -0.1251 -0.8466 -0.1614
S-1490	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1490	To be taken into consideration by patients on a controlled sodium diet .
H-1490	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
D-1490	-0.5530619025230408	<unk> This must be considered when following a sodium controlled diet .
P-1490	-1.1289 -0.3647 -0.9708 -0.1711 -0.9042 -1.7804 -0.6945 -0.2326 -0.0413 -0.7106 -0.3031 -0.0660 -0.1748 -0.1999
S-687	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-687	6.6 Special precautions for disposal and other handling
H-687	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
D-687	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
P-687	-1.2805 -0.1556 -0.0957 -0.3883 -0.0484 -0.0911 -0.1356 -0.2846 -0.1414 -0.1318 -0.1990 -0.1251 -0.8466 -0.1614
S-277	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-277	The recommended dosage is one ADROVANCE tablet once weekly .
H-277	-0.3733346164226532	<unk> The recommended dose is one ADROVANCE tablet weekly .
D-277	-0.3733346164226532	<unk> The recommended dose is one ADROVANCE tablet weekly .
P-277	-1.6223 -0.2042 -0.0492 -0.4178 -0.1303 -0.1532 -0.1660 -0.1022 -0.1583 -0.1005 -0.8060 -0.1473 -0.1101 -1.4677 -0.1450 -0.1931
S-1486	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1486	Rarely , inhibitors may develop after the first 100 exposure days.
H-1486	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
D-1486	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
P-1486	-1.7413 -0.5976 -0.1284 -0.1257 -0.5599 -0.1069 -0.0452 -0.0643 -0.1122 -0.5952 -1.5478 -0.1289 -0.1314 -0.0944 -0.0828 -0.8283 -0.1514 -0.0317 -0.1616 -0.1828
S-1310	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1310	Rarely , inhibitors may develop after the first 100 exposure days.
H-1310	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
D-1310	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
P-1310	-1.7413 -0.5976 -0.1284 -0.1257 -0.5599 -0.1069 -0.0452 -0.0643 -0.1122 -0.5952 -1.5478 -0.1289 -0.1314 -0.0944 -0.0828 -0.8283 -0.1514 -0.0317 -0.1616 -0.1828
S-154	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-154	There are no adequate data from the use of ADROVANCE in pregnant women .
H-154	-0.3711816370487213	<unk> There are no adequate data on the use of ADROVANCE in pregnant women .
D-154	-0.3711816370487213	<unk> There are no adequate data on the use of ADROVANCE in pregnant women .
P-154	-1.4263 -1.7316 -0.2813 -0.0712 -0.8875 -0.1741 -0.4189 -0.1748 -0.2407 -0.1357 -0.1348 -0.0986 -0.1570 -0.1059 -0.7475 -0.1373 -0.0778 -0.0984 -0.1522 -0.1722
S-3	Adenuric ist ein Arzneimittel , das den Wirkstoff Febuxostat enthält .
T-3	Adenuric is a medicine containing the active substance febuxostat .
H-3	-0.20779016613960266	<unk> Adenuric is a medicine containing the active substance Febuxostat .
D-3	-0.20779016613960266	<unk> Adenuric is a medicine containing the active substance Febuxostat .
P-3	-0.8423 -0.1509 -0.1814 -0.1357 -0.1324 -0.1328 -0.1273 -0.1719 -0.4980 -0.1438 -0.0474 -0.0468 -0.0647 -0.1292 -0.1278 -0.5975 -0.1025 -0.1576 -0.1580
S-1942	Die empfohlene Dosierung von Aerinaze beträgt eine Tablette zweimal täglich .
T-1942	The recommended dose of Aerinaze is one tablet twice a day .
H-1942	-0.2759651243686676	<unk> The recommended dose of Aerinaze is one tablet twice daily .
D-1942	-0.2759651243686676	<unk> The recommended dose of Aerinaze is one tablet twice daily .
P-1942	-1.7602 -0.2959 -0.0605 -0.2395 -0.1351 -0.1581 -0.1183 -0.1402 -0.1299 -0.1567 -0.1204 -0.2327 -0.1240 -0.1060 -0.3005 -0.5569 -0.1452 -0.1873
S-1732	Faktor VIII ist notwendig um im Blut Gerinnsel zu bilden und so Blutungen zu stoppen .
T-1732	Factor VIII is necessary for the blood to form clots and stop bleedings .
H-1732	-0.6805964708328247	<unk> factor VIII is necessary to clot in the blood to stop bleeding .
D-1732	-0.6805964708328247	<unk> factor VIII is necessary to clot in the blood to stop bleeding .
P-1732	-0.7353 -2.2738 -0.1659 -0.0927 -0.1331 -0.0798 -0.1453 -1.4385 -0.7474 -0.2579 -0.4966 -0.0655 -2.7298 -1.5968 -0.5923 -0.1963 -0.1642 -0.3394
S-1565	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1565	Keep the vial in the outer carton in order to protect from light .
H-1565	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
D-1565	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
P-1565	-3.4421 -0.9831 -0.1538 -0.0927 -0.1198 -0.1464 -0.1598 -0.7657 -0.0375 -0.3154 -0.0887 -0.2152 -0.1420 -0.1721 -0.1814
S-608	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-608	Rarely , inhibitors may develop after the first 100 exposure days.
H-608	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
D-608	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
P-608	-1.7413 -0.5976 -0.1284 -0.1257 -0.5599 -0.1069 -0.0452 -0.0643 -0.1122 -0.5952 -1.5478 -0.1289 -0.1314 -0.0944 -0.0828 -0.8283 -0.1514 -0.0317 -0.1616 -0.1828
S-1388	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1388	Keep the vial in the outer carton in order to protect from light .
H-1388	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
D-1388	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
P-1388	-3.4421 -0.9831 -0.1538 -0.0927 -0.1198 -0.1464 -0.1598 -0.7657 -0.0375 -0.3154 -0.0887 -0.2152 -0.1420 -0.1721 -0.1814
S-782	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-782	Rarely , inhibitors may develop after the first 100 exposure days.
H-782	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
D-782	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
P-782	-1.7413 -0.5976 -0.1284 -0.1257 -0.5599 -0.1069 -0.0452 -0.0643 -0.1122 -0.5952 -1.5478 -0.1289 -0.1314 -0.0944 -0.0828 -0.8283 -0.1514 -0.0317 -0.1616 -0.1828
S-1212	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1212	Keep the vial in the outer carton in order to protect from light .
H-1212	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
D-1212	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
P-1212	-3.4421 -0.9831 -0.1538 -0.0927 -0.1198 -0.1464 -0.1598 -0.7657 -0.0375 -0.3154 -0.0887 -0.2152 -0.1420 -0.1721 -0.1814
S-1134	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1134	Rarely , inhibitors may develop after the first 100 exposure days.
H-1134	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
D-1134	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
P-1134	-1.7413 -0.5976 -0.1284 -0.1257 -0.5599 -0.1069 -0.0452 -0.0643 -0.1122 -0.5952 -1.5478 -0.1289 -0.1314 -0.0944 -0.0828 -0.8283 -0.1514 -0.0317 -0.1616 -0.1828
S-1036	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1036	Keep the vial in the outer carton in order to protect from light .
H-1036	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
D-1036	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
P-1036	-3.4421 -0.9831 -0.1538 -0.0927 -0.1198 -0.1464 -0.1598 -0.7657 -0.0375 -0.3154 -0.0887 -0.2152 -0.1420 -0.1721 -0.1814
S-958	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-958	Rarely , inhibitors may develop after the first 100 exposure days.
H-958	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
D-958	-0.3708896040916443	<unk> In rare cases , inhibitors may form after the first 100 days of exposure .
P-958	-1.7413 -0.5976 -0.1284 -0.1257 -0.5599 -0.1069 -0.0452 -0.0643 -0.1122 -0.5952 -1.5478 -0.1289 -0.1314 -0.0944 -0.0828 -0.8283 -0.1514 -0.0317 -0.1616 -0.1828
S-860	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-860	Keep the vial in the outer carton in order to protect from light .
H-860	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
D-860	-0.46771126985549927	<unk> Store the vial in a carton to protect from light .
P-860	-3.4421 -0.9831 -0.1538 -0.0927 -0.1198 -0.1464 -0.1598 -0.7657 -0.0375 -0.3154 -0.0887 -0.2152 -0.1420 -0.1721 -0.1814
S-1391	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1391	6.6 Special precautions for disposal and other handling
H-1391	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
D-1391	-0.29179510474205017	6.6 Special precautions for disposal and other handling <unk>
P-1391	-1.2805 -0.1556 -0.0957 -0.3883 -0.0484 -0.0911 -0.1356 -0.2846 -0.1414 -0.1318 -0.1990 -0.1251 -0.8466 -0.1614
S-346	Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-346	It is not known whether alendronate is excreted into human breast milk .
H-346	-0.5616098642349243	<unk> It is not known whether alendronate contributes to breast milk .
D-346	-0.5616098642349243	<unk> It is not known whether alendronate contributes to breast milk .
P-346	-1.0057 -1.2254 -0.1356 -0.2823 -0.0956 -0.4339 -0.0528 -0.0978 -0.0595 -0.0068 -5.0808 -0.0367 -0.1888 -0.3606 -0.1396 -0.1533 -0.1922
S-336	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-336	No adverse reactions attributable to their concomitant use were identified .
H-336	-0.5301811695098877	<unk> Adverse reactions resulting from this combined use were not observed .
D-336	-0.5301811695098877	<unk> Adverse reactions resulting from this combined use were not observed .
P-336	-0.6652 -1.0469 -0.0296 -0.0341 -0.1604 -1.6824 -0.1153 -0.2512 -1.4290 -1.2582 -0.2391 -0.1902 -0.4575 -0.1727 -0.2211
S-349	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-349	No studies on the effects on the ability to drive and use machines have been performed .
H-349	-0.5358777642250061	<unk> No studies were carried out on ability to drive or use machines .
D-349	-0.5358777642250061	<unk> No studies were carried out on ability to drive or use machines .
P-349	-0.6658 -0.4247 -0.1252 -1.9715 -0.5581 -0.1458 -1.1725 -0.3524 -0.1964 -1.2696 -0.1517 -0.3123 -0.3219 -0.1456 -0.2247
S-1966	Ebenfalls zur Vorsicht geraten wird bei Patienten , die mit anderen Sympathomimetika behandelt werden .
T-1966	Caution should also be exercised in patients being treated with other sympathomimetics .
H-1966	-0.432594358921051	<unk> Caution should also be exercised when being treated with other sympathomimetics .
D-1966	-0.432594358921051	<unk> Caution should also be exercised when being treated with other sympathomimetics .
P-1966	-1.1637 -1.1769 -0.0435 -0.8926 -0.1249 -0.2046 -0.1325 -0.1732 -0.3742 -2.7518 -0.1167 -0.1236 -0.2921 -0.0340 -0.0462 -0.0689 -0.1446 -0.1631 -0.1920
S-1611	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
T-1611	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-1611	-0.5275176763534546	<unk> Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
D-1611	-0.5275176763534546	<unk> Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
P-1611	-2.0052 -1.0812 -0.1355 -0.2216 -0.5844 -1.6235 -0.1329 -1.2439 -0.6166 -0.0731 -0.1468 -0.0988 -0.1190 -0.1264 -0.7760 -0.1248 -0.1490 -0.2815 -0.1220 -1.2602 -0.1555
S-148	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-148	No adverse reactions attributable to their concomitant use were identified .
H-148	-0.5301811695098877	<unk> Adverse reactions resulting from this combined use were not observed .
D-148	-0.5301811695098877	<unk> Adverse reactions resulting from this combined use were not observed .
P-148	-0.6652 -1.0469 -0.0296 -0.0341 -0.1604 -1.6824 -0.1153 -0.2512 -1.4290 -1.2582 -0.2391 -0.1902 -0.4575 -0.1727 -0.2211
S-815	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-815	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-815	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-815	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-815	-0.9747 -2.3894 -2.1167 -0.1094 -0.1020 -0.0880 -0.2714 -0.3152 -0.1309 -0.1175 -0.1600 -0.4616 -0.1967 -0.1269 -0.1486 -0.1774 -0.3179 -0.2032 -0.0429 -0.1657 -0.1695
S-161	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-161	No studies on the effects on the ability to drive and use machines have been performed .
H-161	-0.5358777642250061	<unk> No studies were carried out on ability to drive or use machines .
D-161	-0.5358777642250061	<unk> No studies were carried out on ability to drive or use machines .
P-161	-0.6658 -0.4247 -0.1252 -1.9715 -0.5581 -0.1458 -1.1725 -0.3524 -0.1964 -1.2696 -0.1517 -0.3123 -0.3219 -0.1456 -0.2247
S-1903	Sobald die Nase wieder frei ist , können die Patienten Desloratadin allein einnehmen .
T-1903	Once the nose has cleared , patients can use desloratadine alone .
H-1903	-0.49742886424064636	<unk> Once the nose is clear , patients can take desloratadine alone .
D-1903	-0.49742886424064636	<unk> Once the nose is clear , patients can take desloratadine alone .
P-1903	-1.6794 -0.6483 -0.1345 -1.9070 -0.0683 -0.5087 -0.4564 -0.0867 -0.6027 -0.0731 -1.2115 -0.1258 -0.0948 -0.4187 -0.3780 -0.1629 -0.1411 -0.2556
S-1879	Zur Beurteilung eines neuen Antrags benötigt der CHMP in der Regel bis zu 210 Tage .
T-1879	The CHMP normally takes up to 210 days to evaluate a new application .
H-1879	-0.5374349355697632	<unk> The CHMP usually needs up to 210 days to consider a new application .
D-1879	-0.5374349355697632	<unk> The CHMP usually needs up to 210 days to consider a new application .
P-1879	-2.1709 -0.7000 -0.0746 -0.0474 -0.3954 -2.4007 -0.2174 -0.1128 -0.0672 -0.1134 -0.1481 -1.8600 -0.1775 -0.2873 -0.0349 -0.1577 -0.1713
S-307	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-307	While on treatment , these patients should avoid invasive dental procedures if possible .
H-307	-0.6913191080093384	<unk> During treatment , patients should avoid maxillary surgery as much as possible .
D-307	-0.6913191080093384	<unk> During treatment , patients should avoid maxillary surgery as much as possible .
P-307	-0.9043 -1.1084 -0.3221 -0.7565 -1.2863 -0.0729 -0.9018 -0.6298 -0.3532 -2.7429 -0.1763 -0.2458 -0.3397 -1.8062 -0.1637 -0.2832 -0.1520 -0.1986
S-119	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-119	While on treatment , these patients should avoid invasive dental procedures if possible .
H-119	-0.6913191080093384	<unk> During treatment , patients should avoid maxillary surgery as much as possible .
D-119	-0.6913191080093384	<unk> During treatment , patients should avoid maxillary surgery as much as possible .
P-119	-0.9043 -1.1084 -0.3221 -0.7565 -1.2863 -0.0729 -0.9018 -0.6298 -0.3532 -2.7429 -0.1763 -0.2458 -0.3397 -1.8062 -0.1637 -0.2832 -0.1520 -0.1986
S-376	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-376	The bone formed during treatment with alendronate is of normal quality .
H-376	-0.4313533902168274	<unk> The bone formed during alendronate therapy is of normal quality .
D-376	-0.4313533902168274	<unk> The bone formed during alendronate therapy is of normal quality .
P-376	-1.3560 -0.5606 -0.1025 -1.5353 -1.8159 -0.2789 -0.1242 -0.1161 -0.0266 -0.1292 -0.1235 -0.1448 -0.1301 -0.0705 -0.1699 -0.2173
S-641	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-641	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-641	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-641	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-641	-0.9747 -2.3894 -2.1167 -0.1094 -0.1020 -0.0880 -0.2714 -0.3152 -0.1309 -0.1175 -0.1600 -0.4616 -0.1967 -0.1269 -0.1486 -0.1774 -0.3179 -0.2032 -0.0429 -0.1657 -0.1695
S-1877	Als das Unternehmen seinen Antrag zurücknahm , war in dem Antragsverfahren Tag 179 erreicht .
T-1877	The application was at day 179 when the company withdrew .
H-1877	-0.5735938549041748	<unk> When the company withdrew its application , the application procedure achieved day 179 .
D-1877	-0.5735938549041748	<unk> When the company withdrew its application , the application procedure achieved day 179 .
P-1877	-1.4512 -0.2759 -0.1633 -0.2356 -0.4720 -0.4721 -0.1289 -0.0391 -0.2767 -2.1067 -0.2336 -0.7969 -1.5318 -1.2406 -0.3887 -0.1362 -0.1794 -0.1959
S-1245	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1245	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1245	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
D-1245	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
P-1245	-1.5441 -4.4097 -0.0619 -0.2395 -0.3517 -1.0355 -1.0309 -0.1522 -0.5705 -0.1322 -3.0301 -0.0914 -1.9942 -0.1263 -0.1268 -1.8487 -0.0847 -0.5040 -0.1536 -0.1624
S-1069	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1069	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1069	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
D-1069	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
P-1069	-1.5441 -4.4097 -0.0619 -0.2395 -0.3517 -1.0355 -1.0309 -0.1522 -0.5705 -0.1322 -3.0301 -0.0914 -1.9942 -0.1263 -0.1268 -1.8487 -0.0847 -0.5040 -0.1536 -0.1624
S-287	Vitamin D3 einmal pro Woche in ADROVANCE und von 800 I.E.
T-287	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-287	-0.4973166286945343	<unk> Vitamin D3 given weekly in ADROVANCE and 800 IU of <unk> <unk>
D-287	-0.4973166286945343	<unk> Vitamin D3 given weekly in ADROVANCE and 800 IU of <unk> <unk>
P-287	-1.1892 -2.6970 -0.0866 -0.1975 -0.1394 -1.6653 -0.2924 -0.1267 -0.1019 -0.1084 -0.1535 -0.0935 -0.5788 -0.1218 -0.6015 -0.1051 -0.0858 -1.0372 -0.4449 -0.4666 -0.1505
S-1851	Internationaler Freiname ( INN ) : Contusugene Ladenovec
T-1851	International non-proprietary name ( INN ) : contusugene ladenovec
H-1851	-0.5539516806602478	<unk> International Freiname ( INN ) : Contusugene Ladenovec
D-1851	-0.5539516806602478	<unk> International Freiname ( INN ) : Contusugene Ladenovec
P-1851	-2.1419 -0.3735 -1.1702 -0.1389 -0.1823 -0.1562 -0.1417 -0.1019 -0.1512 -0.1422 -1.1975 -0.7926 -0.1143 -0.0868 -2.4788 -0.1269 -0.7513 -0.1245 -0.1526
S-1808	Trometamol , Polysorbat 80 , Glutathion ( reduziert ) .
T-1808	trometamol , polysorbate 80 , and glutathione ( reduced ) .
H-1808	-0.32598355412483215	<unk> trometamol , polysorbate 80 , glutathione ( reduced ) .
D-1808	-0.32598355412483215	<unk> trometamol , polysorbate 80 , glutathione ( reduced ) .
P-1808	-0.9658 -1.7393 -0.1253 -0.1371 -0.0687 -0.1956 -0.2204 -0.0825 -0.0405 -0.1163 -0.1368 -0.1653 -2.0075 -0.0684 -0.0627 -0.1123 -0.1843 -0.1704 -0.0798 -0.1541 -0.1653 -0.1731
S-1598	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1598	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1598	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
D-1598	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
P-1598	-1.5441 -4.4097 -0.0619 -0.2395 -0.3517 -1.0355 -1.0309 -0.1522 -0.5705 -0.1322 -3.0301 -0.0914 -1.9942 -0.1263 -0.1268 -1.8487 -0.0847 -0.5040 -0.1536 -0.1624
S-1421	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1421	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1421	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
D-1421	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
P-1421	-1.5441 -4.4097 -0.0619 -0.2395 -0.3517 -1.0355 -1.0309 -0.1522 -0.5705 -0.1322 -3.0301 -0.0914 -1.9942 -0.1263 -0.1268 -1.8487 -0.0847 -0.5040 -0.1536 -0.1624
S-991	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-991	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-991	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-991	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-991	-0.9747 -2.3894 -2.1167 -0.1094 -0.1020 -0.0880 -0.2714 -0.3152 -0.1309 -0.1175 -0.1600 -0.4616 -0.1967 -0.1269 -0.1486 -0.1774 -0.3179 -0.2032 -0.0429 -0.1657 -0.1695
S-1167	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1167	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1167	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1167	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1167	-0.9747 -2.3894 -2.1167 -0.1094 -0.1020 -0.0880 -0.2714 -0.3152 -0.1309 -0.1175 -0.1600 -0.4616 -0.1967 -0.1269 -0.1486 -0.1774 -0.3179 -0.2032 -0.0429 -0.1657 -0.1695
S-893	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-893	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-893	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
D-893	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
P-893	-1.5441 -4.4097 -0.0619 -0.2395 -0.3517 -1.0355 -1.0309 -0.1522 -0.5705 -0.1322 -3.0301 -0.0914 -1.9942 -0.1263 -0.1268 -1.8487 -0.0847 -0.5040 -0.1536 -0.1624
S-717	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-717	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-717	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
D-717	-0.8825212121009827	<unk> Turn the system upwards ( with the concentrate-vial ) .
P-717	-1.5441 -4.4097 -0.0619 -0.2395 -0.3517 -1.0355 -1.0309 -0.1522 -0.5705 -0.1322 -3.0301 -0.0914 -1.9942 -0.1263 -0.1268 -1.8487 -0.0847 -0.5040 -0.1536 -0.1624
S-1812	Pharmazeutischer Unternehmer Baxter AG Industriestrasse 67 A-1221 Wien , Österreich
T-1812	95 Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna
H-1812	-0.5049713850021362	<unk> Marketing authorisation holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
D-1812	-0.5049713850021362	<unk> Marketing authorisation holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
P-1812	-1.1007 -1.2864 -0.1700 -0.1621 -0.0942 -1.0768 -0.1180 -0.2165 -0.9052 -0.6493 -0.1482 -2.3277 -0.1173 -0.0978 -0.1320 -0.1378 -0.1107 -0.8764 -0.1752 -0.5451 -0.1573
S-1520	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1520	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1520	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1520	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1520	-0.9747 -2.3894 -2.1167 -0.1094 -0.1020 -0.0880 -0.2714 -0.3152 -0.1309 -0.1175 -0.1600 -0.4616 -0.1967 -0.1269 -0.1486 -0.1774 -0.3179 -0.2032 -0.0429 -0.1657 -0.1695
S-1343	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1343	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1343	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1343	-0.4183657765388489	<unk> Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1343	-0.9747 -2.3894 -2.1167 -0.1094 -0.1020 -0.0880 -0.2714 -0.3152 -0.1309 -0.1175 -0.1600 -0.4616 -0.1967 -0.1269 -0.1486 -0.1774 -0.3179 -0.2032 -0.0429 -0.1657 -0.1695
S-188	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-188	The bone formed during treatment with alendronate is of normal quality .
H-188	-0.4313533902168274	<unk> The bone formed during alendronate therapy is of normal quality .
D-188	-0.4313533902168274	<unk> The bone formed during alendronate therapy is of normal quality .
P-188	-1.3560 -0.5606 -0.1025 -1.5353 -1.8159 -0.2789 -0.1242 -0.1161 -0.0266 -0.1292 -0.1235 -0.1448 -0.1301 -0.0705 -0.1699 -0.2173
S-1881	Sobald das Unternehmen Antworten auf diese Fragen übermittelt hat , werden diese vom CHMP geprüft .
T-1881	Once the company has supplied responses to the questions , the CHMP reviews them and may , before giving an opinion , ask any remaining questions at day 180.
H-1881	-0.7802191376686096	<unk> Once the company has supplied answers to these questions , the CHMP will consider them .
D-1881	-0.7802191376686096	<unk> Once the company has supplied answers to these questions , the CHMP will consider them .
P-1881	-1.4641 -0.3998 -0.2920 -0.1410 -0.5769 -4.1245 -0.0991 -1.4736 -0.1766 -0.2524 -0.9506 -0.2081 -2.0838 -0.1193 -0.0816 -0.2737 -0.8351 -1.6894 -0.1648 -0.1981
S-1508	60 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1508	55 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1508	-0.2889430820941925	60 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-1508	-0.2889430820941925	60 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-1508	-2.5770 -0.0849 -0.1766 -0.3475 -0.0595 -0.1281 -0.4069 -0.0295 -0.4995 -0.1082 -0.1472 -0.0881 -0.0881 -0.1371 -0.1550 -0.1150 -0.0977 -0.0940 -0.1501
S-1403	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1403	Remove caps from powder and solvent vials .
H-1403	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
D-1403	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
P-1403	-1.1182 -0.3376 -0.1070 -0.1071 -0.7642 -2.0306 -0.2812 -0.2290 -0.0314 -0.1207 -0.2113 -0.8891 -0.1272 -0.1051 -1.5293 -0.1565 -0.1389 -0.1688
S-1492	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1492	54 No interaction studies have been performed with ADVATE .
H-1492	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
D-1492	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
P-1492	-0.9750 -0.3337 -1.3278 -1.4064 -1.7235 -0.1396 -0.1688 -0.1934 -0.1717 -0.1799 -0.0791 -0.0919 -0.1653 -0.3327 -0.0828 -0.1456 -0.0336 -0.3912 -0.1728
S-614	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-614	No interaction studies have been performed with ADVATE. .
H-614	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
D-614	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
P-614	-0.9750 -0.3337 -1.3278 -1.4064 -1.7235 -0.1396 -0.1688 -0.1934 -0.1717 -0.1799 -0.0791 -0.0919 -0.1653 -0.3327 -0.0828 -0.1456 -0.0336 -0.3912 -0.1728
S-1140	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1140	34 No interaction studies have been performed with ADVATE .
H-1140	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
D-1140	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
P-1140	-0.9750 -0.3337 -1.3278 -1.4064 -1.7235 -0.1396 -0.1688 -0.1934 -0.1717 -0.1799 -0.0791 -0.0919 -0.1653 -0.3327 -0.0828 -0.1456 -0.0336 -0.3912 -0.1728
S-964	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-964	24 No interaction studies have been performed with ADVATE .
H-964	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
D-964	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
P-964	-0.9750 -0.3337 -1.3278 -1.4064 -1.7235 -0.1396 -0.1688 -0.1934 -0.1717 -0.1799 -0.0791 -0.0919 -0.1653 -0.3327 -0.0828 -0.1456 -0.0336 -0.3912 -0.1728
S-788	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-788	14 No interaction studies have been performed with ADVATE .
H-788	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
D-788	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
P-788	-0.9750 -0.3337 -1.3278 -1.4064 -1.7235 -0.1396 -0.1688 -0.1934 -0.1717 -0.1799 -0.0791 -0.0919 -0.1653 -0.3327 -0.0828 -0.1456 -0.0336 -0.3912 -0.1728
S-83	Den vollständigen Wortlaut des EPAR für ADROVANCE finden Sie hier .
T-83	The full EPAR for ADROVANCE is available here .
H-83	-0.39661315083503723	<unk> The full EPAR for ADROVANCE is available here .
D-83	-0.39661315083503723	<unk> The full EPAR for ADROVANCE is available here .
P-83	-2.7924 -0.5007 -0.1976 -0.3250 -0.0437 -0.1663 -0.1722 -0.1124 -0.1536 -0.0982 -0.6910 -0.2072 -0.4353 -0.0938 -0.1601 -0.1961
S-43	Der Inhaber der Genehmigung für das Inverkehrbringen ist Beaufour Ipsen Pharma .
T-43	The marketing authorisation holder is Beaufour Ipsen Pharma .
H-43	-0.5096918940544128	<unk> The holder of the marketing authorisation is Beaufour Ipsen Pharma .
D-43	-0.5096918940544128	<unk> The holder of the marketing authorisation is Beaufour Ipsen Pharma .
P-43	-1.8788 -1.6636 -0.0739 -0.1378 -0.1712 -0.0692 -0.0982 -0.0751 -0.1306 -0.5232 -0.8109 -0.2105 -2.0995 -0.7355 -0.0437 -0.0933 -0.2022 -0.1571
S-1316	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1316	44 No interaction studies have been performed with ADVATE .
H-1316	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
D-1316	-0.4271199405193329	<unk> No studies of the interaction of ADVATE with other medicinal products .
P-1316	-0.9750 -0.3337 -1.3278 -1.4064 -1.7235 -0.1396 -0.1688 -0.1934 -0.1717 -0.1799 -0.0791 -0.0919 -0.1653 -0.3327 -0.0828 -0.1456 -0.0336 -0.3912 -0.1728
S-1580	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1580	Remove caps from powder and solvent vials .
H-1580	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
D-1580	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
P-1580	-1.1182 -0.3376 -0.1070 -0.1071 -0.7642 -2.0306 -0.2812 -0.2290 -0.0314 -0.1207 -0.2113 -0.8891 -0.1272 -0.1051 -1.5293 -0.1565 -0.1389 -0.1688
S-1010	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1010	Activated Factor X converts prothrombin to thrombin .
H-1010	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
D-1010	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
P-1010	-1.4326 -1.2270 -0.0682 -0.1073 -0.0947 -0.1514 -0.1117 -0.4592 -0.1505 -0.0411 -0.3107 -0.1333 -0.7586 -0.1011 -0.4481 -0.1323 -0.1465 -0.1806
S-1227	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1227	Remove caps from powder and solvent vials .
H-1227	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
D-1227	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
P-1227	-1.1182 -0.3376 -0.1070 -0.1071 -0.7642 -2.0306 -0.2812 -0.2290 -0.0314 -0.1207 -0.2113 -0.8891 -0.1272 -0.1051 -1.5293 -0.1565 -0.1389 -0.1688
S-1051	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1051	Remove caps from powder and solvent vials .
H-1051	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
D-1051	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
P-1051	-1.1182 -0.3376 -0.1070 -0.1071 -0.7642 -2.0306 -0.2812 -0.2290 -0.0314 -0.1207 -0.2113 -0.8891 -0.1272 -0.1051 -1.5293 -0.1565 -0.1389 -0.1688
S-875	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-875	Remove caps from powder and solvent vials .
H-875	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
D-875	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
P-875	-1.1182 -0.3376 -0.1070 -0.1071 -0.7642 -2.0306 -0.2812 -0.2290 -0.0314 -0.1207 -0.2113 -0.8891 -0.1272 -0.1051 -1.5293 -0.1565 -0.1389 -0.1688
S-699	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-699	Remove caps from powder and solvent vials .
H-699	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
D-699	-0.4696190357208252	<unk> Remove the caps from the vials with powder and solvents .
P-699	-1.1182 -0.3376 -0.1070 -0.1071 -0.7642 -2.0306 -0.2812 -0.2290 -0.0314 -0.1207 -0.2113 -0.8891 -0.1272 -0.1051 -1.5293 -0.1565 -0.1389 -0.1688
S-539	Falls sich Antikörper entwickeln , ist die Wirksamkeit von Advate nicht gewährleistet .
T-539	If antibodies develop , Advate will not work effectively .
H-539	-0.388761430978775	<unk> If antibodies develop , the efficacy of Advate is not assured .
D-539	-0.388761430978775	<unk> If antibodies develop , the efficacy of Advate is not assured .
P-539	-0.9954 -1.2289 -0.0541 -0.0346 -0.4321 -0.2172 -0.4191 -0.3104 -0.0642 -0.0838 -0.1410 -1.6917 -0.1122 -0.3081 -0.3540 -0.1795 -0.1592 -0.2121
S-279	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-279	To permit adequate absorption of alendronate :
H-279	-0.4737137258052826	<unk> Method to ensure adequate absorption of alendronate :
D-279	-0.4737137258052826	<unk> Method to ensure adequate absorption of alendronate :
P-279	-1.2792 -4.3663 -0.0223 -0.0110 -0.7237 -0.1777 -0.0640 -0.0364 -0.0915 -0.1397 -0.0922 -0.1044 -0.0717 -0.0101 -0.2281 -0.1612
S-92	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-92	To permit adequate absorption of alendronate :
H-92	-0.4737137258052826	<unk> Method to ensure adequate absorption of alendronate :
D-92	-0.4737137258052826	<unk> Method to ensure adequate absorption of alendronate :
P-92	-1.2792 -4.3663 -0.0223 -0.0110 -0.7237 -0.1777 -0.0640 -0.0364 -0.0915 -0.1397 -0.0922 -0.1044 -0.0717 -0.0101 -0.2281 -0.1612
S-1929	Den vollständigen Wortlaut des EPAR für Aerinaze finden Sie hier .
T-1929	The full EPAR for Aerinaze can be found here .
H-1929	-0.3568051755428314	<unk> The full EPAR for Aerinaze is available here .
D-1929	-0.3568051755428314	<unk> The full EPAR for Aerinaze is available here .
P-1929	-2.8310 -0.4506 -0.1964 -0.3263 -0.0396 -0.1554 -0.1555 -0.1068 -0.1328 -0.1390 -0.1570 -0.1665 -0.3924 -0.0976 -0.1616 -0.2004
S-348	16 4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-348	4.7 Effects on ability to drive and use machines
H-348	-0.2737566828727722	16 4.7 Effects on ability to drive and use machines
D-348	-0.2737566828727722	16 4.7 Effects on ability to drive and use machines
P-348	-1.0368 -0.1515 -0.1592 -0.0555 -0.0708 -0.1238 -0.0844 -0.1263 -1.0338 -0.1377 -0.2160 -0.2080 -0.1551
S-834	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-834	Activated Factor X converts prothrombin to thrombin .
H-834	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
D-834	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
P-834	-1.4326 -1.2270 -0.0682 -0.1073 -0.0947 -0.1514 -0.1117 -0.4592 -0.1505 -0.0411 -0.3107 -0.1333 -0.7586 -0.1011 -0.4481 -0.1323 -0.1465 -0.1806
S-1504	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1504	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1504	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
D-1504	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
P-1504	-2.0422 -0.6696 -0.1634 -1.0023 -0.1612 -2.9728 -0.0907 -0.1548 -0.3416 -0.0749 -0.1495 -0.4079 -0.0473 -1.2667 -0.1165 -0.1217 -0.0942 -0.0838 -0.1617 -0.1622
S-1152	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1152	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1152	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
D-1152	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
P-1152	-2.0422 -0.6696 -0.1634 -1.0023 -0.1612 -2.9728 -0.0907 -0.1548 -0.3416 -0.0749 -0.1495 -0.4079 -0.0473 -1.2667 -0.1165 -0.1217 -0.0942 -0.0838 -0.1617 -0.1622
S-1331	49 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1331	45 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1331	-0.2161470651626587	49 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-1331	-0.2161470651626587	49 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-1331	-1.2122 -0.0830 -0.1728 -0.3529 -0.0601 -0.1276 -0.4253 -0.0301 -0.4796 -0.1089 -0.1491 -0.0861 -0.0844 -0.1369 -0.1544 -0.1137 -0.0927 -0.0878 -0.1494
S-1155	38 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1155	35 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1155	-0.21814554929733276	<unk> Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-1155	-0.21814554929733276	<unk> Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-1155	-1.2317 -0.1377 -0.1845 -0.2711 -0.0597 -0.1279 -0.4129 -0.0299 -0.5175 -0.1073 -0.1483 -0.0860 -0.0848 -0.1358 -0.1563 -0.1132 -0.0966 -0.0890 -0.1545
S-979	27 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-979	25 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-979	-0.2463998645544052	27 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-979	-0.2463998645544052	27 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-979	-1.8494 -0.0835 -0.1814 -0.2676 -0.0600 -0.1269 -0.4214 -0.0312 -0.4865 -0.1060 -0.1483 -0.0875 -0.0864 -0.1369 -0.1554 -0.1132 -0.0956 -0.0939 -0.1507
S-803	16 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-803	15 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-803	-0.25179794430732727	16 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-803	-0.25179794430732727	16 Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-803	-1.9632 -0.0908 -0.1794 -0.2439 -0.0588 -0.1278 -0.4172 -0.0304 -0.4975 -0.1065 -0.1487 -0.0876 -0.0871 -0.1366 -0.1553 -0.1140 -0.0959 -0.0919 -0.1515
S-1840	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-1840	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-1840	-0.20419178903102875	<unk> GR-163 41 : <unk> 30-210-99 87 000
D-1840	-0.20419178903102875	<unk> GR-163 41 : <unk> 30-210-99 87 000
P-1840	-0.5635 -0.5186 -0.1072 -0.1442 -0.1325 -0.1535 -0.3482 -0.1179 -0.1782 -0.1147 -0.1786 -0.3551 -0.1158 -0.0691 -0.0493 -0.1775 -0.1475
S-1827	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-1827	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-1827	-0.20419178903102875	<unk> GR-163 41 : <unk> 30-210-99 87 000
D-1827	-0.20419178903102875	<unk> GR-163 41 : <unk> 30-210-99 87 000
P-1827	-0.5635 -0.5186 -0.1072 -0.1442 -0.1325 -0.1535 -0.3482 -0.1179 -0.1782 -0.1147 -0.1786 -0.3551 -0.1158 -0.0691 -0.0493 -0.1775 -0.1475
S-1823	4 D-85716 Unterschleißheim Tel : <unk> 49 89 31 701
T-1823	4 D-85716 Unterschleißheim Tel : <<unk>> 49 89 31 701
H-1823	-0.4634639024734497	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
D-1823	-0.4634639024734497	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
P-1823	-1.1084 -0.2207 -0.1712 -0.1143 -1.6271 -0.1242 -0.9404 -1.4202 -0.1713 -1.8595 -0.0346 -0.1305 -0.1187 -0.1146 -0.1099 -0.1148 -0.1539 -0.1250 -0.1465
S-659	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-659	Activated Factor X converts prothrombin to thrombin .
H-659	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
D-659	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
P-659	-1.4326 -1.2270 -0.0682 -0.1073 -0.0947 -0.1514 -0.1117 -0.4592 -0.1505 -0.0411 -0.3107 -0.1333 -0.7586 -0.1011 -0.4481 -0.1323 -0.1465 -0.1806
S-1328	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1328	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1328	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
D-1328	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
P-1328	-2.0422 -0.6696 -0.1634 -1.0023 -0.1612 -2.9728 -0.0907 -0.1548 -0.3416 -0.0749 -0.1495 -0.4079 -0.0473 -1.2667 -0.1165 -0.1217 -0.0942 -0.0838 -0.1617 -0.1622
S-1186	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1186	Activated Factor X converts prothrombin to thrombin .
H-1186	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
D-1186	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
P-1186	-1.4326 -1.2270 -0.0682 -0.1073 -0.0947 -0.1514 -0.1117 -0.4592 -0.1505 -0.0411 -0.3107 -0.1333 -0.7586 -0.1011 -0.4481 -0.1323 -0.1465 -0.1806
S-976	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-976	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-976	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
D-976	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
P-976	-2.0422 -0.6696 -0.1634 -1.0023 -0.1612 -2.9728 -0.0907 -0.1548 -0.3416 -0.0749 -0.1495 -0.4079 -0.0473 -1.2667 -0.1165 -0.1217 -0.0942 -0.0838 -0.1617 -0.1622
S-800	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-800	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-800	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
D-800	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
P-800	-2.0422 -0.6696 -0.1634 -1.0023 -0.1612 -2.9728 -0.0907 -0.1548 -0.3416 -0.0749 -0.1495 -0.4079 -0.0473 -1.2667 -0.1165 -0.1217 -0.0942 -0.0838 -0.1617 -0.1622
S-626	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-626	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-626	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
D-626	-0.5142520666122437	<unk> The following Table 2 indicates the incidence of adverse reactions in clinical trials :
P-626	-2.0422 -0.6696 -0.1634 -1.0023 -0.1612 -2.9728 -0.0907 -0.1548 -0.3416 -0.0749 -0.1495 -0.4079 -0.0473 -1.2667 -0.1165 -0.1217 -0.0942 -0.0838 -0.1617 -0.1622
S-1780	Sollten Sie weitere Fragen zur Anwendung dieses Arzneimittels haben , wenden Sie sich an Ihren Arzt .
T-1780	If you have any further questions on the use of this product , ask your doctor .
H-1780	-0.5240358710289001	<unk> If you have any further questions about the use of this product , contact your doctor .
D-1780	-0.5240358710289001	<unk> If you have any further questions about the use of this product , contact your doctor .
P-1780	-1.0045 -0.4410 -0.1557 -0.3252 -0.1958 -0.3105 -2.6465 -0.7580 -0.7627 -0.1106 -0.1329 -0.1196 -1.1338 -0.2710 -0.9737 -0.1285 -0.1590 -0.1567 -0.1711
S-1784	- Atembeschwerden , pfeifendes Atmen , Engegefühl in der Brust ,
T-1784	- difficulty in breathing , wheezing , tightness in the chest ,
H-1784	-0.6527679562568665	- difficulty breathing , wheezing , tightness in the chest ,
D-1784	-0.6527679562568665	- difficulty breathing , wheezing , tightness in the chest ,
P-1784	-2.4340 -1.8063 -0.1354 -0.1703 -2.1455 -0.0370 -0.2131 -0.2936 -0.3557 -1.7658 -0.0996 -0.3594 -0.2289 -0.0791 -0.1717 -0.1487
S-1539	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1539	Activated Factor X converts prothrombin to thrombin .
H-1539	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
D-1539	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
P-1539	-1.4326 -1.2270 -0.0682 -0.1073 -0.0947 -0.1514 -0.1117 -0.4592 -0.1505 -0.0411 -0.3107 -0.1333 -0.7586 -0.1011 -0.4481 -0.1323 -0.1465 -0.1806
S-1362	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1362	Activated Factor X converts prothrombin to thrombin .
H-1362	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
D-1362	-0.33639460802078247	<unk> Activated factor X converts prothrombin into thrombin .
P-1362	-1.4326 -1.2270 -0.0682 -0.1073 -0.0947 -0.1514 -0.1117 -0.4592 -0.1505 -0.0411 -0.3107 -0.1333 -0.7586 -0.1011 -0.4481 -0.1323 -0.1465 -0.1806
S-1778	Fahren Sie sofort mit der nächsten vorgesehenen Anwendung fort , wie von Ihrem Arzt angewiesen .
T-1778	Proceed with the next injection as scheduled immediately and continue as advised by your doctor .
H-1778	-0.7129875421524048	<unk> Continue with the next scheduled dosing regimen as advised by your doctor .
D-1778	-0.7129875421524048	<unk> Continue with the next scheduled dosing regimen as advised by your doctor .
P-1778	-1.4947 -1.2652 -0.1545 -0.8959 -0.2265 -0.2619 -1.1825 -2.4670 -0.1350 -0.3573 -0.1144 -0.4370 -3.0322 -0.1557 -0.1099 -0.1711 -0.1678 -0.2054
S-1484	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1484	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1484	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
D-1484	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
P-1484	-1.5568 -0.2517 -0.3073 -0.1279 -1.3689 -0.1509 -0.0679 -0.2792 -0.4978 -0.1452 -0.1397 -0.1532 -2.0568 -1.1055 -0.5435 -0.1465 -0.1710
S-625	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-625	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-625	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
D-625	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
P-625	-0.8188 -0.9424 -1.5114 -0.7955 -2.1625 -0.0823 -1.9739 -0.9245 -0.0069 -0.0476 -0.0459 -0.8806 -0.2544 -0.2822 -0.4013 -0.2986 -1.2703 -0.1396 -0.1609 -0.1688
S-1505	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1505	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1505	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-1505	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-1505	-3.1920 -0.1776 -0.1867 -0.0618 -0.1325 -0.5528 -0.0343 -0.3928 -0.1013 -0.1484 -0.0889 -0.0869 -0.1400 -0.1543 -0.1150 -0.0960 -0.0948 -0.1526
S-975	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-975	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-975	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
D-975	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
P-975	-0.8188 -0.9424 -1.5114 -0.7955 -2.1625 -0.0823 -1.9739 -0.9245 -0.0069 -0.0476 -0.0459 -0.8806 -0.2544 -0.2822 -0.4013 -0.2986 -1.2703 -0.1396 -0.1609 -0.1688
S-1329	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1329	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1329	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-1329	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-1329	-3.1920 -0.1776 -0.1867 -0.0618 -0.1325 -0.5528 -0.0343 -0.3928 -0.1013 -0.1484 -0.0889 -0.0869 -0.1400 -0.1543 -0.1150 -0.0960 -0.0948 -0.1526
S-1308	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1308	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1308	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
D-1308	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
P-1308	-1.5568 -0.2517 -0.3073 -0.1279 -1.3689 -0.1509 -0.0679 -0.2792 -0.4978 -0.1452 -0.1397 -0.1532 -2.0568 -1.1055 -0.5435 -0.1465 -0.1710
S-1153	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1153	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1153	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-1153	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-1153	-3.1920 -0.1776 -0.1867 -0.0618 -0.1325 -0.5528 -0.0343 -0.3928 -0.1013 -0.1484 -0.0889 -0.0869 -0.1400 -0.1543 -0.1150 -0.0960 -0.0948 -0.1526
S-1132	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1132	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1132	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
D-1132	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
P-1132	-1.5568 -0.2517 -0.3073 -0.1279 -1.3689 -0.1509 -0.0679 -0.2792 -0.4978 -0.1452 -0.1397 -0.1532 -2.0568 -1.1055 -0.5435 -0.1465 -0.1710
S-799	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-799	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-799	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
D-799	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
P-799	-0.8188 -0.9424 -1.5114 -0.7955 -2.1625 -0.0823 -1.9739 -0.9245 -0.0069 -0.0476 -0.0459 -0.8806 -0.2544 -0.2822 -0.4013 -0.2986 -1.2703 -0.1396 -0.1609 -0.1688
S-977	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-977	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-977	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
D-977	-0.3282642662525177	Table 2 incidence of adverse reactions ( ADRs ) in clinical trials
P-977	-3.1920 -0.1776 -0.1867 -0.0618 -0.1325 -0.5528 -0.0343 -0.3928 -0.1013 -0.1484 -0.0889 -0.0869 -0.1400 -0.1543 -0.1150 -0.0960 -0.0948 -0.1526
S-1672	300 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1672	300 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1672	-0.3393687605857849	300 IU/ ml after reconstitution Specific activity : approximately
D-1672	-0.3393687605857849	300 IU/ ml after reconstitution Specific activity : approximately
P-1672	-1.7480 -0.1429 -0.1818 -0.1502 -0.0636 -0.5962 -0.4491 -0.0366 -0.4793 -0.0363 -0.0773 -0.1406 -0.5057 -0.1435
S-1654	200 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1654	200 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1654	-0.3475133776664734	<unk> 200 IU/ ml after reconstitution Specific activity : approximately
D-1654	-0.3475133776664734	<unk> 200 IU/ ml after reconstitution Specific activity : approximately
P-1654	-1.5935 -0.4474 -0.1566 -0.1766 -0.1597 -0.0592 -0.4846 -0.5096 -0.0342 -0.5561 -0.0379 -0.0815 -0.1401 -0.6223 -0.1532
S-19	Durch die Verminderung der Harnsäureproduktion kann Adenuric die
T-19	By reducing the production of uric acid , Adenuric can reduce levels of uric acid in the blood and keep them low , stopping crystals from building up .
H-19	-0.6191157102584839	<unk> By decreasing uric acid production , Adenuric acid <unk>
D-19	-0.6191157102584839	<unk> By decreasing uric acid production , Adenuric acid <unk>
P-19	-1.6400 -3.9997 -0.4589 -0.3251 -0.1188 -0.0813 -0.0700 -0.2073 -0.2654 -0.1177 -0.1783 -0.1007 -0.1310 -1.1438 -0.8948 -0.1730
S-1704	600 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1704	600 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1704	-0.3468164801597595	<unk> 600 IU/ ml after reconstitution Specific activity : approximately
D-1704	-0.3468164801597595	<unk> 600 IU/ ml after reconstitution Specific activity : approximately
P-1704	-0.9037 -1.1545 -0.1816 -0.1751 -0.1565 -0.0593 -0.5010 -0.4647 -0.0336 -0.5818 -0.0389 -0.0793 -0.1403 -0.5808 -0.1512
S-1688	400 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1688	400 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1688	-0.33327439427375793	<unk> 400 IU/ ml after reconstitution Specific activity : approximately
D-1688	-0.33327439427375793	<unk> 400 IU/ ml after reconstitution Specific activity : approximately
P-1688	-1.6476 -0.2000 -0.1749 -0.1777 -0.1571 -0.0609 -0.4775 -0.4576 -0.0349 -0.6295 -0.0388 -0.0812 -0.1410 -0.5690 -0.1515
S-1151	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1151	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1151	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
D-1151	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
P-1151	-0.8188 -0.9424 -1.5114 -0.7955 -2.1625 -0.0823 -1.9739 -0.9245 -0.0069 -0.0476 -0.0459 -0.8806 -0.2544 -0.2822 -0.4013 -0.2986 -1.2703 -0.1396 -0.1609 -0.1688
S-1327	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1327	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1327	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
D-1327	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
P-1327	-0.8188 -0.9424 -1.5114 -0.7955 -2.1625 -0.0823 -1.9739 -0.9245 -0.0069 -0.0476 -0.0459 -0.8806 -0.2544 -0.2822 -0.4013 -0.2986 -1.2703 -0.1396 -0.1609 -0.1688
S-1638	100 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1638	100 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1638	-0.32135066390037537	<unk> 100 IU/ ml after reconstitution Specific activity : approximately
D-1638	-0.32135066390037537	<unk> 100 IU/ ml after reconstitution Specific activity : approximately
P-1638	-1.3964 -0.4646 -0.1655 -0.1764 -0.1585 -0.0593 -0.4254 -0.4227 -0.0338 -0.5242 -0.0377 -0.0818 -0.1389 -0.5837 -0.1512
S-1622	50 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1622	50 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1622	-0.3258686065673828	50 IU/ ml after reconstitution Specific activity : approximately
D-1622	-0.3258686065673828	50 IU/ ml after reconstitution Specific activity : approximately
P-1622	-1.6071 -0.1509 -0.1824 -0.1549 -0.0620 -0.5069 -0.4246 -0.0352 -0.4772 -0.0374 -0.0775 -0.1393 -0.5629 -0.1437
S-1503	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1503	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1503	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
D-1503	-0.6584177613258362	<unk> Within the frequencies , undesirable effects are listed in descending severity .
P-1503	-0.8188 -0.9424 -1.5114 -0.7955 -2.1625 -0.0823 -1.9739 -0.9245 -0.0069 -0.0476 -0.0459 -0.8806 -0.2544 -0.2822 -0.4013 -0.2986 -1.2703 -0.1396 -0.1609 -0.1688
S-956	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-956	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-956	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
D-956	-0.5335286259651184	<unk> In such cases it is recommended to contact a haemophile centre .
P-956	-1.5568 -0.2517 -0.3073 -0.1279 -1.3689 -0.1509 -0.0679 -0.2792 -0.4978 -0.1452 -0.1397 -0.1532 -2.0568 -1.1055 -0.5435 -0.1465 -0.1710
S-969	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-969	ADVATE has no influence on the ability to drive and use machines .
H-969	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
D-969	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
P-969	-0.9732 -0.7108 -0.2256 -0.1060 -0.1056 -0.4634 -0.1257 -1.0386 -0.1313 -0.1613 -0.1607 -1.2916 -0.2253 -0.3498 -0.2406 -0.1456 -0.2023
S-1969	Eine fortgesetzte Anwendung kann zu einer Toleranz führen , die ein erhöhtes Risiko für eine Überdosierung bedingt .
T-1969	Continuous use can lead to tolerance resulting in an increased risk of overdosing .
H-1969	-0.5559049248695374	<unk> Continuous use may lead to tolerance resulting in an increased risk of overdose .
D-1969	-0.5559049248695374	<unk> Continuous use may lead to tolerance resulting in an increased risk of overdose .
P-1969	-0.5366 -2.4054 -0.9826 -0.4465 -0.1597 -1.1001 -0.1297 -0.9092 -0.3000 -1.7604 -0.1311 -0.2268 -0.0703 -0.1470 -0.4047 -0.4057 -0.0921 -0.1848 -0.1694
S-1497	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1497	ADVATE has no influence on the ability to drive and use machines .
H-1497	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
D-1497	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
P-1497	-0.9732 -0.7108 -0.2256 -0.1060 -0.1056 -0.4634 -0.1257 -1.0386 -0.1313 -0.1613 -0.1607 -1.2916 -0.2253 -0.3498 -0.2406 -0.1456 -0.2023
S-1321	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1321	ADVATE has no influence on the ability to drive and use machines .
H-1321	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
D-1321	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
P-1321	-0.9732 -0.7108 -0.2256 -0.1060 -0.1056 -0.4634 -0.1257 -1.0386 -0.1313 -0.1613 -0.1607 -1.2916 -0.2253 -0.3498 -0.2406 -0.1456 -0.2023
S-1145	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1145	ADVATE has no influence on the ability to drive and use machines .
H-1145	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
D-1145	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
P-1145	-0.9732 -0.7108 -0.2256 -0.1060 -0.1056 -0.4634 -0.1257 -1.0386 -0.1313 -0.1613 -0.1607 -1.2916 -0.2253 -0.3498 -0.2406 -0.1456 -0.2023
S-125	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-125	The time to onset of symptoms varied from one day to several months after starting treatment .
H-125	-0.33666670322418213	<unk> The timing of these symptoms varied from one day to several months after initiation of therapy .
D-125	-0.33666670322418213	<unk> The timing of these symptoms varied from one day to several months after initiation of therapy .
P-125	-1.1961 -0.6658 -0.4576 -0.1608 -0.6464 -0.1049 -0.1944 -0.1821 -0.1823 -0.1770 -0.1183 -0.1309 -0.1380 -0.1170 -0.3200 -0.8323 -0.1403 -0.6514 -0.3214 -0.1522 -0.1810
S-793	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-793	ADVATE has no influence on the ability to drive and use machines .
H-793	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
D-793	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
P-793	-0.9732 -0.7108 -0.2256 -0.1060 -0.1056 -0.4634 -0.1257 -1.0386 -0.1313 -0.1613 -0.1607 -1.2916 -0.2253 -0.3498 -0.2406 -0.1456 -0.2023
S-619	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-619	ADVATE has no influence on the ability to drive and use machines .
H-619	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
D-619	-0.391629159450531	<unk> ADVATE has no effects on ability to drive and use machines .
P-619	-0.9732 -0.7108 -0.2256 -0.1060 -0.1056 -0.4634 -0.1257 -1.0386 -0.1313 -0.1613 -0.1607 -1.2916 -0.2253 -0.3498 -0.2406 -0.1456 -0.2023
S-1073	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1073	The pulse rate should be determined before and during administration of ADVATE .
H-1073	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
D-1073	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
P-1073	-1.1099 -2.2485 -0.2326 -1.1865 -0.0965 -0.1041 -0.1024 -0.1669 -0.4668 -0.6367 -0.1415 -0.2634 -1.2883 -0.2074 -0.2435 -0.1900 -0.0944 -0.0992 -0.1724 -0.1655
S-1249	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1249	The pulse rate should be determined before and during administration of ADVATE .
H-1249	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
D-1249	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
P-1249	-1.1099 -2.2485 -0.2326 -1.1865 -0.0965 -0.1041 -0.1024 -0.1669 -0.4668 -0.6367 -0.1415 -0.2634 -1.2883 -0.2074 -0.2435 -0.1900 -0.0944 -0.0992 -0.1724 -0.1655
S-901	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-901	ADVATE 1000 IU powder and solvent for solution for injection .
H-901	-0.2731195092201233	<unk> ADVATE 1000 IU of powder and solvents to produce a solution for injection
D-901	-0.2731195092201233	<unk> ADVATE 1000 IU of powder and solvents to produce a solution for injection
P-901	-0.9285 -0.5285 -0.2075 -0.0980 -0.1162 -0.1711 -0.1248 -0.0647 -0.1808 -0.1693 -0.1233 -0.0951 -0.3444 -0.0777 -0.1756 -1.6945 -0.2400 -0.1037 -0.1561 -0.1365 -0.1108 -0.1615
S-269	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-269	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-269	-0.5784211754798889	<unk> Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-269	-0.5784211754798889	<unk> Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-269	-1.5250 -1.6742 -0.2236 -2.2325 -0.0750 -0.1725 -1.3926 -0.1897 -0.3923 -0.4560 -0.8456 -0.1867 -1.7296 -0.0725 -0.1333 -0.1469 -0.1577 -0.1033 -0.1620 -0.1218 -0.1540
S-1077	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1077	ADVATE 1500 IU powder and solvent for solution for injection .
H-1077	-0.33132922649383545	<unk> ADVATE 1500 IU of powder and solvents to produce a solution for injection
D-1077	-0.33132922649383545	<unk> ADVATE 1500 IU of powder and solvents to produce a solution for injection
P-1077	-0.9384 -0.4551 -0.2085 -0.0984 -0.1133 -1.5803 -0.1237 -0.0672 -0.1841 -0.1843 -0.1234 -0.0943 -0.3878 -0.0786 -0.1818 -1.5579 -0.2467 -0.1028 -0.1562 -0.1354 -0.1091 -0.1621
S-725	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-725	ADVATE 500 IU powder and solvent for solution for injection .
H-725	-0.26471200585365295	<unk> ADVATE 500 IU of powder and solvents to produce a solution for injection
D-725	-0.26471200585365295	<unk> ADVATE 500 IU of powder and solvents to produce a solution for injection
P-725	-0.9392 -0.4714 -0.2040 -0.1032 -0.1139 -0.1000 -0.1271 -0.0667 -0.1589 -0.1786 -0.1235 -0.0949 -0.3530 -0.0780 -0.1761 -1.6228 -0.2473 -0.1018 -0.1553 -0.1359 -0.1095 -0.1628
S-1253	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1253	ADVATE 2000 IU powder and solvent for solution for injection .
H-1253	-0.2865692377090454	<unk> ADVATE 2000 IU of powder and solvents to produce a solution for injection
D-1253	-0.2865692377090454	<unk> ADVATE 2000 IU of powder and solvents to produce a solution for injection
P-1253	-0.9017 -0.7519 -0.2018 -0.1030 -0.1200 -0.1251 -0.1350 -0.0657 -0.2793 -0.1650 -0.1236 -0.0937 -0.4036 -0.0789 -0.1876 -1.6399 -0.2554 -0.1053 -0.1567 -0.1365 -0.1103 -0.1643
S-1429	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1429	ADVATE 3000 IU powder and solvent for solution for injection .
H-1429	-0.27333277463912964	<unk> ADVATE 3000 IU of powder and solvents to produce a solution for injection
D-1429	-0.27333277463912964	<unk> ADVATE 3000 IU of powder and solvents to produce a solution for injection
P-1429	-0.8802 -0.7933 -0.2049 -0.1053 -0.1194 -0.0797 -0.1262 -0.0673 -0.1928 -0.1697 -0.1243 -0.0945 -0.3103 -0.0765 -0.1779 -1.5662 -0.2563 -0.1031 -0.1550 -0.1359 -0.1088 -0.1656
S-1743	Falls Ihre Blutungen mit ADVATE nicht kontrolliert werden können , wenden Sie sich umgehend an Ihren Arzt
T-1743	If your bleeding is not controlled with ADVATE , tell your doctor immediately .
H-1743	-0.2932095527648926	<unk> If your bleeding cannot be controlled with ADVATE , contact your doctor immediately
D-1743	-0.2932095527648926	<unk> If your bleeding cannot be controlled with ADVATE , contact your doctor immediately
P-1743	-1.0408 -0.1575 -0.1253 -0.8362 -0.1485 -0.3264 -0.1157 -0.3410 -0.2148 -0.1366 -0.1820 -0.0700 -0.0801 -0.2501 -0.6402 -0.1104 -0.1595 -0.1001 -0.5359
S-159	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-159	Colecalciferol and some of its active metabolites pass into breast milk .
H-159	-0.36193209886550903	<unk> Colecalciferol and some of its active metabolites enter breast milk .
D-159	-0.36193209886550903	<unk> Colecalciferol and some of its active metabolites enter breast milk .
P-159	-1.6730 -1.3525 -0.1050 -0.1493 -0.1590 -0.1021 -0.1060 -0.1303 -0.0912 -0.1403 -0.0531 -0.0861 -0.0802 -0.0300 -0.0979 -1.4630 -0.9900 -0.1009 -0.1499 -0.1788
S-1210	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1210	The beginning of storage at room temperature should be recorded on the product carton .
H-1210	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
D-1210	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
P-1210	-3.2451 -0.3282 -0.9552 -0.1307 -0.9640 -0.1436 -2.4175 -0.0973 -0.1008 -0.1182 -0.1627 -1.7355 -0.1126 -0.1503 -0.4433 -0.0230 -0.1639 -0.1705
S-897	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-897	The pulse rate should be determined before and during administration of ADVATE .
H-897	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
D-897	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
P-897	-1.1099 -2.2485 -0.2326 -1.1865 -0.0965 -0.1041 -0.1024 -0.1669 -0.4668 -0.6367 -0.1415 -0.2634 -1.2883 -0.2074 -0.2435 -0.1900 -0.0944 -0.0992 -0.1724 -0.1655
S-465	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-465	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-465	-0.5784211754798889	<unk> Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-465	-0.5784211754798889	<unk> Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-465	-1.5250 -1.6742 -0.2236 -2.2325 -0.0750 -0.1725 -1.3926 -0.1897 -0.3923 -0.4560 -0.8456 -0.1867 -1.7296 -0.0725 -0.1333 -0.1469 -0.1577 -0.1033 -0.1620 -0.1218 -0.1540
S-721	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-721	The pulse rate should be determined before and during administration of ADVATE .
H-721	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
D-721	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
P-721	-1.1099 -2.2485 -0.2326 -1.1865 -0.0965 -0.1041 -0.1024 -0.1669 -0.4668 -0.6367 -0.1415 -0.2634 -1.2883 -0.2074 -0.2435 -0.1900 -0.0944 -0.0992 -0.1724 -0.1655
S-550	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-550	ADVATE 250 IU powder and solvent for solution for injection
H-550	-0.28134673833847046	<unk> ADVATE 250 IU of powder and solvents to produce a solution for injection
D-550	-0.28134673833847046	<unk> ADVATE 250 IU of powder and solvents to produce a solution for injection
P-550	-1.0672 -0.5237 -0.2151 -0.1078 -0.1160 -0.2350 -0.1277 -0.0650 -0.1676 -0.1731 -0.1229 -0.0935 -0.3686 -0.0786 -0.1791 -1.6386 -0.2479 -0.1016 -0.1547 -0.1350 -0.1088 -0.1623
S-682	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-682	The beginning of storage at room temperature should be recorded on the product carton .
H-682	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
D-682	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
P-682	-3.2451 -0.3282 -0.9552 -0.1307 -0.9640 -0.1436 -2.4175 -0.0973 -0.1008 -0.1182 -0.1627 -1.7355 -0.1126 -0.1503 -0.4433 -0.0230 -0.1639 -0.1705
S-1471	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1471	In case of administration by a non health care professional appropriate training is needed .
H-1471	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
D-1471	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
P-1471	-1.1910 -1.0900 -0.5786 -0.3325 -0.1137 -0.1611 -0.1375 -0.0686 -0.0961 -0.1501 -0.7570 -0.1106 -1.4144 -0.2432 -1.6898 -0.4646 -0.3064 -0.2007
S-1783	- Hautrötung , Ausschlag , Quaddelbildung , Juckreiz am ganzen Körper ,
T-1783	- rash , hives , wheals , generalised itching ,
H-1783	-0.4897724390029907	- Flushing , rash , whealing , itching all over ,
D-1783	-0.4897724390029907	- Flushing , rash , whealing , itching all over ,
P-1783	-1.4541 -0.4693 -0.0324 -0.1610 -0.1017 -0.0547 -0.1599 -0.2772 -2.6321 -0.1557 -0.1333 -0.0684 -0.4517 -0.0816 -1.4506 -0.1527
S-1798	Bitte notieren Sie den Beginn und das Ende der Raumtemperaturlagerung auf dem Umkarton .
T-1798	Please record the beginning of storage at room temperature on the product carton .
H-1798	-0.565417468547821	<unk> Please take a note of the start and end of room temperature storage on the carton .
D-1798	-0.565417468547821	<unk> Please take a note of the start and end of room temperature storage on the carton .
P-1798	-1.8585 -0.7459 -2.2961 -0.5330 -0.1261 -0.1864 -0.2025 -0.6333 -0.1264 -0.7941 -0.1373 -2.0676 -0.1159 -0.2004 -0.1176 -0.1887 -0.6303 -0.0262 -0.1562 -0.1660
S-548	Pulver : Durchstechflasche ( Glas ) Lösungsmittel : Durchstechflasche ( Glas )
T-548	powder : vial ( glass ) ; solvent : vial ( glass )
H-548	-0.542100191116333	<unk> powder : vial ( glass ) Solvents : vial ( glass )
D-548	-0.542100191116333	<unk> powder : vial ( glass ) Solvents : vial ( glass )
P-548	-1.0032 -2.2639 -0.1426 -1.4603 -0.0962 -0.1598 -0.0880 -0.1440 -1.2797 -2.0180 -0.0941 -0.1436 -0.1116 -0.0835 -0.1692 -0.1921 -0.1539 -0.1542
S-1803	Fragen Sie Ihren Apotheker wie das Arzneimittel zu entsorgen ist , wenn Sie es nicht mehr benötigen .
T-1803	Ask your pharmacist how to dispose of medicines no longer required .
H-1803	-0.2970582842826843	<unk> Ask your pharmacist how to dispose if you no longer need it .
D-1803	-0.2970582842826843	<unk> Ask your pharmacist how to dispose if you no longer need it .
P-1803	-1.4216 -0.0888 -0.0861 -0.1439 -0.0657 -0.0890 -0.0974 -0.1218 -0.0439 -0.0524 -1.2031 -0.1223 -0.3940 -0.1887 -0.4260 -0.4569 -0.1506 -0.1949
S-1563	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1563	The beginning of storage at room temperature should be recorded on the product carton .
H-1563	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
D-1563	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
P-1563	-3.2451 -0.3282 -0.9552 -0.1307 -0.9640 -0.1436 -2.4175 -0.0973 -0.1008 -0.1182 -0.1627 -1.7355 -0.1126 -0.1503 -0.4433 -0.0230 -0.1639 -0.1705
S-858	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-858	The beginning of storage at room temperature should be recorded on the product carton .
H-858	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
D-858	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
P-858	-3.2451 -0.3282 -0.9552 -0.1307 -0.9640 -0.1436 -2.4175 -0.0973 -0.1008 -0.1182 -0.1627 -1.7355 -0.1126 -0.1503 -0.4433 -0.0230 -0.1639 -0.1705
S-1034	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1034	The beginning of storage at room temperature should be recorded on the product carton .
H-1034	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
D-1034	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
P-1034	-3.2451 -0.3282 -0.9552 -0.1307 -0.9640 -0.1436 -2.4175 -0.0973 -0.1008 -0.1182 -0.1627 -1.7355 -0.1126 -0.1503 -0.4433 -0.0230 -0.1639 -0.1705
S-1393	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1393	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1393	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-1393	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-1393	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-1386	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1386	The beginning of storage at room temperature should be recorded on the product carton .
H-1386	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
D-1386	-0.6367968916893005	<unk> The start and end of room temperature storage should be marked on the carton .
P-1386	-3.2451 -0.3282 -0.9552 -0.1307 -0.9640 -0.1436 -2.4175 -0.0973 -0.1008 -0.1182 -0.1627 -1.7355 -0.1126 -0.1503 -0.4433 -0.0230 -0.1639 -0.1705
S-347	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-347	Colecalciferol and some of its active metabolites pass into breast milk .
H-347	-0.36193209886550903	<unk> Colecalciferol and some of its active metabolites enter breast milk .
D-347	-0.36193209886550903	<unk> Colecalciferol and some of its active metabolites enter breast milk .
P-347	-1.6730 -1.3525 -0.1050 -0.1493 -0.1590 -0.1021 -0.1060 -0.1303 -0.0912 -0.1403 -0.0531 -0.0861 -0.0802 -0.0300 -0.0979 -1.4630 -0.9900 -0.1009 -0.1499 -0.1788
S-1295	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1295	In case of administration by a non health care professional appropriate training is needed .
H-1295	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
D-1295	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
P-1295	-1.1910 -1.0900 -0.5786 -0.3325 -0.1137 -0.1611 -0.1375 -0.0686 -0.0961 -0.1501 -0.7570 -0.1106 -1.4144 -0.2432 -1.6898 -0.4646 -0.3064 -0.2007
S-1660	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1660	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1660	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1660	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1660	-1.3548 -1.5421 -0.5081 -0.0700 -0.0652 -0.1162 -0.2722 -0.1106 -0.1673 -0.1900 -0.2024 -0.1431 -0.1820 -0.3845 -0.0408 -0.1704 -0.1194 -0.1069 -0.1531 -0.1580
S-1677	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1677	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1677	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1677	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1677	-1.3548 -1.5421 -0.5081 -0.0700 -0.0652 -0.1162 -0.2722 -0.1106 -0.1673 -0.1900 -0.2024 -0.1431 -0.1820 -0.3845 -0.0408 -0.1704 -0.1194 -0.1069 -0.1531 -0.1580
S-1844	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
T-1844	29-1 LT-09129 Vilnius Tel : <<unk>> 370 5 269 16 91
H-1844	-0.35086333751678467	<unk> 370 5 269 16 91 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
D-1844	-0.35086333751678467	<unk> 370 5 269 16 91 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
P-1844	-1.7417 -0.0479 -0.1273 -0.0600 -0.1477 -0.1425 -0.0934 -2.0698 -0.1578 -0.2036 -1.3567 -0.1130 -0.1241 -1.3476 -0.1360 -0.1537 -0.0408 -0.1299 -0.1101 -0.0953 -0.1171 -0.0603 -0.1500 -0.1449 -0.1035 -0.1481
S-1750	Schwangerschaft und Stillzeit Informieren Sie Ihren Arzt , wenn Sie schwanger sind oder stillen .
T-1750	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
H-1750	-0.15367481112480164	<unk> Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
D-1750	-0.15367481112480164	<unk> Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
P-1750	-0.8190 -0.0547 -0.0316 -0.0861 -0.1502 -0.0581 -0.0414 -0.3445 -0.0188 -0.5144 -0.0443 -0.1335 -0.1142 -0.1671 -0.1442 -0.1315 -0.0556 -0.1466 -0.0790 -0.0323 -0.1440 -0.0262 -0.1879 -0.1630
S-1627	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1627	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1627	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1627	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1627	-1.3548 -1.5421 -0.5081 -0.0700 -0.0652 -0.1162 -0.2722 -0.1106 -0.1673 -0.1900 -0.2024 -0.1431 -0.1820 -0.3845 -0.0408 -0.1704 -0.1194 -0.1069 -0.1531 -0.1580
S-1643	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1643	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1643	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1643	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1643	-1.3548 -1.5421 -0.5081 -0.0700 -0.0652 -0.1162 -0.2722 -0.1106 -0.1673 -0.1900 -0.2024 -0.1431 -0.1820 -0.3845 -0.0408 -0.1704 -0.1194 -0.1069 -0.1531 -0.1580
S-1781	Wie alle Arzneimittel kann ADVATE Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-1781	Like all medicines , ADVATE can cause side effects , although not everybody gets them .
H-1781	-0.579443097114563	<unk> Like all medicines , ADVATE can have side effects , but not necessarily in every medicinal product .
D-1781	-0.579443097114563	<unk> Like all medicines , ADVATE can have side effects , but not necessarily in every medicinal product .
P-1781	-1.4786 -0.5175 -0.1173 -0.0939 -0.0840 -0.4090 -0.1439 -0.1880 -0.0742 -0.0821 -0.4655 -0.9900 -0.2386 -0.0740 -1.5341 -0.2003 -3.2472 -0.1247 -1.0592 -0.8255 -1.7519 -0.4137 -0.0597 -0.1549 -0.1581
S-1742	Die Entwicklung von Inhibitoren ist eine bekannte Komplikation der Hämophilie A Behandlung .
T-1742	Development of inhibitors is a known complication in the treatment of haemophilia A.
H-1742	-0.40608569979667664	<unk> The development of inhibitors is a known complication of haemophilia A treatment .
D-1742	-0.40608569979667664	<unk> The development of inhibitors is a known complication of haemophilia A treatment .
P-1742	-1.2090 -1.5117 -0.1495 -0.1414 -0.1327 -0.0571 -0.0855 -0.1206 -0.1283 -0.1152 -0.1936 -0.1484 -0.1390 -0.3055 -0.3824 -0.1382 -1.6222 -1.6751 -0.1727 -0.1819 -0.1574 -0.1666
S-1693	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1693	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1693	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1693	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1693	-1.3548 -1.5421 -0.5081 -0.0700 -0.0652 -0.1162 -0.2722 -0.1106 -0.1673 -0.1900 -0.2024 -0.1431 -0.1820 -0.3845 -0.0408 -0.1704 -0.1194 -0.1069 -0.1531 -0.1580
S-1709	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1709	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1709	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1709	-0.30285266041755676	<unk> Store at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1709	-1.3548 -1.5421 -0.5081 -0.0700 -0.0652 -0.1162 -0.2722 -0.1106 -0.1673 -0.1900 -0.2024 -0.1431 -0.1820 -0.3845 -0.0408 -0.1704 -0.1194 -0.1069 -0.1531 -0.1580
S-1425	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1425	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-1425	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
D-1425	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
P-1425	-1.1099 -2.2485 -0.2326 -1.1865 -0.0965 -0.1041 -0.1024 -0.1669 -0.4668 -0.6367 -0.1415 -0.2634 -1.2883 -0.2074 -0.2435 -0.1900 -0.0944 -0.0992 -0.1724 -0.1655
S-1602	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1602	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-1602	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
D-1602	-0.46084022521972656	<unk> The patient s pulse should be measured before and during administration of ADVATE .
P-1602	-1.1099 -2.2485 -0.2326 -1.1865 -0.0965 -0.1041 -0.1024 -0.1669 -0.4668 -0.6367 -0.1415 -0.2634 -1.2883 -0.2074 -0.2435 -0.1900 -0.0944 -0.0992 -0.1724 -0.1655
S-1748	B. Atembeschwerden und ( Beinahe<unk> -Ohnmacht benötigen eine sofortige Notfallbehandlung .
T-1748	Severe symptoms , including difficulty in breathing and ( near ) fainting , require prompt emergency treatment .
H-1748	-0.6605827212333679	<unk> <unk> respiratory discomfort and ( near fainting need immediate emergency treatment .
D-1748	-0.6605827212333679	<unk> <unk> respiratory discomfort and ( near fainting need immediate emergency treatment .
P-1748	-0.1629 -0.8379 -2.4849 -0.0769 -0.1238 -0.7161 -0.2475 -0.1729 -0.3267 -1.6445 -1.4752 -0.3304 -0.1232 -2.5571 -0.5026 -0.1541 -0.1794 -0.1477 -0.2872
S-689	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-689	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-689	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-689	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-689	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-1810	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1810	After reconstitution , the solution is clear , colourless and free from foreign particles .
H-1810	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-1810	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-1810	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-570	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-570	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-570	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
D-570	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
P-570	-1.8859 -0.5728 -0.1714 -0.9617 -0.1788 -0.6876 -4.1052 -0.5127 -0.0905 -0.2554 -0.1564 -0.2057 -0.7624 -2.0906 -0.2138 -0.0769 -0.1880 -0.6594 -2.3291 -0.1644 -0.1746
S-1041	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1041	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1041	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-1041	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-1041	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-1217	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1217	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1217	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-1217	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-1217	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-1570	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1570	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1570	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-1570	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-1570	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-1757	Die Einnahmehäufigkeit hängt davon ab , wie gut ADVATE bei Ihnen wirkt .
T-1757	The frequency of administration will depend on how well ADVATE is working for you .
H-1757	-0.40073251724243164	<unk> The frequency depends on how well ADVATE works for you .
D-1757	-0.40073251724243164	<unk> The frequency depends on how well ADVATE works for you .
P-1757	-0.9067 -0.5536 -0.4296 -0.1139 -2.8536 -0.1407 -0.0530 -0.1836 -0.1187 -0.1985 -0.0802 -0.0916 -0.4215 -0.2318 -0.1057 -0.1514 -0.1785
S-865	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-865	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-865	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
D-865	-0.38065120577812195	<unk> After reconstitution the solution is clear , colourless and free from foreign particles .
P-865	-1.6465 -0.8138 -0.3654 -0.0504 -0.7131 -0.1373 -0.1226 -0.0547 -0.1636 -0.0112 -0.0688 -0.0886 -0.1213 -0.1971 -0.6011 -1.8768 -0.1507 -0.0813 -0.1459 -0.2028
S-1448	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1448	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1448	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
D-1448	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
P-1448	-1.8859 -0.5728 -0.1714 -0.9617 -0.1788 -0.6876 -4.1052 -0.5127 -0.0905 -0.2554 -0.1564 -0.2057 -0.7624 -2.0906 -0.2138 -0.0769 -0.1880 -0.6594 -2.3291 -0.1644 -0.1746
S-744	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-744	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-744	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
D-744	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
P-744	-1.8859 -0.5728 -0.1714 -0.9617 -0.1788 -0.6876 -4.1052 -0.5127 -0.0905 -0.2554 -0.1564 -0.2057 -0.7624 -2.0906 -0.2138 -0.0769 -0.1880 -0.6594 -2.3291 -0.1644 -0.1746
S-920	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-920	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-920	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
D-920	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
P-920	-1.8859 -0.5728 -0.1714 -0.9617 -0.1788 -0.6876 -4.1052 -0.5127 -0.0905 -0.2554 -0.1564 -0.2057 -0.7624 -2.0906 -0.2138 -0.0769 -0.1880 -0.6594 -2.3291 -0.1644 -0.1746
S-1096	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1096	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1096	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
D-1096	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
P-1096	-1.8859 -0.5728 -0.1714 -0.9617 -0.1788 -0.6876 -4.1052 -0.5127 -0.0905 -0.2554 -0.1564 -0.2057 -0.7624 -2.0906 -0.2138 -0.0769 -0.1880 -0.6594 -2.3291 -0.1644 -0.1746
S-1272	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1272	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1272	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
D-1272	-0.78301602602005	<unk> The following table 1 contains recommendations for dosage in haematological and surgery cases :
P-1272	-1.8859 -0.5728 -0.1714 -0.9617 -0.1788 -0.6876 -4.1052 -0.5127 -0.0905 -0.2554 -0.1564 -0.2057 -0.7624 -2.0906 -0.2138 -0.0769 -0.1880 -0.6594 -2.3291 -0.1644 -0.1746
S-1434	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1434	0.45 mmol sodium ( 10 mg ) per vial .
H-1434	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-1434	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-1434	-1.1004 -0.1666 -0.1502 -0.1259 -0.1941 -0.1177 -0.9531 -0.0692 -0.1123 -0.1509 -0.0613 -0.0922 -0.1471 -0.1022 -0.0401 -0.1487 -0.1053 -0.0381 -0.0736 -0.1584 -0.1697
S-1119	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1119	In case of administration by a non health care professional appropriate training is needed .
H-1119	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
D-1119	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
P-1119	-1.1910 -1.0900 -0.5786 -0.3325 -0.1137 -0.1611 -0.1375 -0.0686 -0.0961 -0.1501 -0.7570 -0.1106 -1.4144 -0.2432 -1.6898 -0.4646 -0.3064 -0.2007
S-1258	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1258	0.45 mmol sodium ( 10 mg ) per vial .
H-1258	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-1258	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-1258	-1.1004 -0.1666 -0.1502 -0.1259 -0.1941 -0.1177 -0.9531 -0.0692 -0.1123 -0.1509 -0.0613 -0.0922 -0.1471 -0.1022 -0.0401 -0.1487 -0.1053 -0.0381 -0.0736 -0.1584 -0.1697
S-1710	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1710	Store in the original package in order to protect from light .
H-1710	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
D-1710	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
P-1710	-2.2658 -1.0551 -0.1799 -4.7512 -0.0718 -0.2056 -0.6803 -1.1084 -0.5659 -0.0941 -0.1411 -0.0880 -0.1149 -0.1570 -0.1604 -0.2061
S-14	Die Behandlung mit Adenuric darf nicht abgesetzt werden , wenn ein Gichtanfall auftritt .
T-14	Adenuric treatment should not be stopped if an attack happens .
H-14	-0.4144430458545685	<unk> Treatment with Adenuric should not be discontinued when gout occurs .
D-14	-0.4144430458545685	<unk> Treatment with Adenuric should not be discontinued when gout occurs .
P-14	-1.0863 -1.4961 -0.0755 -0.1118 -0.1796 -0.1999 -0.2476 -0.1076 -0.1177 -0.7743 -0.1208 -0.0937 -0.0562 -0.0598 -0.4570 -0.3531 -0.6106 -2.1683 -0.0527 -0.1681 -0.1666
S-1727	Nebenwirkungen bemerken , die nicht in dieser Gebrauchsinformation angegeben sind , informieren Sie bitte Ihren Arzt .
T-1727	please tell your doctor .
H-1727	-0.44178953766822815	<unk> If you experience any side effects not listed in this leaflet , please tell your doctor .
D-1727	-0.44178953766822815	<unk> If you experience any side effects not listed in this leaflet , please tell your doctor .
P-1727	-0.5309 -0.2755 -0.1480 -1.4189 -0.8468 -1.0211 -0.0791 -0.7243 -1.7969 -0.1609 -0.1410 -0.1935 -0.0378 -0.0642 -0.4063 -0.5771 -0.1761 -0.1302 -0.1959 -0.1612 -0.1917
S-1628	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1628	Store in the original package in order to protect from light .
H-1628	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
D-1628	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
P-1628	-2.2658 -1.0551 -0.1799 -4.7512 -0.0718 -0.2056 -0.6803 -1.1084 -0.5659 -0.0941 -0.1411 -0.0880 -0.1149 -0.1570 -0.1604 -0.2061
S-1644	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1644	Store in the original package in order to protect from light .
H-1644	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
D-1644	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
P-1644	-2.2658 -1.0551 -0.1799 -4.7512 -0.0718 -0.2056 -0.6803 -1.1084 -0.5659 -0.0941 -0.1411 -0.0880 -0.1149 -0.1570 -0.1604 -0.2061
S-1678	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1678	Store in the original package in order to protect from light .
H-1678	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
D-1678	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
P-1678	-2.2658 -1.0551 -0.1799 -4.7512 -0.0718 -0.2056 -0.6803 -1.1084 -0.5659 -0.0941 -0.1411 -0.0880 -0.1149 -0.1570 -0.1604 -0.2061
S-1694	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1694	Store in the original package in order to protect from light .
H-1694	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
D-1694	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
P-1694	-2.2658 -1.0551 -0.1799 -4.7512 -0.0718 -0.2056 -0.6803 -1.1084 -0.5659 -0.0941 -0.1411 -0.0880 -0.1149 -0.1570 -0.1604 -0.2061
S-1082	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1082	0.45 mmol sodium ( 10 mg ) per vial .
H-1082	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-1082	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-1082	-1.1004 -0.1666 -0.1502 -0.1259 -0.1941 -0.1177 -0.9531 -0.0692 -0.1123 -0.1509 -0.0613 -0.0922 -0.1471 -0.1022 -0.0401 -0.1487 -0.1053 -0.0381 -0.0736 -0.1584 -0.1697
S-1661	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1661	Store in the original package in order to protect from light .
H-1661	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
D-1661	-0.7403615713119507	<unk> Store the contents in their original packaging to protect from light .
P-1661	-2.2658 -1.0551 -0.1799 -4.7512 -0.0718 -0.2056 -0.6803 -1.1084 -0.5659 -0.0941 -0.1411 -0.0880 -0.1149 -0.1570 -0.1604 -0.2061
S-555	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-555	0.45 mmol sodium ( 10 mg ) per vial .
H-555	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-555	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-555	-1.1004 -0.1666 -0.1502 -0.1259 -0.1941 -0.1177 -0.9531 -0.0692 -0.1123 -0.1509 -0.0613 -0.0922 -0.1471 -0.1022 -0.0401 -0.1487 -0.1053 -0.0381 -0.0736 -0.1584 -0.1697
S-593	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-593	In case of administration by a non health care professional appropriate training is needed .
H-593	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
D-593	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
P-593	-1.1910 -1.0900 -0.5786 -0.3325 -0.1137 -0.1611 -0.1375 -0.0686 -0.0961 -0.1501 -0.7570 -0.1106 -1.4144 -0.2432 -1.6898 -0.4646 -0.3064 -0.2007
S-730	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-730	0.45 mmol sodium ( 10 mg ) per vial .
H-730	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-730	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-730	-1.1004 -0.1666 -0.1502 -0.1259 -0.1941 -0.1177 -0.9531 -0.0692 -0.1123 -0.1509 -0.0613 -0.0922 -0.1471 -0.1022 -0.0401 -0.1487 -0.1053 -0.0381 -0.0736 -0.1584 -0.1697
S-767	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-767	In case of administration by a non health care professional appropriate training is needed .
H-767	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
D-767	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
P-767	-1.1910 -1.0900 -0.5786 -0.3325 -0.1137 -0.1611 -0.1375 -0.0686 -0.0961 -0.1501 -0.7570 -0.1106 -1.4144 -0.2432 -1.6898 -0.4646 -0.3064 -0.2007
S-906	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-906	0.45 mmol sodium ( 10 mg ) per vial .
H-906	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-906	-0.20366992056369781	<unk> 0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-906	-1.1004 -0.1666 -0.1502 -0.1259 -0.1941 -0.1177 -0.9531 -0.0692 -0.1123 -0.1509 -0.0613 -0.0922 -0.1471 -0.1022 -0.0401 -0.1487 -0.1053 -0.0381 -0.0736 -0.1584 -0.1697
S-943	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-943	In case of administration by a non health care professional appropriate training is needed .
H-943	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
D-943	-0.5058865547180176	<unk> If it is not to be administered by medical staff appropriate training is necessary .
P-943	-1.1910 -1.0900 -0.5786 -0.3325 -0.1137 -0.1611 -0.1375 -0.0686 -0.0961 -0.1501 -0.7570 -0.1106 -1.4144 -0.2432 -1.6898 -0.4646 -0.3064 -0.2007
S-1207	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1207	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1207	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1207	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1207	-1.2759 -0.4962 -0.1848 -0.1303 -0.0961 -0.1489 -0.7036 -0.1541 -0.3128 -0.8350 -0.2630 -0.1371 -0.0512 -0.1360 -1.4219 -0.1432 -0.1193 -0.6401 -0.3042 -0.0799 -0.1528 -0.1884
S-1383	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1383	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1383	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1383	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1383	-1.2759 -0.4962 -0.1848 -0.1303 -0.0961 -0.1489 -0.7036 -0.1541 -0.3128 -0.8350 -0.2630 -0.1371 -0.0512 -0.1360 -1.4219 -0.1432 -0.1193 -0.6401 -0.3042 -0.0799 -0.1528 -0.1884
S-1560	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1560	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1560	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1560	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1560	-1.2759 -0.4962 -0.1848 -0.1303 -0.0961 -0.1489 -0.7036 -0.1541 -0.3128 -0.8350 -0.2630 -0.1371 -0.0512 -0.1360 -1.4219 -0.1432 -0.1193 -0.6401 -0.3042 -0.0799 -0.1528 -0.1884
S-855	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-855	From a microbiological point of view , the product should be used immediately after reconstitution .
H-855	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-855	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-855	-1.2759 -0.4962 -0.1848 -0.1303 -0.0961 -0.1489 -0.7036 -0.1541 -0.3128 -0.8350 -0.2630 -0.1371 -0.0512 -0.1360 -1.4219 -0.1432 -0.1193 -0.6401 -0.3042 -0.0799 -0.1528 -0.1884
S-1853	Advexin wurde am 23 . Oktober 2006 als Arzneimittel für seltene Leiden ausgewiesen .
T-1853	Advexin was designated as an orphan medicinal product on 23 October 2006.
H-1853	-0.6837578415870667	<unk> Advexin was designated as an orphan medicinal product on 23 October 2006 .
D-1853	-0.6837578415870667	<unk> Advexin was designated as an orphan medicinal product on 23 October 2006 .
P-1853	-1.2746 -2.3025 -0.2152 -0.1360 -0.1658 -2.4056 -0.1137 -1.2351 -0.6031 -1.7319 -1.0463 -0.2916 -0.9897 -0.0508 -0.0569 -0.1312 -0.0810 -0.6885 -0.5229 -0.1593 -0.1573
S-1977	Die gleichzeitige Anwendung von Sympathomimetika kann zu kritischen hypertonen Reaktionen führen .
T-1977	Concurrent administration with sympathomimetic medicines may result in critical hypertension reactions .
H-1977	-0.37705132365226746	<unk> Co-administration of sympathomimetics may lead to critical hypertonic reactions .
D-1977	-0.37705132365226746	<unk> Co-administration of sympathomimetics may lead to critical hypertonic reactions .
P-1977	-1.0856 -0.4307 -0.0635 -0.1011 -0.1935 -0.0128 -0.0667 -0.0730 -0.1415 -0.2464 -0.9675 -0.1126 -0.8854 -0.0537 -2.3779 -0.2331 -0.0914 -0.0652 -0.1663 -0.1733
S-4	Es ist als gelbe , kapselförmige Tabletten ( 80 und 120 mg ) erhältlich .
T-4	It is available as yellow , capsule- shaped tablets ( 80 and 120 mg ) .
H-4	-0.31957876682281494	<unk> It is available as yellow , capsule tablets ( 80 and 120 mg ) .
D-4	-0.31957876682281494	<unk> It is available as yellow , capsule tablets ( 80 and 120 mg ) .
P-4	-1.0042 -0.9686 -0.1464 -0.1717 -0.2763 -0.0538 -1.1302 -0.2888 -0.5104 -0.5122 -0.0939 -0.0843 -0.1490 -0.1560 -0.1852 -0.1129 -0.0599 -0.1498 -0.1645 -0.1732
S-598	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-598	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-598	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-598	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-598	-1.8093 -0.2511 -0.1684 -0.1245 -0.1654 -0.1115 -0.1308 -0.1046 -0.1015 -0.0571 -0.2250 -0.6813 -0.0503 -0.0410 -0.0496 -0.0511 -0.0678 -0.1238 -0.7636 -0.0600 -0.1685 -0.1632
S-1114	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1114	Patients should be monitored for the development of factor VIII inhibitors .
H-1114	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
D-1114	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
P-1114	-0.5067 -0.2198 -0.0796 -0.1241 -0.3214 -0.8349 -0.0907 -0.2051 -0.1703 -0.6179 -0.1135 -0.1330 -0.1264 -0.1650 -0.0563 -0.1018 -0.0408 -0.0470 -0.1085 -0.1475 -0.2018
S-1031	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1031	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1031	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1031	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1031	-1.2759 -0.4962 -0.1848 -0.1303 -0.0961 -0.1489 -0.7036 -0.1541 -0.3128 -0.8350 -0.2630 -0.1371 -0.0512 -0.1360 -1.4219 -0.1432 -0.1193 -0.6401 -0.3042 -0.0799 -0.1528 -0.1884
S-948	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-948	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-948	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-948	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-948	-1.8093 -0.2511 -0.1684 -0.1245 -0.1654 -0.1115 -0.1308 -0.1046 -0.1015 -0.0571 -0.2250 -0.6813 -0.0503 -0.0410 -0.0496 -0.0511 -0.0678 -0.1238 -0.7636 -0.0600 -0.1685 -0.1632
S-679	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-679	From a microbiological point of view , the product should be used immediately after reconstitution .
H-679	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-679	-0.3624792695045471	<unk> From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-679	-1.2759 -0.4962 -0.1848 -0.1303 -0.0961 -0.1489 -0.7036 -0.1541 -0.3128 -0.8350 -0.2630 -0.1371 -0.0512 -0.1360 -1.4219 -0.1432 -0.1193 -0.6401 -0.3042 -0.0799 -0.1528 -0.1884
S-1290	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1290	Patients should be monitored for the development of factor VIII inhibitors .
H-1290	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
D-1290	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
P-1290	-0.5067 -0.2198 -0.0796 -0.1241 -0.3214 -0.8349 -0.0907 -0.2051 -0.1703 -0.6179 -0.1135 -0.1330 -0.1264 -0.1650 -0.0563 -0.1018 -0.0408 -0.0470 -0.1085 -0.1475 -0.2018
S-1466	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1466	Patients should be monitored for the development of factor VIII inhibitors .
H-1466	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
D-1466	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
P-1466	-0.5067 -0.2198 -0.0796 -0.1241 -0.3214 -0.8349 -0.0907 -0.2051 -0.1703 -0.6179 -0.1135 -0.1330 -0.1264 -0.1650 -0.0563 -0.1018 -0.0408 -0.0470 -0.1085 -0.1475 -0.2018
S-762	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-762	Patients should be monitored for the development of factor VIII inhibitors .
H-762	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
D-762	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
P-762	-0.5067 -0.2198 -0.0796 -0.1241 -0.3214 -0.8349 -0.0907 -0.2051 -0.1703 -0.6179 -0.1135 -0.1330 -0.1264 -0.1650 -0.0563 -0.1018 -0.0408 -0.0470 -0.1085 -0.1475 -0.2018
S-938	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-938	Patients should be monitored for the development of factor VIII inhibitors .
H-938	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
D-938	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
P-938	-0.5067 -0.2198 -0.0796 -0.1241 -0.3214 -0.8349 -0.0907 -0.2051 -0.1703 -0.6179 -0.1135 -0.1330 -0.1264 -0.1650 -0.0563 -0.1018 -0.0408 -0.0470 -0.1085 -0.1475 -0.2018
S-1363	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1363	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1363	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
D-1363	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
P-1363	-2.3975 -0.9497 -1.3408 -1.6251 -0.0609 -0.0409 -0.1413 -0.1347 -0.1988 -0.1612 -4.6630 -0.1589 -0.1591 -1.1472 -0.0672 -0.0822 -0.5109 -1.3869 -0.1522 -0.2022
S-276	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-276	ADROVANCE reduces the risk of vertebral and hip fractures .
H-276	-0.3713989853858948	<unk> ADROVANCE decreases the risk for vertebral and hip fractures .
D-276	-0.3713989853858948	<unk> ADROVANCE decreases the risk for vertebral and hip fractures .
P-276	-0.9625 -0.3784 -0.1386 -0.1745 -0.1245 -1.0659 -1.6844 -0.1438 -0.1678 -0.1031 -0.9598 -0.1542 -0.0681 -0.0449 -0.1402 -0.1291 -0.0874 -0.8829 -0.0600 -0.1539 -0.1753
S-89	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-89	ADROVANCE reduces the risk of vertebral and hip fractures .
H-89	-0.3713989853858948	<unk> ADROVANCE decreases the risk for vertebral and hip fractures .
D-89	-0.3713989853858948	<unk> ADROVANCE decreases the risk for vertebral and hip fractures .
P-89	-0.9625 -0.3784 -0.1386 -0.1745 -0.1245 -1.0659 -1.6844 -0.1438 -0.1678 -0.1031 -0.9598 -0.1542 -0.0681 -0.0449 -0.1402 -0.1291 -0.0874 -0.8829 -0.0600 -0.1539 -0.1753
S-1799	Das Produkt darf nach der Lagerung bei Raumtemperatur nicht wieder gekühlt gelagert werden .
T-1799	The product may not be returned to refrigerated storage after storage at room temperature .
H-1799	-0.5682615637779236	<unk> After storage at room temperature the product should not be refrigerated .
D-1799	-0.5682615637779236	<unk> After storage at room temperature the product should not be refrigerated .
P-1799	-2.7670 -1.8776 -0.3566 -0.1163 -0.0744 -0.0846 -0.7364 -0.1050 -1.0070 -0.1335 -0.1641 -1.4892 -0.2078 -0.0789 -0.1207 -0.1703 -0.1712
S-1957	Deshalb ist bei der Anwendung des Kombinationspräparats bei Patienten über 60 Jahren Vorsicht geboten .
T-1957	Therefore the combination product should be used with caution in patients above 60 years of age .
H-1957	-0.40286532044410706	<unk> Therefore caution should be exercised when using the combination in patients over 60 years of age .
D-1957	-0.40286532044410706	<unk> Therefore caution should be exercised when using the combination in patients over 60 years of age .
P-1957	-0.8098 -1.9779 -0.0615 -0.7904 -0.2121 -0.1528 -0.0494 -0.1339 -0.2072 -1.4394 -0.1992 -0.2118 -0.2434 -0.0969 -0.2335 -0.1240 -0.1644 -0.7752 -0.2607 -0.1552 -0.1615
S-72	Die Patienten erhielten einmal pro Woche entweder ADROVANCE oder nur Alendronat .
T-72	Patients received either ADROVANCE or alendronate only once a week .
H-72	-0.27267780900001526	<unk> Patients received either ADROVANCE or alendronate once a week .
D-72	-0.27267780900001526	<unk> Patients received either ADROVANCE or alendronate once a week .
P-72	-0.6366 -0.3789 -0.0852 -0.6933 -0.1655 -0.0722 -0.1038 -0.1385 -0.0912 -0.6538 -0.2283 -0.1662 -0.1031 -0.0706 -0.0128 -0.9223 -0.4632 -0.1363 -0.1471 -0.1847
S-772	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-772	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-772	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-772	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-772	-1.8093 -0.2511 -0.1684 -0.1245 -0.1654 -0.1115 -0.1308 -0.1046 -0.1015 -0.0571 -0.2250 -0.6813 -0.0503 -0.0410 -0.0496 -0.0511 -0.0678 -0.1238 -0.7636 -0.0600 -0.1685 -0.1632
S-588	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-588	Patients should be monitored for the development of factor VIII inhibitors .
H-588	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
D-588	-0.21010200679302216	<unk> Patients should be monitored regularly for the formation of factor VIII inhibitors .
P-588	-0.5067 -0.2198 -0.0796 -0.1241 -0.3214 -0.8349 -0.0907 -0.2051 -0.1703 -0.6179 -0.1135 -0.1330 -0.1264 -0.1650 -0.0563 -0.1018 -0.0408 -0.0470 -0.1085 -0.1475 -0.2018
S-1124	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1124	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1124	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-1124	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-1124	-1.8093 -0.2511 -0.1684 -0.1245 -0.1654 -0.1115 -0.1308 -0.1046 -0.1015 -0.0571 -0.2250 -0.6813 -0.0503 -0.0410 -0.0496 -0.0511 -0.0678 -0.1238 -0.7636 -0.0600 -0.1685 -0.1632
S-881	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-881	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-881	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
D-881	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
P-881	-2.3229 -4.0601 -0.0928 -0.0952 -0.1800 -2.4045 -0.1631 -0.2179 -1.1004 -0.2461 -0.9315 -0.0977 -0.1327 -0.0817 -0.1596 -1.6213 -0.7329 -0.2805 -0.2049 -0.1424 -0.1931 -0.1594
S-1057	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1057	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1057	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
D-1057	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
P-1057	-2.3229 -4.0601 -0.0928 -0.0952 -0.1800 -2.4045 -0.1631 -0.2179 -1.1004 -0.2461 -0.9315 -0.0977 -0.1327 -0.0817 -0.1596 -1.6213 -0.7329 -0.2805 -0.2049 -0.1424 -0.1931 -0.1594
S-1303	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1303	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1303	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1303	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1303	-0.8505 -0.4954 -0.2922 -0.0758 -0.5375 -0.4830 -0.0926 -0.0556 -2.3608 -0.8651 -0.2060 -0.0407 -0.1180 -0.1520 -0.1658 -0.3675 -0.1614 -0.3743
S-1479	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1479	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1479	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1479	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1479	-0.8505 -0.4954 -0.2922 -0.0758 -0.5375 -0.4830 -0.0926 -0.0556 -2.3608 -0.8651 -0.2060 -0.0407 -0.1180 -0.1520 -0.1658 -0.3675 -0.1614 -0.3743
S-705	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-705	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-705	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
D-705	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
P-705	-2.3229 -4.0601 -0.0928 -0.0952 -0.1800 -2.4045 -0.1631 -0.2179 -1.1004 -0.2461 -0.9315 -0.0977 -0.1327 -0.0817 -0.1596 -1.6213 -0.7329 -0.2805 -0.2049 -0.1424 -0.1931 -0.1594
S-951	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-951	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-951	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-951	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-951	-0.8505 -0.4954 -0.2922 -0.0758 -0.5375 -0.4830 -0.0926 -0.0556 -2.3608 -0.8651 -0.2060 -0.0407 -0.1180 -0.1520 -0.1658 -0.3675 -0.1614 -0.3743
S-775	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-775	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-775	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-775	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-775	-0.8505 -0.4954 -0.2922 -0.0758 -0.5375 -0.4830 -0.0926 -0.0556 -2.3608 -0.8651 -0.2060 -0.0407 -0.1180 -0.1520 -0.1658 -0.3675 -0.1614 -0.3743
S-1233	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1233	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1233	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
D-1233	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
P-1233	-2.3229 -4.0601 -0.0928 -0.0952 -0.1800 -2.4045 -0.1631 -0.2179 -1.1004 -0.2461 -0.9315 -0.0977 -0.1327 -0.0817 -0.1596 -1.6213 -0.7329 -0.2805 -0.2049 -0.1424 -0.1931 -0.1594
S-1409	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1409	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1409	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
D-1409	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
P-1409	-2.3229 -4.0601 -0.0928 -0.0952 -0.1800 -2.4045 -0.1631 -0.2179 -1.1004 -0.2461 -0.9315 -0.0977 -0.1327 -0.0817 -0.1596 -1.6213 -0.7329 -0.2805 -0.2049 -0.1424 -0.1931 -0.1594
S-1586	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1586	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1586	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
D-1586	-0.7100393176078796	<unk> Remove the package from the BAXJECT II ( Fig . B ) .
P-1586	-2.3229 -4.0601 -0.0928 -0.0952 -0.1800 -2.4045 -0.1631 -0.2179 -1.1004 -0.2461 -0.9315 -0.0977 -0.1327 -0.0817 -0.1596 -1.6213 -0.7329 -0.2805 -0.2049 -0.1424 -0.1931 -0.1594
S-1127	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1127	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1127	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1127	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1127	-0.8505 -0.4954 -0.2922 -0.0758 -0.5375 -0.4830 -0.0926 -0.0556 -2.3608 -0.8651 -0.2060 -0.0407 -0.1180 -0.1520 -0.1658 -0.3675 -0.1614 -0.3743
S-1300	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1300	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1300	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-1300	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-1300	-1.8093 -0.2511 -0.1684 -0.1245 -0.1654 -0.1115 -0.1308 -0.1046 -0.1015 -0.0571 -0.2250 -0.6813 -0.0503 -0.0410 -0.0496 -0.0511 -0.0678 -0.1238 -0.7636 -0.0600 -0.1685 -0.1632
S-1011	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1011	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1011	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
D-1011	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
P-1011	-2.3975 -0.9497 -1.3408 -1.6251 -0.0609 -0.0409 -0.1413 -0.1347 -0.1988 -0.1612 -4.6630 -0.1589 -0.1591 -1.1472 -0.0672 -0.0822 -0.5109 -1.3869 -0.1522 -0.2022
S-1187	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1187	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1187	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
D-1187	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
P-1187	-2.3975 -0.9497 -1.3408 -1.6251 -0.0609 -0.0409 -0.1413 -0.1347 -0.1988 -0.1612 -4.6630 -0.1589 -0.1591 -1.1472 -0.0672 -0.0822 -0.5109 -1.3869 -0.1522 -0.2022
S-1776	Sollten Sie eine größere Menge angewendet haben , wenden Sie sich bitte schnellstmöglich an Ihren Arzt .
T-1776	If you inject more ADVATE than recommended , tell your doctor as soon as possible .
H-1776	-0.4871246814727783	<unk> If you have used more , contact your doctor as soon as possible .
D-1776	-0.4871246814727783	<unk> If you have used more , contact your doctor as soon as possible .
P-1776	-0.9760 -0.5481 -0.1212 -0.6344 -0.4023 -0.9731 -0.8358 -1.5675 -0.1132 -0.1513 -0.3306 -0.0868 -0.1443 -0.1588 -0.1588 -0.5917
S-660	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-660	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-660	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
D-660	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
P-660	-2.3975 -0.9497 -1.3408 -1.6251 -0.0609 -0.0409 -0.1413 -0.1347 -0.1988 -0.1612 -4.6630 -0.1589 -0.1591 -1.1472 -0.0672 -0.0822 -0.5109 -1.3869 -0.1522 -0.2022
S-835	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-835	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-835	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
D-835	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
P-835	-2.3975 -0.9497 -1.3408 -1.6251 -0.0609 -0.0409 -0.1413 -0.1347 -0.1988 -0.1612 -4.6630 -0.1589 -0.1591 -1.1472 -0.0672 -0.0822 -0.5109 -1.3869 -0.1522 -0.2022
S-1476	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1476	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1476	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
D-1476	-0.2486146092414856	<unk> As with all intravenous proteins , allergic hypersensitivity reactions may occur .
P-1476	-1.8093 -0.2511 -0.1684 -0.1245 -0.1654 -0.1115 -0.1308 -0.1046 -0.1015 -0.0571 -0.2250 -0.6813 -0.0503 -0.0410 -0.0496 -0.0511 -0.0678 -0.1238 -0.7636 -0.0600 -0.1685 -0.1632
S-601	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-601	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-601	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-601	-0.42745551466941833	<unk> If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-601	-0.8505 -0.4954 -0.2922 -0.0758 -0.5375 -0.4830 -0.0926 -0.0556 -2.3608 -0.8651 -0.2060 -0.0407 -0.1180 -0.1520 -0.1658 -0.3675 -0.1614 -0.3743
S-1540	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1540	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1540	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
D-1540	-0.7790297269821167	<unk> This then releases fibrin from fibrin and clotting can occur .
P-1540	-2.3975 -0.9497 -1.3408 -1.6251 -0.0609 -0.0409 -0.1413 -0.1347 -0.1988 -0.1612 -4.6630 -0.1589 -0.1591 -1.1472 -0.0672 -0.0822 -0.5109 -1.3869 -0.1522 -0.2022
S-1918	Aerinaze linderte die Symptome wirksamer als die beiden Wirkstoffe jeweils allein .
T-1918	Aerinaze was more effective in reducing symptoms than either of the two active substances taken alone .
H-1918	-0.47448211908340454	<unk> Aerinaze relieved symptoms more effectively than the two agents alone .
D-1918	-0.47448211908340454	<unk> Aerinaze relieved symptoms more effectively than the two agents alone .
P-1918	-2.1172 -0.8238 -0.1847 -0.1539 -0.1542 -0.1858 -2.5692 -0.0783 -0.0651 -0.1194 -0.2324 -0.0880 -0.3551 -0.1781 -0.6152 -0.2978 -0.1548 -0.1678
S-1991	Desloratadin und Pseudoephedrin gehen in die Muttermilch über .
T-1991	Desloratadine and pseudoephedrine are both excreted in breast milk .
H-1991	-0.6555576324462891	<unk> Desloratadine and pseudoephedrine are metabolised into breast milk .
D-1991	-0.6555576324462891	<unk> Desloratadine and pseudoephedrine are metabolised into breast milk .
P-1991	-0.9971 -3.3195 -0.1492 -0.1058 -0.5400 -1.2252 -0.1451 -0.3014 -2.1480 -0.1105 -0.0836 -0.1854 -0.2303 -0.1292 -1.5045 -2.1143 -0.0400 -0.0628 -0.2518 -1.0005 -0.1156 -0.1415 -0.1767
S-342	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-342	There are no adequate data from the use of ADROVANCE in pregnant women .
H-342	-0.3714679479598999	<unk> There are no adequate data on the use of ADROVANCE in pregnant women .
D-342	-0.3714679479598999	<unk> There are no adequate data on the use of ADROVANCE in pregnant women .
P-342	-1.4263 -1.7316 -0.2813 -0.0712 -0.8875 -0.1741 -0.4189 -0.1760 -0.2412 -0.1356 -0.1338 -0.0986 -0.1580 -0.1058 -0.7516 -0.1374 -0.0784 -0.0977 -0.1522 -0.1722
S-1833	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
T-1833	78 sector 4 Bucure ti 041836-RO Tel . : <<unk>> 40-21-321 16 40
H-1833	-0.5220184326171875	<unk> sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
D-1833	-0.5220184326171875	<unk> sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
P-1833	-1.5173 -2.2756 -0.1382 -1.2397 -1.0455 -2.1999 -0.4824 -0.1471 -0.0593 -0.0960 -0.1099 -0.2111 -0.0303 -0.1434 -0.1327 -0.1215 -1.1659 -0.1347 -1.0228 -0.1246 -0.1467 -0.1029 -0.1258 -0.1303 -0.1470
S-1319	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1319	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1319	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
D-1319	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
P-1319	-0.8085 -0.6205 -0.0643 -0.6722 -0.6070 -0.0775 -0.1338 -0.0741 -0.0398 -0.1725 -0.0277 -0.7683 -0.4980 -0.1379 -0.0618 -0.1544 -0.2666 -0.1577 -0.1403 -1.1566 -1.3587 -0.4259 -1.1148 -0.3801 -0.0288 -0.2066 -0.1920
S-967	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-967	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-967	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
D-967	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
P-967	-0.8085 -0.6205 -0.0643 -0.6722 -0.6070 -0.0775 -0.1338 -0.0741 -0.0398 -0.1725 -0.0277 -0.7683 -0.4980 -0.1379 -0.0618 -0.1544 -0.2666 -0.1577 -0.1403 -1.1566 -1.3587 -0.4259 -1.1148 -0.3801 -0.0288 -0.2066 -0.1920
S-1003	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1003	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1003	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
D-1003	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
P-1003	-0.6770 -3.0485 -0.3694 -0.4484 -0.0927 -0.1629 -0.3409 -0.1272 -0.0695 -0.1263 -1.1969 -1.4701 -0.0206 -0.0368 -0.0509 -0.1440 -0.0703 -0.2721 -0.9845 -0.1091 -0.1680 -0.1650
S-1143	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1143	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1143	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
D-1143	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
P-1143	-0.8085 -0.6205 -0.0643 -0.6722 -0.6070 -0.0775 -0.1338 -0.0741 -0.0398 -0.1725 -0.0277 -0.7683 -0.4980 -0.1379 -0.0618 -0.1544 -0.2666 -0.1577 -0.1403 -1.1566 -1.3587 -0.4259 -1.1148 -0.3801 -0.0288 -0.2066 -0.1920
S-791	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-791	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-791	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
D-791	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
P-791	-0.8085 -0.6205 -0.0643 -0.6722 -0.6070 -0.0775 -0.1338 -0.0741 -0.0398 -0.1725 -0.0277 -0.7683 -0.4980 -0.1379 -0.0618 -0.1544 -0.2666 -0.1577 -0.1403 -1.1566 -1.3587 -0.4259 -1.1148 -0.3801 -0.0288 -0.2066 -0.1920
S-617	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-617	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-617	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
D-617	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
P-617	-0.8085 -0.6205 -0.0643 -0.6722 -0.6070 -0.0775 -0.1338 -0.0741 -0.0398 -0.1725 -0.0277 -0.7683 -0.4980 -0.1379 -0.0618 -0.1544 -0.2666 -0.1577 -0.1403 -1.1566 -1.3587 -0.4259 -1.1148 -0.3801 -0.0288 -0.2066 -0.1920
S-1355	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1355	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1355	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
D-1355	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
P-1355	-0.6770 -3.0485 -0.3694 -0.4484 -0.0927 -0.1629 -0.3409 -0.1272 -0.0695 -0.1263 -1.1969 -1.4701 -0.0206 -0.0368 -0.0509 -0.1440 -0.0703 -0.2721 -0.9845 -0.1091 -0.1680 -0.1650
S-1495	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1495	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1495	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
D-1495	-0.3831973671913147	<unk> Therefore , in pregnancy and breast-feeding , factor VIII should only be used when there is a clear indication .
P-1495	-0.8085 -0.6205 -0.0643 -0.6722 -0.6070 -0.0775 -0.1338 -0.0741 -0.0398 -0.1725 -0.0277 -0.7683 -0.4980 -0.1379 -0.0618 -0.1544 -0.2666 -0.1577 -0.1403 -1.1566 -1.3587 -0.4259 -1.1148 -0.3801 -0.0288 -0.2066 -0.1920
S-1179	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1179	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1179	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
D-1179	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
P-1179	-0.6770 -3.0485 -0.3694 -0.4484 -0.0927 -0.1629 -0.3409 -0.1272 -0.0695 -0.1263 -1.1969 -1.4701 -0.0206 -0.0368 -0.0509 -0.1440 -0.0703 -0.2721 -0.9845 -0.1091 -0.1680 -0.1650
S-827	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-827	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-827	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
D-827	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
P-827	-0.6770 -3.0485 -0.3694 -0.4484 -0.0927 -0.1629 -0.3409 -0.1272 -0.0695 -0.1263 -1.1969 -1.4701 -0.0206 -0.0368 -0.0509 -0.1440 -0.0703 -0.2721 -0.9845 -0.1091 -0.1680 -0.1650
S-1532	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1532	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1532	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
D-1532	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
P-1532	-0.6770 -3.0485 -0.3694 -0.4484 -0.0927 -0.1629 -0.3409 -0.1272 -0.0695 -0.1263 -1.1969 -1.4701 -0.0206 -0.0368 -0.0509 -0.1440 -0.0703 -0.2721 -0.9845 -0.1091 -0.1680 -0.1650
S-653	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-653	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-653	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
D-653	-0.4614139795303345	<unk> symptoms of overdose with recombinant human clotting factor VIII are not known .
P-653	-0.6770 -3.0485 -0.3694 -0.4484 -0.0927 -0.1629 -0.3409 -0.1272 -0.0695 -0.1263 -1.1969 -1.4701 -0.0206 -0.0368 -0.0509 -0.1440 -0.0703 -0.2721 -0.9845 -0.1091 -0.1680 -0.1650
S-1274	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1274	Factor VIII level required ( % or IU/ dl )
H-1274	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
D-1274	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
P-1274	-0.4165 -2.5731 -0.6072 -0.1623 -1.0612 -0.2721 -0.1858 -1.3814 -0.5441 -0.0541 -0.0565 -0.7889 -0.1237 -0.1538 -0.1703 -0.1988 -0.1264 -0.1348 -0.0492 -0.1511 -0.1550
S-1450	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1450	Factor VIII level required ( % or IU/ dl )
H-1450	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
D-1450	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
P-1450	-0.4165 -2.5731 -0.6072 -0.1623 -1.0612 -0.2721 -0.1858 -1.3814 -0.5441 -0.0541 -0.0565 -0.7889 -0.1237 -0.1538 -0.1703 -0.1988 -0.1264 -0.1348 -0.0492 -0.1511 -0.1550
S-746	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-746	Factor VIII level required ( % or IU/ dl )
H-746	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
D-746	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
P-746	-0.4165 -2.5731 -0.6072 -0.1623 -1.0612 -0.2721 -0.1858 -1.3814 -0.5441 -0.0541 -0.0565 -0.7889 -0.1237 -0.1538 -0.1703 -0.1988 -0.1264 -0.1348 -0.0492 -0.1511 -0.1550
S-922	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-922	Factor VIII level required ( % or IU/ dl )
H-922	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
D-922	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
P-922	-0.4165 -2.5731 -0.6072 -0.1623 -1.0612 -0.2721 -0.1858 -1.3814 -0.5441 -0.0541 -0.0565 -0.7889 -0.1237 -0.1538 -0.1703 -0.1988 -0.1264 -0.1348 -0.0492 -0.1511 -0.1550
S-1098	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1098	Factor VIII level required ( % or IU/ dl )
H-1098	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
D-1098	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
P-1098	-0.4165 -2.5731 -0.6072 -0.1623 -1.0612 -0.2721 -0.1858 -1.3814 -0.5441 -0.0541 -0.0565 -0.7889 -0.1237 -0.1538 -0.1703 -0.1988 -0.1264 -0.1348 -0.0492 -0.1511 -0.1550
S-1648	ADVATE 500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1648	ADVATE 500 IU powder for solution for injection Octocog alfa IV use
H-1648	-0.31999504566192627	<unk> ADVATE 500 IU of powder to produce a solution for injection .
D-1648	-0.31999504566192627	<unk> ADVATE 500 IU of powder to produce a solution for injection .
P-1648	-0.8154 -0.6646 -0.2017 -0.0943 -0.1144 -0.1123 -0.1037 -0.0751 -0.3198 -0.0631 -0.1851 -1.7667 -0.3940 -0.0560 -0.1496 -0.1117 -0.0787 -0.1595 -0.6142
S-521	Ausführliche Erläuterungen zur Berechnung der Dosierungen sind der Packungsbeilage zu entnehmen .
T-521	Full details on how to calculate the doses are included in the Package Leaflet .
H-521	-0.4710956811904907	<unk> Detailed information on how to calculate doses is available in the Package Leaflet .
D-521	-0.4710956811904907	<unk> Detailed information on how to calculate doses is available in the Package Leaflet .
P-521	-2.0379 -0.1339 -0.0775 -1.2148 -0.1438 -1.7496 -0.7163 -0.5874 -0.1071 -0.0719 -0.1249 -0.3936 -1.6190 -0.2471 -0.1645 -0.1995 -0.1192 -0.1753 -0.0309 -0.1055 -0.1798 -0.1645
S-444	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-444	Circulating vitamin D3 is bound to vitamin D-binding protein .
H-444	-0.20529568195343018	<unk> Circulating vitamin D3 is bound to vitamin D-binding protein .
D-444	-0.20529568195343018	<unk> Circulating vitamin D3 is bound to vitamin D-binding protein .
P-444	-1.0796 -0.1446 -0.1280 -0.1362 -0.0455 -0.0824 -0.1683 -0.1275 -0.1525 -0.0309 -0.1183 -0.2339 -0.0800 -0.9191 -0.1060 -0.0469 -0.1022 -0.0880 -0.1454 -0.1707
S-1870	Die Wirkungen von Advexin wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-1870	The effects of Advexin were first tested in experimental models before being studied in humans .
H-1870	-0.6956602931022644	<unk> The effects of Advexin were initially evaluated in animal models , before being studied in humans .
D-1870	-0.6956602931022644	<unk> The effects of Advexin were initially evaluated in animal models , before being studied in humans .
P-1870	-1.2356 -0.6508 -0.1186 -0.1347 -2.0413 -0.1954 -0.1392 -0.1305 -0.9124 -3.5071 -0.1065 -0.1134 -3.2057 -0.0651 -0.6252 -0.5201 -0.2337 -0.5570 -0.1261 -0.3151 -0.1690 -0.2021
S-2000	Diese und andere unerwünschte Ereignisse , die in klinischen Prüfungen auftraten , sind in der nachfolgenden Tabelle aufgeführt .
T-2000	These and other undesirable effects reported during the clinical trials are listed in the following table .
H-2000	-0.3324717581272125	<unk> These and other adverse events which occurred in clinical trials are listed in the table below .
D-2000	-0.3324717581272125	<unk> These and other adverse events which occurred in clinical trials are listed in the table below .
P-2000	-1.0317 -0.4963 -0.1540 -0.1186 -0.0576 -0.0433 -0.0387 -1.0073 -0.2065 -0.1828 -0.0724 -0.0776 -0.3665 -0.1300 -0.3996 -0.1696 -1.5187 -0.1868 -0.1660 -0.2254
S-537	Patienten mit Hämophilie A können Antikörper ( Inhibitoren ) gegenüber Faktor VIII bilden .
T-537	Haemophilia A patients may develop antibodies ( inhibitors ) to factor VIII .
H-537	-0.39420947432518005	<unk> Patients with haemophilia A may form antibodies ( inhibitors ) to factor VIII .
D-537	-0.39420947432518005	<unk> Patients with haemophilia A may form antibodies ( inhibitors ) to factor VIII .
P-537	-0.5284 -0.5209 -0.0888 -0.1575 -0.1431 -0.3902 -1.5170 -1.8665 -0.1577 -0.2378 -2.3586 -0.0243 -0.0402 -0.1544 -0.1301 -0.0850 -0.0382 -0.1191 -0.1671 -0.3705 -0.1537 -0.1482 -0.0858 -0.1849 -0.1871
S-1729	2. Was müssen Sie vor der Anwendung von ADVATE beachten ? 3. Wie ist ADVATE anzuwenden ?
T-1729	Before you use ADVATE 3.
H-1729	-0.6870704889297485	3 . How to use ADVATE ? 2 . What should you consider before using ADVATE ?
D-1729	-0.6870704889297485	3 . How to use ADVATE ? 2 . What should you consider before using ADVATE ?
P-1729	-2.0685 -0.2005 -0.6808 -0.2752 -0.1489 -0.3315 -0.2240 -0.1385 -0.1213 -2.6793 -0.6947 -0.3000 -0.3460 -0.7339 -0.4295 -2.9314 -0.6460 -1.2900 -0.3951 -0.1958 -0.1136 -0.1083 -1.1514 -0.2857
S-1716	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1716	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1716	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1716	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1716	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1719	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1719	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1719	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1719	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1719	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1686	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1686	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1686	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1686	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1686	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1699	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1699	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1699	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1699	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1699	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1702	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1702	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1702	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1702	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1702	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1670	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1670	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1670	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1670	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1670	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1652	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1652	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1652	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1652	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1652	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-131	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-131	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-131	-0.2122952789068222	<unk> Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
D-131	-0.2122952789068222	<unk> Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
P-131	-0.7692 -0.0702 -0.4312 -0.0149 -0.1461 -0.1087 -0.1065 -0.1172 -0.1367 -0.0909 -0.0907 -1.4969 -0.0766 -0.2042 -0.1423 -0.1359 -0.0597 -0.0643 -0.0288 -0.0840 -0.1224 -0.4361 -0.1860 -0.2057 -0.0689 -0.1615 -0.1765
S-319	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-319	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-319	-0.2122952789068222	<unk> Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
D-319	-0.2122952789068222	<unk> Other possible causes of osteoporosis besides oestrogen deficiency and age should be considered .
P-319	-0.7692 -0.0702 -0.4312 -0.0149 -0.1461 -0.1087 -0.1065 -0.1172 -0.1367 -0.0909 -0.0907 -1.4969 -0.0766 -0.2042 -0.1423 -0.1359 -0.0597 -0.0643 -0.0288 -0.0840 -0.1224 -0.4361 -0.1860 -0.2057 -0.0689 -0.1615 -0.1765
S-1819	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
T-1819	Opletalova 55 CZ-110 00 Praha 1 Tel . : <<unk>> 420 225774111
H-1819	-0.49511775374412537	<unk> 420 225774111 Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
D-1819	-0.49511775374412537	<unk> 420 225774111 Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
P-1819	-1.5602 -0.2584 -0.1339 -0.1451 -0.1178 -1.3016 -0.1554 -0.1629 -0.9132 -0.1227 -2.4181 -1.9792 -0.1298 -0.1466 -0.1804 -0.1376 -0.2899 -0.1143 -2.0873 -0.9584 -0.1059 -0.0442 -0.1570 -0.1760 -0.1084 -0.2453 -0.1254 -0.1361 -0.1256 -1.3456 -0.1516 -0.1578 -0.1468
S-1683	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1683	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1683	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1683	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1683	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1632	ADVATE 250 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1632	ADVATE 250 IU powder for solution for injection Octocog alfa IV use
H-1632	-0.32772940397262573	<unk> ADVATE 250 IU of powder to produce a solution for injection .
D-1632	-0.32772940397262573	<unk> ADVATE 250 IU of powder to produce a solution for injection .
P-1632	-0.8623 -0.7292 -0.2058 -0.0970 -0.1144 -0.2791 -0.1060 -0.0734 -0.3481 -0.0632 -0.1846 -1.6770 -0.4071 -0.0566 -0.1488 -0.1123 -0.0780 -0.1588 -0.5252
S-1667	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1667	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1667	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1667	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1667	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1959	Das Kombinationspräparat wird für die Anwendung bei Patienten mit eingeschränkter Nieren- oder Leberfunktion nicht empfohlen .
T-1959	The combination product is not recommended for use in patients with impaired renal or hepatic function .
H-1959	-0.2953803837299347	<unk> The combination product is not recommended for use in patients with impaired renal or hepatic impairment .
D-1959	-0.2953803837299347	<unk> The combination product is not recommended for use in patients with impaired renal or hepatic impairment .
P-1959	-1.1158 -1.2095 -0.1736 -1.8497 -0.1335 -0.1227 -0.0389 -0.1230 -0.0694 -0.1215 -0.9189 -0.1475 -0.1812 -0.3804 -0.0902 -0.1506 -0.1534 -0.0495 -0.0268 -0.1024 -0.0381 -0.0156 -0.0349 -0.1174 -0.1487 -0.1669
S-1770	Steigern Sie die Dosierung von ADVATE zur Kontrolle Ihrer Blutung nicht ohne Ihren Arzt zu befragen .
T-1770	Do not increase the total dose of ADVATE to control your bleeding without consulting your doctor .
H-1770	-0.33896270394325256	<unk> Increase the dosage of ADVATE to control your bleeding without consulting your doctor .
D-1770	-0.33896270394325256	<unk> Increase the dosage of ADVATE to control your bleeding without consulting your doctor .
P-1770	-1.1617 -0.4200 -0.0159 -0.1077 -0.1426 -0.1214 -0.0452 -0.0987 -0.1401 -0.1506 -0.1807 -0.0749 -0.0873 -0.1256 -0.1538 -0.1619 -0.7665 -0.2002 -0.3708 -3.2487 -0.1037 -0.1402 -0.1287 -0.1502 -0.1768
S-1682	ADVATE 1500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1682	ADVATE 1500 IU powder for solution for injection Octocog alfa IV use
H-1682	-0.4000612497329712	<unk> ADVATE 1500 IU of powder to produce a solution for injection .
D-1682	-0.4000612497329712	<unk> ADVATE 1500 IU of powder to produce a solution for injection .
P-1682	-0.7919 -0.6286 -0.2023 -0.0920 -0.1115 -1.6556 -0.1029 -0.0726 -0.3504 -0.0677 -0.1953 -1.7082 -0.3888 -0.0563 -0.1515 -0.1115 -0.0792 -0.1606 -0.6742
S-1698	ADVATE 2000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1698	ADVATE 2000 IU powder for solution for injection Octocog alfa IV use
H-1698	-0.3477329909801483	<unk> ADVATE 2000 IU of powder to produce a solution for injection .
D-1698	-0.3477329909801483	<unk> ADVATE 2000 IU of powder to produce a solution for injection .
P-1698	-0.7572 -0.8968 -0.1990 -0.0953 -0.1171 -0.1193 -0.1140 -0.0719 -0.6166 -0.0634 -0.2127 -1.6944 -0.3774 -0.0573 -0.1522 -0.1114 -0.0810 -0.1625 -0.7074
S-1714	ADVATE 3000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1714	ADVATE 3000 IU powder for solution for injection Octocog alfa IV use
H-1714	-0.331914484500885	<unk> ADVATE 3000 IU of powder to produce a solution for injection .
D-1714	-0.331914484500885	<unk> ADVATE 3000 IU of powder to produce a solution for injection .
P-1714	-0.7673 -0.8942 -0.2024 -0.0973 -0.1168 -0.0739 -0.1054 -0.0760 -0.4104 -0.0654 -0.1892 -1.6863 -0.3884 -0.0559 -0.1498 -0.1125 -0.0780 -0.1615 -0.6757
S-1665	ADVATE 1000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1665	ADVATE 1000 IU powder for solution for injection Octocog alfa IV use
H-1665	-0.3269007205963135	<unk> ADVATE 1000 IU of powder to produce a solution for injection .
D-1665	-0.3269007205963135	<unk> ADVATE 1000 IU of powder to produce a solution for injection .
P-1665	-0.8000 -0.7308 -0.2014 -0.0919 -0.1152 -0.1360 -0.1037 -0.0732 -0.4102 -0.0637 -0.1897 -1.7859 -0.3732 -0.0573 -0.1502 -0.1122 -0.0801 -0.1609 -0.5755
S-1649	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1649	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1649	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1649	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1649	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1882	Bevor der CHMP ein Gutachten abgibt , kann er dem Unternehmen an Tag 180 etwaig verbleibende Fragen stellen .
T-1882	Following the CHMP s opinion , it usually takes around two months for the European Commission to grant a licence .
H-1882	-0.5919066071510315	<unk> Before issuing an opinion , the CHMP may ask the company any remaining questions on day 180 .
D-1882	-0.5919066071510315	<unk> Before issuing an opinion , the CHMP may ask the company any remaining questions on day 180 .
P-1882	-0.9816 -0.7516 -1.3624 -0.1477 -0.7684 -1.6652 -0.3731 -0.1648 -0.1258 -0.0575 -0.2931 -0.0746 -0.1496 -0.2393 -0.7441 -0.2179 -1.7586 -0.3166 -2.0299 -0.0802 -0.1836 -0.5361
S-1633	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1633	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1633	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1633	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1633	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-1636	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1636	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1636	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
D-1636	-0.23280222713947296	<unk> BY WEIGHT , VOLUME OR BY UNIT
P-1636	-1.0056 -1.1747 -0.0099 -0.7890 -0.0956 -0.0813 -0.0820 -0.1836 -0.1130 -0.0529 -0.0438 -0.0280 -0.0921 -0.0940 -0.0776 -0.0185 -0.2785 -0.0419 -0.1613
S-572	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-572	Factor VIII level required ( % or IU/ dl )
H-572	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
D-572	-0.4460139870643616	<unk> Required factor VIII plasma level ( % or IU/ dl )
P-572	-0.4165 -2.5731 -0.6072 -0.1623 -1.0612 -0.2721 -0.1858 -1.3814 -0.5441 -0.0541 -0.0565 -0.7889 -0.1237 -0.1538 -0.1703 -0.1988 -0.1264 -0.1348 -0.0492 -0.1511 -0.1550
S-1263	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1263	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1263	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
D-1263	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
P-1263	-1.1387 -0.8983 -0.0581 -0.1256 -0.8129 -0.1333 -0.8691 -0.0974 -0.1719 -0.1208 -1.3344 -2.8067 -0.1462 -0.2136 -0.2407 -0.1592 -0.1182 -1.1004 -1.7637 -2.4225 -0.1734 -0.1832
S-1439	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1439	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1439	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
D-1439	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
P-1439	-1.1387 -0.8983 -0.0581 -0.1256 -0.8129 -0.1333 -0.8691 -0.0974 -0.1719 -0.1208 -1.3344 -2.8067 -0.1462 -0.2136 -0.2407 -0.1592 -0.1182 -1.1004 -1.7637 -2.4225 -0.1734 -0.1832
S-47	Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-47	Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu )
H-47	-0.32646119594573975	<unk> Oral film-coated tablet Blister ( Aclar/ PVC/ aluminium )
D-47	-0.32646119594573975	<unk> Oral film-coated tablet Blister ( Aclar/ PVC/ aluminium )
P-47	-1.1316 -0.6291 -0.1414 -1.3253 -0.1638 -0.3306 -0.0671 -1.6447 -0.0947 -0.0312 -0.0551 -0.1469 -0.1045 -0.2531 -0.1480 -0.2540 -0.1347 -0.1843 -0.1878 -0.1568 -0.2819 -0.0679 -0.1486 -0.1519
S-1087	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1087	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1087	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
D-1087	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
P-1087	-1.1387 -0.8983 -0.0581 -0.1256 -0.8129 -0.1333 -0.8691 -0.0974 -0.1719 -0.1208 -1.3344 -2.8067 -0.1462 -0.2136 -0.2407 -0.1592 -0.1182 -1.1004 -1.7637 -2.4225 -0.1734 -0.1832
S-911	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-911	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-911	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
D-911	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
P-911	-1.1387 -0.8983 -0.0581 -0.1256 -0.8129 -0.1333 -0.8691 -0.0974 -0.1719 -0.1208 -1.3344 -2.8067 -0.1462 -0.2136 -0.2407 -0.1592 -0.1182 -1.1004 -1.7637 -2.4225 -0.1734 -0.1832
S-529	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-529	The study went on to look at the number 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-529	-0.19674718379974365	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-529	-0.19674718379974365	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-529	-0.4571 -0.2191 -0.1402 -0.1372 -0.4214 -0.0904 -0.1676 -0.2619 -0.1066 -0.0805 -0.1595 -0.1086 -0.1693 -0.1283 -0.0902 -0.0998 -0.1872 -0.1426 -0.0955 -0.1768 -0.2019 -0.7734 -0.1542 -0.1524
S-560	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-560	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-560	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
D-560	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
P-560	-1.1387 -0.8983 -0.0581 -0.1256 -0.8129 -0.1333 -0.8691 -0.0974 -0.1719 -0.1208 -1.3344 -2.8067 -0.1462 -0.2136 -0.2407 -0.1592 -0.1182 -1.1004 -1.7637 -2.4225 -0.1734 -0.1832
S-552	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 50 I.E.<unk> ml Octocog alfa .
T-552	After reconstitution , each ml solution for injection contains approximately 50 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-552	-0.2769131660461426	<unk> After reconstitution , each ml of solution contains approximately 50 IU/ ml Octocog alfa .
D-552	-0.2769131660461426	<unk> After reconstitution , each ml of solution contains approximately 50 IU/ ml Octocog alfa .
P-552	-1.4381 -1.0026 -0.3569 -0.0648 -0.2857 -0.2065 -0.0597 -0.1517 -0.0904 -0.0544 -0.1475 -0.1162 -0.1293 -0.1303 -0.1407 -0.1039 -1.0277 -0.0773 -0.1999 -0.2345 -0.1506 -0.0674 -0.2542 -0.1557
S-727	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 100 I.E.<unk> ml Octocog alfa .
T-727	After reconstitution , each ml solution for injection contains approximately 100 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-727	-0.27896222472190857	<unk> After reconstitution , each ml of solution contains approximately 100 IU/ ml Octocog alfa .
D-727	-0.27896222472190857	<unk> After reconstitution , each ml of solution contains approximately 100 IU/ ml Octocog alfa .
P-727	-1.4262 -1.0014 -0.3497 -0.0640 -0.2708 -0.2351 -0.0631 -0.1512 -0.0881 -0.0521 -0.1063 -0.1333 -0.1261 -0.1327 -0.1417 -0.1035 -1.1134 -0.0773 -0.2000 -0.2317 -0.1471 -0.0681 -0.2552 -0.1570
S-903	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 200 I.E.<unk> ml Octocog alfa .
T-903	After reconstitution , each ml solution for injection contains approximately 200 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-903	-0.27956870198249817	<unk> After reconstitution , each ml of solution contains approximately 200 IU/ ml Octocog alfa .
D-903	-0.27956870198249817	<unk> After reconstitution , each ml of solution contains approximately 200 IU/ ml Octocog alfa .
P-903	-1.4688 -0.9970 -0.3665 -0.0638 -0.2738 -0.2185 -0.0631 -0.1501 -0.0885 -0.0540 -0.1102 -0.1201 -0.1209 -0.1323 -0.1386 -0.1028 -1.0948 -0.0780 -0.2014 -0.2351 -0.1486 -0.0688 -0.2576 -0.1564
S-1079	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 300 I.E.<unk> ml Octocog alfa .
T-1079	After reconstitution , each ml solution for injection contains approximately 300 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1079	-0.27932900190353394	<unk> After reconstitution , each ml of solution contains approximately 300 IU/ ml Octocog alfa .
D-1079	-0.27932900190353394	<unk> After reconstitution , each ml of solution contains approximately 300 IU/ ml Octocog alfa .
P-1079	-1.4083 -1.0355 -0.3658 -0.0657 -0.2710 -0.2123 -0.0617 -0.1509 -0.0888 -0.0506 -0.1141 -0.0898 -0.1267 -0.1314 -0.1391 -0.1035 -1.1342 -0.0779 -0.2000 -0.2346 -0.1485 -0.0685 -0.2671 -0.1580
S-1255	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 400 I.E.<unk> ml Octocog alfa .
T-1255	After reconstitution , each ml solution for injection contains approximately 400 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1255	-0.2794308364391327	<unk> After reconstitution , each ml of solution contains approximately 400 IU/ ml Octocog alfa .
D-1255	-0.2794308364391327	<unk> After reconstitution , each ml of solution contains approximately 400 IU/ ml Octocog alfa .
P-1255	-1.4302 -1.0162 -0.3720 -0.0671 -0.2767 -0.2142 -0.0613 -0.1513 -0.0895 -0.0527 -0.1321 -0.0702 -0.1219 -0.1305 -0.1376 -0.1032 -1.1281 -0.0774 -0.2001 -0.2362 -0.1489 -0.0668 -0.2647 -0.1574
S-1431	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 600 I.E.<unk> ml Octocog alfa .
T-1431	After reconstitution , each ml solution for injection contains approximately 600 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1431	-0.27808883786201477	<unk> After reconstitution , each ml of solution contains approximately 600 IU/ ml Octocog alfa .
D-1431	-0.27808883786201477	<unk> After reconstitution , each ml of solution contains approximately 600 IU/ ml Octocog alfa .
P-1431	-1.4400 -1.0064 -0.3657 -0.0652 -0.2679 -0.2273 -0.0640 -0.1517 -0.0886 -0.0501 -0.1237 -0.0880 -0.1319 -0.1296 -0.1383 -0.1025 -1.0848 -0.0769 -0.1998 -0.2328 -0.1507 -0.0675 -0.2641 -0.1568
S-735	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-735	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-735	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
D-735	-0.6858300566673279	<unk> Treatment must be monitored by a doctor familiar with the treatment of haemophilia .
P-735	-1.1387 -0.8983 -0.0581 -0.1256 -0.8129 -0.1333 -0.8691 -0.0974 -0.1719 -0.1208 -1.3344 -2.8067 -0.1462 -0.2136 -0.2407 -0.1592 -0.1182 -1.1004 -1.7637 -2.4225 -0.1734 -0.1832
S-1772	Wenn Sie selbst oder eine andere Person ADVATE verabreichen , darf dies nur nach einem entsprechenden Training geschehen .
T-1772	You or someone else might also administer ADVATE as an injection , but only after receiving adequate training .
H-1772	-0.5727552175521851	<unk> If you or another person is administering ADVATE , this should only be done after appropriate training .
D-1772	-0.5727552175521851	<unk> If you or another person is administering ADVATE , this should only be done after appropriate training .
P-1772	-1.0836 -0.5155 -0.1490 -0.1699 -0.4241 -2.5544 -1.3908 -1.1594 -0.1180 -0.0995 -0.1704 -0.0806 -0.0781 -0.5633 -0.8689 -0.6527 -0.5847 -0.1693 -1.0144 -0.1783 -1.1580 -0.2120 -0.1583 -0.1931
S-186	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption
T-186	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-186	-0.4794021546840668	<unk> Preclinical studies have shown that alendronate prefers sites of active absorption
D-186	-0.4794021546840668	<unk> Preclinical studies have shown that alendronate prefers sites of active absorption
P-186	-0.5517 -0.2656 -0.5797 -0.0867 -0.8432 -0.1466 -1.0391 -0.0682 -0.2007 -0.0383 -0.0986 -0.0685 -0.0090 -1.9200 -0.6521 -2.9406 -0.1457 -0.0534 -0.1014 -0.0931 -0.1653
S-462	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-462	Store in the original blister in order to protect from moisture and light .
H-462	-0.3896622359752655	<unk> Store in the original blister to protect from moisture and light .
D-462	-0.3896622359752655	<unk> Store in the original blister to protect from moisture and light .
P-462	-2.3961 -0.1764 -0.4608 -0.6935 -1.3749 -0.0997 -0.0660 -0.1585 -0.0778 -0.1285 -0.1946 -0.0723 -0.0786 -0.1251 -0.1700 -0.1672 -0.1843
S-266	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-266	Store in the original blister in order to protect from moisture and light .
H-266	-0.3896622359752655	<unk> Store in the original blister to protect from moisture and light .
D-266	-0.3896622359752655	<unk> Store in the original blister to protect from moisture and light .
P-266	-2.3961 -0.1764 -0.4608 -0.6935 -1.3749 -0.0997 -0.0660 -0.1585 -0.0778 -0.1285 -0.1946 -0.0723 -0.0786 -0.1251 -0.1700 -0.1672 -0.1843
S-690	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-690	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-690	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
D-690	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
P-690	-1.8569 -1.0359 -0.3857 -0.0661 -0.2219 -0.2403 -1.7597 -1.5232 -0.1030 -0.1180 -0.2239 -0.1276 -0.1375 -0.1930 -0.1335 -0.7533 -0.1903
S-536	In den zusätzlichen Studien , einschließlich der Studie mit Kindern unter sechs Jahren , wurde die Wirksamkeit von Advate bestätigt .
T-536	The additional studies confirmed Advate s effectiveness , including in children under six years of age .
H-536	-0.5350500345230103	<unk> The additional studies , including the study in children under six years of age , confirmed the efficacy of Advate .
D-536	-0.5350500345230103	<unk> The additional studies , including the study in children under six years of age , confirmed the efficacy of Advate .
P-536	-1.2536 -0.9450 -0.1039 -1.4496 -0.4478 -0.0786 -0.7839 -0.4484 -0.9162 -0.0798 -0.7086 -0.1796 -0.2683 -1.2859 -0.3460 -0.1831 -0.7216 -0.3621 -0.3172 -0.0554 -0.0788 -0.1532 -2.2476 -0.1186 -0.1780 -0.2006
S-535	Darüber hinaus war bei 81 % dieser Blutungsepisoden nur eine einzige Behandlung mit Advate erforderlich .
T-535	In addition , 81 % of these bleeding episodes required only a single treatment with Advate .
H-535	-0.46919533610343933	In addition , in 81 % of these bleeding episodes , only one treatment with Advate was necessary .
D-535	-0.46919533610343933	In addition , in 81 % of these bleeding episodes , only one treatment with Advate was necessary .
P-535	-3.3059 -0.0927 -0.1879 -0.3320 -0.1704 -0.0996 -0.1444 -0.1960 -1.0103 -0.3008 -0.0087 -0.9053 -0.2256 -0.1467 -0.2511 -0.3973 -1.2116 -0.1198 -0.5007 -0.4080 -0.1581 -0.1495
S-1811	Jede Packung beinhaltet des Weiteren ein Gerät zur Rekonstitution ( BAXJECTII ) .
T-1811	Each pack also contains a device for reconstitution ( BAXJECT II ) .
H-1811	-0.6034004092216492	<unk> Each carton also contains a reconstitution unit ( BAXJECTII ) .
D-1811	-0.6034004092216492	<unk> Each carton also contains a reconstitution unit ( BAXJECTII ) .
P-1811	-2.8928 -0.2628 -0.1304 -0.0334 -0.1198 -0.2640 -0.1827 -0.5217 -0.0467 -3.7308 -0.1531 -1.5406 -0.3195 -1.0074 -0.1070 -0.1387 -0.1433 -0.1508 -0.1594 -0.1632
S-1042	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1042	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1042	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
D-1042	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
P-1042	-1.8569 -1.0359 -0.3857 -0.0661 -0.2219 -0.2403 -1.7597 -1.5232 -0.1030 -0.1180 -0.2239 -0.1276 -0.1375 -0.1930 -0.1335 -0.7533 -0.1903
S-1218	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1218	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1218	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
D-1218	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
P-1218	-1.8569 -1.0359 -0.3857 -0.0661 -0.2219 -0.2403 -1.7597 -1.5232 -0.1030 -0.1180 -0.2239 -0.1276 -0.1375 -0.1930 -0.1335 -0.7533 -0.1903
S-1721	Lesen Sie die gesamte Packungsbeilage sorgfältig durch , bevor Sie mit der Anwendung dieses Arzneimittels beginnen .
T-1721	Read all of this leaflet carefully before you start using this medicine .
H-1721	-0.5604721307754517	<unk> Read the entire package leaflet carefully before you start using this product .
D-1721	-0.5604721307754517	<unk> Read the entire package leaflet carefully before you start using this product .
P-1721	-1.5362 -1.3004 -0.4621 -0.3383 -1.2788 -0.0571 -0.0195 -0.0906 -0.0608 -0.2232 -0.5890 -1.4670 -0.7661 -0.1166 -0.8770 -0.1599 -0.1852
S-1754	Dies muss bei Patienten , die einer natriumkontollierten Diät unterliegen , berücksichtigt werden .
T-1754	To be taken into consideration by patients on a controlled sodium diet .
H-1754	-0.6995141506195068	<unk> This must be taken into account when following a sodium controlled diet .
D-1754	-0.6995141506195068	<unk> This must be taken into account when following a sodium controlled diet .
P-1754	-1.0024 -0.4201 -0.9275 -0.1698 -2.1947 -0.2047 -0.2569 -1.4875 -0.6189 -0.2104 -0.0606 -0.5777 -2.6354 -0.0583 -0.1756 -0.1919
S-356	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-356	Musculoskeletal and connective tissue disorders :
H-356	-0.3695363998413086	<unk> Common : musculoskeletal ( bone , muscle or joints ) pain .
D-356	-0.3695363998413086	<unk> Common : musculoskeletal ( bone , muscle or joints ) pain .
P-356	-1.2979 -0.4145 -0.1284 -0.1420 -0.1379 -0.4450 -0.0972 -2.0710 -0.1949 -0.0995 -0.3440 -0.1590 -0.1581 -0.2343 -0.7552 -0.5160 -0.0465 -0.1353 -0.0528 -0.1459 -0.1851
S-168	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-168	Musculoskeletal and connective tissue disorders :
H-168	-0.3695363998413086	<unk> Common : musculoskeletal ( bone , muscle or joints ) pain .
D-168	-0.3695363998413086	<unk> Common : musculoskeletal ( bone , muscle or joints ) pain .
P-168	-1.2979 -0.4145 -0.1284 -0.1420 -0.1379 -0.4450 -0.0972 -2.0710 -0.1949 -0.0995 -0.3440 -0.1590 -0.1581 -0.2343 -0.7552 -0.5160 -0.0465 -0.1353 -0.0528 -0.1459 -0.1851
S-7	Wenn derartige Ablagerungen in den Gelenken entstehen und Schmerzen verursachen , spricht man von einer Gicht .
T-7	When this happens in the joints and causes pain , it is known as gout .
H-7	-0.4077922999858856	<unk> When such deposition in the joints and causes pain , it is called gout .
D-7	-0.4077922999858856	<unk> When such deposition in the joints and causes pain , it is called gout .
P-7	-1.0934 -0.3542 -0.3939 -0.8518 -0.5211 -0.7360 -0.1834 -0.0210 -0.0709 -0.9471 -0.9078 -0.0532 -0.3021 -0.2948 -0.1725 -0.4132 -0.1526 -0.3462 -0.1594 -0.1811
S-1911	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-1911	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-1911	-0.19674718379974365	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-1911	-0.19674718379974365	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-1911	-0.4571 -0.2191 -0.1402 -0.1372 -0.4214 -0.0904 -0.1676 -0.2619 -0.1066 -0.0805 -0.1595 -0.1086 -0.1693 -0.1283 -0.0902 -0.0998 -0.1872 -0.1426 -0.0955 -0.1768 -0.2019 -0.7734 -0.1542 -0.1524
S-866	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-866	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-866	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
D-866	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
P-866	-1.8569 -1.0359 -0.3857 -0.0661 -0.2219 -0.2403 -1.7597 -1.5232 -0.1030 -0.1180 -0.2239 -0.1276 -0.1375 -0.1930 -0.1335 -0.7533 -0.1903
S-311	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-311	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-311	-0.424248605966568	<unk> <unk> Bone , joints , or muscle pain were reported in patients receiving bisphosphonates .
D-311	-0.424248605966568	<unk> <unk> Bone , joints , or muscle pain were reported in patients receiving bisphosphonates .
P-311	-0.5874 -2.5096 -0.2269 -0.1711 -0.1766 -0.4595 -0.3681 -1.2604 -1.1055 -0.0984 -0.0375 -0.8297 -0.2245 -0.1783 -0.5406 -0.2245 -0.1101 -0.0389 -0.0429 -0.0732 -0.0747 -0.1555 -0.2635
S-123	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-123	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-123	-0.424248605966568	<unk> <unk> Bone , joints , or muscle pain were reported in patients receiving bisphosphonates .
D-123	-0.424248605966568	<unk> <unk> Bone , joints , or muscle pain were reported in patients receiving bisphosphonates .
P-123	-0.5874 -2.5096 -0.2269 -0.1711 -0.1766 -0.4595 -0.3681 -1.2604 -1.1055 -0.0984 -0.0375 -0.8297 -0.2245 -0.1783 -0.5406 -0.2245 -0.1101 -0.0389 -0.0429 -0.0732 -0.0747 -0.1555 -0.2635
S-20	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-20	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-20	-0.19674718379974365	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-20	-0.19674718379974365	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-20	-0.4571 -0.2191 -0.1402 -0.1372 -0.4214 -0.0904 -0.1676 -0.2619 -0.1066 -0.0805 -0.1595 -0.1086 -0.1693 -0.1283 -0.0902 -0.0998 -0.1872 -0.1426 -0.0955 -0.1768 -0.2019 -0.7734 -0.1542 -0.1524
S-1972	Sportler müssen darauf hingewiesen werden , dass unter der Therapie mit Pseudoephedrin positive Dopingtests möglich sind .
T-1972	Athletes should be informed that treatment with pseudoephedrine could lead to positive doping tests .
H-1972	-0.6396344304084778	<unk> Athletes should be alerted that pseudoephedrine therapy may <unk> <unk> result in positive doping tests .
D-1972	-0.6396344304084778	<unk> Athletes should be alerted that pseudoephedrine therapy may <unk> <unk> result in positive doping tests .
P-1972	-0.2073 -0.9887 -0.1070 -0.8648 -0.1547 -0.6997 -0.0710 -0.1459 -0.2401 -0.5130 -2.6187 -0.1242 -0.1100 -0.1851 -0.2544 -0.1247 -0.1048 -0.1845 -0.9817 -0.2309 -2.7963 -0.1708 -2.3123 -2.4833 -0.2289 -0.1705 -0.1972
S-513	Advate enthält den Wirkstoff Octocog alfa ( menschlicher Gerinnungsfaktor VIII ) .
T-513	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
H-513	-0.37518951296806335	<unk> Advate contains the active substance Octocog alfa ( human coagulation factor VIII ) .
D-513	-0.37518951296806335	<unk> Advate contains the active substance Octocog alfa ( human coagulation factor VIII ) .
P-513	-1.2633 -2.8317 -0.1322 -0.0819 -0.1714 -0.0360 -0.0404 -1.0544 -0.0703 -0.2000 -0.2824 -0.1158 -0.0596 -0.1410 -0.2477 -0.9015 -0.3570 -0.2342 -0.0387 -0.1627 -0.0755 -0.1437 -0.2054 -0.1580
S-1760	In einigen Fällen jedoch können , besonders bei jüngeren Patienten , häufigere Injektionen oder höhere Dosen erforderlich sein .
T-1760	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
H-1760	-0.29237011075019836	<unk> However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
D-1760	-0.29237011075019836	<unk> However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
P-1760	-2.0599 -1.1222 -0.2339 -0.1050 -0.1051 -0.1114 -0.3561 -0.4676 -0.2417 -0.0577 -0.0820 -0.1614 -0.1302 -0.2322 -0.1016 -0.0571 -0.1590 -0.0970 -0.1039 -0.0987 -0.1271 -0.1851 -0.5410 -0.1657 -0.2067
S-1571	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1571	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1571	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
D-1571	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
P-1571	-1.8569 -1.0359 -0.3857 -0.0661 -0.2219 -0.2403 -1.7597 -1.5232 -0.1030 -0.1180 -0.2239 -0.1276 -0.1375 -0.1930 -0.1335 -0.7533 -0.1903
S-1394	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1394	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1394	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
D-1394	-0.5335143208503723	<unk> For reconstitution only the included sterilised water for injections and <unk>
P-1394	-1.8569 -1.0359 -0.3857 -0.0661 -0.2219 -0.2403 -1.7597 -1.5232 -0.1030 -0.1180 -0.2239 -0.1276 -0.1375 -0.1930 -0.1335 -0.7533 -0.1903
S-449	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-449	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-449	-0.40603214502334595	<unk> In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-449	-0.40603214502334595	<unk> In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-449	-1.6628 -0.3299 -0.1105 -0.1449 -0.8588 -0.5199 -0.0627 -0.1572 -0.5461 -0.0262 -0.1052 -0.1418 -0.9750 -0.1092 -0.6314 -0.0444 -0.0766 -0.4310 -0.1402 -1.6497 -0.2734 -0.1429 -0.1990
S-409	Die zwei Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-409	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-409	-0.32455071806907654	<unk> The two treatment groups were also comparable in BMD increases at other skeletal sites .
D-409	-0.32455071806907654	<unk> The two treatment groups were also comparable in BMD increases at other skeletal sites .
P-409	-1.6520 -0.2072 -0.2323 -0.7879 -0.5310 -0.1723 -0.0827 -0.2933 -0.1294 -0.1423 -0.3400 -0.1577 -0.1894 -0.5189 -0.3443 -0.3381 -0.1180 -0.1912 -0.1281 -0.2465 -0.1511 -0.1863
S-253	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-253	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-253	-0.40603214502334595	<unk> In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-253	-0.40603214502334595	<unk> In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-253	-1.6628 -0.3299 -0.1105 -0.1449 -0.8588 -0.5199 -0.0627 -0.1572 -0.5461 -0.0262 -0.1052 -0.1418 -0.9750 -0.1092 -0.6314 -0.0444 -0.0766 -0.4310 -0.1402 -1.6497 -0.2734 -0.1429 -0.1990
S-52	Dieses Arzneimittel ist identisch mit FOSAVANCE , das bereits in der Europäischen Union zugelassen ist .
T-52	This medicine is the same as FOSAVANCE , which is already authorised in the European Union .
H-52	-0.3717193305492401	<unk> This medicinal product is identical to FOSAVANCE which is already authorised in the European Union .
D-52	-0.3717193305492401	<unk> This medicinal product is identical to FOSAVANCE which is already authorised in the European Union .
P-52	-1.6531 -0.3453 -0.7263 -0.0593 -0.0715 -0.1240 -0.7892 -0.3759 -0.2365 -0.2072 -0.0664 -0.1117 -0.1476 -0.1154 -0.7363 -0.9181 -0.1451 -0.5887 -0.6188 -0.2102 -0.1630 -0.1466 -0.5128 -0.2716 -0.1583 -0.1658
S-716	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-716	Connect the syringe to BAXJECT II ( Fig . d ) .
H-716	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
D-716	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
P-716	-2.2117 -3.4262 -0.1316 -0.1184 -0.1520 -0.1068 -0.0292 -0.0361 -0.1233 -0.2018 -0.7483 -0.2413 -0.9273 -0.0942 -0.1239 -0.0938 -1.2691 -2.4666 -0.4678 -0.0823 -0.1421 -0.1722 -0.1589
S-892	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-892	Connect the syringe to BAXJECT II ( Fig . d ) .
H-892	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
D-892	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
P-892	-2.2117 -3.4262 -0.1316 -0.1184 -0.1520 -0.1068 -0.0292 -0.0361 -0.1233 -0.2018 -0.7483 -0.2413 -0.9273 -0.0942 -0.1239 -0.0938 -1.2691 -2.4666 -0.4678 -0.0823 -0.1421 -0.1722 -0.1589
S-1751	Ihr Arzt wird entscheiden , ob Sie ADVATE in der Schwangerschaft und Stillzeit anwenden können .
T-1751	Your doctor will decide if ADVATE may be used during pregnancy and breast-feeding .
H-1751	-0.2700606882572174	<unk> Your doctor will decide whether you can use ADVATE in pregnancy and breast-feeding .
D-1751	-0.2700606882572174	<unk> Your doctor will decide whether you can use ADVATE in pregnancy and breast-feeding .
P-1751	-1.7226 -0.1904 -0.1417 -0.1879 -0.0652 -0.6123 -0.7679 -0.2949 -0.1864 -0.1252 -0.1928 -0.0763 -0.0924 -0.2215 -0.0778 -0.1359 -0.0824 -0.0458 -0.3373 -0.0258 -0.1728 -0.1861
S-1068	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1068	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1068	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
D-1068	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
P-1068	-2.2117 -3.4262 -0.1316 -0.1184 -0.1520 -0.1068 -0.0292 -0.0361 -0.1233 -0.2018 -0.7483 -0.2413 -0.9273 -0.0942 -0.1239 -0.0938 -1.2691 -2.4666 -0.4678 -0.0823 -0.1421 -0.1722 -0.1589
S-1244	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1244	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1244	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
D-1244	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
P-1244	-2.2117 -3.4262 -0.1316 -0.1184 -0.1520 -0.1068 -0.0292 -0.0361 -0.1233 -0.2018 -0.7483 -0.2413 -0.9273 -0.0942 -0.1239 -0.0938 -1.2691 -2.4666 -0.4678 -0.0823 -0.1421 -0.1722 -0.1589
S-1420	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1420	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1420	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
D-1420	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
P-1420	-2.2117 -3.4262 -0.1316 -0.1184 -0.1520 -0.1068 -0.0292 -0.0361 -0.1233 -0.2018 -0.7483 -0.2413 -0.9273 -0.0942 -0.1239 -0.0938 -1.2691 -2.4666 -0.4678 -0.0823 -0.1421 -0.1722 -0.1589
S-213	8 Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-213	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-213	-0.31801971793174744	<unk> 8 treatment groups were also comparable in BMD increases at other skeletal sites .
D-213	-0.31801971793174744	<unk> 8 treatment groups were also comparable in BMD increases at other skeletal sites .
P-213	-1.1796 -0.1977 -1.1927 -0.4278 -0.2773 -0.1034 -0.2588 -0.1266 -0.1658 -0.3070 -0.1446 -0.2131 -0.4917 -0.3024 -0.3045 -0.1160 -0.1852 -0.1289 -0.2335 -0.1499 -0.1719
S-1992	Verminderte Milchproduktion wurde von stillenden Müttern im Zusammenhang mit Pseudoephedrin berichtet .
T-1992	Decreased milk production in nursing mothers has been reported with pseudoephedrine .
H-1992	-0.5784411430358887	<unk> decreased milk production have been reported by nursing <unk> pseudoephedrine .
D-1992	-0.5784411430358887	<unk> decreased milk production have been reported by nursing <unk> pseudoephedrine .
P-1992	-0.5213 -1.1259 -0.0593 -0.1022 -0.3361 -0.8811 -0.1687 -0.1047 -1.2786 -0.8061 -0.0973 -2.3021 -0.6183 -2.5684 -0.1401 -0.1363 -0.2093 -0.1731 -0.1725 -0.1791 -0.1667
S-526	Es korrigiert den Faktor VIII-Mangel und ermöglicht eine vorübergehende Kontrolle der Blutungsstörung .
T-526	It corrects the factor VIII deficiency and gives temporary control of the bleeding disorder .
H-526	-0.5672541260719299	<unk> corrects factor VIII deficiency and enables transient control of bleeding disorder .
D-526	-0.5672541260719299	<unk> corrects factor VIII deficiency and enables transient control of bleeding disorder .
P-526	-0.8028 -1.0830 -1.0597 -1.1648 -0.5274 -0.1721 -1.5377 -0.3443 -0.0432 -0.0932 -0.2915 -1.5956 -0.1769 -0.7187 -0.0987 -0.0245 -0.4968 -0.1758 -1.6221 -0.2330 -0.2207 -0.1784 -0.3858
S-1762	Der erforderliche Faktor VIII-Spiegel hängt von der Schwere und dem Ort der Blutung ab .
T-1762	The target factor VIII levels will depend on the severity and location of the bleeding .
H-1762	-0.7392173409461975	<unk> The necessary factor VIIII levels vary with the severity and site of bleeding .
D-1762	-0.7392173409461975	<unk> The necessary factor VIIII levels vary with the severity and site of bleeding .
P-1762	-1.1322 -0.5574 -1.8636 -0.1922 -1.2083 -0.1662 -1.0540 -2.0357 -2.1694 -1.0700 -0.2147 -0.0745 -0.3214 -0.1771 -0.1201 -0.1248 -1.3340 -0.1329 -1.7831 -0.1708 -0.1743 -0.1859
S-1594	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1594	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1594	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
D-1594	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
P-1594	-1.7860 -0.8883 -0.4601 -0.0546 -0.7218 -0.1175 -0.0825 -0.1247 -0.0574 -0.1622 -0.0111 -0.0677 -0.0918 -0.1306 -0.1601 -0.5697 -1.7758 -0.1466 -0.0811 -0.1474 -0.1950
S-1417	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1417	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1417	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
D-1417	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
P-1417	-1.7860 -0.8883 -0.4601 -0.0546 -0.7218 -0.1175 -0.0825 -0.1247 -0.0574 -0.1622 -0.0111 -0.0677 -0.0918 -0.1306 -0.1601 -0.5697 -1.7758 -0.1466 -0.0811 -0.1474 -0.1950
S-1241	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1241	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1241	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
D-1241	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
P-1241	-1.7860 -0.8883 -0.4601 -0.0546 -0.7218 -0.1175 -0.0825 -0.1247 -0.0574 -0.1622 -0.0111 -0.0677 -0.0918 -0.1306 -0.1601 -0.5697 -1.7758 -0.1466 -0.0811 -0.1474 -0.1950
S-1065	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1065	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1065	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
D-1065	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
P-1065	-1.7860 -0.8883 -0.4601 -0.0546 -0.7218 -0.1175 -0.0825 -0.1247 -0.0574 -0.1622 -0.0111 -0.0677 -0.0918 -0.1306 -0.1601 -0.5697 -1.7758 -0.1466 -0.0811 -0.1474 -0.1950
S-889	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-889	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-889	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
D-889	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
P-889	-1.7860 -0.8883 -0.4601 -0.0546 -0.7218 -0.1175 -0.0825 -0.1247 -0.0574 -0.1622 -0.0111 -0.0677 -0.0918 -0.1306 -0.1601 -0.5697 -1.7758 -0.1466 -0.0811 -0.1474 -0.1950
S-1960	Aerinaze darf nicht bei Kindern unter 12 Jahren angewendet werden ( siehe Abschnitt 4.2 ) .
T-1960	Aerinaze should not be used in children below the age of 12 years ( see section 4.2 ) .
H-1960	-0.3037925064563751	<unk> Aerinaze should not be used in children under 12 years ( see section 4.2 ) .
D-1960	-0.3037925064563751	<unk> Aerinaze should not be used in children under 12 years ( see section 4.2 ) .
P-1960	-1.3282 -0.3177 -0.1622 -0.1509 -0.1565 -0.1833 -0.5319 -0.1161 -0.1345 -0.1953 -0.3970 -0.0738 -1.1032 -0.1243 -0.2694 -0.4037 -0.1669 -0.1823 -0.1497 -0.1577 -0.1507 -0.3744 -0.1579
S-1597	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1597	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1597	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
D-1597	-0.5880463123321533	<unk> Connect the syringe to the BAXJECT II ( fig.d ) .
P-1597	-2.2117 -3.4262 -0.1316 -0.1184 -0.1520 -0.1068 -0.0292 -0.0361 -0.1233 -0.2018 -0.7483 -0.2413 -0.9273 -0.0942 -0.1239 -0.0938 -1.2691 -2.4666 -0.4678 -0.0823 -0.1421 -0.1722 -0.1589
S-713	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-713	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-713	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
D-713	-0.3729571998119354	<unk> After reconstitution the solution should be clear , colourless and free from foreign particles .
P-713	-1.7860 -0.8883 -0.4601 -0.0546 -0.7218 -0.1175 -0.0825 -0.1247 -0.0574 -0.1622 -0.0111 -0.0677 -0.0918 -0.1306 -0.1601 -0.5697 -1.7758 -0.1466 -0.0811 -0.1474 -0.1950
S-470	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
T-470	Via Complutense , 140 ES-28805 Alcalá de Henares Madrid , Spain
H-470	-0.3789956569671631	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
D-470	-0.3789956569671631	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
P-470	-3.1105 -0.1436 -0.8785 -0.3496 -0.1076 -0.4139 -0.1655 -0.3369 -0.0922 -0.1254 -0.0806 -0.0986 -0.0885 -0.1370 -0.1241 -0.0610 -0.1621 -0.8476 -0.7316 -0.1797 -0.1755 -0.1597 -0.1469
S-1019	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1019	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1019	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
D-1019	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
P-1019	-0.9094 -0.1191 -0.1569 -0.3002 -0.1760 -0.1430 -0.0615 -0.2983 -0.1459 -0.0423 -0.1394 -0.6024 -0.4560 -0.1213 -0.1477 -0.1567 -1.0384 -0.1466 -2.7185
S-843	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-843	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-843	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
D-843	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
P-843	-0.9094 -0.1191 -0.1569 -0.3002 -0.1760 -0.1430 -0.0615 -0.2983 -0.1459 -0.0423 -0.1394 -0.6024 -0.4560 -0.1213 -0.1477 -0.1567 -1.0384 -0.1466 -2.7185
S-278	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-278	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-278	-0.5822954177856445	<unk> <unk> Due to the progression of osteoporosis , ADROVANCE is indicated for long-term therapy .
D-278	-0.5822954177856445	<unk> <unk> Due to the progression of osteoporosis , ADROVANCE is indicated for long-term therapy .
P-278	-0.9309 -2.4312 -1.8465 -0.1752 -0.1085 -1.3043 -2.0243 -0.1050 -0.2337 -0.1175 -0.0810 -0.1054 -0.1211 -0.0798 -0.0892 -0.3491 -0.1356 -0.0993 -0.1645 -0.0967 -0.8669 -0.6027 -2.7423 -0.6472 -1.3090 -0.1221 -0.1562 -0.0753 -0.1766 -0.1717
S-91	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-91	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-91	-0.5822954177856445	<unk> <unk> Due to the progression of osteoporosis , ADROVANCE is indicated for long-term therapy .
D-91	-0.5822954177856445	<unk> <unk> Due to the progression of osteoporosis , ADROVANCE is indicated for long-term therapy .
P-91	-0.9309 -2.4312 -1.8465 -0.1752 -0.1085 -1.3043 -2.0243 -0.1050 -0.2337 -0.1175 -0.0810 -0.1054 -0.1211 -0.0798 -0.0892 -0.3491 -0.1356 -0.0993 -0.1645 -0.0967 -0.8669 -0.6027 -2.7423 -0.6472 -1.3090 -0.1221 -0.1562 -0.0753 -0.1766 -0.1717
S-300	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden
T-300	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-300	-0.5093455910682678	<unk> It is very important that all dosage instructions are relayed to the patient and understood by the patient
D-300	-0.5093455910682678	<unk> It is very important that all dosage instructions are relayed to the patient and understood by the patient
P-300	-0.9809 -0.3574 -0.1166 -0.3507 -0.0874 -0.1485 -0.2302 -0.2300 -1.4781 -0.1004 -0.2041 -0.2842 -2.0946 -1.3760 -0.1331 -0.1328 -0.1297 -0.1333 -2.3244 -0.1336 -0.1388 -0.1990 -0.3513
S-1548	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1548	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1548	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
D-1548	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
P-1548	-0.9094 -0.1191 -0.1569 -0.3002 -0.1760 -0.1430 -0.0615 -0.2983 -0.1459 -0.0423 -0.1394 -0.6024 -0.4560 -0.1213 -0.1477 -0.1567 -1.0384 -0.1466 -2.7185
S-1371	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1371	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1371	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
D-1371	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
P-1371	-0.9094 -0.1191 -0.1569 -0.3002 -0.1760 -0.1430 -0.0615 -0.2983 -0.1459 -0.0423 -0.1394 -0.6024 -0.4560 -0.1213 -0.1477 -0.1567 -1.0384 -0.1466 -2.7185
S-1195	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1195	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1195	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
D-1195	-0.4147089123725891	<unk> AUC0 ( IU h/ dl ) t 1/ 2 ( h )
P-1195	-0.9094 -0.1191 -0.1569 -0.3002 -0.1760 -0.1430 -0.0615 -0.2983 -0.1459 -0.0423 -0.1394 -0.6024 -0.4560 -0.1213 -0.1477 -0.1567 -1.0384 -0.1466 -2.7185
S-1822	Kobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
T-1822	Kobaltweg 49 NL-3542 CE Utrecht Tel : <<unk>> 31 30 2488911
H-1822	-0.5022684931755066	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
D-1822	-0.5022684931755066	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
P-1822	-5.8952 -0.3593 -0.0183 -0.1091 -0.2159 -0.2229 -0.1038 -0.3216 -0.0776 -0.3584 -0.1038 -0.1009 -0.6454 -0.0384 -0.1292 -0.1168 -0.1516 -0.2367 -0.1414 -1.8165 -0.1324 -0.1089 -0.1482
S-1838	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
T-1838	Viale Tiziano , 25 I-00196 Roma Tel : <<unk>> 39 06 324911
H-1838	-0.4217110872268677	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
D-1838	-0.4217110872268677	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
P-1838	-2.4596 -0.0992 -1.7697 -0.0780 -1.3018 -0.1678 -0.1254 -0.1369 -0.1241 -0.1049 -0.3769 -0.1443 -1.3533 -0.0423 -0.1306 -0.1092 -0.3354 -0.1683 -0.1418 -0.1182 -0.1528 -0.1107 -0.1481
S-293	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-293	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-293	-0.2930070459842682	<unk> ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
D-293	-0.2930070459842682	<unk> ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
P-293	-0.9316 -0.3577 -0.1192 -0.1767 -0.1239 -0.8925 -0.2415 -0.1108 -0.1196 -0.8023 -0.1339 -0.1084 -0.1396 -0.0349 -0.0377 -0.0381 -0.1390 -0.5026 -0.7806 -0.1446 -0.1474 -0.2789 -0.2108 -0.7156 -0.1519 -0.1784
S-105	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-105	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-105	-0.2930070459842682	<unk> ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
D-105	-0.2930070459842682	<unk> ADROVANCE has not been studied in children and adolescents and should therefore not be used in them .
P-105	-0.9316 -0.3577 -0.1192 -0.1767 -0.1239 -0.8925 -0.2415 -0.1108 -0.1196 -0.8023 -0.1339 -0.1084 -0.1396 -0.0349 -0.0377 -0.0381 -0.1390 -0.5026 -0.7806 -0.1446 -0.1474 -0.2789 -0.2108 -0.7156 -0.1519 -0.1784
S-1946	Die Dauer der Anwendung ist so kurz wie möglich zu halten und sollte nach Abklingen der Symptome nicht fortgesetzt werden .
T-1946	The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared .
H-1946	-0.5077824592590332	<unk> The duration of administration should be as short as possible and should not be continued after symptoms have resolved .
D-1946	-0.5077824592590332	<unk> The duration of administration should be as short as possible and should not be continued after symptoms have resolved .
P-1946	-1.6363 -1.5663 -0.0780 -0.1164 -0.1327 -0.5252 -0.3227 -0.2744 -0.6269 -0.9283 -0.1745 -0.1342 -0.2302 -0.1765 -0.2405 -0.1193 -0.9926 -0.3425 -0.1088 -1.5090 -1.1083 -0.1678 -0.1677
S-1813	Hersteller Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgien
T-1813	Manufacturer Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-1813	-0.4435137212276459	<unk> Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
D-1813	-0.4435137212276459	<unk> Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
P-1813	-1.1806 -1.8121 -0.1241 -0.2334 -0.3644 -0.0753 -1.3350 -0.1178 -0.9708 -0.5487 -0.0675 -0.1315 -0.0926 -0.1252 -0.1346 -0.7533 -0.1288 -0.1660 -0.2487 -0.1213 -0.1760 -1.1382 -0.1549
S-61	Die Patientinnen sollen außerdem zusätzlich Calcium einnehmen , falls über die Nahrung nicht genügend aufgenommen wird .
T-61	Patients should also take calcium supplements if they are not getting enough calcium from their diet .
H-61	-0.5252270698547363	<unk> Patients should also take additional calcium if dietary intake does not <unk> adequately <unk> <unk>
D-61	-0.5252270698547363	<unk> Patients should also take additional calcium if dietary intake does not <unk> adequately <unk> <unk>
P-61	-0.5782 -0.3795 -0.0840 -0.2379 -0.0875 -0.0806 -1.0578 -0.1226 -0.0596 -0.1139 -0.5181 -1.8535 -0.0644 -0.1722 -0.3059 -2.1583 -0.1452 -0.9970 -0.6047 -0.0828 -0.2061 -1.9745 -0.1959
S-1954	Die empfohlene Dosierung und die Dauer der Behandlung dürfen nicht überschritten werden ( siehe Abschnitt 4.2 ) .
T-1954	Do not exceed the recommended dosage and the duration of treatment ( see section 4.2 ) .
H-1954	-0.2868930995464325	<unk> The recommended dosage and duration of treatment should not be exceeded ( see section 4.2 ) .
D-1954	-0.2868930995464325	<unk> The recommended dosage and duration of treatment should not be exceeded ( see section 4.2 ) .
P-1954	-1.3320 -0.6290 -0.0633 -0.1591 -0.5517 -0.1020 -0.1288 -1.0664 -0.1123 -0.1401 -0.1819 -0.5832 -0.1234 -0.1458 -0.1275 -0.0839 -0.1471 -0.1567 -0.1827 -0.1477 -0.1526 -0.1526 -0.2569 -0.1590
S-313	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-313	The time to onset of symptoms varied from one day to several months after starting treatment .
H-313	-0.3373466432094574	<unk> The timing of these symptoms varied from one day to several months after initiation of therapy .
D-313	-0.3373466432094574	<unk> The timing of these symptoms varied from one day to several months after initiation of therapy .
P-313	-1.1959 -0.6618 -0.4641 -0.1607 -0.6485 -0.1058 -0.1944 -0.1820 -0.1824 -0.1773 -0.1183 -0.1310 -0.1377 -0.1170 -0.3208 -0.8385 -0.1402 -0.6514 -0.3232 -0.1522 -0.1811
S-704	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-704	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-704	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
D-704	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
P-704	-1.7481 -5.3579 -0.0720 -0.1691 -0.3148 -1.4826 -0.5834 -0.1215 -2.3670 -0.1580 -1.6300 -0.6206 -2.6687 -0.0591 -0.6160 -0.1450 -1.9579 -0.2716 -0.1805 -0.5094 -0.1420 -0.2643 -0.8710 -1.0940 -0.4554 -0.1480 -0.1646
S-581	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-581	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-581	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
D-581	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
P-581	-1.2960 -0.4914 -0.3159 -0.1370 -0.0621 -0.0936 -0.7263 -0.1375 -0.1124 -1.2819 -0.1238 -0.1696 -0.2170 -0.1056 -0.0754 -0.0837 -0.1487 -0.1420 -0.2143 -0.3385 -1.2069 -0.1033 -0.1482 -0.1750
S-1232	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1232	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1232	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
D-1232	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
P-1232	-1.7481 -5.3579 -0.0720 -0.1691 -0.3148 -1.4826 -0.5834 -0.1215 -2.3670 -0.1580 -1.6300 -0.6206 -2.6687 -0.0591 -0.6160 -0.1450 -1.9579 -0.2716 -0.1805 -0.5094 -0.1420 -0.2643 -0.8710 -1.0940 -0.4554 -0.1480 -0.1646
S-1107	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1107	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1107	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
D-1107	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
P-1107	-1.2960 -0.4914 -0.3159 -0.1370 -0.0621 -0.0936 -0.7263 -0.1375 -0.1124 -1.2819 -0.1238 -0.1696 -0.2170 -0.1056 -0.0754 -0.0837 -0.1487 -0.1420 -0.2143 -0.3385 -1.2069 -0.1033 -0.1482 -0.1750
S-1413	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1413	Insert the white plastic spike through the ADVATE stopper .
H-1413	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
D-1413	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
P-1413	-2.0727 -1.1439 -0.1448 -1.5640 -0.0578 -0.5238 -0.1895 -1.2824 -0.2509 -0.8344 -0.0628 -0.4024 -0.1152 -0.9176 -0.1408 -0.4581 -0.4942 -0.1620 -0.7988 -0.1346 -0.4734 -0.1647 -0.0979 -0.1607 -0.1849 -0.1409 -0.1664
S-931	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-931	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-931	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
D-931	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
P-931	-1.2960 -0.4914 -0.3159 -0.1370 -0.0621 -0.0936 -0.7263 -0.1375 -0.1124 -1.2819 -0.1238 -0.1696 -0.2170 -0.1056 -0.0754 -0.0837 -0.1487 -0.1420 -0.2143 -0.3385 -1.2069 -0.1033 -0.1482 -0.1750
S-880	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-880	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-880	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
D-880	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
P-880	-1.7481 -5.3579 -0.0720 -0.1691 -0.3148 -1.4826 -0.5834 -0.1215 -2.3670 -0.1580 -1.6300 -0.6206 -2.6687 -0.0591 -0.6160 -0.1450 -1.9579 -0.2716 -0.1805 -0.5094 -0.1420 -0.2643 -0.8710 -1.0940 -0.4554 -0.1480 -0.1646
S-755	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-755	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-755	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
D-755	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
P-755	-1.2960 -0.4914 -0.3159 -0.1370 -0.0621 -0.0936 -0.7263 -0.1375 -0.1124 -1.2819 -0.1238 -0.1696 -0.2170 -0.1056 -0.0754 -0.0837 -0.1487 -0.1420 -0.2143 -0.3385 -1.2069 -0.1033 -0.1482 -0.1750
S-1056	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1056	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1056	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
D-1056	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
P-1056	-1.7481 -5.3579 -0.0720 -0.1691 -0.3148 -1.4826 -0.5834 -0.1215 -2.3670 -0.1580 -1.6300 -0.6206 -2.6687 -0.0591 -0.6160 -0.1450 -1.9579 -0.2716 -0.1805 -0.5094 -0.1420 -0.2643 -0.8710 -1.0940 -0.4554 -0.1480 -0.1646
S-1585	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1585	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1585	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
D-1585	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
P-1585	-1.7481 -5.3579 -0.0720 -0.1691 -0.3148 -1.4826 -0.5834 -0.1215 -2.3670 -0.1580 -1.6300 -0.6206 -2.6687 -0.0591 -0.6160 -0.1450 -1.9579 -0.2716 -0.1805 -0.5094 -0.1420 -0.2643 -0.8710 -1.0940 -0.4554 -0.1480 -0.1646
S-285	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-285	12 Patients should not lie down for at least 30 minutes after taking ADROVANCE .
H-285	-0.5309057235717773	<unk> Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
D-285	-0.5309057235717773	<unk> Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
P-285	-0.5624 -0.2457 -0.0916 -0.1703 -0.7698 -2.4600 -0.1234 -0.2211 -0.1371 -0.1294 -0.0640 -0.1216 -2.1740 -1.0546 -0.0253 -3.2931 -0.2050 -0.1116 -0.1722 -1.5629 -0.3588 -0.1462 -0.1664 -0.2047 -0.1464 -0.1522 -0.1532 -0.2106 -0.1628
S-1590	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1590	Insert the white plastic spike through the ADVATE stopper .
H-1590	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
D-1590	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
P-1590	-2.0727 -1.1439 -0.1448 -1.5640 -0.0578 -0.5238 -0.1895 -1.2824 -0.2509 -0.8344 -0.0628 -0.4024 -0.1152 -0.9176 -0.1408 -0.4581 -0.4942 -0.1620 -0.7988 -0.1346 -0.4734 -0.1647 -0.0979 -0.1607 -0.1849 -0.1409 -0.1664
S-1131	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1131	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1131	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
D-1131	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
P-1131	-1.0422 -1.6005 -0.1280 -0.8257 -0.6329 -1.8850 -0.1435 -0.0578 -0.0995 -0.0438 -0.0636 -0.1150 -0.2373 -1.1333 -0.0986 -1.6332 -0.1554 -0.8601 -0.4858 -0.0527 -0.9016 -0.1809 -0.2454
S-1237	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1237	Insert the white plastic spike through the ADVATE stopper .
H-1237	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
D-1237	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
P-1237	-2.0727 -1.1439 -0.1448 -1.5640 -0.0578 -0.5238 -0.1895 -1.2824 -0.2509 -0.8344 -0.0628 -0.4024 -0.1152 -0.9176 -0.1408 -0.4581 -0.4942 -0.1620 -0.7988 -0.1346 -0.4734 -0.1647 -0.0979 -0.1607 -0.1849 -0.1409 -0.1664
S-1061	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1061	Insert the white plastic spike through the ADVATE stopper .
H-1061	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
D-1061	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
P-1061	-2.0727 -1.1439 -0.1448 -1.5640 -0.0578 -0.5238 -0.1895 -1.2824 -0.2509 -0.8344 -0.0628 -0.4024 -0.1152 -0.9176 -0.1408 -0.4581 -0.4942 -0.1620 -0.7988 -0.1346 -0.4734 -0.1647 -0.0979 -0.1607 -0.1849 -0.1409 -0.1664
S-885	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-885	Insert the white plastic spike through the ADVATE stopper .
H-885	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
D-885	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
P-885	-2.0727 -1.1439 -0.1448 -1.5640 -0.0578 -0.5238 -0.1895 -1.2824 -0.2509 -0.8344 -0.0628 -0.4024 -0.1152 -0.9176 -0.1408 -0.4581 -0.4942 -0.1620 -0.7988 -0.1346 -0.4734 -0.1647 -0.0979 -0.1607 -0.1849 -0.1409 -0.1664
S-1283	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1283	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1283	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
D-1283	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
P-1283	-1.2960 -0.4914 -0.3159 -0.1370 -0.0621 -0.0936 -0.7263 -0.1375 -0.1124 -1.2819 -0.1238 -0.1696 -0.2170 -0.1056 -0.0754 -0.0837 -0.1487 -0.1420 -0.2143 -0.3385 -1.2069 -0.1033 -0.1482 -0.1750
S-709	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-709	Insert the white plastic spike through the ADVATE stopper .
H-709	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
D-709	-0.4866524636745453	<unk> The white thorn of the BAXJECT II through the rubber stopper on the ADVATE bottle .
P-709	-2.0727 -1.1439 -0.1448 -1.5640 -0.0578 -0.5238 -0.1895 -1.2824 -0.2509 -0.8344 -0.0628 -0.4024 -0.1152 -0.9176 -0.1408 -0.4581 -0.4942 -0.1620 -0.7988 -0.1346 -0.4734 -0.1647 -0.0979 -0.1607 -0.1849 -0.1409 -0.1664
S-1459	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1459	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1459	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
D-1459	-0.3294195234775543	<unk> The dose and frequency should be adjusted according to the clinical efficacy of the product in individual cases .
P-1459	-1.2960 -0.4914 -0.3159 -0.1370 -0.0621 -0.0936 -0.7263 -0.1375 -0.1124 -1.2819 -0.1238 -0.1696 -0.2170 -0.1056 -0.0754 -0.0837 -0.1487 -0.1420 -0.2143 -0.3385 -1.2069 -0.1033 -0.1482 -0.1750
S-98	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-98	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-98	-0.5309057235717773	<unk> Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
D-98	-0.5309057235717773	<unk> Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
P-98	-0.5624 -0.2457 -0.0916 -0.1703 -0.7698 -2.4600 -0.1234 -0.2211 -0.1371 -0.1294 -0.0640 -0.1216 -2.1740 -1.0546 -0.0253 -3.2931 -0.2050 -0.1116 -0.1722 -1.5629 -0.3588 -0.1462 -0.1664 -0.2047 -0.1464 -0.1522 -0.1532 -0.2106 -0.1628
S-17	Der in Adenuric enthaltene Wirkstoff Feboxustat vermindert die Bildung von Harnsäure .
T-17	The active substance in Adenuric , feboxustat , reduces the formation of uric acid .
H-17	-0.3432321846485138	<unk> Feboxustat , the active substance in Adenuric decreases the formation of uric acid .
D-17	-0.3432321846485138	<unk> Feboxustat , the active substance in Adenuric decreases the formation of uric acid .
P-17	-2.1024 -1.0997 -0.2933 -0.1568 -0.2439 -0.0732 -0.7127 -0.2666 -0.0625 -0.0627 -0.2910 -0.1720 -0.1587 -0.1418 -0.1235 -0.7948 -0.1193 -0.6319 -0.1144 -0.1441 -0.3088 -0.0888 -0.0845 -0.1563 -0.1775
S-955	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-955	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-955	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
D-955	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
P-955	-1.0422 -1.6005 -0.1280 -0.8257 -0.6329 -1.8850 -0.1435 -0.0578 -0.0995 -0.0438 -0.0636 -0.1150 -0.2373 -1.1333 -0.0986 -1.6332 -0.1554 -0.8601 -0.4858 -0.0527 -0.9016 -0.1809 -0.2454
S-779	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-779	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-779	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
D-779	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
P-779	-1.0422 -1.6005 -0.1280 -0.8257 -0.6329 -1.8850 -0.1435 -0.0578 -0.0995 -0.0438 -0.0636 -0.1150 -0.2373 -1.1333 -0.0986 -1.6332 -0.1554 -0.8601 -0.4858 -0.0527 -0.9016 -0.1809 -0.2454
S-605	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-605	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-605	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
D-605	-0.5487754940986633	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
P-605	-1.0422 -1.6005 -0.1280 -0.8257 -0.6329 -1.8850 -0.1435 -0.0578 -0.0995 -0.0438 -0.0636 -0.1150 -0.2373 -1.1333 -0.0986 -1.6332 -0.1554 -0.8601 -0.4858 -0.0527 -0.9016 -0.1809 -0.2454
S-1856	Advexin hätte zur Behandlung von Li-Fraumeni-Krebs bei Patienten ab einem Alter von 18 Jahren angewendet werden sollen .
T-1856	Advexin was expected to be used to treat Li-Fraumeni cancer in patients from the age of 18 years .
H-1856	-0.4594550132751465	<unk> Advexin should have been used to treat Li-Fraumeni cancer in patients aged 18 years and over .
D-1856	-0.4594550132751465	<unk> Advexin should have been used to treat Li-Fraumeni cancer in patients aged 18 years and over .
P-1856	-0.9796 -3.2026 -0.2162 -0.1392 -0.1206 -0.3161 -0.0914 -0.1350 -0.1272 -0.0995 -1.8342 -0.3049 -1.2468 -0.0358 -0.4238 -0.3450 -0.1276 -0.1573 -0.5043 -0.0673 -0.1393 -0.2091 -0.3268 -0.1643 -0.1724
S-429	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-429	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-429	-0.4924476444721222	<unk> The mean steady-state volume of distribution excluding bone is at least 28 litres in humans .
D-429	-0.4924476444721222	<unk> The mean steady-state volume of distribution excluding bone is at least 28 litres in humans .
P-429	-1.1881 -0.6794 -0.1014 -0.5448 -0.2290 -0.1334 -0.1423 -0.0433 -0.0589 -0.1546 -0.8311 -3.0395 -0.5920 -0.7297 -0.2397 -0.0987 -0.1124 -0.0901 -0.2883 -0.7292 -0.1325 -0.2908 -1.5012 -0.1534 -0.2072
S-233	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-233	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-233	-0.4924476444721222	<unk> The mean steady-state volume of distribution excluding bone is at least 28 litres in humans .
D-233	-0.4924476444721222	<unk> The mean steady-state volume of distribution excluding bone is at least 28 litres in humans .
P-233	-1.1881 -0.6794 -0.1014 -0.5448 -0.2290 -0.1334 -0.1423 -0.0433 -0.0589 -0.1546 -0.8311 -3.0395 -0.5920 -0.7297 -0.2397 -0.0987 -0.1124 -0.0901 -0.2883 -0.7292 -0.1325 -0.2908 -1.5012 -0.1534 -0.2072
S-1408	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1408	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1408	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
D-1408	-0.8952735066413879	<unk> Turn the opening downwards and press the transparent plastic thorn through the rubber stopper on the solvent-bottle .
P-1408	-1.7481 -5.3579 -0.0720 -0.1691 -0.3148 -1.4826 -0.5834 -0.1215 -2.3670 -0.1580 -1.6300 -0.6206 -2.6687 -0.0591 -0.6160 -0.1450 -1.9579 -0.2716 -0.1805 -0.5094 -0.1420 -0.2643 -0.8710 -1.0940 -0.4554 -0.1480 -0.1646
S-190	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-190	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-190	-0.7554381489753723	<unk> In case of insufficient sunlight , it is essential that vitamin D3 is part of food .
D-190	-0.7554381489753723	<unk> In case of insufficient sunlight , it is essential that vitamin D3 is part of food .
P-190	-1.1590 -1.3958 -1.6940 -0.2157 -0.4007 -0.4547 -3.4691 -0.5171 -0.5685 -1.4122 -0.1254 -0.9357 -0.1499 -0.0394 -0.0889 -0.1885 -0.1313 -0.4682 -1.4870 -0.1438 -1.9505 -0.1547 -0.2251
S-42	Am 21.April 2008 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Adenuric in der gesamten Europäischen Union .
T-42	The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
H-42	-0.6248933672904968	<unk> On 21 April 2008 , the European Commission authorised the marketing of Adenuric throughout the European Union .
D-42	-0.6248933672904968	<unk> On 21 April 2008 , the European Commission authorised the marketing of Adenuric throughout the European Union .
P-42	-2.3071 -0.3802 -0.6276 -1.8961 -0.8284 -0.8384 -0.1526 -0.4485 -0.5609 -2.0185 -0.2345 -0.4711 -1.3098 -0.1462 -0.1376 -0.1780 -0.1167 -0.1286 -0.9644 -0.1457 -0.5188 -0.2623 -0.1643 -0.1611
S-432	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-432	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-432	-0.21558210253715515	<unk> Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-432	-0.21558210253715515	<unk> Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-432	-0.8457 -1.1299 -0.1071 -0.0870 -0.1180 -0.0470 -0.2487 -0.1822 -0.0800 -0.1696 -0.4536 -0.0540 -0.0950 -0.0517 -0.0083 -0.2724 -0.0616 -0.0072 -0.0693 -0.2689 -0.3442 -0.1590 -0.1983 -0.1547 -0.1761
S-236	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-236	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-236	-0.21558210253715515	<unk> Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-236	-0.21558210253715515	<unk> Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-236	-0.8457 -1.1299 -0.1071 -0.0870 -0.1180 -0.0470 -0.2487 -0.1822 -0.0800 -0.1696 -0.4536 -0.0540 -0.0950 -0.0517 -0.0083 -0.2724 -0.0616 -0.0072 -0.0693 -0.2689 -0.3442 -0.1590 -0.1983 -0.1547 -0.1761
S-38	Die vollständige Auflistung der im Zusammenhang mit Adenuric berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-38	For the full list of all side effects reported with Adenuric , see the Package Leaflet .
H-38	-0.38168269395828247	<unk> For a full list of reported side effects with Adenuric see the Package Leaflet .
D-38	-0.38168269395828247	<unk> For a full list of reported side effects with Adenuric see the Package Leaflet .
P-38	-2.4618 -0.4314 -0.1275 -0.1071 -0.1009 -0.1386 -0.1177 -2.5228 -0.0917 -0.3428 -0.1218 -0.1720 -0.1284 -0.1250 -0.7500 -0.1781 -0.1264 -0.1209 -0.1246 -0.0416 -0.0839 -0.2021 -0.1616
S-1785	Schwere Nebenwirkungen einschließlich Atmenot , und ( Beinahe<unk> -Ohnmachten erfordern eine sofortige Notfallbehandlung .
T-1785	Severe symptoms , including difficulty in breathing and ( nearly ) fainting , require prompt emergency treatment .
H-1785	-0.47027090191841125	<unk> Severe adverse reactions including breathlessness , and ( near fainting require immediate emergency treatment .
D-1785	-0.47027090191841125	<unk> Severe adverse reactions including breathlessness , and ( near fainting require immediate emergency treatment .
P-1785	-0.8696 -0.8571 -0.1015 -1.2085 -0.0522 -0.2296 -0.0971 -0.0905 -1.8138 -0.3843 -0.0336 -0.0924 -0.4084 -0.1963 -0.3285 -1.3361 -1.1169 -0.3528 -0.1370 -1.0586 -0.3261 -0.0946 -0.1701 -0.1602 -0.2410
S-378	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-378	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-378	-0.7554381489753723	<unk> In case of insufficient sunlight , it is essential that vitamin D3 is part of food .
D-378	-0.7554381489753723	<unk> In case of insufficient sunlight , it is essential that vitamin D3 is part of food .
P-378	-1.1590 -1.3958 -1.6940 -0.2157 -0.4007 -0.4547 -3.4691 -0.5171 -0.5685 -1.4122 -0.1254 -0.9357 -0.1499 -0.0394 -0.0889 -0.1885 -0.1313 -0.4682 -1.4870 -0.1438 -1.9505 -0.1547 -0.2251
S-406	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-406	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-406	-0.280920147895813	<unk> 4.8 , 5.4 % ) in the 70 mg weekly group and 5.4 % ( 95 % CI :
D-406	-0.280920147895813	<unk> 4.8 , 5.4 % ) in the 70 mg weekly group and 5.4 % ( 95 % CI :
P-406	-1.3196 -0.2398 -0.1195 -0.2016 -0.1365 -0.1402 -0.1453 -0.1655 -0.1755 -0.1471 -0.4490 -0.0296 -1.0948 -0.2940 -0.1517 -0.6210 -0.1373 -0.2840 -0.1536 -0.1311 -0.1710 -0.1802 -0.2283 -0.1517 -0.1551
S-1805	- Der arzneilich wirksame Bestandteil ist Octocog alfa ( Blutgerinnungsfaktor VIII vom Menschen ,
T-1805	- The active substance is octocog alfa ( human coagulation Factor VIII produced by recombinant
H-1805	-0.376415878534317	<unk> The active substance is octocog alfa ( human clotting factor VIII ,
D-1805	-0.376415878534317	<unk> The active substance is octocog alfa ( human clotting factor VIII ,
P-1805	-2.0356 -0.1549 -0.0467 -0.2520 -0.1402 -1.0702 -0.0666 -0.1811 -0.2679 -0.1175 -0.0555 -0.1470 -0.7179 -1.8798 -0.0143 -0.0412 -0.0300 -0.1675 -0.0665 -0.2682 -0.1844
S-1829	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
T-1829	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <<unk>> 48 22 4883 777
H-1829	-0.6773566007614136	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
D-1829	-0.6773566007614136	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
P-1829	-6.7275 -0.8176 -2.1387 -0.0890 -0.0550 -0.0948 -0.0937 -0.1924 -0.1418 -0.1371 -0.0970 -1.1795 -0.2358 -0.1238 -2.3089 -1.5041 -0.0453 -0.1510 -0.1458 -0.1181 -0.1706 -0.1018 -1.1485 -0.0833 -0.1435 -0.0964 -0.1478
S-1733	Bei Patienten mit Hämophilie A ( angeborenem Faktor VIII-Mangel ) fehlt er oder funktioniert nicht korrekt .
T-1733	In patients with haemophilia A ( inborn factor VIII deficiency ) , it is missing or not working properly .
H-1733	-0.5782377123832703	<unk> In patients with haemophilia A ( congenital factor VIII deficiency ) it is missing or does not function correctly .
D-1733	-0.5782377123832703	<unk> In patients with haemophilia A ( congenital factor VIII deficiency ) it is missing or does not function correctly .
P-1733	-0.7454 -0.4590 -0.1680 -0.1402 -0.0898 -1.1371 -1.6588 -1.9181 -0.1163 -0.1421 -0.2487 -0.6143 -1.8711 -0.0457 -0.2798 -0.2070 -1.2129 -0.0305 -0.0616 -0.0948 -0.1430 -1.0130 -0.1348 -1.7673 -0.2010 -2.1543 -0.1096 -0.2149 -0.1527 -1.0105 -0.1801 -0.1810
S-210	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-210	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-210	-0.280920147895813	<unk> 4.8 , 5.4 % ) in the 70 mg weekly group and 5.4 % ( 95 % CI :
D-210	-0.280920147895813	<unk> 4.8 , 5.4 % ) in the 70 mg weekly group and 5.4 % ( 95 % CI :
P-210	-1.3196 -0.2398 -0.1195 -0.2016 -0.1365 -0.1402 -0.1453 -0.1655 -0.1755 -0.1471 -0.4490 -0.0296 -1.0948 -0.2940 -0.1517 -0.6210 -0.1373 -0.2840 -0.1536 -0.1311 -0.1710 -0.1802 -0.2283 -0.1517 -0.1551
S-88	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel .
T-88	Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency .
H-88	-0.23654843866825104	<unk> Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency .
D-88	-0.23654843866825104	<unk> Treatment of post-menopausal osteoporosis in patients at risk for vitamin D deficiency .
P-88	-0.3325 -2.9068 -0.1129 -0.1161 -0.1409 -0.0754 -0.1351 -0.0245 -0.1145 -0.0256 -0.1302 -0.1684 -0.0958 -0.1111 -0.1162 -0.0864 -0.0890 -0.1498 -0.2803 -0.0761 -0.0275 -0.9004 -0.1522 -0.0626 -0.1181 -0.0376 -0.0354 -0.0995 -0.1700 -0.2057
S-565	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E.
T-565	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU
H-565	-0.30831050872802734	<unk> The calculation of the necessary factor VIII dose is based on the empirical finding that 1 IU
D-565	-0.30831050872802734	<unk> The calculation of the necessary factor VIII dose is based on the empirical finding that 1 IU
P-565	-1.2127 -1.0283 -0.1815 -0.3793 -0.0886 -0.1557 -0.1833 -0.8520 -0.8121 -0.1128 -0.0810 -0.0265 -0.1327 -0.0477 -0.1566 -0.5664 -0.3106 -0.1183 -0.3115 -0.1943 -0.3178 -0.1921 -0.1197 -0.1163 -0.1031 -0.2151
S-1591	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1591	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1591	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1591	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1591	-2.9362 -1.3253 -0.3109 -1.4485 -0.3109 -2.6413 -0.2993 -0.1389 -0.3496 -0.1556 -0.0706 -0.1958 -0.2129 -0.2867 -1.2080 -0.6209 -0.4394 -0.1400 -0.1402 -0.1812 -0.1636
S-1414	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1414	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1414	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1414	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1414	-2.9362 -1.3253 -0.3109 -1.4485 -0.3109 -2.6413 -0.2993 -0.1389 -0.3496 -0.1556 -0.0706 -0.1958 -0.2129 -0.2867 -1.2080 -0.6209 -0.4394 -0.1400 -0.1402 -0.1812 -0.1636
S-1238	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1238	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1238	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1238	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1238	-2.9362 -1.3253 -0.3109 -1.4485 -0.3109 -2.6413 -0.2993 -0.1389 -0.3496 -0.1556 -0.0706 -0.1958 -0.2129 -0.2867 -1.2080 -0.6209 -0.4394 -0.1400 -0.1402 -0.1812 -0.1636
S-1062	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1062	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1062	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1062	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1062	-2.9362 -1.3253 -0.3109 -1.4485 -0.3109 -2.6413 -0.2993 -0.1389 -0.3496 -0.1556 -0.0706 -0.1958 -0.2129 -0.2867 -1.2080 -0.6209 -0.4394 -0.1400 -0.1402 -0.1812 -0.1636
S-886	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-886	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-886	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-886	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-886	-2.9362 -1.3253 -0.3109 -1.4485 -0.3109 -2.6413 -0.2993 -0.1389 -0.3496 -0.1556 -0.0706 -0.1958 -0.2129 -0.2867 -1.2080 -0.6209 -0.4394 -0.1400 -0.1402 -0.1812 -0.1636
S-1963	Diese Wirkungen sind bei Kindern , älteren Patienten oder im Falle einer Überdosierung wahrscheinlicher ( siehe Abschnitt 4.9 ) .
T-1963	These effects may be more likely to occur in children , elderly patients , or in cases of overdose ( see section 4.9 ) .
H-1963	-0.31171366572380066	<unk> These effects are more likely in children , elderly patients or in case of overdose ( see section 4.9 ) .
D-1963	-0.31171366572380066	<unk> These effects are more likely in children , elderly patients or in case of overdose ( see section 4.9 ) .
P-1963	-1.3721 -0.5957 -0.0468 -0.2074 -0.2143 -0.8572 -0.2963 -0.3931 -0.1556 -0.1255 -0.0501 -0.3802 -0.1789 -1.0483 -0.1415 -0.3232 -0.0594 -0.1439 -0.1553 -0.2049 -0.1511 -0.1556 -0.1502 -0.2270 -0.1591
S-455	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-455	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-455	-0.355190247297287	<unk> No non-clinical trials with the combination of alendronate and colecalciferol .
D-455	-0.355190247297287	<unk> No non-clinical trials with the combination of alendronate and colecalciferol .
P-455	-0.7429 -0.8122 -0.2287 -0.0955 -0.0939 -0.3561 -0.9711 -1.3370 -0.1281 -0.1362 -0.1387 -0.1012 -0.0586 -0.0154 -0.1281 -0.2256 -0.1517 -0.1573 -0.1541 -0.0936 -0.1207 -1.7097 -0.2127
S-1373	52 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1373	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1373	-0.4863348603248596	<unk> 52 data from a single-use of ADVATE in 53 children under 6 years were used to draw up this table .
D-1373	-0.4863348603248596	<unk> 52 data from a single-use of ADVATE in 53 children under 6 years were used to draw up this table .
P-1373	-1.3742 -0.2053 -1.2193 -0.9686 -0.4178 -1.7240 -0.2967 -0.0608 -0.3091 -0.5507 -0.1346 -0.1905 -0.0777 -0.0917 -0.1276 -0.0997 -0.1216 -0.4715 -0.2252 -0.1284 -1.3436 -0.2182 -0.1542 -2.4300 -0.2336 -0.1581 -0.4381 -0.1677 -0.1655
S-1197	41 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1197	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1197	-0.5233312845230103	<unk> 41 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
D-1197	-0.5233312845230103	<unk> 41 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
P-1197	-1.1116 -1.7302 -2.3004 -1.3465 -0.2721 -0.2325 -0.1238 -0.1894 -0.0795 -0.0913 -0.1454 -0.0948 -0.1153 -0.4643 -0.2246 -0.1246 -0.8986 -0.3199 -0.2050 -0.2486 -0.1515 -2.4751 -0.2439 -0.1658 -0.4347 -0.1681 -0.1725
S-1984	In einer klinisch- pharmakologischen Studie wurde bei gleichzeitiger Einnahme von Desloratadin und Alkohol die
T-1984	However , in a clinical pharmacology trial desloratadine taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol .
H-1984	-0.5255433917045593	<unk> In a clinical pharmacology study , concomitant administration of desloratadine and alcohol <unk>
D-1984	-0.5255433917045593	<unk> In a clinical pharmacology study , concomitant administration of desloratadine and alcohol <unk>
P-1984	-0.9832 -0.3511 -0.1685 -0.3695 -0.1073 -0.5885 -0.8837 -0.8087 -1.4235 -0.0095 -0.0073 -0.1456 -0.8649 -0.1515 -1.4334 -0.1099 -0.0908 -0.4632 -1.1776 -0.1674 -0.1048 -1.2467 -0.4308
S-1600	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1600	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1600	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
D-1600	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
P-1600	-2.2401 -2.5407 -1.1340 -0.0384 -1.1524 -1.2954 -0.1312 -1.0465 -0.1388 -0.0868 -0.0242 -0.0263 -0.1251 -0.0892 -0.4606 -0.1331 -0.1736 -0.1773 -0.4104 -0.2335 -0.3145 -0.1642 -0.1731
S-1550	63 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1550	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1550	-0.45800307393074036	<unk> 63 data from a single-use of ADVATE in 53 children under 6 years were used to draw up this table .
D-1550	-0.45800307393074036	<unk> 63 data from a single-use of ADVATE in 53 children under 6 years were used to draw up this table .
P-1550	-0.8930 -0.1362 -1.0114 -1.1251 -0.4208 -1.6470 -0.2991 -0.0602 -0.3099 -0.5805 -0.1383 -0.1901 -0.0799 -0.0912 -0.1272 -0.0953 -0.1182 -0.4552 -0.2351 -0.1313 -1.2435 -0.2205 -0.1570 -2.3515 -0.2345 -0.1594 -0.4411 -0.1664 -0.1633
S-1423	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1423	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1423	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
D-1423	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
P-1423	-2.2401 -2.5407 -1.1340 -0.0384 -1.1524 -1.2954 -0.1312 -1.0465 -0.1388 -0.0868 -0.0242 -0.0263 -0.1251 -0.0892 -0.4606 -0.1331 -0.1736 -0.1773 -0.4104 -0.2335 -0.3145 -0.1642 -0.1731
S-669	8 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-669	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-669	-0.5041955709457397	<unk> 8 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
D-669	-0.5041955709457397	<unk> 8 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
P-669	-2.1788 -0.6795 -1.5255 -1.3803 -0.3255 -0.2706 -0.1326 -0.1873 -0.0790 -0.0918 -0.1455 -0.0963 -0.1173 -0.4767 -0.2179 -0.1222 -0.9682 -0.3177 -0.2035 -0.2445 -0.1545 -2.5257 -0.2294 -0.1601 -0.4451 -0.1664 -0.1715
S-1247	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1247	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1247	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
D-1247	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
P-1247	-2.2401 -2.5407 -1.1340 -0.0384 -1.1524 -1.2954 -0.1312 -1.0465 -0.1388 -0.0868 -0.0242 -0.0263 -0.1251 -0.0892 -0.4606 -0.1331 -0.1736 -0.1773 -0.4104 -0.2335 -0.3145 -0.1642 -0.1731
S-719	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-719	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-719	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
D-719	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
P-719	-2.2401 -2.5407 -1.1340 -0.0384 -1.1524 -1.2954 -0.1312 -1.0465 -0.1388 -0.0868 -0.0242 -0.0263 -0.1251 -0.0892 -0.4606 -0.1331 -0.1736 -0.1773 -0.4104 -0.2335 -0.3145 -0.1642 -0.1731
S-1071	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1071	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1071	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
D-1071	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
P-1071	-2.2401 -2.5407 -1.1340 -0.0384 -1.1524 -1.2954 -0.1312 -1.0465 -0.1388 -0.0868 -0.0242 -0.0263 -0.1251 -0.0892 -0.4606 -0.1331 -0.1736 -0.1773 -0.4104 -0.2335 -0.3145 -0.1642 -0.1731
S-1021	30 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1021	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1021	-0.5195534229278564	<unk> 30 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
D-1021	-0.5195534229278564	<unk> 30 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
P-1021	-1.7858 -0.2562 -2.9733 -1.2544 -0.3059 -0.2798 -0.1298 -0.1854 -0.0792 -0.0910 -0.1431 -0.0907 -0.1199 -0.4623 -0.2147 -0.1229 -0.9456 -0.3092 -0.2140 -0.2498 -0.1570 -2.4872 -0.2401 -0.1622 -0.4305 -0.1678 -0.1700
S-895	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-895	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-895	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
D-895	-0.5351852178573608	<unk> The perfusion cutlery to the syringe and intravenously inject the product .
P-895	-2.2401 -2.5407 -1.1340 -0.0384 -1.1524 -1.2954 -0.1312 -1.0465 -0.1388 -0.0868 -0.0242 -0.0263 -0.1251 -0.0892 -0.4606 -0.1331 -0.1736 -0.1773 -0.4104 -0.2335 -0.3145 -0.1642 -0.1731
S-845	19 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-845	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-845	-0.460053026676178	<unk> 19 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
D-845	-0.460053026676178	<unk> 19 Single use data of ADVATE in 53 children under 6 years of age were used to draw up this table .
P-845	-1.4333 -0.7335 -1.1649 -1.2977 -0.3136 -0.3119 -0.1255 -0.1869 -0.0784 -0.0909 -0.1419 -0.0915 -0.1192 -0.4387 -0.2249 -0.1255 -0.9323 -0.3139 -0.2039 -0.2559 -0.1552 -2.5066 -0.2423 -0.1583 -0.4325 -0.1700 -0.1723
S-710	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-710	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-710	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-710	-0.6464712619781494	<unk> The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-710	-2.9362 -1.3253 -0.3109 -1.4485 -0.3109 -2.6413 -0.2993 -0.1389 -0.3496 -0.1556 -0.0706 -0.1958 -0.2129 -0.2867 -1.2080 -0.6209 -0.4394 -0.1400 -0.1402 -0.1812 -0.1636
S-522	Der Wirkstoff in Advate , Octocog alfa , ist ein Protein des Blutgerinnungsfaktors .
T-522	The active substance in Advate , octocog alfa , is a blood coagulation factor protein .
H-522	-0.4538983404636383	<unk> The active substance in Advate , Octocog alfa , is a protein in the clotting factor .
D-522	-0.4538983404636383	<unk> The active substance in Advate , Octocog alfa , is a protein in the clotting factor .
P-522	-2.5148 -0.3335 -0.0485 -0.0561 -0.1351 -1.7007 -0.1100 -0.1793 -0.9150 -0.0667 -0.2088 -0.2620 -0.1260 -0.0605 -0.2485 -0.1117 -0.1279 -0.6188 -1.0159 -0.2022 -2.2694 -0.0193 -0.0405 -0.0988 -0.1723 -0.1592
S-259	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-259	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-259	-0.355190247297287	<unk> No non-clinical trials with the combination of alendronate and colecalciferol .
D-259	-0.355190247297287	<unk> No non-clinical trials with the combination of alendronate and colecalciferol .
P-259	-0.7429 -0.8122 -0.2287 -0.0955 -0.0939 -0.3561 -0.9711 -1.3370 -0.1281 -0.1362 -0.1387 -0.1012 -0.0586 -0.0154 -0.1281 -0.2256 -0.1517 -0.1573 -0.1541 -0.0936 -0.1207 -1.7097 -0.2127
S-520	Die Dosierung wird darüber hinaus je nach Schweregrad der Blutung und Art des chirurgischen Eingriffes angepasst .
T-520	The dose is also adjusted depending on the severity of the haemorrhage or the type of surgery .
H-520	-0.44984397292137146	<unk> Moreover , the dosage is adjusted according to the severity of bleeding and the type of surgery .
D-520	-0.44984397292137146	<unk> Moreover , the dosage is adjusted according to the severity of bleeding and the type of surgery .
P-520	-1.7507 -0.7529 -0.1709 -0.2179 -0.1312 -0.0355 -0.0981 -1.0430 -0.3798 -1.5407 -0.1172 -0.2740 -0.2420 -0.1107 -0.1485 -1.7670 -0.1477 -0.1289 -0.4080 -0.3553 -0.1389 -0.1378 -0.5128 -0.1868
S-1026	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1026	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1026	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1026	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1026	-0.8011 -1.0374 -0.0674 -0.0587 -0.0469 -0.2929 -0.1196 -0.7238 -0.2296 -0.1140 -0.1482 -0.1486 -0.1829 -0.0815 -0.0825 -0.1653 -0.3508 -0.1024 -0.1098 -0.0813 -0.8083 -0.1991
S-239	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-239	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-239	-0.3338724672794342	<unk> Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
D-239	-0.3338724672794342	<unk> Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
P-239	-0.9443 -1.6720 -0.1050 -0.0871 -0.0830 -0.0524 -0.0661 -1.8087 -0.1248 -0.2359 -0.1554 -0.0883 -0.1143 -0.1742 -0.1325 -0.0897 -1.0596 -0.2192 -0.0982 -0.0999 -0.1671 -0.1134 -0.1530 -0.1690
S-435	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-435	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-435	-0.3338724672794342	<unk> Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
D-435	-0.3338724672794342	<unk> Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
P-435	-0.9443 -1.6720 -0.1050 -0.0871 -0.0830 -0.0524 -0.0661 -1.8087 -0.1248 -0.2359 -0.1554 -0.0883 -0.1143 -0.1742 -0.1325 -0.0897 -1.0596 -0.2192 -0.0982 -0.0999 -0.1671 -0.1134 -0.1530 -0.1690
S-383	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-383	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-383	-0.6231157779693604	<unk> A vitamin D deficiency occurs when insufficient exposure to the sun and dietary uptake .
D-383	-0.6231157779693604	<unk> A vitamin D deficiency occurs when insufficient exposure to the sun and dietary uptake .
P-383	-0.7323 -2.3180 -0.4245 -0.0595 -0.0822 -0.0307 -0.0349 -0.0848 -1.4330 -0.0516 -0.0706 -0.9208 -0.6292 -2.5324 -0.9109 -1.4298 -0.9167 -0.1604 -1.4711 -0.0239 -0.2609 -0.0148 -0.1902 -0.1715
S-674	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-674	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-674	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-674	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-674	-0.8011 -1.0374 -0.0674 -0.0587 -0.0469 -0.2929 -0.1196 -0.7238 -0.2296 -0.1140 -0.1482 -0.1486 -0.1829 -0.0815 -0.0825 -0.1653 -0.3508 -0.1024 -0.1098 -0.0813 -0.8083 -0.1991
S-73	Hauptindikator der Wirksamkeit war der Prozentsatz der Patienten mit geringem Vitamin-D-Spiegel .
T-73	The main measure of effectiveness was the percentage of patients with low vitamin D levels .
H-73	-0.37027209997177124	<unk> The main measure of efficacy was the percentage of patients with low vitamin D levels .
D-73	-0.37027209997177124	<unk> The main measure of efficacy was the percentage of patients with low vitamin D levels .
P-73	-1.1859 -0.8482 -0.5300 -0.1202 -0.1655 -0.1985 -0.0883 -0.0976 -0.1401 -0.1757 -0.2423 -0.1544 -0.7070 -0.8173 -0.2063 -0.5204 -0.0729 -0.0912 -1.0615 -0.1617 -0.1909
S-850	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-850	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-850	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-850	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-850	-0.8011 -1.0374 -0.0674 -0.0587 -0.0469 -0.2929 -0.1196 -0.7238 -0.2296 -0.1140 -0.1482 -0.1486 -0.1829 -0.0815 -0.0825 -0.1653 -0.3508 -0.1024 -0.1098 -0.0813 -0.8083 -0.1991
S-1202	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1202	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1202	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1202	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1202	-0.8011 -1.0374 -0.0674 -0.0587 -0.0469 -0.2929 -0.1196 -0.7238 -0.2296 -0.1140 -0.1482 -0.1486 -0.1829 -0.0815 -0.0825 -0.1653 -0.3508 -0.1024 -0.1098 -0.0813 -0.8083 -0.1991
S-1378	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1378	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1378	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1378	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1378	-0.8011 -1.0374 -0.0674 -0.0587 -0.0469 -0.2929 -0.1196 -0.7238 -0.2296 -0.1140 -0.1482 -0.1486 -0.1829 -0.0815 -0.0825 -0.1653 -0.3508 -0.1024 -0.1098 -0.0813 -0.8083 -0.1991
S-1555	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1555	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1555	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1555	-0.27055442333221436	<unk> No pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1555	-0.8011 -1.0374 -0.0674 -0.0587 -0.0469 -0.2929 -0.1196 -0.7238 -0.2296 -0.1140 -0.1482 -0.1486 -0.1829 -0.0815 -0.0825 -0.1653 -0.3508 -0.1024 -0.1098 -0.0813 -0.8083 -0.1991
S-195	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-195	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-195	-0.6231157779693604	<unk> A vitamin D deficiency occurs when insufficient exposure to the sun and dietary uptake .
D-195	-0.6231157779693604	<unk> A vitamin D deficiency occurs when insufficient exposure to the sun and dietary uptake .
P-195	-0.7323 -2.3180 -0.4245 -0.0595 -0.0822 -0.0307 -0.0349 -0.0848 -1.4330 -0.0516 -0.0706 -0.9208 -0.6292 -2.5324 -0.9109 -1.4298 -0.9167 -0.1604 -1.4711 -0.0239 -0.2609 -0.0148 -0.1902 -0.1715
S-1939	Ovale Tablette mit einer blauen und einer weißen Schicht , die blaue Schicht trägt die Prägung D12 .
T-1939	Blue and white bilayer oval tablet with D12 branded to blue layer .
H-1939	-0.5911797285079956	<unk> Oval tablet with a blue and a white layer , the blue layer is marked with D12 .
D-1939	-0.5911797285079956	<unk> Oval tablet with a blue and a white layer , the blue layer is marked with D12 .
P-1939	-0.9738 -2.8308 -0.1079 -0.0933 -0.2467 -0.1750 -0.0671 -0.1559 -0.2437 -0.1290 -2.5381 -0.3618 -0.1707 -0.4727 -2.2308 -0.8525 -0.2570 -0.3582 -0.2241 -0.1694 -0.1671 -0.1803
S-1206	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1206	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1206	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1206	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1206	-0.9618 -1.4651 -0.3277 -0.0498 -0.2164 -0.3015 -0.1415 -0.1416 -0.0927 -0.5513 -0.3439 -0.3225 -0.1621 -0.3133 -0.1094 -0.1211 -0.2734 -0.3478 -0.1307 -0.2050 -0.1721 -0.1587
S-1030	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1030	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1030	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1030	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1030	-0.9618 -1.4651 -0.3277 -0.0498 -0.2164 -0.3015 -0.1415 -0.1416 -0.0927 -0.5513 -0.3439 -0.3225 -0.1621 -0.3133 -0.1094 -0.1211 -0.2734 -0.3478 -0.1307 -0.2050 -0.1721 -0.1587
S-678	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-678	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-678	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-678	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-678	-0.9618 -1.4651 -0.3277 -0.0498 -0.2164 -0.3015 -0.1415 -0.1416 -0.0927 -0.5513 -0.3439 -0.3225 -0.1621 -0.3133 -0.1094 -0.1211 -0.2734 -0.3478 -0.1307 -0.2050 -0.1721 -0.1587
S-1382	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1382	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1382	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1382	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1382	-0.9618 -1.4651 -0.3277 -0.0498 -0.2164 -0.3015 -0.1415 -0.1416 -0.0927 -0.5513 -0.3439 -0.3225 -0.1621 -0.3133 -0.1094 -0.1211 -0.2734 -0.3478 -0.1307 -0.2050 -0.1721 -0.1587
S-1559	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1559	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1559	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1559	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1559	-0.9618 -1.4651 -0.3277 -0.0498 -0.2164 -0.3015 -0.1415 -0.1416 -0.0927 -0.5513 -0.3439 -0.3225 -0.1621 -0.3133 -0.1094 -0.1211 -0.2734 -0.3478 -0.1307 -0.2050 -0.1721 -0.1587
S-1764	Wenn Sie den Eindruck haben , dass die Wirkung von ADVATE unzureichend ist , informieren Sie Ihren Arzt .
T-1764	If you have the impression that the effect of ADVATE is insufficient , talk to your doctor .
H-1764	-0.27378466725349426	<unk> If you have the impression that the effect of ADVATE is insufficient , tell your doctor .
D-1764	-0.27378466725349426	<unk> If you have the impression that the effect of ADVATE is insufficient , tell your doctor .
P-1764	-1.2973 -0.2229 -0.1404 -0.5102 -0.1624 -0.2181 -0.1455 -0.3069 -0.4998 -0.1295 -0.1429 -0.1910 -0.0785 -0.0890 -0.1258 -0.2615 -0.2594 -0.2199 -0.6457 -0.1215 -0.1711 -0.1549 -0.2027
S-854	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-854	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-854	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-854	-0.31406375765800476	<unk> After reconstitution The chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-854	-0.9618 -1.4651 -0.3277 -0.0498 -0.2164 -0.3015 -0.1415 -0.1416 -0.0927 -0.5513 -0.3439 -0.3225 -0.1621 -0.3133 -0.1094 -0.1211 -0.2734 -0.3478 -0.1307 -0.2050 -0.1721 -0.1587
S-512	Advate besteht aus einem Pulver und einem Lösungsmittel , die zur Herstellung einer Injektionslösung gemischt werden .
T-512	Advate is a powder and solvent that are mixed together to make a solution for injection .
H-512	-0.5719945430755615	<unk> Advate consists of a powder and an solvent mixed to produce a solution for injection .
D-512	-0.5719945430755615	<unk> Advate consists of a powder and an solvent mixed to produce a solution for injection .
P-512	-1.0992 -2.7439 -0.1245 -0.0741 -0.0956 -0.1474 -0.1220 -0.1257 -0.1309 -1.3668 -0.5367 -1.6698 -1.9650 -0.1588 -1.1718 -0.2292 -0.0948 -0.1646 -0.1191 -0.0899 -0.1892 -0.1647
S-518	Advate wird durch eine Injektion in eine Vene mit einer Geschwindigkeit von bis zu 10 ml pro Minute verabreicht .
T-518	Advate is given by injection into a vein at a rate of up to 10 ml per minute .
H-518	-0.452304869890213	<unk> Advate is given by injection into a vein at a rate of up to 10 ml per minute .
D-518	-0.452304869890213	<unk> Advate is given by injection into a vein at a rate of up to 10 ml per minute .
P-518	-1.0975 -3.0547 -0.1204 -0.1243 -0.9867 -0.1408 -0.5971 -0.0555 -0.1375 -0.1289 -0.0935 -0.0909 -0.1423 -1.6996 -0.8201 -0.1574 -0.2351 -0.1260 -0.1599 -0.1112 -0.2095 -0.2082 -0.1958 -0.1623
S-1890	Das Schreiben , in dem das Unternehmen die EMEA über die Rücknahme des Antrags informiert , kann hier aufgerufen werden .
T-1890	The letter from the company notifying the EMEA of the withdrawal of the application is available here .
H-1890	-0.5809334516525269	<unk> The letter informing the EMEA about the withdrawal of the application can be found here .
D-1890	-0.5809334516525269	<unk> The letter informing the EMEA about the withdrawal of the application can be found here .
P-1890	-2.6538 -0.4813 -2.0480 -0.5284 -0.8752 -0.4042 -0.1152 -0.0595 -0.1585 -1.4727 -0.1480 -0.8106 -0.4405 -0.2245 -0.0471 -0.5996 -0.1920 -0.4455 -0.1248 -0.1778 -0.1924
S-1769	Möglicherweise werden Sie höhere ADVATE-Dosen oder sogar ein anderes Produkt benötigen , um die Blutungen zu kontrollieren .
T-1769	You might need a higher dose of ADVATE or even a different product to control bleedings .
H-1769	-0.37586379051208496	<unk> You may need higher ADVATE doses or even another product to control bleeding .
D-1769	-0.37586379051208496	<unk> You may need higher ADVATE doses or even another product to control bleeding .
P-1769	-0.7364 -1.2108 -0.3724 -0.3196 -0.0541 -0.7713 -0.1470 -0.0687 -0.1673 -0.1238 -0.0912 -0.3603 -0.4435 -0.2738 -0.1637 -0.1270 -0.1787 -1.2084 -0.2179 -0.1573 -0.6997
S-542	Die vollständige Auflistung der im Zusammenhang mit Advate berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-542	For the full list of all side effects reported with Advate , see the Package Leaflet .
H-542	-0.4327619969844818	<unk> For a full list of reported side effects with Advate see the Package Leaflet .
D-542	-0.4327619969844818	<unk> For a full list of reported side effects with Advate see the Package Leaflet .
P-542	-2.2808 -0.3941 -0.1294 -0.1078 -0.1123 -0.1416 -0.0770 -1.5333 -0.0920 -0.3673 -1.7721 -0.1213 -0.8254 -0.2196 -0.1428 -0.1240 -0.1373 -0.0416 -0.0870 -0.2161 -0.1652
S-639	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-639	6 The immunogenicity of ADVATE was evaluated in previously treated patients .
H-639	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
D-639	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
P-639	-0.9341 -1.8821 -0.1400 -0.1351 -0.0780 -0.6475 -0.1276 -0.1666 -0.1417 -0.1779 -0.0763 -0.0857 -0.1476 -1.0260 -0.1052 -0.1210 -0.6092 -0.2100 -0.0923 -0.1584 -0.1811
S-517	Die Behandlung mit Advate sollte von einem Arzt eingeleitet werden , der über Erfahrung in der Behandlung von Hämophilie verfügt .
T-517	Advate should be started by a doctor who has experience in the treatment of haemophilia .
H-517	-0.5326948165893555	<unk> Treatment with Advate should be initiated by a physician with experience in the treatment of haemophilia .
D-517	-0.5326948165893555	<unk> Treatment with Advate should be initiated by a physician with experience in the treatment of haemophilia .
P-517	-0.7209 -1.7390 -0.0792 -0.1266 -0.1785 -1.8908 -0.1108 -0.1150 -0.1119 -0.0533 -0.1054 -0.1598 -0.1586 -1.5555 -0.0785 -1.0933 -0.1919 -0.1737 -0.1994 -0.1763 -0.1475 -0.1048 -0.7957 -1.6043 -2.3313 -0.1655 -0.2153
S-1341	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1341	46 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1341	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1341	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1341	-0.9341 -1.8821 -0.1400 -0.1351 -0.0780 -0.6475 -0.1276 -0.1666 -0.1417 -0.1779 -0.0763 -0.0857 -0.1476 -1.0260 -0.1052 -0.1210 -0.6092 -0.2100 -0.0923 -0.1584 -0.1811
S-245	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-245	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-245	-0.5078585743904114	<unk> After absorption , vitamin D3 is absorbed into the blood as a chylomicron substance .
D-245	-0.5078585743904114	<unk> After absorption , vitamin D3 is absorbed into the blood as a chylomicron substance .
P-245	-1.2548 -1.1897 -0.0389 -0.0945 -0.8175 -0.0215 -0.0549 -0.1719 -0.1257 -2.3140 -0.5460 -0.0577 -0.6400 -0.1453 -0.0852 -0.1197 -0.3034 -1.3311 -0.1181 -0.0997 -0.1165 -0.1342 -1.1704 -1.9170 -0.1478 -0.1885
S-1730	WAS IST ADVATE UND WOFÜR WIRD ES ANGEWENDET ?
T-1730	WHAT ADVATE IS AND WHAT IT IS USED FOR
H-1730	-0.4876667261123657	<unk> What ADVATE IS AND WHAT IT IS USED FOR <unk>
D-1730	-0.4876667261123657	<unk> What ADVATE IS AND WHAT IT IS USED FOR <unk>
P-1730	-1.1727 -3.6222 -0.1136 -0.1757 -0.1082 -0.0954 -0.4323 -0.1694 -0.0510 -0.0281 -0.8623 -0.1692 -0.1822 -0.0427 -0.0732 -0.1000 -1.1985 -0.1813
S-1998	Es wird nicht erwartet , dass Pseudoephedrinsulfat die psychomotorische Leistungsfähigkeit beeinträchtigt .
T-1998	It is not expected that pseudoephedrine sulphate impairs psychomotor performance .
H-1998	-0.691856861114502	<unk> Pseudoephedrine sulphate is not expected to impair psychomotor performance .
D-1998	-0.691856861114502	<unk> Pseudoephedrine sulphate is not expected to impair psychomotor performance .
P-1998	-0.9032 -0.3652 -2.2736 -0.1183 -0.2422 -0.1323 -2.8163 -1.6067 -0.1153 -0.2089 -0.1212 -0.1737 -0.1137 -0.1367 -0.1073 -1.6311 -0.0692 -3.1556 -0.1154 -0.2340 -0.4346 -1.1860 -0.1634 -0.1808
S-695	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-695	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-695	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
D-695	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
P-695	-1.3370 -0.6174 -0.1021 -0.0614 -0.1515 -1.2156 -0.2529 -0.8791 -0.1087 -0.1264 -1.4393 -2.7728 -0.1368 -0.7342 -0.0825 -0.0627 -0.0306 -0.6016 -0.5951 -0.3700 -0.4844 -0.1744
S-1835	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
T-1835	elezna cesta 14 SI-1000 Ljubljana Tel . : <<unk>> 386 1 420 16 80
H-1835	-0.3832623064517975	<unk> 386 1 420 16 80 elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
D-1835	-0.3832623064517975	<unk> 386 1 420 16 80 elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
P-1835	-1.9274 -0.5999 -0.1351 -0.1233 -0.1651 -0.1336 -0.1375 -0.1304 -3.3308 -0.1015 -1.5405 -0.1414 -0.1006 -0.1423 -0.1001 -0.2197 -0.1138 -0.0589 -0.1247 -1.0102 -0.1106 -0.8824 -0.0402 -0.1485 -0.1388 -0.1070 -0.2478 -0.1413 -0.1193 -0.1866 -0.1243 -0.1637 -0.1373 -0.1463
S-1737	- wenn Sie allergisch ( überempfindlich ) gegen Octocog alfa oder einem der sonstigen Bestandteile
T-1737	- if you are allergic ( hypersensitive ) to octocog alfa or any of the other ingredients of ADVATE
H-1737	-0.35003554821014404	<unk> if you are allergic ( hypersensitive ) to octocog alfa or any of the ingredients
D-1737	-0.35003554821014404	<unk> if you are allergic ( hypersensitive ) to octocog alfa or any of the ingredients
P-1737	-1.6354 -1.5122 -0.1220 -0.2331 -0.3666 -0.0306 -0.1621 -0.3919 -0.2570 -0.1684 -0.1288 -0.9377 -0.0753 -0.1875 -0.3017 -0.1195 -0.0706 -0.1519 -0.4543 -0.1350 -0.1846 -0.0858 -0.3386
S-1576	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1576	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1576	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
D-1576	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
P-1576	-1.3370 -0.6174 -0.1021 -0.0614 -0.1515 -1.2156 -0.2529 -0.8791 -0.1087 -0.1264 -1.4393 -2.7728 -0.1368 -0.7342 -0.0825 -0.0627 -0.0306 -0.6016 -0.5951 -0.3700 -0.4844 -0.1744
S-1399	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1399	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1399	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
D-1399	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
P-1399	-1.3370 -0.6174 -0.1021 -0.0614 -0.1515 -1.2156 -0.2529 -0.8791 -0.1087 -0.1264 -1.4393 -2.7728 -0.1368 -0.7342 -0.0825 -0.0627 -0.0306 -0.6016 -0.5951 -0.3700 -0.4844 -0.1744
S-1223	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1223	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1223	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
D-1223	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
P-1223	-1.3370 -0.6174 -0.1021 -0.0614 -0.1515 -1.2156 -0.2529 -0.8791 -0.1087 -0.1264 -1.4393 -2.7728 -0.1368 -0.7342 -0.0825 -0.0627 -0.0306 -0.6016 -0.5951 -0.3700 -0.4844 -0.1744
S-1047	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1047	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1047	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
D-1047	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
P-1047	-1.3370 -0.6174 -0.1021 -0.0614 -0.1515 -1.2156 -0.2529 -0.8791 -0.1087 -0.1264 -1.4393 -2.7728 -0.1368 -0.7342 -0.0825 -0.0627 -0.0306 -0.6016 -0.5951 -0.3700 -0.4844 -0.1744
S-871	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-871	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-871	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
D-871	-0.5607513189315796	<unk> Do not use the BAXJECT II Unit if its sterile barrier is broken ,
P-871	-1.3370 -0.6174 -0.1021 -0.0614 -0.1515 -1.2156 -0.2529 -0.8791 -0.1087 -0.1264 -1.4393 -2.7728 -0.1368 -0.7342 -0.0825 -0.0627 -0.0306 -0.6016 -0.5951 -0.3700 -0.4844 -0.1744
S-15	Die Wirksamkeit und Sicherheit von Adenuric wurden bei Patienten mit schweren Nieren- oder Leberproblemen nicht untersucht .
T-15	The safety and effectiveness of Adenuric have not been studied in patients with severe kidney or liver problems .
H-15	-0.28305622935295105	<unk> The efficacy and safety of Adenuric were not investigated in patients with severe renal or hepatic impairment .
D-15	-0.28305622935295105	<unk> The efficacy and safety of Adenuric were not investigated in patients with severe renal or hepatic impairment .
P-15	-1.6926 -0.6589 -0.0415 -0.0644 -0.0847 -0.1295 -0.0378 -0.1254 -0.1559 -0.2092 -0.1100 -0.1218 -0.7353 -0.1295 -1.9014 -0.1361 -0.1663 -0.2119 -0.0928 -0.0937 -0.1426 -0.1327 -0.3125 -0.0208 -0.0960 -0.5595 -0.1135 -0.0232 -0.1578 -0.1555 -0.1620
S-1860	Der Wirkstoff in Advexin , Contusugene Ladenovec , ist ein viraler Vektor .
T-1860	The active substance in Advexin , contusugene ladenovec , is a viral vector .
H-1860	-0.5194621682167053	<unk> The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
D-1860	-0.5194621682167053	<unk> The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
P-1860	-2.4282 -0.3773 -0.0630 -0.0464 -0.1351 -2.0923 -0.1925 -0.1398 -0.1741 -0.5114 -0.7824 -0.1241 -0.0237 -2.5961 -0.1319 -0.6660 -0.1292 -0.2264 -0.1079 -0.1105 -1.3120 -0.0646 -0.2101 -0.1748 -0.1668
S-1518	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1518	56 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1518	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1518	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1518	-0.9341 -1.8821 -0.1400 -0.1351 -0.0780 -0.6475 -0.1276 -0.1666 -0.1417 -0.1779 -0.0763 -0.0857 -0.1476 -1.0260 -0.1052 -0.1210 -0.6092 -0.2100 -0.0923 -0.1584 -0.1811
S-1165	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1165	36 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1165	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1165	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1165	-0.9341 -1.8821 -0.1400 -0.1351 -0.0780 -0.6475 -0.1276 -0.1666 -0.1417 -0.1779 -0.0763 -0.0857 -0.1476 -1.0260 -0.1052 -0.1210 -0.6092 -0.2100 -0.0923 -0.1584 -0.1811
S-813	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-813	16 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-813	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
D-813	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
P-813	-0.9341 -1.8821 -0.1400 -0.1351 -0.0780 -0.6475 -0.1276 -0.1666 -0.1417 -0.1779 -0.0763 -0.0857 -0.1476 -1.0260 -0.1052 -0.1210 -0.6092 -0.2100 -0.0923 -0.1584 -0.1811
S-989	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-989	26 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-989	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
D-989	-0.3449212610721588	<unk> Neoantigenicity of ADVATE was evaluated in previously treated patients .
P-989	-0.9341 -1.8821 -0.1400 -0.1351 -0.0780 -0.6475 -0.1276 -0.1666 -0.1417 -0.1779 -0.0763 -0.0857 -0.1476 -1.0260 -0.1052 -0.1210 -0.6092 -0.2100 -0.0923 -0.1584 -0.1811
S-441	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-441	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-441	-0.5078585743904114	<unk> After absorption , vitamin D3 is absorbed into the blood as a chylomicron substance .
D-441	-0.5078585743904114	<unk> After absorption , vitamin D3 is absorbed into the blood as a chylomicron substance .
P-441	-1.2548 -1.1897 -0.0389 -0.0945 -0.8175 -0.0215 -0.0549 -0.1719 -0.1257 -2.3140 -0.5460 -0.0577 -0.6400 -0.1453 -0.0852 -0.1197 -0.3034 -1.3311 -0.1181 -0.0997 -0.1165 -0.1342 -1.1704 -1.9170 -0.1478 -0.1885
S-374	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption konzentriert .
T-374	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-374	-0.4431914687156677	<unk> Preclinical studies have shown that alendronate prefers to concentrate at sites of active absorption .
D-374	-0.4431914687156677	<unk> Preclinical studies have shown that alendronate prefers to concentrate at sites of active absorption .
P-374	-0.6605 -0.2368 -0.6378 -0.0975 -0.8955 -0.1576 -1.0595 -0.0648 -0.1696 -0.0408 -0.0993 -0.0661 -0.0080 -2.1065 -0.5911 -0.1065 -1.5899 -0.3351 -1.4631 -0.1324 -0.0502 -0.1048 -0.0900 -0.1471 -0.1696
S-24	Die Wirkungen von Adenuric wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-24	The effects of Adenuric were first tested in experimental models before being studied in humans .
H-24	-0.6599500775337219	<unk> Adenuric effects were initially evaluated in animal models , before being studied in humans .
D-24	-0.6599500775337219	<unk> Adenuric effects were initially evaluated in animal models , before being studied in humans .
P-24	-1.6663 -0.3898 -0.1884 -0.1070 -0.1135 -1.2023 -0.1048 -0.8892 -3.3573 -0.1033 -0.1163 -2.8640 -0.0598 -0.6980 -0.4909 -0.2004 -0.4828 -0.1284 -0.3527 -0.1699 -0.1739
S-1755	Die Behandlung mit ADVATE wird von einem in der Behandlung von Hämophilie A erfahrenen Arzt eingeleitet .
T-1755	Treatment with ADVATE will be started by a doctor who is experienced in the care of patients with haemophilia A.
H-1755	-0.46582522988319397	<unk> Treatment with ADVATE is initiated by a physician experienced in the treatment of haemophilia A .
D-1755	-0.46582522988319397	<unk> Treatment with ADVATE is initiated by a physician experienced in the treatment of haemophilia A .
P-1755	-0.8545 -2.6811 -0.0845 -0.1296 -0.1689 -0.1694 -0.1967 -0.0919 -0.0823 -0.1446 -0.0397 -0.1019 -0.1518 -0.5630 -0.7569 -0.0714 -1.9366 -0.1285 -0.2052 -0.1873 -0.1483 -0.0655 -0.1592 -1.5243 -1.7172 -0.2597 -0.2573 -0.1656
S-1630	74 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1630	68 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1630	-0.16666939854621887	74 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
D-1630	-0.16666939854621887	74 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
P-1630	-2.0821 -0.0692 -0.1597 -0.0762 -0.2002 -0.1651 -0.1887 -0.0905 -0.0464 -0.0416 -0.0490 -0.0676 -0.0391 -0.2205 -0.1132 -0.0503 -0.0355 -0.9094 -0.0117 -0.0059 -0.0094 -0.0193 -0.0379 -0.0327 -0.1046 -0.0833 -0.1501 -0.0178 -0.0767 -0.1272 -0.0177 -0.0527 -0.1492
S-1663	82 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1663	76 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1663	-0.21471373736858368	82 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
D-1663	-0.21471373736858368	82 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
P-1663	-3.5928 -0.0720 -0.1536 -0.0727 -0.2029 -0.1699 -0.1773 -0.0958 -0.0474 -0.0423 -0.0505 -0.0675 -0.0395 -0.2191 -0.1143 -0.0484 -0.0355 -0.9806 -0.0120 -0.0065 -0.0097 -0.0187 -0.0384 -0.0323 -0.1070 -0.0823 -0.1500 -0.0176 -0.0769 -0.1332 -0.0176 -0.0521 -0.1491
S-523	Faktor VIII ist eine der Substanzen ( Faktoren ) im Körper , die an der Blutgerinnung beteiligt sind .
T-523	In the body , factor VIII is one of the substances ( factors ) involved in blood coagulation ( clotting ) .
H-523	-0.42694202065467834	<unk> factor VIII is one of the substances ( factors ) in the body involved in blood clotting .
D-523	-0.42694202065467834	<unk> factor VIII is one of the substances ( factors ) in the body involved in blood clotting .
P-523	-0.5983 -2.6829 -0.1834 -0.1008 -0.1464 -0.0999 -0.1391 -0.1937 -1.3790 -0.0833 -0.1871 -0.1290 -0.1711 -0.1430 -0.2168 -0.0630 -1.7470 -0.1260 -0.8901 -0.4804 -0.0220 -0.0935 -0.1598 -0.2109
S-1878	Nachdem der CHMP die Antworten des Unternehmens auf die ihm gestellten Fragen geprüft hatte , waren immer noch einige Fragen ungeklärt .
T-1878	After the CHMP had assessed the responses from the company to a list of questions , there were still some unresolved issues outstanding .
H-1878	-1.062550663948059	<unk> After the CHMP considered the company s replies to the questions asked , some questions were still unresolved .
D-1878	-1.062550663948059	<unk> After the CHMP considered the company s replies to the questions asked , some questions were still unresolved .
P-1878	-1.6658 -0.8323 -2.4708 -0.0610 -0.0744 -1.7169 -0.2677 -0.3652 -3.5727 -2.1591 -0.7434 -0.1794 -0.2164 -1.4598 -2.9333 -0.4594 -0.4164 -2.4733 -1.0098 -0.4650 -0.7281 -0.8640 -0.1748 -0.1924
S-1646	78 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1646	72 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1646	-0.22358004748821259	78 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
D-1646	-0.22358004748821259	78 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
P-1646	-4.0671 -0.0715 -0.1479 -0.0743 -0.2008 -0.1688 -0.1935 -0.0917 -0.0462 -0.0410 -0.0493 -0.0677 -0.0390 -0.2040 -0.1154 -0.0507 -0.0360 -0.8114 -0.0119 -0.0063 -0.0093 -0.0193 -0.0377 -0.0328 -0.1063 -0.0814 -0.1462 -0.0183 -0.0775 -0.1358 -0.0175 -0.0525 -0.1489
S-351	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-351	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-351	-0.501490592956543	<unk> The following adverse reactions were reported during clinical trials and/ or after the alendronate launch .
D-351	-0.501490592956543	<unk> The following adverse reactions were reported during clinical trials and/ or after the alendronate launch .
P-351	-1.7198 -0.2958 -0.0837 -0.8441 -0.0928 -0.6547 -0.0864 -0.2951 -0.0974 -0.1008 -0.1492 -0.4786 -0.0162 -0.1312 -0.1856 -0.4406 -0.3299 -1.6974 -0.1161 -0.0585 -0.0191 -3.8075 -0.1679 -0.1672
S-1680	86 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1680	80 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1680	-0.18278858065605164	86 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
D-1680	-0.18278858065605164	86 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
P-1680	-2.7036 -0.0735 -0.1508 -0.0701 -0.2014 -0.1651 -0.1900 -0.0945 -0.0455 -0.0406 -0.0497 -0.0678 -0.0399 -0.2875 -0.1153 -0.0507 -0.0351 -0.7609 -0.0119 -0.0053 -0.0094 -0.0188 -0.0383 -0.0329 -0.1029 -0.0835 -0.1518 -0.0183 -0.0780 -0.1194 -0.0178 -0.0531 -0.1488
S-1696	90 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1696	84 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1696	-0.18074998259544373	90 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
D-1696	-0.18074998259544373	90 MINIMUM PARTICULARS TO APPEAR SMALL IMMEDIATE PACKAGING UNITS
P-1696	-2.5551 -0.0662 -0.1695 -0.0724 -0.1950 -0.1686 -0.1771 -0.0905 -0.0472 -0.0414 -0.0502 -0.0662 -0.0403 -0.1968 -0.1130 -0.0499 -0.0360 -0.9279 -0.0118 -0.0049 -0.0094 -0.0190 -0.0389 -0.0327 -0.1017 -0.0854 -0.1549 -0.0176 -0.0769 -0.1303 -0.0177 -0.0513 -0.1490
S-1712	94 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1712	88 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1712	-0.23294243216514587	<unk> <unk> MINIMUM PARTICULARS TO SMALL IMMEDIATE PACKAGING UNITS
D-1712	-0.23294243216514587	<unk> <unk> MINIMUM PARTICULARS TO SMALL IMMEDIATE PACKAGING UNITS
P-1712	-1.6287 -0.7875 -0.2110 -0.1538 -0.0625 -0.1987 -0.1554 -0.2153 -0.1047 -0.0451 -0.0418 -0.0512 -0.0673 -0.0386 -2.2544 -0.0128 -0.0055 -0.0090 -0.0314 -0.0424 -0.0460 -0.1060 -0.0912 -0.1360 -0.0187 -0.0760 -0.1637 -0.0157 -0.0523 -0.1658
S-248	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-248	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden . Circulating vitamin D3 is bound to vitamin D-binding protein .
H-248	-0.20559734106063843	<unk> Circulating vitamin D3 is bound to vitamin D-binding protein .
D-248	-0.20559734106063843	<unk> Circulating vitamin D3 is bound to vitamin D-binding protein .
P-248	-1.0796 -0.1453 -0.1281 -0.1361 -0.0455 -0.0824 -0.1682 -0.1264 -0.1537 -0.0309 -0.1182 -0.2327 -0.0804 -0.9245 -0.1068 -0.0469 -0.1022 -0.0880 -0.1454 -0.1706
S-1873	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-1873	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-1873	-0.25816041231155396	<unk> 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-1873	-0.25816041231155396	<unk> 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-1873	-1.7873 -0.3433 -0.1929 -0.1297 -0.1324 -0.3755 -0.0802 -0.1703 -0.2728 -0.1072 -0.0747 -0.1583 -0.1045 -0.1700 -0.1667 -0.1027 -0.1059 -0.1921 -0.1445 -0.0986 -0.1812 -0.2395 -0.8099 -0.1591 -0.1548
S-150	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-150	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-150	-0.47057265043258667	<unk> Cholestyramine , colestipol ) may impair the absorption of vitamin D .
D-150	-0.47057265043258667	<unk> Cholestyramine , colestipol ) may impair the absorption of vitamin D .
P-150	-0.6054 -1.1369 -0.1986 -0.0694 -0.1022 -0.0788 -0.2659 -0.1631 -0.2107 -0.6185 -3.7282 -0.1409 -0.0835 -2.0446 -0.0586 -0.5716 -0.0407 -0.0885 -0.1363 -0.1333 -0.0847 -0.2080 -0.3403 -0.1849
S-338	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-338	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-338	-0.47057265043258667	<unk> Cholestyramine , colestipol ) may impair the absorption of vitamin D .
D-338	-0.47057265043258667	<unk> Cholestyramine , colestipol ) may impair the absorption of vitamin D .
P-338	-0.6054 -1.1369 -0.1986 -0.0694 -0.1022 -0.0788 -0.2659 -0.1631 -0.2107 -0.6185 -3.7282 -0.1409 -0.0835 -2.0446 -0.0586 -0.5716 -0.0407 -0.0885 -0.1363 -0.1333 -0.0847 -0.2080 -0.3403 -0.1849
S-163	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-163	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-163	-0.501490592956543	<unk> The following adverse reactions were reported during clinical trials and/ or after the alendronate launch .
D-163	-0.501490592956543	<unk> The following adverse reactions were reported during clinical trials and/ or after the alendronate launch .
P-163	-1.7198 -0.2958 -0.0837 -0.8441 -0.0928 -0.6547 -0.0864 -0.2951 -0.0974 -0.1008 -0.1492 -0.4786 -0.0162 -0.1312 -0.1856 -0.4406 -0.3299 -1.6974 -0.1161 -0.0585 -0.0191 -3.8075 -0.1679 -0.1672
S-426	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-426	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-426	-0.48160502314567566	<unk> Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 <unk>
D-426	-0.48160502314567566	<unk> Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 <unk>
P-426	-2.2393 -2.8902 -0.1194 -0.0656 -0.0116 -0.2573 -0.0018 -0.0033 -0.4826 -0.0899 -0.1753 -0.5606 -0.1273 -1.0246 -1.2082 -0.3715 -0.1121 -0.0738 -0.1879 -0.1890 -0.1406 -0.1713 -0.5736
S-1779	Wenn Sie die Anwendung von ADVATE abbrechen Brechen Sie die Anwendung von ADVATE nicht ab ohne Ihren Arzt zu befragen .
T-1779	If you stop using ADVATE Do not stop using ADVATE without consulting your doctor .
H-1779	-0.5794161558151245	<unk> If you are considering discontinuation of use of ADVATE , do not discontinue use of ADVATE without consulting your doctor .
D-1779	-0.5794161558151245	<unk> If you are considering discontinuation of use of ADVATE , do not discontinue use of ADVATE without consulting your doctor .
P-1779	-0.9185 -0.5409 -0.1280 -1.5472 -0.1960 -2.3841 -0.1426 -0.1387 -0.1529 -0.8065 -0.2125 -0.3318 -0.1987 -0.1071 -0.0995 -0.5573 -1.7104 -0.1076 -2.0694 -0.8043 -0.7313 -0.2587 -0.6116 -0.2142 -0.1356 -0.1132 -0.2411 -2.9666 -0.1038 -0.1461 -0.1194 -0.1517 -0.1735
S-819	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-819	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-819	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
D-819	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
P-819	-1.3608 -0.3653 -1.7018 -0.1575 -1.2954 -0.0595 -0.4423 -0.1706 -0.2048 -0.4334 -0.6317 -0.0976 -0.0396 -0.0601 -0.1100 -1.5012 -0.1194 -2.5331 -0.3167 -1.2224 -0.1031 -0.3824 -0.1759 -0.1417 -1.7260 -0.2009 -0.1684 -0.1642 -0.1655
S-1752	Verkehrstüchtigkeit und das Bedienen von Maschinen ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und das Bedienen von Maschinen .
T-1752	Driving and using machines ADVATE has no influence on your ability to drive or to use machines .
H-1752	-0.43162447214126587	<unk> ability to drive and use machines ADVATE has no effects on ability to drive and use machines .
D-1752	-0.43162447214126587	<unk> ability to drive and use machines ADVATE has no effects on ability to drive and use machines .
P-1752	-0.6001 -2.5164 -0.1922 -0.5735 -0.1460 -0.0459 -0.0641 -1.0254 -0.1800 -0.0818 -0.0921 -0.2529 -0.1447 -1.4246 -0.1441 -0.6264 -0.1719 -0.6766 -0.1595 -0.3332 -0.0907 -0.1671 -0.2181
S-1794	Verwenden Sie ADVATE nicht mehr nach dem Verfalldatum , das auf dem Etikett nach verwendbar bis angegeben ist . .
T-1794	Do not use ADVATE after the expiry date , which is stated on the label after EXP .
H-1794	-0.34593233466148376	<unk> Do not use ADVATE after the expiry date indicated on the label . <unk> <unk>
D-1794	-0.34593233466148376	<unk> Do not use ADVATE after the expiry date indicated on the label . <unk> <unk>
P-1794	-0.6533 -0.2246 -0.1220 -0.1265 -0.1560 -0.2017 -0.0874 -0.0878 -0.6876 -0.1730 -0.0235 -0.0527 -0.1037 -1.0811 -0.1019 -0.1482 -0.0524 -0.4739 -1.3299 -1.1485 -0.2288
S-645	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-645	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-645	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
D-645	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
P-645	-1.3608 -0.3653 -1.7018 -0.1575 -1.2954 -0.0595 -0.4423 -0.1706 -0.2048 -0.4334 -0.6317 -0.0976 -0.0396 -0.0601 -0.1100 -1.5012 -0.1194 -2.5331 -0.3167 -1.2224 -0.1031 -0.3824 -0.1759 -0.1417 -1.7260 -0.2009 -0.1684 -0.1642 -0.1655
S-230	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-230	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-230	-0.48160502314567566	<unk> Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 <unk>
D-230	-0.48160502314567566	<unk> Alendronate concomitant administration with coffee or orange juice reduced bioavailability by approximately 60 <unk>
P-230	-2.2393 -2.8902 -0.1194 -0.0656 -0.0116 -0.2573 -0.0018 -0.0033 -0.4826 -0.0899 -0.1753 -0.5606 -0.1273 -1.0246 -1.2082 -0.3715 -0.1121 -0.0738 -0.1879 -0.1890 -0.1406 -0.1713 -0.5736
S-1347	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1347	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1347	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
D-1347	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
P-1347	-1.3608 -0.3653 -1.7018 -0.1575 -1.2954 -0.0595 -0.4423 -0.1706 -0.2048 -0.4334 -0.6317 -0.0976 -0.0396 -0.0601 -0.1100 -1.5012 -0.1194 -2.5331 -0.3167 -1.2224 -0.1031 -0.3824 -0.1759 -0.1417 -1.7260 -0.2009 -0.1684 -0.1642 -0.1655
S-638	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-638	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-638	-0.35029059648513794	<unk> Following continuous infusion , tests for factor VIIII inhibitors were negative at the end of the study .
D-638	-0.35029059648513794	<unk> Following continuous infusion , tests for factor VIIII inhibitors were negative at the end of the study .
P-638	-1.1374 -1.8640 -0.8575 -0.1433 -0.1250 -0.0886 -0.1910 -0.2265 -0.2588 -0.0637 -0.6136 -0.1491 -0.7132 -0.6309 -0.1076 -0.0541 -0.0770 -0.1032 -0.2614 -0.0658 -0.2217 -0.1612 -0.4335 -0.1526 -0.1746 -0.5743 -0.1663 -0.1922
S-469	Name und Anschrift des ( der ) Hersteller<unk> s ) , der ( die ) für die Chargenfreigabe verantwortlich ist ( sind )
T-469	Name and address of the manufacturer<<unk>> s ) responsible for batch release
H-469	-0.3666183352470398	<unk> Name and address of the manufacturer ( s ) responsible for batch release ( s )
D-469	-0.3666183352470398	<unk> Name and address of the manufacturer ( s ) responsible for batch release ( s )
P-469	-0.9370 -0.3314 -0.1614 -0.0840 -0.1659 -0.3067 -2.0100 -0.1599 -0.1877 -0.1411 -0.1379 -0.1813 -0.3041 -0.0657 -0.7897 -0.3291 -0.2924 -0.1450 -0.2355
S-1736	WAS MÜSSEN SIE VOR DER ANWENDUNG VON ADVATE BEACHTEN ?
T-1736	BEFORE YOU USE ADVATE
H-1736	-0.5816301703453064	<unk> <unk> BEFORE USE OF ADVATE <unk> <unk>
D-1736	-0.5816301703453064	<unk> <unk> BEFORE USE OF ADVATE <unk> <unk>
P-1736	-0.7994 -1.8519 -0.9096 -0.0177 -0.0041 -0.1053 -0.2691 -1.7974 -0.0475 -0.5694 -0.1623 -0.0678 -0.0985 -0.8946 -0.2359 -1.4758
S-995	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-995	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-995	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
D-995	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
P-995	-1.3608 -0.3653 -1.7018 -0.1575 -1.2954 -0.0595 -0.4423 -0.1706 -0.2048 -0.4334 -0.6317 -0.0976 -0.0396 -0.0601 -0.1100 -1.5012 -0.1194 -2.5331 -0.3167 -1.2224 -0.1031 -0.3824 -0.1759 -0.1417 -1.7260 -0.2009 -0.1684 -0.1642 -0.1655
S-169	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-169	Metabolism and nutrition disorders :
H-169	-0.31795525550842285	<unk> Rare : severe musculoskeletal ( bone , muscle or joints ) pain ( see section 4.4 ) .
D-169	-0.31795525550842285	<unk> Rare : severe musculoskeletal ( bone , muscle or joints ) pain ( see section 4.4 ) .
P-169	-1.4205 -0.3074 -0.1647 -0.1368 -0.2252 -0.1230 -0.4639 -0.1028 -2.0598 -0.2457 -0.1005 -0.3294 -0.2431 -0.1586 -0.2748 -0.4970 -0.4846 -0.0542 -0.1389 -0.0500 -0.1479 -0.1583 -0.1980 -0.1576 -0.1442 -0.1486 -0.2029 -0.1645
S-1368	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1368	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1368	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
D-1368	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
P-1368	-1.1732 -2.2303 -0.0730 -0.1607 -0.5511 -0.1267 -0.1514 -0.1160 -0.1904 -0.1252 -0.4624 -0.1284 -0.0705 -0.4725 -0.1358 -2.4245 -0.0269 -0.3085 -3.1303 -1.2186 -0.0323 -0.0563 -0.3707 -0.1548 -0.1654
S-1016	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1016	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1016	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
D-1016	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
P-1016	-1.1732 -2.2303 -0.0730 -0.1607 -0.5511 -0.1267 -0.1514 -0.1160 -0.1904 -0.1252 -0.4624 -0.1284 -0.0705 -0.4725 -0.1358 -2.4245 -0.0269 -0.3085 -3.1303 -1.2186 -0.0323 -0.0563 -0.3707 -0.1548 -0.1654
S-53	Der Hersteller von FOSAVANCE hat zugestimmt , dass die wissenschaftlichen Daten dieses Produkts auch für ADROVANCE verwendet werden können .
T-53	The company that makes FOSAVANCE has agreed that its scientific data can be used for ADROVANCE .
H-53	-0.4427097737789154	<unk> The manufacturer of FOSAVANCE has agreed that the scientific data of this product may also be used for ADROVANCE .
D-53	-0.4427097737789154	<unk> The manufacturer of FOSAVANCE has agreed that the scientific data of this product may also be used for ADROVANCE .
P-53	-1.4132 -0.5904 -1.6349 -0.1765 -0.1686 -0.0807 -0.1167 -0.1521 -0.1232 -0.8491 -0.2027 -0.6053 -0.1149 -0.1928 -0.6656 -0.2183 -1.1219 -0.1558 -0.2065 -0.2744 -0.1141 -1.2100 -0.7328 -0.5424 -0.3596 -0.1060 -0.1609 -0.1346 -0.9244 -0.1638 -0.2116
S-1996	In klinischen Studien zur Beurteilung der Verkehrstüchtigkeit wurde bei Patienten , die Desloratadin erhielten , keine Beeinträchtigung festgestellt .
T-1996	In clinical trials that assessed the driving ability , no impairment occurred in patients receiving desloratadine .
H-1996	-0.44649478793144226	<unk> In clinical trials to evaluate ability to drive , no impairment was detected in patients receiving desloratadine .
D-1996	-0.44649478793144226	<unk> In clinical trials to evaluate ability to drive , no impairment was detected in patients receiving desloratadine .
P-1996	-0.5342 -0.2642 -0.1731 -1.1294 -1.7814 -1.1701 -0.1164 -0.3921 -0.1565 -0.5779 -0.1732 -0.2568 -0.6675 -0.0604 -0.0209 -0.1025 -0.1204 -1.6141 -0.0710 -0.4808 -0.3093 -0.0450 -1.4036 -0.1142 -0.0891 -0.4351 -0.3216 -0.1721 -0.1956
S-1545	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1545	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1545	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
D-1545	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
P-1545	-1.1732 -2.2303 -0.0730 -0.1607 -0.5511 -0.1267 -0.1514 -0.1160 -0.1904 -0.1252 -0.4624 -0.1284 -0.0705 -0.4725 -0.1358 -2.4245 -0.0269 -0.3085 -3.1303 -1.2186 -0.0323 -0.0563 -0.3707 -0.1548 -0.1654
S-1171	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1171	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1171	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
D-1171	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
P-1171	-1.3608 -0.3653 -1.7018 -0.1575 -1.2954 -0.0595 -0.4423 -0.1706 -0.2048 -0.4334 -0.6317 -0.0976 -0.0396 -0.0601 -0.1100 -1.5012 -0.1194 -2.5331 -0.3167 -1.2224 -0.1031 -0.3824 -0.1759 -0.1417 -1.7260 -0.2009 -0.1684 -0.1642 -0.1655
S-1192	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1192	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1192	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
D-1192	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
P-1192	-1.1732 -2.2303 -0.0730 -0.1607 -0.5511 -0.1267 -0.1514 -0.1160 -0.1904 -0.1252 -0.4624 -0.1284 -0.0705 -0.4725 -0.1358 -2.4245 -0.0269 -0.3085 -3.1303 -1.2186 -0.0323 -0.0563 -0.3707 -0.1548 -0.1654
S-1524	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1524	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1524	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
D-1524	-0.553489625453949	<unk> The detection frequency of FVIII inhibitors to date has been expected and is within the previously observed range .
P-1524	-1.3608 -0.3653 -1.7018 -0.1575 -1.2954 -0.0595 -0.4423 -0.1706 -0.2048 -0.4334 -0.6317 -0.0976 -0.0396 -0.0601 -0.1100 -1.5012 -0.1194 -2.5331 -0.3167 -1.2224 -0.1031 -0.3824 -0.1759 -0.1417 -1.7260 -0.2009 -0.1684 -0.1642 -0.1655
S-840	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-840	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-840	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
D-840	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
P-840	-1.1732 -2.2303 -0.0730 -0.1607 -0.5511 -0.1267 -0.1514 -0.1160 -0.1904 -0.1252 -0.4624 -0.1284 -0.0705 -0.4725 -0.1358 -2.4245 -0.0269 -0.3085 -3.1303 -1.2186 -0.0323 -0.0563 -0.3707 -0.1548 -0.1654
S-665	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-665	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-665	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
D-665	-0.5622347593307495	<unk> Plasma samples were evaluated in a central laboratory using a single-stage clotting test .
P-665	-1.1732 -2.2303 -0.0730 -0.1607 -0.5511 -0.1267 -0.1514 -0.1160 -0.1904 -0.1252 -0.4624 -0.1284 -0.0705 -0.4725 -0.1358 -2.4245 -0.0269 -0.3085 -3.1303 -1.2186 -0.0323 -0.0563 -0.3707 -0.1548 -0.1654
S-1866	Da Krebszellen beschädigte DNA enthalten , hilft das p53-Protein , die DNA wiederherzustellen oder verursacht , dass die Zellen absterben .
T-1866	Because cancer cells contain damaged DNA , the p53 protein either helps to repair the DNA or causes the cells to die .
H-1866	-0.48211905360221863	<unk> Since cancer cells contain damaged DNA , the p53 protein will help to recover the DNA or cause the cells to die .
D-1866	-0.48211905360221863	<unk> Since cancer cells contain damaged DNA , the p53 protein will help to recover the DNA or cause the cells to die .
P-1866	-2.0710 -0.6911 -0.1198 -0.0639 -0.0735 -2.2597 -0.0362 -0.1784 -0.2030 -0.2670 -0.0767 -0.2085 -1.3131 -0.1016 -0.2409 -2.2376 -0.4673 -0.1047 -0.3193 -0.0793 -0.3965 -0.0729 -0.1011 -0.2128 -0.1627 -0.4765
S-357	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-357	Metabolism and nutrition disorders :
H-357	-0.31795525550842285	<unk> Rare : severe musculoskeletal ( bone , muscle or joints ) pain ( see section 4.4 ) .
D-357	-0.31795525550842285	<unk> Rare : severe musculoskeletal ( bone , muscle or joints ) pain ( see section 4.4 ) .
P-357	-1.4205 -0.3074 -0.1647 -0.1368 -0.2252 -0.1230 -0.4639 -0.1028 -2.0598 -0.2457 -0.1005 -0.3294 -0.2431 -0.1586 -0.2748 -0.4970 -0.4846 -0.0542 -0.1389 -0.0500 -0.1479 -0.1583 -0.1980 -0.1576 -0.1442 -0.1486 -0.2029 -0.1645
S-1422	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1422	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1422	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
D-1422	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
P-1422	-2.1502 -1.0376 -0.4653 -0.9330 -0.1635 -1.0066 -0.0235 -0.0885 -0.4268 -0.3036 -0.1436 -0.0755 -0.0286 -0.0321 -0.1799 -3.1857 -0.3978 -0.4779 -0.6442 -0.1371 -0.1964 -0.1594
S-1246	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1246	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1246	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
D-1246	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
P-1246	-2.1502 -1.0376 -0.4653 -0.9330 -0.1635 -1.0066 -0.0235 -0.0885 -0.4268 -0.3036 -0.1436 -0.0755 -0.0286 -0.0321 -0.1799 -3.1857 -0.3978 -0.4779 -0.6442 -0.1371 -0.1964 -0.1594
S-894	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-894	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-894	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
D-894	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
P-894	-2.1502 -1.0376 -0.4653 -0.9330 -0.1635 -1.0066 -0.0235 -0.0885 -0.4268 -0.3036 -0.1436 -0.0755 -0.0286 -0.0321 -0.1799 -3.1857 -0.3978 -0.4779 -0.6442 -0.1371 -0.1964 -0.1594
S-1424	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1424	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-1424	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1424	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1424	-1.5266 -0.6246 -0.1428 -0.0844 -0.1316 -0.7112 -0.1142 -0.0980 -0.5512 -0.1524 -0.7344 -1.1892 -0.0830 -0.4075 -0.1385 -0.1073 -0.1274 -1.1136 -0.2431 -0.1315 -0.1929 -0.1552 -0.1481 -0.4994 -0.1591 -0.1894
S-1599	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1599	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1599	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
D-1599	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
P-1599	-2.1502 -1.0376 -0.4653 -0.9330 -0.1635 -1.0066 -0.0235 -0.0885 -0.4268 -0.3036 -0.1436 -0.0755 -0.0286 -0.0321 -0.1799 -3.1857 -0.3978 -0.4779 -0.6442 -0.1371 -0.1964 -0.1594
S-1601	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1601	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-1601	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1601	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1601	-1.5266 -0.6246 -0.1428 -0.0844 -0.1316 -0.7112 -0.1142 -0.0980 -0.5512 -0.1524 -0.7344 -1.1892 -0.0830 -0.4075 -0.1385 -0.1073 -0.1274 -1.1136 -0.2431 -0.1315 -0.1929 -0.1552 -0.1481 -0.4994 -0.1591 -0.1894
S-1887	Der Ausschuss hatte ferner Bedenken bezüglich der Verarbeitung des Arzneimittels im Körper , der Art der Verabreichung sowie der Sicherheit des Arzneimittels .
T-1887	The Committee also had concerns over what happens to the medicine in the body , how it should be given and how safe it is .
H-1887	-0.5833733677864075	<unk> The Committee also had concerns about how the medicinal product is disposed of , and the safety of the medicinal product .
D-1887	-0.5833733677864075	<unk> The Committee also had concerns about how the medicinal product is disposed of , and the safety of the medicinal product .
P-1887	-2.2693 -0.3173 -0.0918 -0.1098 -0.3127 -0.3554 -0.7524 -1.8386 -0.1295 -1.6309 -0.1842 -0.0672 -1.0832 -1.7782 -0.0745 -0.6951 -1.8139 -0.2263 -0.2358 -0.1193 -0.1430 -0.1311 -0.8707 -0.1136 -0.0752 -0.1588 -0.1732
S-1070	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1070	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1070	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
D-1070	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
P-1070	-2.1502 -1.0376 -0.4653 -0.9330 -0.1635 -1.0066 -0.0235 -0.0885 -0.4268 -0.3036 -0.1436 -0.0755 -0.0286 -0.0321 -0.1799 -3.1857 -0.3978 -0.4779 -0.6442 -0.1371 -0.1964 -0.1594
S-720	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-720	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-720	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
D-720	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
P-720	-1.5266 -0.6246 -0.1428 -0.0844 -0.1316 -0.7112 -0.1142 -0.0980 -0.5512 -0.1524 -0.7344 -1.1892 -0.0830 -0.4075 -0.1385 -0.1073 -0.1274 -1.1136 -0.2431 -0.1315 -0.1929 -0.1552 -0.1481 -0.4994 -0.1591 -0.1894
S-718	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-718	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-718	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
D-718	-0.5571351647377014	<unk> Slowly withdraw the reconstituted solution into the syringe ( Fig . e ) .
P-718	-2.1502 -1.0376 -0.4653 -0.9330 -0.1635 -1.0066 -0.0235 -0.0885 -0.4268 -0.3036 -0.1436 -0.0755 -0.0286 -0.0321 -0.1799 -3.1857 -0.3978 -0.4779 -0.6442 -0.1371 -0.1964 -0.1594
S-322	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-322	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-322	-0.42228055000305176	<unk> The vitamin D level of ADROVANCE is not indicated to treat vitamin D deficiency .
D-322	-0.42228055000305176	<unk> The vitamin D level of ADROVANCE is not indicated to treat vitamin D deficiency .
P-322	-0.9379 -1.4516 -0.3144 -0.0638 -0.1423 -2.1629 -0.2013 -0.2110 -0.1094 -0.1450 -0.0970 -0.5964 -0.1648 -0.1601 -1.5379 -0.7094 -0.4737 -0.3876 -0.0554 -0.1108 -0.0375 -0.0329 -0.0931 -0.1725 -0.1883
S-134	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-134	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-134	-0.42228055000305176	<unk> The vitamin D level of ADROVANCE is not indicated to treat vitamin D deficiency .
D-134	-0.42228055000305176	<unk> The vitamin D level of ADROVANCE is not indicated to treat vitamin D deficiency .
P-134	-0.9379 -1.4516 -0.3144 -0.0638 -0.1423 -2.1629 -0.2013 -0.2110 -0.1094 -0.1450 -0.0970 -0.5964 -0.1648 -0.1601 -1.5379 -0.7094 -0.4737 -0.3876 -0.0554 -0.1108 -0.0375 -0.0329 -0.0931 -0.1725 -0.1883
S-55	ADROVANCE vermindert das Risiko für Wirbel<unk> säulen<unk> - und Hüftfrakturen ( Brüche ) .
T-55	ADROVANCE reduces the risk of vertebral ( spine ) and hip fractures ( breaks ) .
H-55	-0.42280933260917664	<unk> ADROVANCE decreases the risk for spinal and hip fractures ( fractures ) .
D-55	-0.42280933260917664	<unk> ADROVANCE decreases the risk for spinal and hip fractures ( fractures ) .
P-55	-0.9286 -0.5238 -0.1484 -0.1765 -0.1234 -1.1704 -1.2873 -0.1527 -0.2014 -0.1235 -1.1223 -0.6234 -0.7392 -0.1864 -0.0622 -0.6002 -0.0881 -0.1525 -0.7615 -0.0459 -0.1446 -0.1545 -0.2079
S-1971	Deshalb ist es im Falle eines operativen Eingriffs vorzuziehen , die Behandlung 24 Stunden vor der Einleitung der Narkose abzusetzen .
T-1971	Therefore , if surgery is scheduled , it is preferable to discontinue treatment 24 hours before anaesthesia .
H-1971	-0.49641406536102295	<unk> Therefore , in the event of surgery , it is preferable to discontinue treatment 24 hours prior to initiation of anaesthesia .
D-1971	-0.49641406536102295	<unk> Therefore , in the event of surgery , it is preferable to discontinue treatment 24 hours prior to initiation of anaesthesia .
P-1971	-1.3186 -0.9666 -0.0751 -0.3742 -0.2932 -0.6491 -1.0023 -0.1392 -2.1085 -0.3581 -0.3138 -0.2797 -0.0705 -0.1033 -0.1450 -0.4633 -0.4469 -0.1432 -0.1237 -0.1294 -0.9515 -0.1210 -2.4828 -0.3202 -0.1558 -0.2192 -1.0069 -0.2392 -0.0631 -0.1482 -0.1771
S-113	Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-113	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-113	-0.39970001578330994	<unk> Patients should be alerted that the risk of oesophageal problems may be increased if they do not follow these instructions .
D-113	-0.39970001578330994	<unk> Patients should be alerted that the risk of oesophageal problems may be increased if they do not follow these instructions .
P-113	-0.5478 -0.3015 -0.0884 -0.1625 -0.1584 -1.6576 -0.1461 -0.1592 -0.1514 -2.0480 -0.0775 -0.1476 -0.1034 -0.0846 -0.2260 -0.0632 -0.0656 -0.1383 -0.2593 -0.0716 -0.4567 -0.3523 -0.5500 -0.1655 -1.6125 -0.1695 -1.6066 -0.1192 -0.3507 -0.1545 -0.1952
S-1995	Es wurden keine Studien zu den Auswirkungen von Aerinaze auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-1995	No studies on the effects on the ability to drive and use machines have been performed with Aerinaze .
H-1995	-0.32165542244911194	<unk> No studies were carried out on the effects of Aerinaze on ability to drive and use machines .
D-1995	-0.32165542244911194	<unk> No studies were carried out on the effects of Aerinaze on ability to drive and use machines .
P-1995	-0.9399 -0.2582 -0.0519 -0.8799 -0.6105 -0.1365 -0.7109 -0.2153 -0.4932 -0.1290 -0.1669 -0.1169 -0.1357 -0.1312 -0.1424 -0.1426 -0.1510 -0.1470 -1.2267 -0.1492 -0.1724 -0.2748 -0.1466 -0.1909
S-769	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-769	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-769	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-769	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-769	-1.7046 -1.6753 -0.3023 -0.4980 -0.1504 -0.1613 -0.4796 -0.5374 -0.1538 -0.0748 -0.1766 -0.9701 -0.9097 -0.4989 -0.1816 -0.0728 -0.0991 -0.1549 -0.5043 -0.0896 -0.4420 -3.0367 -0.3088 -0.6496 -0.7260 -0.1251 -0.1235 -0.0915 -0.1601 -0.1413 -0.1493 -0.2065 -0.1536 -0.2001
S-68	Alendronat ist ein Biphosphonat , das seit Mitte der 1990er Jahre gegen Osteoporose eingesetzt wird .
T-68	Vitamin D3 , along with other forms of vitamin D , is required for calcium absorption and normal bone formation .
H-68	-0.3580729365348816	<unk> Alendronate is a biphosphonate that has been used to treat osteoporosis since the <unk> <unk> 90s .
D-68	-0.3580729365348816	<unk> Alendronate is a biphosphonate that has been used to treat osteoporosis since the <unk> <unk> 90s .
P-68	-1.4509 -0.4406 -0.1385 -0.0672 -0.0093 -0.1385 -0.1149 -0.0803 -0.1017 -0.0402 -0.0732 -0.9907 -0.1995 -0.0756 -0.1833 -0.2590 -0.2569 -0.1062 -0.0951 -0.1094 -0.1194 -0.0853 -0.0974 -0.4563 -0.1434 -2.4355 -1.4984 -0.5143 -0.4732 -0.1863 -0.1599
S-1814	102 Falls weitere Informationen über das Arzneimittel gewünscht werden , setzen Sie sich bitte mit dem örtlichen Vertreter des Zulassungsinhabers in Verbindung .
T-1814	96 For any information about this medicine , please contact the local representative of the Marketing Authorisation Holder :
H-1814	-0.6404042840003967	<unk> For any information <unk> on the medicinal product , contact the local representative of the marketing authorisation holder .
D-1814	-0.6404042840003967	<unk> For any information <unk> on the medicinal product , contact the local representative of the marketing authorisation holder .
P-1814	-2.5997 -1.5863 -0.0488 -0.4103 -2.5548 -1.2622 -0.1460 -0.4776 -0.0591 -0.0567 -0.3120 -0.7399 -0.1317 -2.0809 -1.2699 -0.1744 -0.1353 -0.1862 -0.0390 -0.0592 -0.0475 -0.1732 -0.1788
S-896	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-896	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-896	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
D-896	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
P-896	-1.5266 -0.6246 -0.1428 -0.0844 -0.1316 -0.7112 -0.1142 -0.0980 -0.5512 -0.1524 -0.7344 -1.1892 -0.0830 -0.4075 -0.1385 -0.1073 -0.1274 -1.1136 -0.2431 -0.1315 -0.1929 -0.1552 -0.1481 -0.4994 -0.1591 -0.1894
S-1988	In Tierversuchen war weder Desloratadin noch die Kombination von Loratadin und Pseudoephedrin teratogen .
T-1988	Neither desloratadine nor the combination of loratadine and pseudoephedrine were teratogenic in animal studies .
H-1988	-0.5152252912521362	<unk> In animal trials , neither desloratadin nor combination of loratadin and pseudoephedrine was teratogenic .
D-1988	-0.5152252912521362	<unk> In animal trials , neither desloratadin nor combination of loratadin and pseudoephedrine was teratogenic .
P-1988	-1.8858 -0.6206 -0.0152 -1.6804 -0.2447 -1.1997 -1.0881 -0.1132 -0.0969 -0.9417 -0.2578 -0.1039 -0.3376 -0.1361 -0.3725 -0.0996 -1.3737 -0.3891 -0.1465 -0.3772 -2.1382 -0.1291 -0.1036 -0.1880 -0.2893 -0.1731 -0.8559 -0.1637 -0.0738 -0.5406 -0.9192 -0.1369 -0.1611 -0.1648
S-305	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-305	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-305	-0.18681907653808594	<unk> Osteonecrosis of the jaw has also been reported in osteoporosis patients receiving oral bisphosphonates .
D-305	-0.18681907653808594	<unk> Osteonecrosis of the jaw has also been reported in osteoporosis patients receiving oral bisphosphonates .
P-305	-1.1502 -0.3658 -0.0823 -0.1083 -0.0744 -0.0342 -0.0989 -0.1406 -0.1757 -0.0366 -0.0793 -1.0329 -0.1128 -0.1924 -0.1089 -0.1742 -0.5300 -0.0662 -0.1065 -0.1234 -0.0751 -0.0897 -0.0858 -0.2519 -0.0348 -0.1305 -0.0235 -0.0459 -0.0542 -0.0817 -0.1485 -0.1626
S-1872	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden .
T-1872	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden . The effectiveness of the medicine was assessed by using scans to look at how the tumours responded to treatment .
H-1872	-0.33319219946861267	<unk> The patient received 12 Advexin injections over five months which were injected into some of the tumours .
D-1872	-0.33319219946861267	<unk> The patient received 12 Advexin injections over five months which were injected into some of the tumours .
P-1872	-1.1758 -0.5406 -0.1446 -0.7410 -0.0662 -0.9699 -0.2770 -0.1371 -0.0739 -0.0621 -0.1956 -0.1582 -0.1474 -2.0224 -0.1497 -0.2421 -0.1164 -0.1888 -0.1103 -0.1361 -0.1485 -0.0679 -0.0591 -0.1534 -0.2457
S-1473	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1473	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1473	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-1473	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-1473	-1.7046 -1.6753 -0.3023 -0.4980 -0.1504 -0.1613 -0.4796 -0.5374 -0.1538 -0.0748 -0.1766 -0.9701 -0.9097 -0.4989 -0.1816 -0.0728 -0.0991 -0.1549 -0.5043 -0.0896 -0.4420 -3.0367 -0.3088 -0.6496 -0.7260 -0.1251 -0.1235 -0.0915 -0.1601 -0.1413 -0.1493 -0.2065 -0.1536 -0.2001
S-1297	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1297	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1297	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-1297	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-1297	-1.7046 -1.6753 -0.3023 -0.4980 -0.1504 -0.1613 -0.4796 -0.5374 -0.1538 -0.0748 -0.1766 -0.9701 -0.9097 -0.4989 -0.1816 -0.0728 -0.0991 -0.1549 -0.5043 -0.0896 -0.4420 -3.0367 -0.3088 -0.6496 -0.7260 -0.1251 -0.1235 -0.0915 -0.1601 -0.1413 -0.1493 -0.2065 -0.1536 -0.2001
S-1121	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1121	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1121	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-1121	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-1121	-1.7046 -1.6753 -0.3023 -0.4980 -0.1504 -0.1613 -0.4796 -0.5374 -0.1538 -0.0748 -0.1766 -0.9701 -0.9097 -0.4989 -0.1816 -0.0728 -0.0991 -0.1549 -0.5043 -0.0896 -0.4420 -3.0367 -0.3088 -0.6496 -0.7260 -0.1251 -0.1235 -0.0915 -0.1601 -0.1413 -0.1493 -0.2065 -0.1536 -0.2001
S-945	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-945	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-945	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-945	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-945	-1.7046 -1.6753 -0.3023 -0.4980 -0.1504 -0.1613 -0.4796 -0.5374 -0.1538 -0.0748 -0.1766 -0.9701 -0.9097 -0.4989 -0.1816 -0.0728 -0.0991 -0.1549 -0.5043 -0.0896 -0.4420 -3.0367 -0.3088 -0.6496 -0.7260 -0.1251 -0.1235 -0.0915 -0.1601 -0.1413 -0.1493 -0.2065 -0.1536 -0.2001
S-595	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-595	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-595	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-595	-0.4679228365421295	<unk> For the benefit of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-595	-1.7046 -1.6753 -0.3023 -0.4980 -0.1504 -0.1613 -0.4796 -0.5374 -0.1538 -0.0748 -0.1766 -0.9701 -0.9097 -0.4989 -0.1816 -0.0728 -0.0991 -0.1549 -0.5043 -0.0896 -0.4420 -3.0367 -0.3088 -0.6496 -0.7260 -0.1251 -0.1235 -0.0915 -0.1601 -0.1413 -0.1493 -0.2065 -0.1536 -0.2001
S-1072	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1072	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-1072	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1072	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1072	-1.5266 -0.6246 -0.1428 -0.0844 -0.1316 -0.7112 -0.1142 -0.0980 -0.5512 -0.1524 -0.7344 -1.1892 -0.0830 -0.4075 -0.1385 -0.1073 -0.1274 -1.1136 -0.2431 -0.1315 -0.1929 -0.1552 -0.1481 -0.4994 -0.1591 -0.1894
S-1771	Wie ADVATE angewendet wird ADVATE wird normalerweise vom Arzt in eine Vene ( intravenös ) verabreicht .
T-1771	How ADVATE is given ADVATE is usually injected into a vein ( intravenously ) by your doctor or nurse .
H-1771	-0.36451905965805054	<unk> How ADVATE is administered ADVATE is usually administered by the doctor into a vein ( intravenously ) .
D-1771	-0.36451905965805054	<unk> How ADVATE is administered ADVATE is usually administered by the doctor into a vein ( intravenously ) .
P-1771	-1.6230 -1.5738 -0.2403 -0.2357 -0.1379 -0.1021 -0.1269 -1.2372 -0.1030 -0.6552 -0.2058 -0.1317 -0.1089 -0.1109 -0.1637 -0.5800 -0.0994 -0.2788 -0.1525 -1.2932 -0.9465 -0.1500 -0.0909 -0.0699 -0.1464 -0.2032 -0.1128 -0.0988 -0.2024 -0.1513 -0.1739 -0.1584
S-1248	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1248	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-1248	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
D-1248	-0.37525561451911926	<unk> The solution should be administered slowly at a rate convenient to the patient and maximum of 10 ml/ minute .
P-1248	-1.5266 -0.6246 -0.1428 -0.0844 -0.1316 -0.7112 -0.1142 -0.0980 -0.5512 -0.1524 -0.7344 -1.1892 -0.0830 -0.4075 -0.1385 -0.1073 -0.1274 -1.1136 -0.2431 -0.1315 -0.1929 -0.1552 -0.1481 -0.4994 -0.1591 -0.1894
S-117	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-117	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-117	-0.18681907653808594	<unk> Osteonecrosis of the jaw has also been reported in osteoporosis patients receiving oral bisphosphonates .
D-117	-0.18681907653808594	<unk> Osteonecrosis of the jaw has also been reported in osteoporosis patients receiving oral bisphosphonates .
P-117	-1.1502 -0.3658 -0.0823 -0.1083 -0.0744 -0.0342 -0.0989 -0.1406 -0.1757 -0.0366 -0.0793 -1.0329 -0.1128 -0.1924 -0.1089 -0.1742 -0.5300 -0.0662 -0.1065 -0.1234 -0.0751 -0.0897 -0.0858 -0.2519 -0.0348 -0.1305 -0.0235 -0.0459 -0.0542 -0.0817 -0.1485 -0.1626
S-1913	Die Wirksamkeit von Aerinaze wurde in zwei Hauptstudien mit insgesamt 1 248 erwachsenen und jugendlichen Patienten untersucht .
T-1913	The effectiveness of Aerinaze was assessed in two main studies involving a total of 1,248 adult and adolescent patients .
H-1913	-0.3353921175003052	<unk> Aerinaze s efficacy was investigated in two main studies involving a total of 1,248 adult and adolescent patients .
D-1913	-0.3353921175003052	<unk> Aerinaze s efficacy was investigated in two main studies involving a total of 1,248 adult and adolescent patients .
P-1913	-2.1970 -0.6585 -0.1358 -0.1428 -0.1334 -0.1589 -0.9892 -0.0731 -0.0626 -0.0696 -0.1538 -1.2470 -0.1093 -0.1128 -0.1237 -0.3653 -0.6116 -0.1302 -0.1125 -0.1662 -0.3523 -0.0815 -0.1173 -0.0963 -0.1359 -0.2102 -0.0601 -1.1336 -0.1170 -0.1808 -0.1589
S-1895	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-1895	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-1895	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-1895	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-1895	-1.9192 -1.5176 -2.0667 -0.0847 -0.5594 -0.2569 -0.0733 -0.1840 -0.1970 -0.1917 -0.0360 -0.0986 -0.6140 -0.3597 -0.2633 -0.0455 -0.0556 -0.0619 -0.0709 -0.0702 -0.1544 -0.1517 -0.1627 -0.1405 -0.1417 -0.1080 -0.0487 -0.1474 -0.2288 -0.1638
S-511	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-511	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-511	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-511	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-511	-1.9192 -1.5176 -2.0667 -0.0847 -0.5594 -0.2569 -0.0733 -0.1840 -0.1970 -0.1917 -0.0360 -0.0986 -0.6140 -0.3597 -0.2633 -0.0455 -0.0556 -0.0619 -0.0709 -0.0702 -0.1544 -0.1517 -0.1627 -0.1405 -0.1417 -0.1080 -0.0487 -0.1474 -0.2288 -0.1638
S-50	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-50	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-50	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-50	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-50	-1.9192 -1.5176 -2.0667 -0.0847 -0.5594 -0.2569 -0.0733 -0.1840 -0.1970 -0.1917 -0.0360 -0.0986 -0.6140 -0.3597 -0.2633 -0.0455 -0.0556 -0.0619 -0.0709 -0.0702 -0.1544 -0.1517 -0.1627 -0.1405 -0.1417 -0.1080 -0.0487 -0.1474 -0.2288 -0.1638
S-2	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-2	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-2	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-2	-0.3391314148902893	<unk> For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-2	-1.9192 -1.5176 -2.0667 -0.0847 -0.5594 -0.2569 -0.0733 -0.1840 -0.1970 -0.1917 -0.0360 -0.0986 -0.6140 -0.3597 -0.2633 -0.0455 -0.0556 -0.0619 -0.0709 -0.0702 -0.1544 -0.1517 -0.1627 -0.1405 -0.1417 -0.1080 -0.0487 -0.1474 -0.2288 -0.1638
S-1868	Advexin hätte die Krankheit heilen oder deren Fortschreiten verlangsamen sollen , indem die normale Schutzfunktion der Zellen wiederhergestellt wird .
T-1868	Advexin was expected to cure or slow down the disease by restoring the normal protective function of the cells .
H-1868	-0.6359497904777527	<unk> Advexin should have cured the disease or slowed its progression by restoring cells to their normal protective function .
D-1868	-0.6359497904777527	<unk> Advexin should have cured the disease or slowed its progression by restoring cells to their normal protective function .
P-1868	-1.4707 -2.0859 -0.2114 -0.1390 -0.2028 -0.2699 -2.0549 -0.2073 -1.5787 -0.0513 -0.2039 -0.3861 -0.0465 -0.0573 -0.0978 -0.1677 -0.1243 -0.1965 -0.1482 -3.5795 -1.6429 -0.8554 -0.1502 -0.2294 -0.6665 -0.1634 -0.1832
S-1411	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1411	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1411	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
D-1411	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
P-1411	-1.6983 -2.0981 -0.0737 -0.1638 -0.9839 -0.1281 -0.1397 -0.1120 -0.1999 -0.1361 -0.1525 -0.5488 -1.7674 -0.0944 -0.6440 -0.1920 -0.1995 -0.1975
S-1588	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1588	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1588	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
D-1588	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
P-1588	-1.6983 -2.0981 -0.0737 -0.1638 -0.9839 -0.1281 -0.1397 -0.1120 -0.1999 -0.1361 -0.1525 -0.5488 -1.7674 -0.0944 -0.6440 -0.1920 -0.1995 -0.1975
S-400	3,2 % in der 5.600-I.E.-Vitamin-D3-Gruppe . Der Anteil an Patientinnen mit
T-400	3.2 % in the Vitamin D3 5600 group through the 24-week extension .
H-400	-0.2693994343280792	<unk> 3.2 % in the 5.600 IU vitamin D3 group . <unk> <unk>
D-400	-0.2693994343280792	<unk> 3.2 % in the 5.600 IU vitamin D3 group . <unk> <unk>
P-400	-0.8175 -0.2513 -0.1508 -0.1137 -0.2237 -0.1327 -0.1216 -0.2588 -0.0981 -0.0911 -0.0700 -0.0785 -0.9433 -0.1025 -0.2318 -0.4818 -0.4225 -0.2544 -0.2745
S-458	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-458	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-458	-0.4355068504810333	<unk> In studies , high doses in rats increased occurrence of incomplete ossification in the foetus .
D-458	-0.4355068504810333	<unk> In studies , high doses in rats increased occurrence of incomplete ossification in the foetus .
P-458	-0.9160 -0.1580 -0.7105 -0.2408 -0.4037 -0.0414 -0.0510 -0.1405 -0.0601 -1.6006 -1.3313 -0.0196 -0.0852 -0.0929 -0.1405 -0.2054 -0.6679 -1.3842 -0.3532 -0.1612 -0.2886 -1.4419 -0.0107 -0.3015 -0.1645 -0.3520
S-1747	Treten irgendwelche dieser Symptome auf , brechen Sie die Injektion sofort ab und kontaktieren Sie Ihren Arzt . Schwere Symptome wie z.
T-1747	If any of these symptoms occur , stop the injection immediately and contact your doctor .
H-1747	-0.41934627294540405	<unk> If any of these symptoms occur , cancel the injection immediately and contact your doctor . Severe symptoms such as <unk> <unk>
D-1747	-0.41934627294540405	<unk> If any of these symptoms occur , cancel the injection immediately and contact your doctor . Severe symptoms such as <unk> <unk>
P-1747	-1.0488 -0.3558 -0.1177 -0.1340 -0.1071 -0.0603 -0.5877 -0.1552 -3.1236 -0.4387 -0.0804 -0.1059 -0.0824 -0.1384 -0.1196 -0.1400 -0.1477 -0.1403 -1.1311 -0.1102 -0.0876 -0.0769 -0.1337 -1.2559 -0.5103 -0.5136
S-262	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-262	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-262	-0.4355068504810333	<unk> In studies , high doses in rats increased occurrence of incomplete ossification in the foetus .
D-262	-0.4355068504810333	<unk> In studies , high doses in rats increased occurrence of incomplete ossification in the foetus .
P-262	-0.9160 -0.1580 -0.7105 -0.2408 -0.4037 -0.0414 -0.0510 -0.1405 -0.0601 -1.6006 -1.3313 -0.0196 -0.0852 -0.0929 -0.1405 -0.2054 -0.6679 -1.3842 -0.3532 -0.1612 -0.2886 -1.4419 -0.0107 -0.3015 -0.1645 -0.3520
S-1235	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1235	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1235	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
D-1235	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
P-1235	-1.6983 -2.0981 -0.0737 -0.1638 -0.9839 -0.1281 -0.1397 -0.1120 -0.1999 -0.1361 -0.1525 -0.5488 -1.7674 -0.0944 -0.6440 -0.1920 -0.1995 -0.1975
S-707	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-707	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-707	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
D-707	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
P-707	-1.6983 -2.0981 -0.0737 -0.1638 -0.9839 -0.1281 -0.1397 -0.1120 -0.1999 -0.1361 -0.1525 -0.5488 -1.7674 -0.0944 -0.6440 -0.1920 -0.1995 -0.1975
S-883	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-883	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-883	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
D-883	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
P-883	-1.6983 -2.0981 -0.0737 -0.1638 -0.9839 -0.1281 -0.1397 -0.1120 -0.1999 -0.1361 -0.1525 -0.5488 -1.7674 -0.0944 -0.6440 -0.1920 -0.1995 -0.1975
S-1059	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1059	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1059	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
D-1059	-0.5294287800788879	<unk> Use only the included water for injections and the included Reconstitution Kit .
P-1059	-1.6983 -2.0981 -0.0737 -0.1638 -0.9839 -0.1281 -0.1397 -0.1120 -0.1999 -0.1361 -0.1525 -0.5488 -1.7674 -0.0944 -0.6440 -0.1920 -0.1995 -0.1975
S-1066	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1066	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1066	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
D-1066	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
P-1066	-0.9605 -0.4173 -0.1957 -0.1446 -0.1961 -0.8646 -0.1614 -1.2086 -0.2024 -0.1707 -1.6388 -0.1042 -0.5516 -0.0168 -0.8183 -0.1736 -2.4301 -0.7385 -0.0788 -0.4336 -0.1827 -0.1613 -0.1942
S-1242	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1242	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1242	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
D-1242	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
P-1242	-0.9605 -0.4173 -0.1957 -0.1446 -0.1961 -0.8646 -0.1614 -1.2086 -0.2024 -0.1707 -1.6388 -0.1042 -0.5516 -0.0168 -0.8183 -0.1736 -2.4301 -0.7385 -0.0788 -0.4336 -0.1827 -0.1613 -0.1942
S-1418	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1418	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1418	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
D-1418	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
P-1418	-0.9605 -0.4173 -0.1957 -0.1446 -0.1961 -0.8646 -0.1614 -1.2086 -0.2024 -0.1707 -1.6388 -0.1042 -0.5516 -0.0168 -0.8183 -0.1736 -2.4301 -0.7385 -0.0788 -0.4336 -0.1827 -0.1613 -0.1942
S-714	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-714	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-714	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
D-714	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
P-714	-0.9605 -0.4173 -0.1957 -0.1446 -0.1961 -0.8646 -0.1614 -1.2086 -0.2024 -0.1707 -1.6388 -0.1042 -0.5516 -0.0168 -0.8183 -0.1736 -2.4301 -0.7385 -0.0788 -0.4336 -0.1827 -0.1613 -0.1942
S-1595	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1595	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1595	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
D-1595	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
P-1595	-0.9605 -0.4173 -0.1957 -0.1446 -0.1961 -0.8646 -0.1614 -1.2086 -0.2024 -0.1707 -1.6388 -0.1042 -0.5516 -0.0168 -0.8183 -0.1736 -2.4301 -0.7385 -0.0788 -0.4336 -0.1827 -0.1613 -0.1942
S-339	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-339	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-339	-0.34660324454307556	<unk> Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
D-339	-0.34660324454307556	<unk> Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
P-339	-1.0544 -1.6881 -0.1276 -0.0139 -0.1362 -0.8858 -0.1629 -0.3270 -0.1164 -0.2365 -0.0909 -0.1594 -0.1433 -0.0256 -0.1054 -0.0634 -0.1016 -0.4568 -0.8921 -0.4014 -1.3742 -0.6928 -0.0523 -0.1042 -0.1334 -0.0995 -0.0891 -0.2449 -0.2054 -0.2137
S-1863	Das Gen , welches das Virus in Advexin trägt , ist das normale ( nicht defekte ) p53-Gen .
T-1863	The gene carried by the virus in Advexin is the normal ( non-defective ) p53 gene .
H-1863	-0.5425835251808167	<unk> The gene that the virus carries in Advexin is the normal ( non-defective ) p53 gene .
D-1863	-0.5425835251808167	<unk> The gene that the virus carries in Advexin is the normal ( non-defective ) p53 gene .
P-1863	-2.1887 -0.3600 -0.1208 -1.2402 -0.1933 -1.1060 -2.8358 -0.2614 -1.3095 -0.2617 -0.1321 -0.1148 -0.2944 -0.0600 -0.2260 -0.8244 -0.2717 -0.6499 -0.1109 -0.1539 -0.2942 -0.0859 -0.1488 -0.1536 -0.1667
S-890	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-890	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-890	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
D-890	-0.5236696600914001	<unk> If solution and containers permit , always check parenterals for suspended particles before administration .
P-890	-0.9605 -0.4173 -0.1957 -0.1446 -0.1961 -0.8646 -0.1614 -1.2086 -0.2024 -0.1707 -1.6388 -0.1042 -0.5516 -0.0168 -0.8183 -0.1736 -2.4301 -0.7385 -0.0788 -0.4336 -0.1827 -0.1613 -0.1942
S-541	Bei einigen Patienten , die mit Arzneimitteln behandelt wurden , welche Faktor VIII enthalten , wurde Überempfindlichkeit ( allergische Reaktion ) beobachtet .
T-541	Hypersensitivity ( allergic reactions ) has sometimes been seen in patients treated with factor VIII-containing products .
H-541	-0.3078469932079315	<unk> In some patients treated with medicines containing factor VIII , hypersensitivity ( allergic reaction ) was observed .
D-541	-0.3078469932079315	<unk> In some patients treated with medicines containing factor VIII , hypersensitivity ( allergic reaction ) was observed .
P-541	-0.5735 -2.3601 -0.0768 -0.1241 -0.5119 -0.1239 -0.6373 -0.1104 -0.1918 -0.1152 -0.1879 -0.0613 -0.4331 -0.0737 -0.0444 -0.0656 -0.1321 -0.0904 -0.0674 -0.0943 -0.1501 -0.9788 -0.1213 -0.1658 -0.2051
S-1923	Die vollständige Auflistung der im Zusammenhang mit Aerinaze berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-1923	For the full list of all side effects reported with Aerinaze , see the Package Leaflet .
H-1923	-0.32970237731933594	<unk> For a full list of reported side effects with Aerinaze see the Package Leaflet .
D-1923	-0.32970237731933594	<unk> For a full list of reported side effects with Aerinaze see the Package Leaflet .
P-1923	-2.3393 -0.4319 -0.1298 -0.1074 -0.1064 -0.1401 -0.1164 -1.5824 -0.0877 -0.2921 -0.1468 -0.1162 -0.1295 -0.1308 -0.1574 -0.7616 -0.1970 -0.1957 -0.1224 -0.1238 -0.0436 -0.0816 -0.2074 -0.1656
S-566	Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-566	2 factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-566	-0.26797211170196533	<unk> VIII per kg bodyweight increasing factor VIII activity in plasma by 2 IU/ dl .
D-566	-0.26797211170196533	<unk> VIII per kg bodyweight increasing factor VIII activity in plasma by 2 IU/ dl .
P-566	-0.5999 -0.8137 -0.1135 -0.1619 -0.0930 -0.1977 -0.1294 -0.4446 -0.3625 -0.4008 -0.1664 -1.2146 -0.0479 -0.1194 -0.2697 -0.0678 -0.0789 -0.1770 -0.1011 -0.1320 -0.1484 -0.1531 -0.0459 -0.4899 -0.1700
S-78	Die vollständige Auflistung der im Zusammenhang mit ADROVANCE berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-78	For the full list of all side effects reported with ADROVANCE , see the Package Leaflet .
H-78	-0.3627393841743469	<unk> For a full list of reported side effects with ADROVANCE see the Package Leaflet .
D-78	-0.3627393841743469	<unk> For a full list of reported side effects with ADROVANCE see the Package Leaflet .
P-78	-2.1902 -0.4022 -0.1296 -0.1060 -0.1067 -0.1416 -0.1167 -2.1201 -0.0974 -0.4181 -0.1903 -0.1137 -0.1622 -0.1000 -0.6009 -0.6363 -0.1788 -0.1495 -0.1251 -0.1242 -0.0391 -0.0842 -0.2062 -0.1666
S-1940	Symptomatische Behandlung der saisonalen allergischen Rhinitis mit begleitender Nasenschleimhautschwellung .
T-1940	Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion .
H-1940	-0.26325613260269165	<unk> Symptomatic treatment of seasonal allergic rhinitis with concomitant nasal swelling .
D-1940	-0.26325613260269165	<unk> Symptomatic treatment of seasonal allergic rhinitis with concomitant nasal swelling .
P-1940	-0.6261 -1.9458 -0.0713 -0.0860 -0.2331 -0.1416 -1.3274 -0.1304 -0.0366 -0.0755 -0.0935 -0.0728 -0.0847 -0.0683 -0.1685 -0.4617 -0.0024 -0.0048 -0.0907 -0.1069 -0.0639 -0.1615 -0.3328 -0.1096 -0.1677 -0.1810
S-1381	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1381	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1381	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1381	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1381	-1.5915 -1.0336 -0.1595 -0.6849 -0.0875 -0.1546 -0.1646 -0.4065 -0.1248 -0.1581 -0.1687 -0.2122 -0.1360 -0.1672 -0.0489 -0.0546 -0.8308 -0.1393 -0.1237 -0.2960 -0.1506 -0.1490 -0.3763 -0.1110 -0.0292 -0.1430 -0.1450 -0.1046 -0.0796 -0.1570 -0.1766
S-1489	59 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1489	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1489	-0.28951796889305115	<unk> This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1489	-0.28951796889305115	<unk> This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1489	-2.1489 -0.3957 -0.0963 -0.0760 -0.0865 -1.2748 -1.2789 -0.0722 -0.0750 -0.0861 -0.1221 -0.1043 -0.1964 -0.0887 -0.0393 -0.0402 -0.1485 -0.1233 -0.0548 -0.1535 -0.1174 -0.0593 -0.0814 -0.1525 -0.1660
S-1313	48 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1313	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1313	-0.2543605864048004	48 This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1313	-0.2543605864048004	48 This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1313	-0.8668 -0.4247 -0.3890 -0.0698 -0.0762 -1.2230 -1.4848 -0.0694 -0.0765 -0.0839 -0.1126 -0.1039 -0.1970 -0.0871 -0.0368 -0.0399 -0.1416 -0.1154 -0.0538 -0.1519 -0.1143 -0.0559 -0.0829 -0.1532 -0.1487
S-1137	37 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1137	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1137	-0.29302239418029785	<unk> This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1137	-0.29302239418029785	<unk> This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1137	-2.2039 -0.3779 -0.1021 -0.0759 -0.0820 -1.2576 -1.3415 -0.0731 -0.0750 -0.0881 -0.1195 -0.1046 -0.1954 -0.0888 -0.0396 -0.0395 -0.1480 -0.1232 -0.0579 -0.1521 -0.1163 -0.0570 -0.0813 -0.1504 -0.1748
S-961	26 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-961	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-961	-0.25799742341041565	26 This medicinal product after its reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-961	-0.25799742341041565	26 This medicinal product after its reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-961	-0.9415 -0.4262 -0.3480 -0.0684 -0.0772 -1.2983 -1.3690 -0.3258 -0.1110 -0.0660 -0.0826 -0.1125 -0.1055 -0.1950 -0.0858 -0.0351 -0.0397 -0.1428 -0.1144 -0.0537 -0.1526 -0.1147 -0.0570 -0.0820 -0.1543 -0.1490
S-538	Ein Antikörper ist ein Protein , das vom Körper aufgrund seines natürlichen Schutzmechanismus als Reaktion auf unbekannte Stoffe gebildet wird .
T-538	An antibody is a protein produced by the body in reaction to unknown agents as part of the natural defence system of the body .
H-538	-0.4187389314174652	<unk> An antibody is a protein produced by the body in reaction to unknown compounds .
D-538	-0.4187389314174652	<unk> An antibody is a protein produced by the body in reaction to unknown compounds .
P-538	-1.2865 -0.4285 -0.1226 -0.0749 -0.1293 -0.1406 -0.1399 -1.6736 -0.1223 -0.1293 -0.0549 -1.0343 -0.9558 -0.1161 -0.8278 -0.2903 -0.0865 -0.1554 -0.1875
S-611	4 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-611	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-611	-0.24740800261497498	4 This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-611	-0.24740800261497498	4 This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-611	-0.5677 -0.5658 -0.4491 -0.0708 -0.0755 -1.3108 -1.3253 -0.0718 -0.0695 -0.0846 -0.1138 -0.1036 -0.1996 -0.0864 -0.0378 -0.0400 -0.1426 -0.1154 -0.0523 -0.1519 -0.1142 -0.0559 -0.0815 -0.1507 -0.1484
S-1281	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1281	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1281	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
D-1281	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
P-1281	-0.4961 -2.9935 -0.1888 -0.1035 -0.1528 -0.3623 -0.1413 -0.4707 -0.1343 -1.1151 -0.0892 -1.0093 -0.2434 -0.1253 -0.1591 -0.1215 -0.1929 -0.1395 -0.1865 -0.1157 -0.1470 -1.9199 -0.4023 -0.0817 -0.1591 -0.1124 -0.2026 -0.2288
S-929	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-929	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-929	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
D-929	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
P-929	-0.4961 -2.9935 -0.1888 -0.1035 -0.1528 -0.3623 -0.1413 -0.4707 -0.1343 -1.1151 -0.0892 -1.0093 -0.2434 -0.1253 -0.1591 -0.1215 -0.1929 -0.1395 -0.1865 -0.1157 -0.1470 -1.9199 -0.4023 -0.0817 -0.1591 -0.1124 -0.2026 -0.2288
S-371	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-371	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-371	-0.27788856625556946	<unk> vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
D-371	-0.27788856625556946	<unk> vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
P-371	-0.6546 -2.8429 -0.0614 -0.1880 -0.1390 -0.8300 -0.1146 -0.1405 -0.0504 -0.1410 -0.2007 -0.0452 -0.1391 -0.1355 -0.0944 -0.1681 -0.0400 -0.0418 -0.1394 -0.1929 -0.1328 -0.1113 -0.1267 -0.1161 -0.1578 -0.2209
S-183	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-183	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-183	-0.27788856625556946	<unk> vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
D-183	-0.27788856625556946	<unk> vitamin D3 not associated with hypercalciuria or hypercalcaemia for up to 5 months .
P-183	-0.6546 -2.8429 -0.0614 -0.1880 -0.1390 -0.8300 -0.1146 -0.1405 -0.0504 -0.1410 -0.2007 -0.0452 -0.1391 -0.1355 -0.0944 -0.1681 -0.0400 -0.0418 -0.1394 -0.1929 -0.1328 -0.1113 -0.1267 -0.1161 -0.1578 -0.2209
S-1914	In beiden Studien wurde Aerinaze mit Desloratadin allein und mit Pseudoephedrin allein verglichen .
T-1914	In both studies , Aerinaze was compared with desloratadine alone and with pseudoephedrine alone .
H-1914	-0.42590492963790894	<unk> In both studies , Aerinaze was compared with desloratadine alone and with pseudoephedrine alone .
D-1914	-0.42590492963790894	<unk> In both studies , Aerinaze was compared with desloratadine alone and with pseudoephedrine alone .
P-1914	-1.9645 -0.6099 -0.1225 -0.6865 -0.4975 -0.1869 -0.1195 -0.1280 -0.1262 -0.1550 -0.1755 -0.2082 -0.3111 -1.5076 -0.1008 -0.0916 -0.7667 -0.4997 -0.1052 -0.1492 -0.8205 -0.2939 -2.3252 -0.1287 -0.1242 -0.1938 -0.2538 -0.1722 -0.0521 -0.1556 -0.1711
S-1836	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
T-1836	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <<unk>> 354 533 6100
H-1836	-0.4024239480495453	<unk> 354 533 6100 Sudl 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
D-1836	-0.4024239480495453	<unk> 354 533 6100 Sudl 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
P-1836	-0.7417 -1.4757 -0.0873 -0.1123 -0.1061 -0.1527 -0.1505 -0.3948 -5.8581 -0.1988 -0.1238 -0.1251 -0.2067 -0.1256 -0.1176 -0.1323 -0.9253 -0.1640 -0.0825 -0.1192 -0.1493 -0.0460 -0.0614 -0.1277 -0.1291 -0.1667 -0.0894 -0.1180 -0.1059 -0.1755 -0.1603 -0.1482
S-1825	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
T-1825	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <<unk>> 372 6 515 100
H-1825	-0.2952185273170471	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
D-1825	-0.2952185273170471	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
P-1825	-1.7619 -0.0980 -0.1152 -0.1573 -0.1980 -1.7038 -0.1213 -0.0902 -0.3381 -0.1319 -0.1015 -0.1179 -0.1152 -1.1929 -0.1029 -0.1225 -0.4256 -0.1108 -0.0526 -0.1509 -0.1365 -0.1220 -0.1919 -0.1951 -0.1560 -0.0978 -0.1630 -0.1444 -0.1464
S-1824	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
T-1824	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <<unk>> 47 22 58 4800
H-1824	-0.34376198053359985	<unk> 47 22 58 4800 Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
D-1824	-0.34376198053359985	<unk> 47 22 58 4800 Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
P-1824	-1.8541 -0.4122 -0.2533 -0.0763 -0.1505 -0.0996 -0.1351 -0.1186 -0.9192 -0.1259 -0.2412 -0.1379 -0.1375 -0.7353 -0.1571 -2.0093 -0.1077 -1.1204 -0.0935 -0.1925 -0.1198 -0.4365 -0.0790 -0.8579 -0.1318 -0.1143 -0.0923 -0.1274 -0.1309 -0.1903 -0.1856 -0.0886 -0.1477 -0.1056 -0.1468
S-1457	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1457	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1457	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
D-1457	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
P-1457	-0.4961 -2.9935 -0.1888 -0.1035 -0.1528 -0.3623 -0.1413 -0.4707 -0.1343 -1.1151 -0.0892 -1.0093 -0.2434 -0.1253 -0.1591 -0.1215 -0.1929 -0.1395 -0.1865 -0.1157 -0.1470 -1.9199 -0.4023 -0.0817 -0.1591 -0.1124 -0.2026 -0.2288
S-677	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-677	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-677	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-677	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-677	-1.5915 -1.0336 -0.1595 -0.6849 -0.0875 -0.1546 -0.1646 -0.4065 -0.1248 -0.1581 -0.1687 -0.2122 -0.1360 -0.1672 -0.0489 -0.0546 -0.8308 -0.1393 -0.1237 -0.2960 -0.1506 -0.1490 -0.3763 -0.1110 -0.0292 -0.1430 -0.1450 -0.1046 -0.0796 -0.1570 -0.1766
S-1105	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1105	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1105	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
D-1105	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
P-1105	-0.4961 -2.9935 -0.1888 -0.1035 -0.1528 -0.3623 -0.1413 -0.4707 -0.1343 -1.1151 -0.0892 -1.0093 -0.2434 -0.1253 -0.1591 -0.1215 -0.1929 -0.1395 -0.1865 -0.1157 -0.1470 -1.9199 -0.4023 -0.0817 -0.1591 -0.1124 -0.2026 -0.2288
S-151	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-151	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-151	-0.34660324454307556	<unk> Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
D-151	-0.34660324454307556	<unk> Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
P-151	-1.0544 -1.6881 -0.1276 -0.0139 -0.1362 -0.8858 -0.1629 -0.3270 -0.1164 -0.2365 -0.0909 -0.1594 -0.1433 -0.0256 -0.1054 -0.0634 -0.1016 -0.4568 -0.8921 -0.4014 -1.3742 -0.6928 -0.0523 -0.1042 -0.1334 -0.0995 -0.0891 -0.2449 -0.2054 -0.2137
S-753	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-753	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-753	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
D-753	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
P-753	-0.4961 -2.9935 -0.1888 -0.1035 -0.1528 -0.3623 -0.1413 -0.4707 -0.1343 -1.1151 -0.0892 -1.0093 -0.2434 -0.1253 -0.1591 -0.1215 -0.1929 -0.1395 -0.1865 -0.1157 -0.1470 -1.9199 -0.4023 -0.0817 -0.1591 -0.1124 -0.2026 -0.2288
S-579	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-579	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-579	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
D-579	-0.4212358891963959	<unk> every 24 hours ( 12-24 hours for patients under 6 years ) for at least 1 day until wound healing is achieved .
P-579	-0.4961 -2.9935 -0.1888 -0.1035 -0.1528 -0.3623 -0.1413 -0.4707 -0.1343 -1.1151 -0.0892 -1.0093 -0.2434 -0.1253 -0.1591 -0.1215 -0.1929 -0.1395 -0.1865 -0.1157 -0.1470 -1.9199 -0.4023 -0.0817 -0.1591 -0.1124 -0.2026 -0.2288
S-16	Das Arzneimittel wird nicht empfohlen bei Kindern und bei Patienten , die eine Organtransplantation hatten , da es für diese Gruppen nicht untersucht wurde .
T-16	It is not recommended for use in children or in patients who have had an organ transplant because it has not been studied in these groups .
H-16	-0.43250158429145813	<unk> This medicinal product is not recommended in children and patients who had an organ transplant as it has not been studied for these groups .
D-16	-0.43250158429145813	<unk> This medicinal product is not recommended in children and patients who had an organ transplant as it has not been studied for these groups .
P-16	-1.1655 -1.6994 -1.2932 -0.0809 -0.0605 -0.1138 -0.1174 -0.0613 -0.1228 -0.1500 -0.1474 -0.4149 -0.2562 -0.2030 -0.5500 -0.7749 -0.9330 -0.1851 -0.3573 -0.1871 -0.7410 -0.1122 -0.1348 -1.3449 -0.2426 -0.4361 -0.2414 -0.1657 -0.2501
S-1558	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1558	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1558	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1558	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1558	-1.5915 -1.0336 -0.1595 -0.6849 -0.0875 -0.1546 -0.1646 -0.4065 -0.1248 -0.1581 -0.1687 -0.2122 -0.1360 -0.1672 -0.0489 -0.0546 -0.8308 -0.1393 -0.1237 -0.2960 -0.1506 -0.1490 -0.3763 -0.1110 -0.0292 -0.1430 -0.1450 -0.1046 -0.0796 -0.1570 -0.1766
S-1205	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1205	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1205	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1205	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1205	-1.5915 -1.0336 -0.1595 -0.6849 -0.0875 -0.1546 -0.1646 -0.4065 -0.1248 -0.1581 -0.1687 -0.2122 -0.1360 -0.1672 -0.0489 -0.0546 -0.8308 -0.1393 -0.1237 -0.2960 -0.1506 -0.1490 -0.3763 -0.1110 -0.0292 -0.1430 -0.1450 -0.1046 -0.0796 -0.1570 -0.1766
S-853	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-853	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-853	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-853	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-853	-1.5915 -1.0336 -0.1595 -0.6849 -0.0875 -0.1546 -0.1646 -0.4065 -0.1248 -0.1581 -0.1687 -0.2122 -0.1360 -0.1672 -0.0489 -0.0546 -0.8308 -0.1393 -0.1237 -0.2960 -0.1506 -0.1490 -0.3763 -0.1110 -0.0292 -0.1430 -0.1450 -0.1046 -0.0796 -0.1570 -0.1766
S-1029	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1029	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1029	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
D-1029	-0.26982682943344116	<unk> As no compatibility studies have been carried out , this medicinal product should not be mixed with other medicinal products or solvents .
P-1029	-1.5915 -1.0336 -0.1595 -0.6849 -0.0875 -0.1546 -0.1646 -0.4065 -0.1248 -0.1581 -0.1687 -0.2122 -0.1360 -0.1672 -0.0489 -0.0546 -0.8308 -0.1393 -0.1237 -0.2960 -0.1506 -0.1490 -0.3763 -0.1110 -0.0292 -0.1430 -0.1450 -0.1046 -0.0796 -0.1570 -0.1766
S-785	15 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-785	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-785	-0.2873944342136383	15 This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
D-785	-0.2873944342136383	15 This medicinal product after reconstitution contains 0.45 mmol sodium ( 10 mg ) per vial .
P-785	-1.6457 -0.4333 -0.4717 -0.0710 -0.0773 -1.3081 -1.3510 -0.0702 -0.0724 -0.0851 -0.1151 -0.1040 -0.1978 -0.0864 -0.0379 -0.0404 -0.1426 -0.1163 -0.0553 -0.1517 -0.1143 -0.0563 -0.0806 -0.1525 -0.1478
S-312	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-312	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-312	-0.5375049710273743	<unk> These symptoms were rare severe and/ or associated with mobility impairment ( see section 4.8 ) .
D-312	-0.5375049710273743	<unk> These symptoms were rare severe and/ or associated with mobility impairment ( see section 4.8 ) .
P-312	-0.6755 -2.6736 -0.1096 -0.1621 -0.7611 -0.5283 -0.0275 -0.1193 -0.2034 -3.5333 -0.1390 -1.4728 -0.3827 -1.1121 -0.0818 -0.0260 -0.1570 -0.1452 -0.1622 -0.1743 -0.1397 -0.1518 -0.1509 -0.1882 -0.1600
S-384	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-384	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-384	-0.4110105335712433	<unk> Deficiency is associated with negative calcium balance , bone loss and an increased risk for skeletal fractures .
D-384	-0.4110105335712433	<unk> Deficiency is associated with negative calcium balance , bone loss and an increased risk for skeletal fractures .
P-384	-0.5705 -2.6498 -0.1031 -0.0838 -1.3713 -0.1240 -0.1207 -0.2741 -0.0737 -0.0666 -0.1076 -2.1208 -0.1669 -0.1325 -0.1385 -0.3386 -0.1613 -0.0545 -0.1124 -0.5676 -0.1127 -0.0776 -0.3210 -0.1336 -1.0726 -0.0678 -0.1797 -0.2049
S-1937	Jede Tablette enthält 2,5 mg Desloratadin und 120 mg Pseudoephedrin ( als Sulfat ) .
T-1937	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
H-1937	-0.36749058961868286	<unk> Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
D-1937	-0.36749058961868286	<unk> Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
P-1937	-1.6368 -0.1798 -0.0926 -0.0902 -0.0726 -0.1837 -0.0553 -2.1999 -0.1037 -0.0909 -0.5729 -0.5460 -0.1274 -0.0907 -0.0895 -0.4599 -2.3962 -0.1180 -0.1019 -0.1930 -0.3038 -0.1847 -0.1656 -0.1180 -0.0685 -0.1677 -0.1055 -0.1541 -0.1866 -0.1692
S-196	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-196	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-196	-0.4110105335712433	<unk> Deficiency is associated with negative calcium balance , bone loss and an increased risk for skeletal fractures .
D-196	-0.4110105335712433	<unk> Deficiency is associated with negative calcium balance , bone loss and an increased risk for skeletal fractures .
P-196	-0.5705 -2.6498 -0.1031 -0.0838 -1.3713 -0.1240 -0.1207 -0.2741 -0.0737 -0.0666 -0.1076 -2.1208 -0.1669 -0.1325 -0.1385 -0.3386 -0.1613 -0.0545 -0.1124 -0.5676 -0.1127 -0.0776 -0.3210 -0.1336 -1.0726 -0.0678 -0.1797 -0.2049
S-124	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-124	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-124	-0.5375049710273743	<unk> These symptoms were rare severe and/ or associated with mobility impairment ( see section 4.8 ) .
D-124	-0.5375049710273743	<unk> These symptoms were rare severe and/ or associated with mobility impairment ( see section 4.8 ) .
P-124	-0.6755 -2.6736 -0.1096 -0.1621 -0.7611 -0.5283 -0.0275 -0.1193 -0.2034 -3.5333 -0.1390 -1.4728 -0.3827 -1.1121 -0.0818 -0.0260 -0.1570 -0.1452 -0.1622 -0.1743 -0.1397 -0.1518 -0.1509 -0.1882 -0.1600
S-6	Bei der Hyperurikämie können sich Uratkristalle bilden und in den Gelenken und Nieren ablagern .
T-6	Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys .
H-6	-0.41976213455200195	<unk> Hyperuricaemia urine crystals can form and deposit in the joints and kidney .
D-6	-0.41976213455200195	<unk> Hyperuricaemia urine crystals can form and deposit in the joints and kidney .
P-6	-1.7057 -0.4471 -0.1203 -0.1886 -0.3649 -0.0519 -0.1396 -0.9326 -0.6391 -0.0424 -0.0297 -0.1440 -0.7792 -1.1705 -0.1313 -1.7160 -0.3685 -0.4901 -0.0088 -0.0539 -0.1398 -0.1744 -0.2190 -0.2474 -0.1894
S-1483	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1483	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1483	-0.5492821335792542	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
D-1483	-0.5492821335792542	<unk> In patients who develop factor VIII inhibitors , this may result in inadequate clinical response .
P-1483	-1.0481 -1.5993 -0.1279 -0.8270 -0.6312 -1.8931 -0.1425 -0.0586 -0.1003 -0.0438 -0.0636 -0.1151 -0.2390 -1.1269 -0.0987 -1.6346 -0.1567 -0.8621 -0.4859 -0.0527 -0.9019 -0.1795 -0.2450
S-681	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-681	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-681	-0.38491901755332947	<unk> During runtime the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-681	-0.38491901755332947	<unk> During runtime the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-681	-1.8806 -0.6632 -2.2602 -0.2294 -0.7698 -0.1318 -0.5416 -0.1731 -0.0778 -0.1359 -0.4307 -0.0746 -0.0946 -0.1118 -0.2935 -0.1132 -0.1832 -0.9982 -0.2240 -0.1445 -0.1440 -0.2411 -0.0579 -0.1665 -0.1770 -0.1257 -0.1439 -0.1899
S-857	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-857	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-857	-0.38491901755332947	<unk> During runtime the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-857	-0.38491901755332947	<unk> During runtime the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-857	-1.8806 -0.6632 -2.2602 -0.2294 -0.7698 -0.1318 -0.5416 -0.1731 -0.0778 -0.1359 -0.4307 -0.0746 -0.0946 -0.1118 -0.2935 -0.1132 -0.1832 -0.9982 -0.2240 -0.1445 -0.1440 -0.2411 -0.0579 -0.1665 -0.1770 -0.1257 -0.1439 -0.1899
S-1033	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1033	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1033	-0.38491901755332947	<unk> During runtime the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-1033	-0.38491901755332947	<unk> During runtime the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-1033	-1.8806 -0.6632 -2.2602 -0.2294 -0.7698 -0.1318 -0.5416 -0.1731 -0.0778 -0.1359 -0.4307 -0.0746 -0.0946 -0.1118 -0.2935 -0.1132 -0.1832 -0.9982 -0.2240 -0.1445 -0.1440 -0.2411 -0.0579 -0.1665 -0.1770 -0.1257 -0.1439 -0.1899
S-1209	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .